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Abstract  
Clinical depression is a chronic and comorbid condition with cardiovascular 
disorders (CVDs), with its presence leading to worse medical outcomes, higher rates of 
mortality, poor quality of life, poor adherence to treatment, and high health care costs. 
Psychological factors, such as higher rumination and health related worry and lower 
self-efficacy and self-care have been found to be associated with both conditions. As a 
result, it has been suggested that any psychological intervention aiming to treat co-
morbid depression in CVDs needs to target these factors. 
 Mindfulness-based cognitive therapy (MBCT) is a mind-body treatment that 
has shown promising effects in a wide range of physical conditions, with small to 
medium effect sizes. However, whether MBCT can help manage comorbid depression 
in CVD populations remains unclear. Therefore, the Heart and Living Mindfully 
(HeLM) project was developed to explore this issue. We developed a bespoke MBCT 
for people with comorbid depression and CVD through three phases. The first phase 
involved establishing the evidence base for developing the manual through conducting 
a systematic review and secondary analysis. The second phase pertained to conducting 
a pilot group for modifying the manual and checking its acceptability. The third and 
last phase was a feasibility randomised controlled trial (RCT) to uncover uncertainties 
around the MBCT-HeLM before proceeding with a definitive trial.  
Overall, the three phases were successful and achieved their goals. The 
feasibility RCT provided useful information for future studies in terms of using a 3-arm 
design, recruitment, attrition and retention. The key learning point was that it was 
challenging to recruit a sufficient number of people into the trial, suggesting future 
research will need to develop alternative recruitment procedures to be feasible.  
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Chapter 1.0  
Literature Review 
1.1 Introduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Cardiovascular disorders (CVDs) are the main causes of mortality and 
morbidity in the UK. Clinical depression is a chronic and comorbid condition with 
CVDs, with its presence leading to worse medical outcomes and poor adherence to 
treatment. This chapter provides a comprehensive review of depression and 
cardiovascular disorders. First, how common these disorders are in the UK, the 
consequences of comorbidity between depression and CVDs, and the underlying links 
between these conditions are reviewed. Second, how depression has been measured and 
treated in the context of CVDs is discussed, highlighting the need for innovative 
treatments that both address acute and residual symptoms and prevent depressive 
relapse. Third, mindfulness-based cognitive therapy (MBCT) as a potential treatment is 
considered. Fourth, the need for developing a bespoke MBCT course for comorbid 
depression and CVDs is discussed. Finally, an overview of the other chapters in this 
thesis that aim to develop and evaluate such an approach is provided.  
1.2 Depression and Cardiovascular Disorders (CVDs) 
1.2.1 Depression. 
Depression affects 350 million people, with it being the second most prevalent 
cause of disability-adjusted life years worldwide (World Health Organization, 2012). In 
the UK, 10.2 million people suffer from mental health problems, and depression is one 
of the most prevalent (Naylor et al., 2012). Major depressive disorder (MDD), as the 
most common of the depressive disorders, is characterised by one or more major 
depressive episodes (MDEs). An MDE is defined as the presence of between five and 
nine specified depressive symptoms for a period of at least two weeks, with one of 
14 
 
these being either depressed mood or loss of interest or pleasure (DSM-5, 2013, p. 
160). The seven other symptoms of are: significant weight loss, insomnia or 
hypersomnia, psychometric agitation or retardation, fatigue or loss of energy, feelings 
of worthlessness or excessive or inappropriate guilt, decreased ability to think or 
concentrate and recurrent thoughts of death (DSM-5, 2013, p. 161). 
Major depressive disorder (MDD) often follows a chronic relapsing course, 
with approximately 80 % of people with it having another episode (Judd, 1997). A 
review of 27 studies found that the recurrence of major depression in clinical settings 
was 60 % to 85 % over the following five to 15 years (Hardeveld, Spijker, De Graaf, 
Nolen & Beekman, 2010). Higher relapse rates have been found in those with a higher 
number of previous episodes, greater comorbidity, and greater severity of depression 
(Kennedy & Paykel, 2004; Melartin et al., 2004; Paykel et al., 1995). Even if 
individuals do not relapse, they are often left with residual symptoms. Up to 32 % of 
individuals suffer from residual symptoms in the first 15 months after an acute episode 
(Paykel et al., 1995) and this predicts difficulties in marital, social and work 
functioning (Kennedy & Paykel, 2004).  
Other depressive disorders are minor depression and dysthymia, being called 
subthreshold depressive symptoms. Minor depression1, which is categorised in 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) under depressive disorder not otherwise specified, is defined as the 
presence of two to four of the nine depressive symptoms for at least two weeks, with 
one of these being either depressed mood or loss of interest or pleasure (DSM-IV-TR, 
2000, p. 777). Dysthymia (persistent depressive disorder) is characterised by a chronic 
depressed mood that occurs on most days for a period of at least two years. During this 
                                                 
1 Note. “Minor depression” is not mentioned in DSM-5. 
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period, there is the presence of two or more of the following symptoms: poor appetite 
or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor 
concentration and feelings of hopelessness (DSM-5, 2013, p. 168). Whilst minor 
depression and dysthymia comprise symptoms that do not meet the criteria for MDD, 
they can cause very significant impairment in various aspects of a person’s life. For 
example, dysthymia is by definition a chronic disorder, with estimates of 73 % of 
people with the condition requiring at least 52 months to recover (Klein, Shankman, & 
Rose, 2006). It has also been found to be related to a high risk of relapse (Klein et al., 
2006). 
Depression alone causes long-lasting suffering, substantial disability and a low 
quality of life (National Institute for Health and Care Excellence, 2009). This picture is 
exacerbated when it comes with a physical condition like cardiovascular disorders 
(CVDs) and according to the World Health Organization (WHO), depression and 
CVDs will be the main cause of morbidity worldwide by the year 2020 (Murray & 
Lopez, 1997).  
1.2.2 Cardiovascular disorders (CVDs).  
Cardiovascular disorders (CVDs) refer to the diseases that affect the heart and 
blood vessels (Mendis, Puska, & Norrving, 2011). There are different types of CVDs, 
such as cerebrovascular disease (e.g., stroke), diseases of the aorta and arteries (e.g., 
hypertension), peripheral vascular disease, congenital heart disease, rheumatic heart 
disease, cardiomyopathies and coronary heart disease (CHD) (e.g., myocardial 
infarction (heart attack), angina and heart failure). For example, coronary heart disease 
(CHD) (sometimes called coronary artery disease or ischemic heart disease) refers to 
“diseases that occur when the walls of the coronary arteries become narrowed by a 
16 
 
gradual build-up of fatty material called atheroma” (HFA, Townsend, Williams, 
Bhatnagar, Wickramasinghe & Rayner, 2014, p. 10). 
CVDs have been the leading cause of morbidity and mortality in the UK since 
1961 (Naylor et al., 2012). According to the heart foundation association (HFA), CVDs 
caused 28% of all deaths in the UK in 2012. Of these CVD related deaths, 46 % were 
due to coronary heart disease (CHD), while 15 % were due to stroke. Moreover, 
approximately 1.6 million people were admitted to hospital due to one or more 
cardiovascular events, including heart attacks or strokes (HFA, Townsend, Williams, 
Bhatnagar, Wickramasinghe & Rayner, 2014). 
There is strong evidence for certain key risk factors of CVDs, including 
hypertension (high blood pressure), smoking, obesity and blood cholesterol, which are 
often triggered by unhealthy diet, physical inactivity and negative illness perceptions. 
For example, high blood pressure is considered as an important risk factor for 
developing a cardiovascular disorder (Kelly & Fuster, 2010). In a contemporary cohort 
study of 1.25 million people, it emerged that high blood pressure was significantly 
associated with a wide range of CVDs, such as angina, heart failure and cardiac arrest 
(Rapsomaniki et al., 2014). Hypertension (high blood pressure) is well-known as a 
resistant (difficult to treat) condition. A cross-sectional observational study in 12 
European countries (n = 5,222) found that half of people treated for hypertension 
continued with high blood pressure, with approximately 14 % of them having resistant 
hypertension (Borghi et al., 2016). A systematic review of 147 studies covering 
464,000 people with a history of CHD, stroke or no history of cardiovascular disorders 
suggested that reducing blood pressure is crucial to the prevention of CVDs (Law, 
Morris & Wald, 2009).  
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1.2.3 Comorbidity between depression and CVDs. 
There is evidence that depression is two to three times more common in a wide 
range of CVDs compared with the healthy population (Naylor et al., 2012). It has been 
estimated that 15 % to 20 % of  people with coronary heart disease (CHD) suffer from 
a major depressive disorder (MDD), while between 30 % to 50 % suffer from minor 
depression (Davidson, 2012; Huffman et al., 2013; Thombs et al., 2006). 
Approximately 47 % of people with CHD have significant depressive symptoms that do 
not meet the criteria of MDD (Stewart, Ricci, Chee, Hahn & Morganstein, 2003).  
Moreover, evidence suggests that the relationship between mental health and 
cardiovascular disorders is bidirectional (Baune et al., 2012; Khawaja, Westermeyer, 
Gajwani & Feinstein, 2009). This means that people suffering from mental health 
conditions are more likely to develop cardiovascular problems and vice versa. 
Regarding which, empirical research has indicated that people with mental health 
problems, such as depression, anxiety, stress and bipolar disorder, are at a higher risk of 
cardiovascular morbidity and mortality compared to the healthy population (Colton & 
Manderscheid, 2006; DE Hert et al., 2011; Sowden & Huffman, 2009). These findings 
are supported by different systematic reviews that found that depression is an 
independent risk factor, with an estimate that it doubles the risk of the development and 
progression of cardiovascular disorders (Huffman, Celano, Beach, Motiwala & Januzzi, 
2013; Lett et al., 2004; Lichtman et al., 2008; Van der Kooy et al., 2007). 
Other mental health problems, such as anxiety and stress, are very common in 
people with cardiovascular disorders (Goodwin, Davidson & Keyes, 2009). A meta-
analysis of 20 longitudinal studies suggested that anxiety is a risk factor for coronary 
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heart disease (CHD) (hazard ratio (HR): 1.262) and cardiac mortality (hazard ratio 
(HR): 1.483) (Roest, Martens, de Jonge & Denollet, 2010). 
1.2.4 Consequences of comorbidity.  
1.2.4.1 Mortality rate. Existing evidence shows that the comorbidity between 
depression and CVDs is associated with worse medical outcomes, including increased 
mortality rate. Ariyo et al. (2000) conducted a cardiovascular health study over six-
years of follow up to examine the relationship between depression and the development 
of coronary heart disease (CHD) and cardiovascular mortality in elderly people 
(n = 5,888), who were without cardiovascular disorders at baseline. After adjustment 
for some cardiac risk factors, including diabetes, hypertension, stroke, antidepressant 
medication usage and smoking, the authors found that depression, as assessed by the 
Center for Epidemiological Studies-Depression Scale, was a risk factor of the 
development of CHD (adjusted odds ratio4: 1.15) and for all-cause mortality (adjusted 
odds ratio: 1.16). Parashar et al. (2006) conducted a study aimed at determining the 
association between acute myocardial infarction (MI) and depression. The study 
assessed 2,498 people with MI, of which 2,096 were eligible for this study, and 
categorised people with depression at baseline only (transient), at 1-month (new) or at 
baseline and 1-month (persistent) using the Patient Health Questionnaire-9 (PHQ-9). 
The adjusted hazard ratios (adjusted-HR5) for rehospitalisation or mortality were higher 
in people with depression (n = 499) with an adjusted hazard ratio of 1.34 for transient 
                                                 
2 A hazard ratio of 1.26 here means that people with anxiety are 1.26 times as likely to develop coronary 
heart disease compared to those without.  
3 A hazard ratio of 1.48 here means that people with anxiety are 1.48 times as likely to die for cardiac 
reason compared to those without. 
4 Odds ratio is usually used with case-control, cross-sectional and cohort study designs.  
5 Hazard ratio is usually used with survival analysis. 
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depression, 1.71 for new and 1.42 for persistent compared to those without depression 
(n = 1,382).  
The hazard ratios reported in Airyo et al. (2000) and Parashar et al. (2006) are 
lower than those reported in a five years study by Lespérance, Frasure-Smith, Talajic & 
Bourassa (2002). This study was aimed to examining the effects of baseline depresion 
at rehospitalisation and mortality in people with acute myocardial infarction (MI). The 
adjusted hazard ratios (HR) for rehospitalisation or mortality were higher in people 
with depression, with an HR of 3.17 for moderate depression, and 3.13 for those with 
severe depression compared to those without depression. The study cohort was adjusted 
for age, gender, diabetes and smoking, with depression being assessed by the Beck 
depression inventory (BDI). 
In the previous studies, there is inconsistency regarding the reported adjusted 
hazard ratios for mortality arising from depression, which could be due to the use of 
self-reported measures of depression and measuring depression at baseline only. There 
are also limitations resulting from the heterogeneity of heart conditions, mortality 
causes and follow-up length. Nevertheless, van Melle et al. (2004) and Meijer et al. 
(2011) conducted meta-analyses of studies that considered the association between 
depression and mortality rate in myocardial infarction (MI) population and found that 
the pooled odds ratio for cardiac and all-cause mortality ranged between 2 and 2.5. 
1.2.4.2 Non-adherence and hospitalisation. Importantly, evidence also 
suggests that depression is associated with poor cardiac or psychiatric medication 
adherence in the context of CVD, which leads to poor treatment outcomes. A number 
of systematic reviews have shown that people with cardiac problems, with a major 
depressive disorder (MDD) or dysthymia, are likely to have a high non-adherence to 
their medication (cardiac or antidepressant) and completion of cardiac rehabilitation 
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programmes (Joynt, Whellan & Connor, 2004; Khawaja et al., 2009; Naylor et al., 
2012; Rustad, Stern, Hebert & Musselman, 2013). Depression has also related to 
increasing hospital admission rates, the use of health services by people with coronary 
artery disease (Baumeister, Haschke, Munzinger, Hutter & Tully, 2015) and increased 
emergency admission rates for people with CVDs (Naylor et al., 2012; Rustad, Stern, 
Hebert & Musselman, 2013).   
1.2.4.3 Quality of life. Depression is related to the quality of life for people with 
cardiovascular disorders. Quality of life refers to “individuals’ perception of their 
position in life in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns” (WHO, 1998, p. 1).  
A prospective study (de Jonge, Spijkerman, van den Brink & Ormel, 2006) with a 12-
months follow-up showed that people with depression had poorer quality of life and 
higher health and cardiac complaints compared to people without, for those who had 
experienced a myocardial infarction (MI). Cerniauskaite et al. (2012) conducted a study 
of disability and quality of life in people who had had a stroke and found that they had 
a lower quality of life and higher disability compared to the healthy population. A 
longitudinal cohort study with 803 people with coronary heart disease (CHD) found 
that people who had depression and anxiety at baseline had a lower quality of life 
compared to those who had no depression and anxiety at baseline over a three year 
follow-up (Palacios, Khondoker, Achilla, Tylee & Hotopf , 2016). These findings are 
consistent with a systematic review of 11 studies that concluded that depression is 
associated with poor physical quality of life for people with coronary heart disease 
(Dickens, Cherrington & McGowan, 2012).  
Health-related quality of life is considered to be an important indicator of the 
effectiveness of any treatment in people with heart disorders (Garster, Palta, Sweitzer, 
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Kaplan & Fryback, 2009). There are two kinds of quality of life measures. The first 
pertains to generic measures, such as the World Health Organization Quality of Life 
measure WHOQOL (WHO, 1998) and the 36- item Short-Form Health Survey (SF-36) 
(Hays, Sherbourne & Mazel, 1993; Ware & Sherbourne, 1992), assess different aspects 
of quality of life and can be used for a wide range of psychological and physical 
conditions. Second, there are specific disorder quality of life measures that can capture 
some areas that are affected by a particular disorder. For example, the Seattle Angina 
Questionnaire (SAQ; Spertus et al., 1995) assesses the quality of life for people with 
angina. 
1.2.4.4 CVDs risk factors. Notably, depression has been associated with some 
CVD risk factors, including unhealthy behaviours, like smoking or drinking (Khawaja 
et al., 2009), physical inactivity (Bonnet et al., 2005; Naylor et al., 2012; Win et al., 
2011) and poor diet. It also leads to greater inability to perform routine activities for 
heart disease people (Walters, Barley, Mann & Phillips, 2014). Depression also has 
been correlated negatively with people self-care and self-efficacy (Cameron, Worrall-
Carter, Riegel, Lo & Stewart, 2009; Holzapfel et al., 2009).  
Other mental health problems, such as anxiety and irritability after myocardial 
infarction (MI), have been associated with speeds of recovery, ability to adjust to 
medical problems (Melamed, Heruti, Shiloh, Zeidan & David, 1999), quality of life and 
increased functional disability (Yohannes, Willgoss, Baldwin & Connolly, 2010). 
Anxiety has also been related to worse major adverse cardiac events, such as heart 
attacks and cardiac death (Frasure-Smith & Lesperance, 2008). Stress has also been 
found to be associated with  myocardial ischemia (Gullette et al., 1997; Strike & 
Steptoe, 2003). 
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An important point regarding the literature of comorbidity between 
depression/other mental health problems and CVDs is that most of studies examining 
mortality rate, worse outcomes and the risk factors of CVDs used association designs, 
thus it was not possible to establish good evidence around causality. To summarise, 
depression and cardiovascular disorders (CVDs) have a notable prevalence within the 
UK, being associated with poor medication adherence and medical outcomes, low 
quality of life and increased use of the health service. However, there were 
methodological limitations in studies examining the comorbidity between depression 
and CVDs, including study design, use of depression self-reported measures, measuring 
depression at baseline only, the heterogeneity of heart conditions and follow-up length. 
It is important to determine the underlying links (mechanisms) between depression and 
CVDs in order to identify and develop new treatments that can target such mechanisms. 
The next subsection reviews some of mechanisms of the relationship between 
depression and CVDs.  
1.2.5 Underlying links between depression and CVDs.  
Evidence shows that there is a combination of biological, environmental, 
psychological and social factors that may explain why depression is linked to CVDs 
(Naylor et al., 2012), including, cigarette smoking, hypertension, diabetes, obesity, 
poor nutrition, sedentary lifestyle, stress, reduced functional capacity, nonadherence to 
cardiac prevention, lower heart rate variability (HRV), lack of physical activity, poor 
self-care and inflammation (Cameron et al., 2009; Carney, Freedland, Miller & Jaffe, 
2002; Dickens, 2015; Guarneri, Mercado & Suhar, 2009; Miller & Blackwell, 2006).  
Theoretically, some models have been proposed to explain the relationship 
between depression and CVDs. For example, Lett and colleagues (2004) suggested a 
model for biobehavioural mechanisms with two interacting factors that explain why 
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depression causes subsequent cardiac events. The first pathway includes behavioural 
risk factors, such as smoking, physical activity and medical adherence, whilst the 
second includes physiological risk factors, such as inflammation, platelet activity, 
diabetes, hypertension and obesity. Consistent with this biobehavioural model, 
Huffman and colleagues (2013) proposed a model that includes two factors (impaired 
health-promoting behaviour and adverse physiologic effects). In this model, depression 
in people with cardiac problems leads to impaired health-promoting behaviours that 
consequently, results in reduced adherence to a low-fat diet, physical activity, 
medication and rehabilitation attendance. At the same time, depression causes adverse 
physiologic effects that lead to, for example, increased inflammation and decreased 
heart rate variability. Taken together, these factors can cause adverse cardiac events. 
Empirically, numerous studies have explored various biological, behavioural, social 
and psychological mechanisms linking depression to CVDs. The evidence for some of 
these mechanisms is described below, with a particular focus on possible psychological 
factors.  
1.2.5.1 Some biological and behavioural mechanisms.  
One possible biological mechanism is platelet reactivity. Laghrissi-Thode, 
Wagner, Pollock, Johnson & Finkel (1997) found that people with depression 
compared to people without in ischemic heart disease population showed higher 
reactivity of platelet aggregation (the process by which cells form clots in the blood 
stream), which is known to trigger heart attacks, strokes, and peripheral vascular 
disease (Gregg & Goldschmidt-Clermont, 2003). Serebruany et al. (2003) concurred 
with Laghrissi-Thode et al. (1997) that people with depression and acute coronary 
syndrome (ACS) were likely to have a higher platelet reactivity than a healthy group. 
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Another possible biological mechanism that has recently received increased 
attention is inflammation, which is defined as “a primary component of the immune 
system that is triggered by any stimulus that poses a real or perceived threat to tissue 
homeostasis” (Maskrey, Megson, Whitfield & Rossi, 2011, p. 1001). Stewart, Rand, 
Muldoon & Kamarck (2009) conducted a study over six years to examine whether 
baseline depression, as assessed by the Beck depression inventory (BDI), would predict 
inflammation markers (interleukin-6 (IL-6) and C-reactive protein (CRP) in healthy 
people (n = 263). The authors found that people with high baseline depression showed 
higher levels of interleukin-6 (IL-6) compared to those with less baseline depression. 
Poole, Dickens & Steptoe. (2011) concluded that, in a sample of people with acute 
coronary syndrome (ACS) and coronary artery bypass graft (CABG), inflammation is 
associated with the onset of depression and adverse cardiac outcomes.  
There is also increasing evidence that behavioural mechanisms, including non-
adherence to medication and unhealthy behaviours (e.g., cigarette smoking and 
physical inactivity) may have a negative impact on cardiac outcomes. Gehi, Haas, 
Pipkin & Whooley (2005) found in a sample of people with coronary heart diseases 
 (n = 940) that people with current major depression reported less adherence to 
medication compared to those without it. These findings were elicited after controlling 
for cardiac disease severity, age, ethnicity, education and social support. Rieckmann et 
al. (2006) agreed with Gehi et al.’s (2005) study outcomes, eliciting that people with 
coronary artery syndrome (CAS) who had high baseline depression during 
hospitalisation were likely to report less adherence to medical medication over 3-
months follow up compared to those without depression. A clinical review of the 
relationship between depression and CVDs concluded that people with depression 
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reported a twofold non-adherence rate to medication (cardiac or psychiatric) compared 
to people without it (Hare, Toukhsati, Johansson & Jaarsma, 2014).  
Bonnet et al. (2005) studied unhealthy behaviours in people (n = 1,612) at high 
risk of CVDs and concluded that unhealthey diet, cigarette smoking and physical 
inactivity were associated with depression and anxiety. Whooley et al. (2008) followed 
people with coronary heart disease (CHD) over six years and found that physical 
inactivity played a role in relation to the association between baseline depression and 
an adverse cardiac event. Also, depression and physical inactivity, together, were found 
to be associated with a higher mortality rate compared to people with one of these 
manifestations alone (Win et al., 2011).  
In conclusion, despite the long history of examining the potential role that 
biological/behavioural factors may play in how depression is linked to CVDs, it would 
still seem that much of this relationship has yet to be explained. Recently, the interest 
has been directed towards psychological factors, including self-efficacy and related 
self-care as well as psychological resilience, rumination and worry, all of which have 
been identified as important factors that need to be targeted, the evidence regarding 
each of these is presented below.  
1.2.5.2 Psychological mechanisms. 
1.2.5.2.1 Rumination and worry. Perseverative/repetitive negative thinking is 
defined as “a style of thinking about one’s problems (current, past, or future) or 
negative experiences (past or anticipated) that shows three key characteristics: (1a) the 
thinking is repetitive, (1b) it is at least partly intrusive, and (1c) it is difficult to 
disengage from” (Ehring et al., 2011, p. 226). According to Ehring & Watkins (2008), 
there are three characteristics associated with repetitive negative thinking: passivity or 
uncontrollability, negativity and repetition. The main perseverative negative cognitive 
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processes include rumination and worry. Nolen-Hoeksema (1991) describes rumination 
as a “a mode of responding to distress that involves repetitively and passively focusing 
on symptoms of distress and on the possible causes and consequences of these 
symptoms” (p. 1). Some studies have suggested that rumination has two types 
(brooding and reflection), with the former being a passive focus on distress symptoms 
and the latter an active attempt to understand the problem (Sorg, Vögele, Furka, & 
Meyer, 2012). With regards to worry, it refers to “a chain of thoughts and images that 
are affectively negative and relatively uncontrollable” (Borkovec, Robinson, Pruzinsky 
& DePree, 1983, p. 10).  
Importantly, Harvey, Watkins, Mansell, & Shafran (2004) suggest that 
perseverative negative thinking is a transdiagnostic process as it presents with a large 
number of disorders. Despite rumination and worry being intrinsically linked, there is a 
notable difference between the two, with rumination focusing on the past and worry on 
the future (Ehring & Watkins, 2008). Practically, rumination has been shown to 
increase the likelihood, severity and duration of depression (Watkins, 2008; Watkins & 
Teasdale, 2004) as well as predict the onset and recurrence of depressive episodes 
(Sorg et al., 2012). Also, it has been found that brooding as a type of rumination is 
related to concurrent and prospective depression (Ehring & Watkins, 2008).  
Brosschot, Gerin, & Thayer (2006) explain how these perseverative cognitive 
processes are related to physical conditions in their perseverative cognition theory. 
Under this theory, perseverative cognition is described as “the repeated or chronic 
activation of the cognitive representation of one or more psychological stressors” 
(Brosschot et al., 2006, p. 114). The authors suggest that a perseverative cognition can 
last way beyond the duration of the stressor. Ill health can be induced by expanding the 
temporal duration of the stressor beyond its natural reaction period by including 
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recovery and anticipation, thereby prolonging the physiological activation. Gerin et al. 
(2012) and based on this theory, propose a model that describes rumination as a 
mediator of chronic stress effects on hypertension. They sugget that rumination around 
a stressful event can cause activation of a physiological response similar to that 
happening during the original stressful event, which can continue for a long time after 
its conclusion and thus, leads to high blood pressure.  
A number of authors have associated the perseverative cognitive processes with 
CVDs, including hypertension and coronary heart disease (Gerin et al., 2012; 
Kubzansky et al., 1997; Radstaak, Geurts, Brosschot, Cillessen, & Kompier, 2011). 
Trick, Watkins, Windeatt, & Dickens (2016) completed a systematic review that 
focused on the temporal relationship between depression, anxiety and emotional 
distress and perseverative negative thinking. The uncontrolled studies included in the 
review showed that there was an association between catastrophising and rumination 
with depression, anxiety and emotional distress. While, the studies that controlled for 
covariates, such as baseline depression, reported mixed outcomes. Also, the review 
showed that the controlled studies did find that catastrophising resulted in the strongest 
associations. Importantly, this review showed that people with chronic pain and 
cardiovascular disease have a greater association between perseverative negative 
thinking and anxiety, emotional distress and depression.  
Moulds et al. (2008) discuss some similarities between rumination and 
cognitive reactivity which refers to “the degree to which a mild dysphoric state 
reactivates negative thinking patterns” (Raes, Dewulf, Van Heeringen, & Williams, 
2009, p. 623). For example, both concepts describe an individual’s response to low 
mood and can be used as a vulnerability factor to predict depression recurrence 
(Moulds et al., 2008). Moulds et al. (2008) in their study, showed that there was a 
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positive correlation between rumination and cognitive reactivity even after controlling 
for the current level of depression.  
1.2.5.2.2 Self-efficacy and related variables. The concept of self-efficacy was 
first introduced by Bandura (1977) in his theory of personal expectations and their 
impacts on health outcomes. It can be defined as “people’s confidence in their ability to 
take care of their health” (Sarkar, Ali & Whooley, 2007, p. 2). Accordingly, applying 
this notion to CVD populations, the more confidence that a person with cardiac 
problems has in terms of controlling their condition the greater the likelihood of 
positive cardiac outcomes.  
Practically, self-efficacy was found to be associated positively with motivation 
and performance in learning settings (Vancouver & Kendall, 2006) and health 
behaviour changes (Strecher, McEvoy DeVellis, Becker, & Rosenstock, 1986). Also, 
self-efficacy has been found to be a mediator6 of the relationship between depression 
and CVDs (Greco et al., 2014). In addition, it has been revealed that low self-efficacy 
predicts lower quality of life for people with depression (Loo et al., 2016) and mediates 
the relationship between depression and adherence (Tovar et al., 2015). Also, low self-
efficacy is associated with high symptoms burden, physical limitations in people with 
chronic heart failure (Sarkar et al., 2007) and post-stroke depression (PSD) (Volz, 
Mobus, Letsch & Werheid, 2016).  
Interestingly, Sarkar, Ali, & Whooley (2009) found in a sample of people with 
heart failure (HF) that low self-efficacy was able to predict all-cause mortality and a 
greater hospitalisation rate for HF reasons. However, the findings of this study may 
have been limited by methodological issues. For example, the authors discussed the 
                                                 
6 A mediator is defined as “an intervening variable that may account statistically for the 
relationship between the independent variable and dependent variable” (Kazdin, 2007, p. 3). 
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issues around measuring self-efficacy at baseline only, which means that there are 
likely to be other important factors that appear on a longitudinal basis. Also, there is an 
issue regarding the used self-efficacy measure, in that it was only a 5-item self-report. 
A systematic review of management programmes in people with CVDs has suggested 
that interventions would benefit from including self-efficacy as a component (Katch & 
Mead, 2010).  
Self-care, which is related to self-efficacy, is another issue that has been noticed 
as affecting medical outcomes and family function in people with chronic heart failure 
(Riegel, Dickson, Goldberg & Deatrick, 2007). A study (Holzapfel et al., 2009) 
pertaining to people with chronic heart failure measured self-care in three groups, 
people with: major depression, minor depression and non-depressed people. The 
findings indicated that those with minor depression reported lower self-care compared 
to the other two groups. The authors attributed this counter-intuitive finding to people 
with serious conditions, including major depression, focusing more on self-care 
compared to those with only minor symptoms, as their awareness of the need to take 
care of themselves is more acute and pervasive. However, we think that it is more 
likely that the findings were the result of methodological limitations, such as the stage 
of heart failure, the sample size and the depression assessment method. Additionally, it 
has been shown that people with good self-care are likely to have better health 
improvement, less inflammation and less hospitalisation than those without it (Riegel, 
Lee & Dickson, 2011). The ways of taking care of a CVD condition differ depending 
on the type of CVD and its severity, with some of these including keeping to a diet, 
undertaking physical activity, attending rehabilitation programmes and taking 
medication, either psychiatric or medical. 
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Psychological resilience is another factor that has been found to be related to 
some physical conditions, including cardiovascular disorders and refers to “people’s 
ability to “bounce back” from stressful experiences quickly and efficiently” (Carver, 
1998, p. 246). A main difference between self-efficacy and resilience is that resilience 
presents if there is a stressful event while self-efficacy can be present regardless of 
stressful events (Schwarzer, R., & Warner, 2013). A study (Schure, Odden, & Goins, 
2013) with old people found that resilience was negatively associated with depression. 
Also, resilience has been found to affect the relationship between depression and 
psychological quality of life in people with heart failure (HF) (Liu, Chang, Wu, & Tsai, 
2015). Toukhsati, Jovanovic, Dehghani, Tran & Tran (2016) conducted a study with 
people with CVDs and found that low psychological resilience is significantly 
associated with depressive symptoms; mainly anhedonia and hopelessness.  
1.2.5.2.3 Illness perception. Symptom and illness perception is a variable found 
to be associated with people’s perceptions of their health. It refers to “the process of 
becoming aware of bodily dysfunction” (Van den Bergh, Bogaerts, & Diest, 2015,  
p. 866). This concept assumes that the physical symptoms that people experience and 
describe are an interpretation of their inherent beliefs regarding interoceptive 
information. That is, they are descriptions based more on symptom perception that 
developed from previous learning of the potential causes of somatosensory inputs than 
on direct records of physical activity within their body (Van den Bergh et al., 2015). In 
their recent model, Van den Bergh, Witthoft, Petersen, & Brown (2017) proposed that 
experience of somatic symptoms is as a result of ongoing interplay between ‘priors’ 
and ‘prediction errors’. Symptom perception is potentially influenced by a range of 
factors, including symptom schemata, threat, negative affect (NA), illness beliefs, 
anticipation, varieties of attention and gender (Van den Bergh et al., 2015). One of 
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these factors, namely symptom schemata, comprises representations of an individual’s 
history of symptom episodes that have been stored in their memory and includes 
aspects that are common to episodes experienced by that individual (Van den Bergh et 
al., 2015). With regards to negative affect (NA), it has been found that trait NA, 
affective disturbance and anxiety states are associated with an increase in reporting of 
physical symptoms (Van den Bergh et al., 2015). Hagger & Orbell (2003) reported that 
the concepts of coping mechanisms, perceptions of risk and psychological well-being 
are related to individuals’ thoughts and concerns about specific aspects that might 
constitute their cognitive models of their illnesses. Such a model may include the 
condition nature and its causes, timeline and consequences and the potential for its 
control (Hagger & Orbell, 2003).  
The self-regulation model (SRM), as described by Leventhal, Diefenbach, & 
Leventhal (1992), is one of the most prevalent theoretical frameworks applied to 
cognitions associated with health and illness. In this model, individuals are regarded as 
building personal representations, which subsequently have an impact on making sense 
of their experiences. The SRM proposes that an individual’s illness perceptions are 
organised around the following components: identity (the tag, or label a person 
employs to provide an account of their illness, along with the symptoms that are 
perceived as part of the condition); timeline (a person’s perception of the length of time 
for which they will suffer from the condition); control (whether the illness can be 
controlled); consequences (how severe the impacts of the condition in terms of its 
physical, psychological, and social implications); cause (reasons for the condition); and 
coherence (whether the condition is comprehensible) (Petrie, Weinman, Sharpe, & 
Buckley, 1996).   
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Practically, examining of the way in which these illness perceptions impact on 
health and health-related outcomes has been studied in the literature. This is especially 
with respect to cardiovascular disorders (CVDs) and certain psychological problems, 
including depression and anxiety. It has been shown that illness perceptions are related 
to some important outcomes, including adjustment, self-reported well-being and 
functional status, survival and return to work in people with heart diseases (Barefoot et 
al., 2011; Petrie, Weinman, Sharpe, & Buckley, 1996). Moreover, evidence indicates 
that illness perceptions are related to seeking- help in people with different physical 
conditions (Hsiao, Chang, & Chen, 2012; Morgan, Villiers-Tuthill, Barker, & Mcgee, 
2014). For instance, if people believe that their conditions are serious, then they are 
more likely to seek help (Hsiao et al., 2012). Also, a study conducted by Hallas, Wray, 
Andreou, & Banner (2011) found that negative illness perceptions (particularly relating 
to heart failure consequences) contributed to an increased likelihood of inappropriate 
coping strategies (e.g., denial and introversion). van der Wal, Stromberg, van 
Veldhuisen, & Jaarsma (2016) showed that people with heart failure (HF) who have 
negative expectations such as “my condition is going to be worse” are likely to have 
worse outcomes.  
Adherence is a crucial factor that has been found to be related to positive 
physical and psychological outcomes. The degree to which an individual is likely to 
adhere to any given treatment has been elicited as being correlated with the nature of 
their beliefs (Hsiao et al., 2012; Petrie et al., 1996). Petrie et al. (1996) found that 
people’s initial beliefs about myocardial infarction (MI) were associated with 
adherence-related variables, including presence at cardiac rehabilitation sessions and 
return to work. Also, there is evidence that indicates that people’s medication-related 
beliefs are correlated with adherence. In fact, Horne & Weinman (1999) found that 
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people beliefs about their illness had greater predictive power in determining adherence 
when compared to clinical and sociodemographic characteristics.  
It is important to consider how depression may impact on illness related beliefs 
about CVDs. Given that depression is proposed to lead to global negative beliefs about 
the self, world and future (e.g., Beck, 1979), it seems likely it would also lead to more 
negative views about recovery from heart disease. Moreover, given that depression has 
been associated with elevated rumination (repetitive negative thinking) (see Watkins, 
2008), it is likely that individuals with depression will spend more time dwelling on 
their views regarding, causes, meanings and consequences of recovery from CVDs. 
These negative and repetitive negative thought cycles may then impact on illness 
related behaviours, for example reduced adherence to treatment. It is also possible that 
the relationship could go in the reverse direction. For example, those who hold negative 
views about recovery from CVD that they dwell on which may in turn become more 
depressed. These ideas have only partially been tested in the literature, which has 
established illness beliefs around CVDs and depression are related but have not 
established the direction or causal nature of these relationships. Researchers have found 
that emotional outcomes can be predicted by rumination, which in turn, is related to 
perceived identity, the emotional representation of the illness, the consequences of the 
illness, and negative emotions (Lu et al., 2014). Morgan, Villiers-tuthill, Barker & 
Mcgee. (2014) conducted a study on 95 people with heart failure (HF) and found that 
negative illness perceptions were associated with more marked depression and anxiety. 
Their study also showed that people with heart failure experienced high negative illness 
perceptions in some respects, such as their perceived personal consequences of HF and 
negative emotional responses. 
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1.3 Depression in the Context of CVDs  
Ormel & De Jonge (2011) have proposed an integrative dynamic model aimed 
at understanding depression in the context of coronary artery disease (CAD). It 
categorises depression into two types: cognitive/affective (e.g., depressed mood, 
suicidal thoughts, negative feelings, self-sense of failure, self-criticism, feeling of guilt 
and/or future pessimism) and somatic/ affective (e.g., fatigability, psychomotor 
agitation/retardation, work difficulty, sleep problems, pain, appetite disturbance, weight 
disturbance and/or depressed mood). With this model, the effects of depression on 
people with CAD are considered to be related not only to these two types, but also, to 
the longer duration of depression. In addition, notably, this model highlights that 
behavioural factors significantly impact on the relationship between recurrent 
depression and cardiac prognosis regardless of the type of depression.  
Dickens (2015) conducted a review of depression in people with coronary heart 
disease (CHD). In this review, Dickens revealed a number of characteristics that could 
explain why depression leads to worse outcomes in CHD populations, which include: 
timing of the depression onset, severity of the symptoms and type of depression 
(somatic or cognitive). The author proposed that this focus on characteristics could be 
the key to identifying the type of depression and its mechanisms that cause worse 
outcomes. In addition, this research focus could help in the identification of those 
people at higher risk of poor outcomes and in the development of novel interventions 
for reducing the impact of depression on people with CHD. The next subsections 
consider some of these characteristics. 
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1.3.1 Types of depression.  
The most common type of depressive disorder, which has received much 
attention in populations with CVD, is major depressive disorder (MDD), whilst minor 
depression and dysthymia have received less attention in this context. These three types 
of depression place a significant burden on people with pure or comorbid depression in 
the context of physical health conditions and have also been related to increasing 
likelihood of subsequent relapse (Boland & Keller, 2002; Hardeveld et al., 2010; Judd, 
1997). Evidence suggests that MDD and dysthymia are associated with poorer 
comorbid medical outcomes, lower adherence to medication, poor diet, and lack of 
exercise when compared to people without these conditions in acute myocardial 
infarction (MI) populations (Kennedy & Foy, 2005; Ziegelstein et al., 2000).  
1.3.2 Timing of depression.  
There has been some focus in the literature on the timing of depression onset in 
CVDs (i.e. whether depression is a new event following the cardiac event or there is a 
history of depression prior to this). This timing of depression onset has been linked to 
the development or progression of cardiovascular conditions. For example, regarding 
new-onset depression, a study of 489 people admitted to hopsital for acute coronry 
syndrome (ACS) involved interviewing at one and 12 months to assess for depression. 
The findings found that after the adjustment of important covariates, people diagnosed 
with new depression after ACS showed poorer cardiac outcomes compared to those 
who had a history of depression before it happened (Parker et al., 2008). 
However, in a recent UK cohort study (Daskalopoulou et al., 2016) of 
1,937,360 adults without cardiovascular disorders at baseline, researchers found that 
after two to 10 years of follow-up, both a history of and new-onset depression were 
associated with an increased prevalence in several CVDs, including stable angina, 
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unstable angina, heart failure, myocardial infarction, cardiac arrest, transient ischemic 
attack, ischemic stroke and peripheral arterial disease, when compared to those without 
depression. Also, a systematic review of 17 prospective studies indicated that people 
with a history of depression had a 34 % higher risk of having a stroke than those 
without after controlling for certain variables, including age, gender, history cardiac 
disease history, smoking, hypertension and diabetes. The review also found that 
depression increases, independently, the risk factors of a stroke, such as hypertension 
and diabetes (Dong, Zhang, Tong & Qin, 2012). Despite the conflicting evidence 
around the timing of the onset of depression and its role in worsening cardiovascular 
outcomes, a meta-analysis by Leung et al. (2012) has highlighted that both (new onset 
or a history of depression) are important and that the timing is irrelevant when 
considering adverse cardiac outcomes. 
1.3.3 Types of depressive symptoms. 
  Within the CVD literature, an appreciable amount of attention has been placed 
on the way depression presents. It is generally agreed that depression can be 
categorised in a number of ways, including: psychological, cognitive and somatic. 
There is evidence that different characteristics have different impacts on cardiac 
outcomes. Regarding which, Smolderen et al. (2009) found a link between somatic 
depression and elevated rates of myocardial infarction (MI) hospital readmission 
(Hazard ratio, HR=1.16; 95 % CI: 1.06-1.27; p = 0.01) that was not presented in 
cognitive depressive symptoms. These findings are supported in a study by (Martens, 
Hoen, Mittelhaeuser, de Jonge, & Denollet, 2010), who examined the association 
between different types of depressive symptoms regarding the severity and prognosis of 
myocardial infarction (MI). The authors found that somatic depressive symptoms were 
37 
 
associated with returning MI and cardiac mortality, whilst cognitive symptoms had no 
such association.  
Despite the differences in these studies, with regards to depression measures 
and cardiac risk factors, they have highlighted the importance of the link between 
CVDs and somatic depression, thus promoting the need for the development of 
screening and new treatments for people with CVD who show its symptoms.   
1.3.4 Recurrent depression and CVDs. 
There is evidence that suggests a link between recurrent depression and 
subsequent cardiac events in people with cardiac diseases. Indeed, a study by 
Lesperance, Frasure-smith, & Talajic (1996) suggested that recurrent depression is a 
more important risk factor for CVDs than that of incident depression. The authors 
reported that people with a history of major depression disorder (MDD), who had a 
recurrent episode within a week of suffering a myocardial infarction, had a higher 
incidence of death than those with first time incident depression (40 % compared to 
10 %, respectively). A prospective study on 336 healthy women, carried out by Jones, 
Bromberger, Sutton-tyrrell, & Matthews (2003) determined the associations between 
subclinical atherosclerosis and recurrent depression. The study showed that a lifetime 
history of depression was correlated with subclinical atherosclerosis, while there were 
no associations with single major depressive episodes. A longitudinal study, completed 
by Windle & Windle (2013), reported a five-year follow-up of 557 people. The study 
aimed to determine the concurrent and prospective correlations between single and 
recurrent MDD and diabetes, cardiovascular disease and other CVD risk markers, such 
as high cholesterol and hypertension. The prospective, cross-sectional analysis showed 
recurrent MDD was a significant predictor of diabetes and CVD risk and also, an 
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increase in the risk of both disorders, even after controlling for BMI, smoking and 
alcohol use, while single episode MDD had no such correlations.  
Nevertheless, a number of other studies, including those by Grace et al. (2005), 
de Jonge et al. (2006) and Goodman et al. (2008) reported that there was a correlation 
between incident depression at the time of hospitalisation with mortality and future 
cardiac events, whilst a history of depression showed no such correlations. Carney & 
Freedland (2012) hold that recurrent depression enhances the development of CVDs by 
placing people in the risk factor situation for a long time.  
It is important to consider the underlying mechanisms through which recurrent 
depression might be linked to worse cardiovascular disorder prognosis. A range of 
possible underlying mechanisms has been proposed in the literature (see review by 
Dickens, 2015). Different lifestyle behaviours associated with depression may lead to 
poor cardiac outcomes, including: a greater tendency to smoke and a reduced likelihood 
of discontinuing smoking in depression (Whooley et al., 2008; Ye et al., 2013); a poor 
diet leading to a greater chance of obesity (especially vascular obesity) and type II 
diabetes in depression (Knol et al., 2006; Luppino et al., 2010); reduced exercise and a 
greater likelihood of a sedentary lifestyle in depression (Bonnet et al., 2005; Brummett 
et al., 2003); reduced adherence to treatment recommendations, both for depression and 
cardiovascular disorders (Rieckmann et al., 2006, 2011); and poor attendance at cardiac 
rehabilitation in depression (Casey, Hughes, Waechter, Josephson, & Rosneck, 2008). 
Underpinning this poor self-care are likely to be deficits in motivation, reduced 
sense of self-efficacy, and pessimistic beliefs relating to the potential benefits of 
treatment (Wang et al., 2002). For instance, self-efficacy has been found to be a 
mediator of the relationship between depression and CVDs (Greco et al., 2014) as well 
as mediating the relationship between depression and adherence (Tovar et al., 2015). 
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Also, low self-efficacy is associated with high symptoms burden, physical limitations 
in people with chronic heart failure (Sarkar et al., 2007) and post-stroke depression 
(PSD) (Volz et al., 2016). It has been elicited that self-care, which is related to self-
efficacy, influences medical outcomes and family function in people with chronic heart 
failure (Riegel et al., 2007). Also, it has been shown that people with good self-care are 
likely to have better health improvement, less inflammation and less hospitalisation 
than those without it (Riegel et al., 2011).  
It is also important to consider the impact that perseverative cognitive processes 
have on depression and CVDs. Brosschot et al. (2006) explain how these perseverative 
cognitive processes are related to physical conditions in their perseverative cognition 
theory. The authors suggest that a perseverative cognition can last way beyond the 
duration of the stressor (Brosschot et al., 2006). Based on this theory, it is possible to 
aggravate adverse health conditions, such as CVDs, by augmenting the stressor’s 
timeline far past the natural reaction period, and this can be achieved by incorporating 
recovery and anticipation, thereby prolonging associated physiological activation 
(Brosschot et al., 2006). Based on this scenario, an individual may experience elevated 
blood pressure (BP) long after exposure to a stressor, because of rumination (which, in 
turn, stimulates a physiological response) (Gerin et al., 2012). The literature suggests 
that these perseverative cognitive processes are linked with CVDs (e.g., hypertension 
and coronary heart disease) (Gerin et al., 2012; Kubzansky et al., 1997; Radstaak et al., 
2011) and can promote negative prognoses such as impaired immune response 
(Brosschot et al., 2006). Larsen & Christenfeld (2009) concluded that rumination is a 
mechanism that links the co-occurrence of cardiovascular disorders and psychiatric 
disorders. Specifically, the researchers argued that rumination postpones recovery 
following exposure to stress, which is thus considered a predictor of future 
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cardiovascular health (Larsen & Christenfeld, 2009). Busch, Pössel, & Valentine 
(2017) meta-analysis, which investigated rumination as a potential causal explanation 
for the link between depression and CVDs, revealed that rumination (irrespective of its 
types) stimulates significant cardiovascular reactivity. Trick et al. (2016) concluded 
that there is a connection between perseverative negative thinking and emotional 
distress, depression, and anxiety in people with CVD and chronic pain. Regarding 
depression populations, Sorg et al. (2012), Watkins (2008), and Watkins & Teasdale 
(2004) have found that rumination is linked to an increased likelihood of initial and 
recurrent depression, along with more severe and longer depressive episodes. 
It is also possible that the increased and chronic inflammatory response seen in 
depression may worsen cardiovascular disorders (Dickens, 2015). Research indicates 
that elevated inflammation and inflammatory cytokine levels constitute risk factors for 
coronary disease. In particular, they have an adverse impact on the pathogenesis of 
coronary heart disease (Berton et al., 2010; Poole, Dickens, & Steptoe, 2011). 
Furthermore, the literature suggests that depression is associated with a heightened 
level of various inflammation biomarkers, including c-reactive protein (CRP), 
interleukin 1 (IL-1), and interleukin 6 (IL-6) (Howren, Lamkin, & Suls, 2009; Stewart 
et al., 2009).  
The social signal transduction theory of depression (Slavich & Irwin, 2014), 
which connects stress to internal biological mechanisms (primarily inflammation) 
associated with the development of depression suggests ways in which experiential 
stress impacts on inflammation, along with the ways stress-inflammation pathways may 
be related to depression. The authors hold that sympathetic nervous system (SNS) and 
hypothalamic–pituitary–adrenal (HPA) responses to stress are potentiated by past 
experiences with depression, thereby facilitating the galvanisation of the regulatory 
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connection between the brain and the body’s inflammation system. Based on this 
theory, the two-way connections between the brain and inflammatory system become 
stronger over time and the neural and physiological pathways responsible for regulating 
inflammation could stay active without being exposed to stress (Slavich & Irwin, 
2014). This chronic inflammation may exacerbate CVD risk. 
Finally, it is important to mention that most of the existing literature has 
focused on studying the links underlying the relationship between CVDs and single 
episode depression. Further work is needed to examine whether recurrent depression 
further exacerbates this picture.   
1.3.5 Depression in elderly people with CVDs. 
Importantly, given that high numbers of people with CVD are elderly, it is 
important to note that depression in this context can come with different symptoms. 
More prevalent in this age group are loss of enjoyment, increased lack of energy and 
somatic symptoms, whilst less prevalent are sadness or a depressed mood (Wilson, 
Mottram & Vassilas, 2008). Also, there is an overlap between depression and some 
symptoms of CVD, which can lead to difficulty in making a differential diagnosis. For 
example, symptoms such as weight change, fatigue and insomnia in congestive heart 
failure can be misdiagnosed as depression (Rustad et al., 2013).   
In summary, the previously mentioned published studies have provided 
evidence showing that depression is linked to poor cardiac outcomes with regards to 
quality of life, medication adherence and rehabilitation. Whilst considerable attention 
has been focused on people with CVD with major depression, there has been a lack of 
studies that have considered minor depression or dysthymia. Nonetheless, whilst it is 
acknowledged that depression or mental health problems are burdensome for all 
affected, people with CVD are faced with considerable struggles due to low self-
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efficacy, poor quality of life, poor illness perception and decreased self-care. 
Consequently, it is important to consider these factors in any interventions for people 
with depression and CVD. The existing treatments for depression in the context of 
CVDs are described below.   
1.4 Existing Treatments for Depression in the Context of CVD 
As mentioned previously, depression is an important risk factor for developing 
and/or progressing a wide range of cardiovascular disorders, having a significant 
impact on all aspects of a person’s life, including increasing healthcare costs. 
Consequently, treating comorbid depression in such populations with these disorders is 
essential for improving CVD outcomes. The National Institute for Health and Care 
Excellence (NICE) has proposed that treating depression in people with chronic 
physical health problems is likely to increase the quality of life and life expectancy 
(NICE, 2009). At present, there are different psychiatric, psychological and behavioural 
treatments that can help people with CVDs (Lichtman et al., 2008). Some of these are 
targeted at decreasing comorbid mental health problems, such as depression and 
anxiety, whilst others are focused on the risk factors relating to CVDs, such as a high 
blood pressure and physical inactivity. 
One of the key treatments for depression in the context of CVD is 
antidepressant medication. Some research was conducted to target the biological 
mechanisms linking depression and CVDs, such as platelet activity and inflammation. 
Regarding which, Serebruany et al. (2003) showed that the selective serotonin reuptake 
inhibitor sertraline (SSRIs) when compared to a placebo led to platelet activation 
reductions. Other research was aimed at investigating the effectiveness of 
antidepressants on cardiovascular mortality and morbidity. For example, Kimmel et al. 
(2011) found that prolonged use of selective serotonin reuptake-inhibiting 
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antidepressants (SSRIs) led to a reduction in the risk of myocardial infarction (MI) 
(odds ratio = 0.77, 95 %, CI: 0.57, 1.03) in a group of people with depression compared 
to those without. Also, there is evidence that using antidepressant medications 
decreases comorbid mental health problems, including MDD, anxiety and stress in 
people with CVDs (Lichtman et al., 2008; Thombs et al., 2008).  
However, antidepressants have been found to be related to an increase in stroke 
risk and myocardial infarction (Smoller et al., 2009; Undela, Parthasarathi, & John, 
2015) as well as adverse cardiac events (Ramamurthy, Trejo, & Faraone, 2013). 
Approximately 90 % of 943 people treated with citalopram reported at least one 
residual symptom, with sleep disturbance being the most common persistent symptom 
(Nierenberg et al., 2016). It has also been found that physical burden can affect the 
response to antidepressants (Habra et al., 2010). In addition, people’s choice is 
important for consideration, as some are averse to taking medication.  
Consequently, recent treatment guidance for depression in people with long 
term conditions has recommended using conventional psychological treatments 
alongside antidepressants, including cognitive behavioural therapy (CBT) and 
interpersonal therapy (NICE, 2009). In a big randomised controlled trial (Berkman et 
al., 2003), people with post myocardial infarction (n = 2481) and major depressive 
disorder or minor depression were randomised to CBT or TAU plus education. The 
findings showed that the CBT group showed better improvements in depression 
compared to the TAU group at 6 months follow up, however, the latter showed 
improvements as well. Another randomised controlled trial, targeting  people who had 
major or minor depression after coronary artery bypass surgery using CBT, found that 
CBT showed large effect sizes compared to supportive stress management and usual 
care (Freedland et al., 2009). 
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According to Dickens et al., 2004, recurring physical symptoms, greater anxiety 
regarding wellbeing and persistent social problems may decrease the response to these 
psychological treatments. Furthermore, conventional psychological treatments can put 
substantial demands on people in relation to remembering past difficult experiences, 
challenging maladaptive thoughts and changing their behaviour. For people suffering 
from cardiovascular disorders, especially those who have suffered a recent serious 
threat to their life following a stroke or heart attack, this may be burdensome. Hence, 
researchers should consider when a psychological treatment is offered. For instance, it 
may not be appropriate to offer therapy immediately post a cardiac event. Additionally, 
treatment must be cost-effective and as a result, group treatment may be preferable to 
individual therapy.  
Consequently, there is a need for a psychological intervention that leads to 
behaviour change (Casey, Hughes, Waechter, Josephson & Rosneck, 2008) and helps 
people to make a full recovery from depression by targeting residual depressive 
symptoms (Boulenger, 2004; Vos et al., 2004). In addition, there needs to be a focus on 
staying well over the long-term, given the chronic relapsing nature of depression. 
Relapse prevention has arguably not received sufficient attention in the CVD literature 
and mindfulness interventions have the potential for reducing depressive relapse rates 
as well as dealing with depressive residual symptoms.  
1.5 Mindfulness-Based Interventions  
Mindfulness is defined as “paying attention in a particular way: on purpose, in 
the present moment, and nonjudgmentally” (Kabat-Zinn, 1994. p. 4). Initially, 
mindfulness-based interventions (MBIs) were developed as a type of treatment for 
pain, low mood and health-related anxiety. These interventions teach people different 
ways to regulate their feelings, thoughts and body sensations by paying attention to the 
45 
 
present experience with an attitude of allowing curiosity, kindness and patience. 
Mindfulness-Based Stress Reduction (MBSR) (Kabat-Zinn, 1990, 2013) is one popular 
mindfulness programme, during which people are exposed to core mental exercises that 
focus on breathing and body scanning along with physical exercises that concentrate on 
bodily sensations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
1.5.1 Mindfulness-Based Cognitive Therapy (MBCT). 
Mindfulness-Based Cognitive Therapy (MBCT) was developed by Segal, 
Teasdale and Williams (2002, 2013) to prevent depressive relapse in people with a 
history of recurrent major depression disorder (MDD). This course is an 8-week group-
based programme, based on MBSR, which cultivates the capacity to ‘attend to’ 
whatever is happening in ways that are purposeful and well-balanced. MBCT releases 
the mind from habitual patterns that undermine coping and lead to anxiety and 
depression (Kuyken et al., 2010), thus facilitating more resilient responses to 
challenges. It enables perseverative cognitions, such as worry and rumination, to be 
recognised and responded to in a “decentered “way. MBCT is an integrative therapy 
that combines meditation exercises and certain cognitive therapy techniques. Such 
integrative therapies seem to have the potential to fit with different people, problems 
and contexts as well as to be more flexible in relation to people’s needs (Norcross & 
Wampold, 2011).   
1.5.1.1 MBCT with depression. A substantial body of research has focused on 
the efficacy7 or effectiveness8 of MBCT in preventing people with a history of 
recurrent MDD from relapsing. In early research, Ma & Teasdale (2004) revealed that 
individuals with more than three episodes showed less depression relapse following 
                                                 
7Studies that are conducted to test the effects of an intervention in a research setting. 
8 Studies that are conducted to test the effects of an intervention in the real world.  
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MBCT compared to a treatment as usual (TAU) group over 12 months. Similarly, 
Godfrin & van Heeringen. (2010) found that people with three and more previous 
episodes in MBCT plus TAU group showed a lower depression relapse rate over 12 
months compared to a TAU alone group.  
Using antidepressant medication as a comparator, Kuyken et al. (2008) found 
that an MBCT group did not differ from a maintenance antidepressant medication (m-
ADM) group in terms of relapse rate and residual depressive symptoms. However, 
Segal, Martin & Joseph (2010) reported that MBCT and maintenance antidepressant 
medication (m-ADM) groups showed a lower relapse rate compared to a placebo group 
for people with unstable remission. Another RCT (Huijbers et al., 2015) found no 
differences between MBCT plus maintenance antidepressant (m-ADM) and m-ADM 
groups in terms of relapse prevention over 15-month follow-up. A recent randomised 
controlled trial (RCT) (Kuyken et al., 2016) with 424 people with recurrent depression, 
randomised to MBCT with medication tapering or to maintenance antidepressants (m-
ADM) over 24 months of follow-up, revealed that both treatments were effective in 
terms of relapse rate and residual depressive symptoms, but that there was no 
difference between them.  
An RCT study (Williams et al., 2014) comparing MBCT to cognitive 
psychological education (CPE) and treatment as usual (TAU) for 274 people with 
history of MDD (at least three episodes) found no significant differences between the 
three groups in terms of relapse prevention over 12 months, with MBCT outperforming 
the other conditions in people with a history of childhood trauma. Piet & Hougaard 
(2011), in their systematic review and meta-analysis, concluded that MBCT was 
effective in terms of relapse prevention, especially for people with at least three or 
more previous MDD episodes. Similarly, another systematic review (Chiesa & Serretti, 
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2011) found that the effects of MBCT were similar to the antidepressant effects on 
relapse rates. 
Considering residual depressive symptoms, Barnhofer and his colleagues (2009) 
conducted a pilot RCT assessing the efficacy of MBCT for people with chronic 
depression. They found that people in the MBCT group showed reductions in residual 
depressive symptoms compared to a TAU group. Geschwind, Peeters, Huibers, Van Os 
& Wichers (2012), in their RCT, compared people with two or three previous episodes 
of depression, finding that MBCT led to decreased residual depressive symptoms 
regardless of the number of previous episodes, compared to treatment as usual (TAU) 
group. A recent RCT (Eisendrath et al., 2016) with people with treatment-resistant 
depression revealed that an MBCT group showed greater reduction in depression 
severity and better responses to the treatment compared to those undertaking a Health 
Enhancement Programme (HEP) (a mixture of aerobic exercise, functional movement, 
music therapy and dietary education). Levels of residual symptoms may moderate the 
efficacy of MBCT at relapse prevention. A recent individual patient data meta-analysis 
found that MBCT is more effective for people with high severity of residual symptoms 
who have had recurrent depression (Kuyken et al., 2016). 
 There have been a few studies examining effects of MBCT on dysthymia and 
minor depression and their results were promising. Kenny & Williams (2007) showed a 
significant improvement in depressive symptoms following MBCT intervention in 
people suffering from dysthymia, bipolar or MDD. Similarly, another study (Mathew, 
Whitford, Kenny, & Denson, 2010) of people with MDD, bipolar or dysthymia showed 
improvements in depressive symptoms post-MBCT treatment. A randomised control 
comparison study completed by Hamidian, Omidi, Mousavinasab, & Naziri (2013), 
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showed that combining MBCT with antidepressant medication led to better outcomes 
for people with dysthymia compared to antidepressant medication alone group.  
Regarding minor depression, Kaviani, Hatami, & Javaheri (2012) in their study, 
which focused on people with minor depression, reported improvements in depression, 
quality of life, anxiety and negative automatic thoughts following the MBCT 
intervention, when compared to a control group. Similar results were reported by Pots, 
Meulenbeek, Veehof, & Klungers (2014) from their randomised control trial that 
compared MBCT intervention with a control group. The participants in MBCT group 
showed improvements in anxiety, mindfulness, depression, emotional and 
psychological well-being as well as experiential avoidance. However, despite the 
positive results that have been reported in these studies with people with dysthymia and 
minor depression, the methodological issues, such as the design used as well as the 
depression types, need to be borne in mind.  
As there is evidence that MBCT is effective in treating residual depression and 
reducing relapse rates, whether it could be useful in the context of physical health 
conditions, including CVDs, is considered next. 
1.5.1.2 MBCT with physical conditions. The literature about the efficacy of 
MBCT with physical conditions is still in its early phase, but there are promising 
results. For example, MBCT has been shown to have more impact on depression, trait 
anxiety and dispositional mindfulness for people with inflammatory bowel disease 
(IBD), when compared to a control group (Schoultz, Atherton & Watson, 2015). A 
study in individuals with multiple chemical sensitivities (MCS) found that an MBCT 
group showed better coping strategies and sleep quality compared to a control group, 
while there were no differences in psychological distress or illness perceptions 
(Skovbjerg, Hauge, Rasmussen, Winkel & Elberling, 2012). For people with type 1 and 
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2 diabetes, MBCT has been found to be effective in terms of perceived stress, anxiety 
and depressive symptoms compared to a TAU group. However, the findings also 
indicated that there was no difference between the two groups regarding diabetes 
distress and HbA1c (the amount of glycated hemoglobin in blood) (van Son et al., 
2014). Moreover, MBCT has also been used with those with serious physical 
conditions, such as cancer and has delivered promising findings in relation to chronic 
cancer fatigue, when compared to a waiting list control group, but exhibited no 
differences in terms of functional impairment (Van Der Lee & Garssen, 2012). 
However, whilst MBCT has been designed as prevention programme, it is noted that 
most of studies targeting physical conditions have not examined its effects on relapse 
rate or the treatment of residual depressive symptoms.  
1.5.1.3 MBCT with CVDs. Conceptually, there are reasons to believe that 
MBCT may act on key trans-diagnostic mechanisms known to maintain depression and 
this may also be important in CVDs, especially in relation to rumination and worry. For 
example, rumination and worry have been found to be associated with developing or 
progressing depression (McLaughlin & Nolen-Hoeksema, 2011; Watkins, 2008; 
Watkins & Teasdale, 2004) and has also emerged that subsequent depression episodes 
can be triggered by ruminative thinking (Nolen-Hoeksema, 1991, 2000). Moreover, 
rumination would appear to predict relapse in people with MDD (Michalak, Holz, & 
Teismann, 2011). With regards to CVD populations, rumination and worry have been 
found to be associated with coronary heart disease and hypertension (Gerin et al., 2012; 
Kubzansky et al., 1997; Radstaak et al., 2011). Practically, MBCT has been shown to 
reduce levels of rumination and worry significantly in people suffering from major 
depression  (Kingston, Dooley, Bates, Lawlor & Malone, 2007; Michalak et al., 2011; 
van Aalderen et al., 2012).  
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To this researcher’s knowledge, only one study (O’Doherty et al., 2015) has 
been conducted to assess the efficacy of MBCT for people specifically with coronary 
heart disease (CHD), who suffer from current major depressive disorder (MDD). This 
study used a controlled design to compare standard-MBCT (n = 60) and a waitlist 
group (n = 57) on current depression, quality of life and adjustment to illness. The 
recruitment process was carried out over approximately three years, with cardiology 
wards being the main resource for recruitment. The findings indicated that people in the 
MBCT group showed improvements on current depression, quality of life and 
adjustment to illness with medium to large effect sizes. Whilst this study was one of the 
first that used MBCT with heart conditions and current depression, the non-randomised 
design used was a shortcoming in terms of assessing the efficacy of the treatment and 
thus, further research is needed. Also, the standard MBCT programme was used rather 
than making a bespoke adaptation to meet the needs of people with comorbid CVD. 
Consequently, further research needs to be conducted utilising an improved study 
design. One such method is a randomised control trial design testing a bespoke 
adaptation of MBCT to a control condition in terms of its impact on preventing relapse 
and treating residual symptoms in the context of CVDs. 
1.5.2 Methodological issues around mindfulness research.   
A notable point, is that mindfulness interventions studies either targeting 
psychological or physical conditions seem to have experienced limitations in terms of 
their ability to link research and practice. Dimidjian & Segal (2015), in their review of 
the mindfulness field, noted a gap between mindfulness interventions research and 
practice. In response, they proposed a “mapping approach” based on the National 
Institutes of Health (NIH) stage model (Onken, Carroll, Shoham, Cuthbert, & Riddle, 
2014) to assist with the development and improvement of mindfulness interventions. 
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They also put forward recommendations that might fill the existing gaps between 
research and practice. Also, Davidson & Kaszniak (2015) reviewed the conceptual and 
methodological issues surrounding mindfulness research and highlighted a number of 
improvements that could improve practice. As an example, they emphasised the 
importance of describing the delivery of the intervention. In addition, they discussed 
the difficulties associated with assessing mindfulness interventions using randomised 
controlled trials and suggested the use of an active comparator in dual blind study 
designs as well as a multi-measure, which would help in the capture of the mindfulness 
construct. 
To summarise, MBCT, as a mind-body intervention, has shown postive effects 
on depression outcomes in RCTs targeting recurrent depression. Also, it has shown 
promising outcomes in relation to a wide range of psychological symptoms across 
diverse phyiscal condtions, but this evidence is still in its early phase. However, 
mindfulness intervention studies suffer from limitations in relation to linking research 
with practice. 
1.6 Mechanisms of Action  
One way to maximise the efficacy of MBCT in a given condition further is to 
determine its key mechanisms of action (e.g., mediators or moderators) in that sample, 
and then to refine it so as to focus more on these key mechanisms.  
1.6.1 Mechanisms of action in psychotherapy. 
For several decades, studying the effectiveness or efficacy of psychotherapies 
has been one of the main interest of psychological researchers, which has led to a good 
body evidence on the efficacy of some psychological interventions. However, there has 
been a lack of explanation as to why or how these interventions produce their effects. 
Recently, interest in seeing behind the interventions’ efficacy through studying the 
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mechanisms of change has increased. This is because considering these mechanisms 
might lead to a focus on the salient components of any intervention as well as the 
identification non-important components that can be removed  (Kazdin & Nock, 2003). 
This should lead to more efficient and streamlined treatments. 
Kazdin stated that “beyond knowing that A may cause B, the mechanism 
elaborates precisely what happens (psychologically, biologically) that explains how B 
results” (2003, p. 117). Mediators and moderators are two paths for examining 
mechanisms of change in psychotherapy. Mediators are variables that tell how and why 
change happens (Johansson & Høglend, 2007), which should correlate significantly 
with the interventions, come after the intervention and can explain its effects on the 
outcomes (Murphy, Cooper, Hollon & Fairburn, 2009). Moderators come prior to the 
intervention, need to be correlated with the intervention and can explain the 
relationship between the intervention and outcomes as well as help with knowing who 
would benefit more from the intervention (Johansson & Høglend, 2007; Murphy et al., 
2009). 
Recently, efforts have been made to establish good practice when studying 
mechanisms conceptually, such as in the conceptual work of Kazdin (2007, 2009) and 
the statistical work of Kraemer, Wilson, Fairburn & Agras ( 2002). Kazdin (2007, 
2009) put forward some requirements that need to be considered in order to understand 
how an intervention leads to a change, including strong association, specificity, 
consistency, experimental manipulation, timeline and gradient. For example, a timeline 
criterion refers to the study needing to be able to determine the precedence of the 
relationship between the mediator and the outcome using multiple assessment time 
points that can capture the changes over time for both aspects. The Kazdin criteria are 
explained further in Chapter 2.0. Kraemer and colleagues (2002) have produced a 
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method by which mechanisms of change (mediators) can be measured statistically in 
RCTs. In brief, the treatment should affect the outcomes; the mediators should be 
correlated with the treatment; and the interaction between treatment and mediators 
should be significant.  
1.6.2 Mechanisms of action in mindfulness interventions.    
1.6.2.1 Mechanisms of action in MBCT for depression. Recently, there have 
been some attempts to understand how MBCT works. For example, it has been 
suggested that changes in mindfulness mediate the efficacy of MBCT on residual 
depressive symptoms and recurrent depression (Shahar, Britton, Sbarra, Figueredo & 
Bootzin, 2010; van Aalderen et al., 2012). In addition, rumination, worry and emotional 
reactivity have been found to have a mediating role on MBCT effects in a recurrent 
depression population (Batink et al., 2013; Britton, Shahar, Szepsenwol & Jacobs, 
2012; van Aalderen et al., 2012). However, in other research rumination seemed not to 
show up as a mediator for MBCT effects on depression (Bieling et al., 2012; Kearns et 
al., 2015). According to two recent reviews (Gu, Strauss, Bond & Cavanagh, 2015; van 
der Velden et al., 2015), the effects of MBCT and MBSR on depression and anxiety are 
mediated by a range of variables, including mindfulness, rumination, self-compassion 
and positive affect. However, these two reviews agreed that the extant literature suffers 
from several shortcomings. 
1.6.2.2 Mechanisms of action in MBCT for CVD. As far as this researcher is 
aware, there has been only one study (O’Doherty et al., 2015) that assessed the 
mediating role of mindfulness skills in the relationship between MBCT and current 
depression in people with coronary heart disease (CHD). The findings showed that 
there are significant associations between increased mindfulness skills and 
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improvements in outcomes. However, the correlation analysis that was used in this 
study was not able to test the full mediation of effects of MBCT on depression.  
 Moreover, the question of how mindfulness interventions might potentially 
target mechanisms across both physical and psychological health remains largely 
unanswered. Carlson (2012), in a review, suggested that mindful attention, acceptance 
and exposure could be common mechanisms across a wide range of physical 
conditions, including those relating to heart diseases, but these ideas remain largely 
untested. A recent review by Loucks et al. (2015) identified three mechanisms that may 
explain the way in which mindfulness interventions can influence the outcomes of 
CVDs, these being: attention control, emotion regulation and self-awareness. Attention 
control refers to an individual’s ability to keep his/her attention on CVD risk factors, 
including diet, smoking, physical activity and adherence to medication. Emotion 
regulation pertains to the way in which the individuals can develop skills to manage 
cravings for cigarettes, their sedentary lifestyle and poor diet as well as improving their 
self-efficacy and stress response. Finally, the self-awareness component concerns the 
physical sensations associated with CVD risk factors and self-referential processing, 
which is defined as “the cognitive process of relating information, often from the 
external world, to the self” (Nejad, Fossati, & Lemogne, 2013, p. 7). 
1.7 Adapting MBCT for People with CVDs 
 In addition to the MBCT providing promising results in terms of treating both 
acute and residual symptoms as well as preventing relapse, there is increased 
preliminary evidence that it can help to decrease psychological symptoms associated 
with a number of physical conditions. Also, it has also been shown to be effective in 
changing other factors, including rumination and worry (Kingston et al., 2007; 
Michalak et al., 2011; van Aalderen et al., 2012) that have also been linked with CVDs 
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(Gerin et al., 2012; Kubzansky et al., 1997; Radstaak et al., 2011). Moreover, its group 
format makes it more likely to be cost-effective than individual interventions.  
As standard MBCT is designed solely with a focus on depression and may 
neglect important parts of the CVD picture, it was surmised by the HeLM team that 
bespoke adaptations may be required so that it focuses on themes common to both 
depression and CVDs as well as targeting common underlying mechanisms. In 
particular, standard MBCT focuses mainly on depression specific mechanisms, for 
example, rumination about causes, meanings and the consequences of low mood. 
However, people with cardiovascular disorders worry about the cardiovascular event 
returning or the causes, meanings and consequences of a cardiac condition (Larsen & 
Christenfeld, 2009; Rozanski, Blumenthal, & Kaplan, 1999). Moreover, given the 
nature of cardiovascular disorders, the body cannot be assumed to provide a safe, 
neutral anchor for mindfulness practice and a different focus may be required; attending 
to bodily sensations may increase anxiety by activating worries of a further cardiac 
event, which can increase the pulse and/or heart rate. Furthermore, a number of studies 
have indicated that people with CVDs have low confidence regarding their ability to 
take care of their condition, also known as self-efficacy, and the associated impacts on 
their self-care, which can lead to worse medical outcomes (Greco et al., 2014; Riegel et 
al., 2011, 2007; Tovar et al., 2015; Volz et al., 2016). Hence, care is needed to consider 
how best to enhance self-efficacy. This focus would help to maximise the efficacy and 
acceptability of MBCT for this population.  
1.8 Summary of the Literature Gaps and Contributions of the PhD 
Cardiovascular disorders are considered to be the main causes of mortality and 
morbidity in the UK. It is evident that depression is a common and chronic comorbid 
condition in this population and causes worse medical outcomes and poor adherence to 
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treatment. MBCT has shown promising effects in terms of decreasing relapse and 
depressive symptoms in people with recurrent depression. However, in the field of 
cardiovascular disorders, MBCT has yet to receive sufficient attention in terms of 
assessing its efficacy. Also, factors such as self-efficacy, self-care, and disorder-
specific worries have all been associated with the development and/or persistence 
of depression and anxiety in those with cardiovascular disorders. Consequently, 
developing a bespoke MBCT that integrates techniques targeting some of the issues 
that matter to people with CVDs might improve its efficacy and produce better 
outcomes. With regards to the mechanisms of action, it remains largely unknown how 
mindfulness interventions work on physical conditions and hence, future MBCT 
intervention research needs to involve more systematic evaluation of the mechanisms 
of action. With awareness of these gaps in the literature pertaining to depression and 
CVDs, the Heart and Living Mindfully (HeLM) project was conducted to develop and 
evaluate an MBCT intervention manual specifically for people with cardiovascular 
disorders and mood problems.  
1.9 Heart and Living Mindfully (HeLM) phases 
The Heart and Living Mindfully (HeLM) project is aimed at adapting standard 
MBCT, so as to meet some of the needs of people with depression and cardiovascular 
disorders better. This project has been following the Medical Research Council (MRC) 
framework (Craig et al., 2008) and the NIH stage model (Onken et al.,  2014) regarding 
complex intervention development and evaluation.  
The MRC framework identifies four key elements for improving and evaluating 
complex interventions. The first, is the development phase that includes identifying the 
existing evidence base and recognising or developing appropriate theory. The second 
key element pertains to assessing the feasibility and piloting methods through 
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qualitative or quantitative studies or a mixture of both. The third and fourth key 
elements involve evaluating the intervention (e.g., assessing the effectiveness and 
understanding process) and implementation. The NIH stage model proposes six stages. 
Stage 0 refers to conducting basic research aimed at providing a base for developing a 
new intervention or refining an existing one. Studies considering how and for whom 
the intervention works are considered as basic research in this model. Stage 1 includes 
two phases: a) activities aimed at improving or refining the intervention (e.g., 
identifying promising clinical or basic results); and b) piloting the intervention. The 
other four stages are stage II (testing the intervention in research settings), stage III 
(testing the intervention in community clinics), stage IV (testing the effectiveness of the 
intervention in community settings) and stage V (implementation and dissemination).  
Consequently, in line with the MRC guidelines and NIH stage model, the 
project was planned with three phases (see Figure 1.1). The first phase was aimed at 
establishing the evidence base (basic research stage) by carrying out three pieces of 
work (for previous phases please see Appendix A). A systematic review of the 
mechanisms of action in MBCT and MBSR for people with physical and/or 
psychological conditions was carried out. Given the awareness obtained from the first 
systematic review (Abbott et al., 2014) conducted in the early phase of this project that 
there have been very few studies that have examined MBCT/MBSR with 
cardiovascular disorders, the intention was to include physical conditions and not just 
CVDs. This systematic review was conducted to gain understanding as to how MBCT 
and MBSR interventions work in terms of physical/psychological conditions, so as to 
be able to maximise their effects for people with those conditions. More details about 
this review are presented in Chapter 2.0. 
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Second, a secondary analysis of a big randomised controlled trial looking at the 
impact of MBCT on medical symptoms was conducted. The aim of this study was to 
see whether standard MBCT could help people with physical symptoms and whether 
these symptoms would moderate effects of standard MBCT compared to other 
treatments. The findings of this study are presented in Chapter 3.0.  
With regards to refining the intervention (MRC development phase and NIH 
model stage 1, phase A), the original MBCT manual was adapted for people with 
cardiovascular disorders and depression by a panel comprising experts on MBCT and 
physical conditions as well as people from the Public and Patient Involvement group 
(PPI group). Additionally, two manual development pilot groups were conducted. The 
second manual development pilot group comprised the first experimental study of this 
PhD. A detailed description of the manual development stages and the second pilot 
group is presented in Chapter 4.0. 
In terms of addressing the second key element of the MRC framework 
regarding piloting and feasibility (stage1, phase B in the NIH model), a randomised 
controlled trial on the feasibility and acceptability of mindfulness-based cognitive 
therapy for people with depression and cardiovascular disorders was conducted. The 
aim of this study was to see whether it was feasible to conduct a definitive RCT of 
adapted-MBCT and whether the new course was acceptable to this population. This 
feasibility randomised controlled trial and the acceptability interviews are presented in 
Chapter 5.0.   
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Figure 1.1 Flowchart for the PhD (HeLM Project) Phases 
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2.1 Abstract 
Background: Recently, there has been an increased interest in studying the 
effects of mindfulness-based interventions for people with psychological and physical 
problems. However, the mechanisms of action in these interventions that lead to 
beneficial physical and psychological outcomes have yet to be clearly identified. 
Purpose: The aim of this paper is to review, systematically, the evidence to date on the 
mechanisms of action in mindfulness interventions in populations with physical and/or 
psychological conditions. Method: Searches of seven databases (PsycINFO, Medline 
(Ovid), Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, AMED, 
clinicaltrials.gov) were undertaken in June 2014 and July 2015. We evaluated to what 
extent the studies we identified met the criteria suggested by Kazdin for establishing 
mechanisms of action within a psychological treatment (2007, 2009). Results: We 
identified four trials examining mechanisms of mindfulness interventions in those with 
comorbid psychological and physical health problems and 14 in those with psychological 
conditions. These studies examined a diverse range of potential mindfulness 
mechanisms, including mindfulness and rumination. Of these candidate mechanisms, the 
most consistent finding was that greater self-reported change in mindfulness mediated 
superior clinical outcomes. However, very few studies fully met the Kazdin criteria for 
examining treatment mechanisms. Conclusion: There was evidence that global changes 
in mindfulness are linked to better outcomes. This evidence pertained more to 
interventions targeting psychological rather than physical health problems. While there is 
promising evidence that MBCT/MBSR intervention effects are mediated by 
hypothesised mechanisms, there is a lack of methodological rigour in the field of testing 
mechanisms of action for both MBCT and MBSR, which precludes definitive 
conclusions.   
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2.2 Background  
Long-term physical and mental health problems affect a significant proportion of 
the population, place an enormous burden on health care systems, are a very significant 
cost to society and cause immeasurable suffering. It is estimated that 46 % of people in 
the UK with mental health problems also suffer from long-term physical conditions, such 
as heart conditions, stroke, diabetes and cancer (Naylor et al., 2012). This comorbidity is 
responsible for poor medical outcomes (Katon, 2011; Kisely, Smith, Lawrence, & 
Maaten, 2005; Wright et al., 2008), significant decrements in quality of life (Fortin et al., 
2006; Moussavi et al., 2007; Sareen. et al., 2006) and increased costs of health care 
(Naylor et al., 2012). Therefore, there is a need to develop integrated treatments that can 
effectively treat people with comorbid mental and physical health presentations. It is 
increasingly argued that there could be some overlap in the biological, behavioural and 
psychosocial mechanisms linked to these physical and psychological conditions 
(Carlson, 2012; DE Hert et al., 2011; Dickens, 2015; Miller, Chen, & Cole, 2009). 
Consequently, researchers are increasingly trying to develop integrated mind-body 
theoretical models that can potentially capture the shared mechanisms and support the 
development of effective treatments for physical conditions that have mental health co-
morbidity.  
Mindfulness-based interventions were developed for people with chronic 
physical problems, who were managing pain, low mood and health-related anxiety. 
Mindfulness is most typically defined as “paying attention in a particular way: on 
purpose, in the present moment, and non-judgementally” (Kabat-Zinn, 1994, p. 4). An 
operational definition of mindfulness would include at least three components: 
attentional control, the intention of attentional control (e.g., to decenter from negative 
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thinking) and attitudes that are being trained (e.g., approach orientation and non-
judgment).  
Mindfulness-Based Stress Reduction (MBSR) has been used since 1979 as a 
training vehicle for the relief of pain and distress in people with chronic health problems 
(Kabat-Zinn, 1990, 2013). Mindfulness-Based Cognitive Therapy (MBCT) (Segal, 
Williams, & Teasdale, 2013; 2002) integrates MBSR with cognitive science and 
Cognitive Behavioural Therapy. It was initially developed as a relapse prevention 
treatment in those with a high risk of depression recurring, but has since been adapted to 
a range of different populations and contexts. Both MBSR and MBCT incorporate a 
range of formal mindfulness practices as a key method for training attentional control as 
well as the non-judgemental attitudinal dimensions of mindfulness (Crane et al., 2017). 
MBSR has been found to have positive effects on pain, anxiety and stress in 
people with chronic disorders, such as fibromyalgia, coronary artery disease, back pain 
and arthritis (Grossman, Niemann, Schmidt, & Walach, 2004; Rosenzweig et al., 2010). 
Preliminary evidence suggests that MBCT can decrease depression, anxiety and fatigue 
in some physical conditions, such as coronary heart disease (O’Doherty et al., 2015), 
diabetes (van Son et al., 2014; Van Son, Nyklíček, Pop, & Pouwer, 2011) and cancer 
(Van Der Lee & Garssen, 2012). Moreover, recent systematic reviews have indicated 
that MBSR and MBCT have small to medium effect sizes on psychological and physical 
symptoms across a range of chronic somatic conditions including cancer, cardiovascular 
disorders and arthritis (Abbott et al., 2014; Bohlmeijer, Prenger, Taal, & Cuijpers, 2010; 
Hofmann, Sawyer, Witt, & Oh, 2010).  
In addition to research evaluating clinical efficacy, there is also a need to 
understand the mechanisms of action of these mindfulness interventions (Craig et al., 
2008; Moore, Audrey, Barker, & Bond, 2014). A greater understanding of the 
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mechanisms through which interventions bring about change will enable these 
interventions to be refined, which will potentially increase their potency and provide 
“larger effect sizes at lower cost or risk” (Kraemer, Wilson, Fairburn, & Agras, 2002, p. 
878). Moreover, it will shed light on the theories that explain how these conditions arise. 
A mechanism is defined as “the process that is responsible for change”, while a 
mediator is “an intervening variable that may account statistically for the relationship 
between independent variable and dependent variable” (Kazdin, 2007, p. 3). Kazdin 
(2007, 2009) proposes essential criteria for identifying mechanisms or mediators of 
action in psychotherapy. To begin with, there needs to be a clear association between 
change in the proposed mechanism/mediator and the proposed outcome (strong 
correlation criterion). In addition, the outcomes and mediating variables need to be 
measured at multiple time points, thus making it possible to establish that change in the 
mediator precedes change in the outcome (temporal precedence criterion). Manipulation 
designs (where a specific mechanism is increased or decreased), active and/or 
dismantling designs (where intervention elements targeting a specific mechanism are left 
out) need to be utilised to determine the specificity of effects (specificity criterion). 
Further, a dose-response relationship needs to be observed, such that the more a 
mechanism is targeted, the greater the degree of change in the outcome observed 
(gradient criterion). The findings should be replicable; ideally by an independent 
research group (consistency criterion). Kraemer and colleagues suggest that randomised 
controlled trials (RCTs) are needed to test the mechanisms or mediators routinely and 
that experimental studies need to take into account the RCTs results in their designs 
(Kraemer et al., 2002).  
There is as yet no consensually agreed unifying theoretical framework of how 
MBCT/MBSR effect change, but rather a breadth of theoretical models. A recent 
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editorial suggested that there is some consensus that MBCT/MBSR helps people ‘learn 
that habitual reactive patterns stem from unhelpful habits of the mind; that fear, denial 
and discrepancy-based thinking create and exacerbate distress; and that skilful ways of 
relating to experience can be developed through awareness, wise discernment and 
practice which offer the potential for (moments of) freedom from reactivity’ (Crane et 
al., 2017).  
Several early studies have started to explore the mechanisms in MBCT/MBSR 
(Batink, Peeters, Geschwind, van Os, & Wichers, 2013; Geschwind, Peeters, Drukker, 
van Os, & Wichers, 2011; Nyklícek & Kuijpers, 2008;Vøllestad et al., 2011). To date 
most mechanisms studies have either not explicitly drawn on a particular theoretical 
model or have drawn on different models and selected out particular mechanisms and 
defined these with varying degrees of precision. Moreover, they have failed to employ 
robust designs to assess the proposed mechanisms (Gu et al., 2015; van der Velden et al., 
2015).  
It is as yet unclear whether mechanisms of action in MBCT/MBSR are shared 
across physical and psychological health conditions or are specific to particular physical 
or psychological health conditions. Some researchers think that there are potential 
common or universal mechanisms of action in MBCT/MBSR regardless of whether the 
specific disorder is physical (Carlson, 2012) or  psychological (Teasdale, Segal, & 
Williams, 2003). A narrative review (Carlson, 2012) of mindfulness interventions in 
physical conditions has indicated that mechanisms such as mindful attention, acceptance 
and exposure are important in understanding how MBCT/MBSR are effective for 
different physical conditions. Other researchers suggest that some mechanisms of action 
are disorder-specific. For example, Loucks and his colleagues in their recent review 
(Loucks et al., 2015) put forward some mechanisms that might explain how mindfulness 
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works with cardiovascular disorders (CVD), including attentional control of some of the 
risk factors of CVD and self-awareness of cardiac experiences that are potentially 
modifiable.  
The delineation of universal and specific vulnerabilities that may also be 
mechanisms of change leads to the generation of key hypotheses that can inform both 
primary research and interpretation of secondary research (Teasdale et al., 2003). In 
terms of vulnerability, unhelpful repetitive thinking hijacking attention could be 
universal (Watkins, 2008), while in people with a history of depression cognitive 
reactivity, characterised by negative self-referential thoughts, might be a specific 
vulnerability (Segal et al., 2013). In terms of the hypothesised mechanisms, learning to 
stabilise attention (a universal mechanism), which refers to our capacity to cultivate and 
stabilise or focus attention in the body (Williams & Kabat-Zinn, 2013), could be a pre-
requisite to first recognising cognitive reactivity (a specific mechanism in this 
population) and then decentering from negative thinking (an emotion regulation 
strategy). Cognitive reactivity is defined as ‘the degree to which a mild dysphoric state 
reactivates negative thinking patterns” (Raes, Dewulf, Van Heeringen, & Williams, 
2009, p. 623)  
Recently, Van der Velden et al. (2015) conducted a systematic review of the 
mechanisms of MBCT in RCTs looking at how MBCT produced its effects on both 
relapse prevention and acute depression in people with major depressive disorders 
(MDD). The results showed good evidence supporting the mediating role for 
mindfulness, rumination, worry, compassion, meta-awareness with preliminary evidence 
for attention, memory specificity, self-discrepancy, emotional reactivity as well as 
positive and negative affect. This review only considered MDD not physical conditions 
and primarily focused on depression outcomes. Although, the review mentioned some of 
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the Kazdin criteria, it did not systematically evaluate each study against these. Another 
recent systematic review and meta-analysis, conducted by Gu et al. (2015), tested the 
mechanisms of both MBSR/MBCT on mental health and wellbeing outcomes, including 
for those with primary physical health problems (e.g., cancer). In this review, RCTs or 
quasi-experimental design studies were included, and they found strong evidence for 
cognitive and emotional reactivity, moderate evidence for mindfulness, rumination, and 
worry as potential mechanisms of change, and preliminary but insufficient evidence for 
self-compassion and psychological flexibility. This review involved using a well-
established method of mediation analysis and had a quantitative assessment of change in 
the outcome and mediators. However, the review had some limitations, such as not 
considering the methodological quality, not commenting on the Kazdin’s criteria in 
detail and considering only mechanisms with a strong theoretical rationale, thus 
excluding some potential more exploratory variables. In addition, even though the review 
targeted a broad range of populations, including people with cancer, it did not focus on 
whether the same mechanisms play a role in depression versus depression in the context 
of long term conditions.   
There is therefore a need for a further systematic review of mechanisms of action 
in mindfulness interventions that deals with these shortcomings. In this review, we 
further explored the evidence, to date, on mechanisms of action in MBCT/MBSR 
interventions for populations with physical and/or psychological conditions. We included 
studies that focused on populations with physical and/or psychological conditions to 
assess whether the evidence for mechanisms accounting for psychological symptom 
improvement has been found both in those with psychological and physical health 
presentations. We looked at whether the same mechanisms have been identified across 
different populations (primarily depression or primarily physical health), which would 
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suggest they may be universal. Also, we aimed to assess methodological adequacy of 
these studies according to the Kazdin criteria for examining mechanisms of change in 
treatments. We approached the mechanisms of action in an exploratory (rather than 
theory driven) way, that is, simply identifying and reporting the mechanisms/mediators 
that were reported in the identified studies. Moreover, we considered the 
recommendations mentioned in Gu and her colleagues (2015) review in terms of 
publication bias and variation in the nature of the outcome variable (acute versus relapse 
prevention; physical or psychological). The aim of this work is to usefully frame future 
primary research.  
 2.3 Method 
2.3.1 Inclusion and Exclusion Criteria  
The systematic review was conducted following the general principles published 
by the NHS Centre for Reviews and Dissemination (CRD, 2009) and reported according 
to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009). It included published 
randomised controlled trials (RCTs), and controlled trials (CTs) that aimed to examine 
potential mechanisms or mediators of change in MBCT/MBSR in adults diagnosed with 
physical and/or psychological conditions. Studies using shortened forms of either MBCT 
or MBSR were excluded. No language or date restrictions were applied for this review. 
Details of the inclusion and exclusion criteria are presented in Table 2.1 
2.3.2 Identification of Studies  
2.3.2.1 Search strategy.  
The first electronic search of seven databases (PsycINFO, Medline (Ovid), 
Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, AMED, 
clinicaltrials.gov) was undertaken in June 2014 and we conducted an update search in 
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July 2015. The search strategy varied across the databases, but the same keywords 
applied throughout. An example of the search strategy is presented in Appendix B. 
2.3.2.2 Study selection. 
After removing duplicates, the titles and abstracts were screened independently 
by MA and TK, with the aim of identifying potentially relevant studies. During this 
phase, inclusion and exclusion criteria were applied and disagreement was resolved 
through discussion with a third reviewer, RA. Subsequently, full texts of the promising 
studies were obtained, and their reference lists were examined by MA. In the second 
phase of screening, the full texts were assessed further for eligibility by MA and checked 
by RA.  
2.3.2.3 Data extraction. 
We collected the characteristics of studies using the PICOS (Population, 
Intervention, Comparator, Outcomes and Study design) framework. The population 
features included age, gender, sample size and whether it was a psychological or physical 
condition. Intervention covered whether the intervention used was MBCT or MBSR and 
if had been administered as its developers had intended or had been adapted. Comparator 
features consisted of the number of study arms and type of control group (waitlist, other 
active intervention or treatment as usual). The outcomes pertained to the main findings in 
terms of physical and/or psychological aspects, whilst the study design included whether 
it was a randomised controlled trial (RCT) or a controlled trial (CT). We additionally 
extracted all information that would enable us to evaluate how well the Kazdin criteria 
(2007, 2009) were met. Data extraction was conducted by MA and checked by RA. 
2.3.2.4 Data synthesis.  
The aims of this review were not to examine the effectiveness or efficacy of 
interventions, but rather, to describe and evaluate potential mechanisms or mediators. 
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We anticipated identifying studies that used a range of different interventions, with 
possible different mechanisms or mediators of action in different populations. We 
anticipated that pooling the data would distract from the main aims of the review, would 
be difficult to interpret, and would not add value. Therefore, where sufficient data was 
available we decided to classify data by population type and then evaluate the status of 
the evidence for each hypothesized mechanism/mediator within each population type.   
2.3.3 Risk of Bias in RCTs   
The methodological quality of each included study was assessed using the 
Cochrane ‘risk of bias’ tool (Higgins et al., 2011). Each study was evaluated based on 
certain parameters, such as random sequence generation, allocation concealment, 
blinding and selective reports. The risk of bias in the RCTs’ evaluation was conducted by 
MA and checked by RA.  
2.3.4 Conceptual Framework for Abstracting and Interpreting Studies 
We developed a framework derived from the recommendations put forward by 
Kazdin (2007, 2009), which both informed the data extraction and the interpretation of 
the findings. This framework included the following questions:  
1. Did the study use a theory or treatment rationale to articulate the mechanism 
through which the intervention is hypothesised to work? This includes: 
- Were hypotheses about the mechanism of change articulated?  
- Were the hypothesised processes of change articulated, defined and 
operationalised?   
2. Did the study use process measures that assess the constructs, if necessary, from a 
variety of perspectives? A variety of perspectives means here the study’s use of a 
variety of assessment methods in addition to self-report measures, which could 
include experimental or neuroscience measures”. 
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3. Did the study design ensure the hypotheses could be addressed? This includes:   
- Making explicit that changes in processes are specifically targeted by the 
treatment;   
- That changes occur during treatment;  
- That these changes precede change in the outcome; 
- Using different time-points assessments. 
4. Did the study use appropriate statistical analysis? 
2.4 Results 
2.4.1 Studies Flow  
The electronic searches of seven databases retrieved 3,290 titles and abstracts. 
After adjusting for duplicates and reviewing the titles and abstracts, 3,234 studies were 
removed. In the first phase of the screening for eligibility, 56 abstracts and titles were 
screened against the inclusion and exclusion criteria, resulting in 15 studies being 
excluded for the following reasons: five were not MBCT or MBSR, two focused on 
healthy populations, two were short MBSR (six weeks), four did not examine 
mechanisms or mediators and two were not randomised controlled trials or controlled 
trials. In the second phase, 35 of the 41 full texts were obtained while six were 
conference abstracts rather than published papers and the necessary information was not 
available. The 35 full texts were screened further against the inclusion and exclusion 
criteria. In this phase, 17 studies were excluded for the following reasons: four for not 
being MBCT or MBSR, four focused on healthy populations, four used short MBSR 
(four-six weeks), three were not randomised controlled trials or controlled trials, one did 
not examine mechanisms or mediators and one tested moderators of MBCT. Finally, four 
studies with physical conditions populations and 14 studies with psychological 
conditions populations met the inclusion criteria of this review (see Figure 2.1). 
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2.4.2 Studies Focused on Populations with Physical Conditions 
2.4.2.1 Characteristics of the studies.  
Table 2.2 summarises the characteristics of the included studies that focused on 
people with physical conditions and co-existing psychological problems. Four studies 
met the review criteria: three focused on people with cancer (Bränström, Kvillemo, 
Brandberg, & Moskowitz, 2010; Labelle, Campbell, & Carlson, 2010; Labelle, 
Campbell, Faris, & Carlson, 2015) and one (O’Doherty et al., 2015) targeted people with 
coronary heart disease (CHD). One study (Bränström et al., 2010)employed an RCT 
design and three used a CT design (Labelle et al., 2010, 2015; O’Doherty et al., 2015). 
All the studies compared MBSR/MBCT to waitlist control. The sample sizes ranged 
from 71 to 211 with a total of 71 randomised and 405 non-randomised. Two studies 
included only females (n = 147) (Bränström et al., 2010; Labelle et al., 2010).  
Two out of the four included studies examined more than one mediator, which 
were mindfulness skills (n = 4), rumination (n = 2) and cancer-related worry (n = 1). All 
the studies used self-report questionnaires to assess the proposed mediators. Three 
(Bränström et al., 2010; Labelle et al., 2010, 2015) made some adaptations to the MBSR 
original manual so as to make it appropriate for people with cancer, but with the same 
length of course, whilst the only study that used MBCT followed the programme as 
outlined by Segal et al. (2002, 2013). 
2.4.2.2 Mechanisms/mediators in studies with physical conditions 
populations. 
2.4.2.2.1 Mindfulness, rumination and worry. Mindfulness, as a potential 
mediator, was tested in the all of these studies and rumination was assessed in two.  
Of the four studies looking at mindfulness as the mediator, two (Bränström et al., 2010; 
O’Doherty et al., 2015) showed it mediated the effects of MBCT/MBSR on perceived 
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stress, posttraumatic avoidance, positive state of mind, current depression, anxiety, 
psychosocial adjustment to illness, mood and health-related quality of life. In these 
studies, mindfulness was assessed by different measures that have different conceptual 
backgrounds. For example, the Kentucky inventory of mindfulness (KIMS) (Baer, 2004) 
and five-facet mindfulness questionnaire (FFMQ) (Baer et al., 2006, 2008) were 
developed based on the assumption that mindfulness is a multifaceted construct, 
including facets such as observing, describing, acting with awareness, non-judgment and 
non-reactivity, while the mindful attention awareness scale (MAAS) was developed with 
a single-factor structure (receptive attention to and awareness of present events and 
experience) (Brown & Ryan, 2003). The other two studies (Labelle et al., 2010, 2015) 
found no mediation effect of mindfulness on depression, experiential avoidance and 
stress symptoms. Both studies (Labelle et al., 2010, 2015) that assessed rumination as a 
mediator found it to be a significant mediator of MBSR for depression, experiential 
avoidance and stress symptoms (Labelle et al., 2010, 2015). 
Bränström and his colleagues (2010), in their RCT with two time-points (pre-
post), tested whether mindfulness skills would mediate the effects of adapted-MBSR in 
females with cancer (n = 71). The results indicated that the positive effects of the MBSR 
intervention on stress, posttraumatic avoidance and positive states of mind were 
mediated by significant increases in mindfulness skills. A study by O’Doherty et al. 
(2015) used a controlled trial with three time-points (pre-post-follow up) to evaluate the 
effectiveness of MBCT on people with coronary heart disease (CHD) and current 
depression, and test whether mindfulness would lead to changes in outcomes. The results 
revealed that the MBCT group when compared to the waiting list group showed 
improvements for current depression, anxiety, psychological adjustments to illness, 
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quality of life and mindfulness, with these improvements being correlated significantly 
with the increases in mindfulness.  
Labelle et al. (2010) in a controlled study of 77 females with cancer using two 
time- points, found that mindfulness did not mediate the significant effect of adapted-
MBSR on depressive symptoms, while rumination did. Consistent with this result, a 
recent controlled study (Labelle et al., 2015) with three time-points (pre, mid, and post 
intervention), showed that early decreases in rumination and cancer-related worry 
mediated the effects of adapted-MBSR on the outcomes, while mindfulness skills did 
not.  
2.4.3 Studies Focused on Populations with Psychological Conditions   
2.4.3.1 Characteristics of studies. 
 Table 2.3 shows the characteristics of the included studies that focused on people 
with psychological conditions (depression and anxiety). 14 published trials met the 
review criteria, three of which used the same dataset (Batink et al., 2013; van Aalderen et 
al., 2012; van den Hurk et al., 2012). All the studies employed an RCT design. The 
sample sizes ranged from 29 to 219 with a total of 1,122 randomised males and females. 
Four studies compared MBCT to treatment as usual (TAU), four compared MBCT 
(n = 3) or MBSR (n = 1) to waitlist, three studies compared MBSR to active groups 
(aerobic exercise, stress management), one compared MBCT plus discontinuation of 
antidepressant medication to maintenance antidepressant medication (m-ADM), one 
study used the depression relapse active monitor (DRAM) as a control group and one 
had three arms: MBCT, m-ADM and a placebo. Among the depression studies, the 
majority focused on recurrent MDD, whereas one (van Aalderen et al., 2012) targeted 
recurrent and current depression. The studies used different criteria to establish MDD, 
such as the Structured Clinical Interview for DSM-IV (SCID) and the Hamilton Rating 
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Scale for Depression (HRSD). All studies followed the MBCT/MBSR programmes, as 
outlined by Segal et al. (2002, 2013) and Kabat-Zinn (1990, 2013).  
The majority of the studies (n = 11) examined two or more mediators. Those 
examined included mindfulness skills (n = 8), rumination (n = 5), positive affect (n = 2), 
worry (n = 2), cognitive function and reactivity (n = 2), emotional reactivity (n = 1), 
attentional processes (n = 1), self-compassion (n = 1), decentering (n = 2), self-referential 
brain network (n = 1), brain activation and connectivity (n = 1). With regard to 
measuring the mediators, the majority of the studies (n = 10) relied on self-report. 
Emotional and cognitive tasks in addition to self-report measures were used to assess 
attentional processes as well as emotional and cognitive reactivity (n = 3), whilst two 
studies used fMRI.  
2.4.3.2 Mechanisms/mediators in studies with psychological conditions 
populations.  
2.4.3.2.1 Anxiety disorders. 
2.4.3.2.1.1 Mindfulness and decentering. Two studies examined mindfulness as 
the mechanism of change for MBSR in people with anxiety disorders. Vøllestad, 
Sivertsen, and Nielsen (2011) looked at mindfulness as a mediator of the relationship 
between MBSR and improvements in anxiety, worry and depression in a randomised 
controlled trial for people with anxiety disorders. The results indicated that during 
MBSR significant increases in mindfulness skills mediated the relationship between 
MBSR and anxiety and worry, but not depression when compared to waitlist control. 
Another randomised study (Hoge et al., 2015) that compared adapted-MBSR to stress 
management education (SME) in people with generalised anxiety disorders (GAD), 
found that a significant increase in decentering was a mediator for MBSR in relation to 
anxiety, while significant increases in mindfulness skills mediated the effects of MBSR 
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on worry when compared to a stress management group. In this study, decentering is 
defined as “a metacognitive capacity of individuals to observe items that arise in the 
mind (e.g., thoughts, feelings, memories, etc.) as mere psychological events” (Hoge et 
al., 2015, p. 229).   
2.4.3.2.1.2 Brain network and connectivity. Goldin, Ziv, Jazaieri, & Gross  
(2012) tested the correlation between self-referential brain networks and improvements 
in social anxiety symptoms in people undertaking MBSR compared with a group 
undertaking aerobic exercise (AE). The fMRI and self-referential encoding task results 
showed that significant changes in self-views as well as dorsomedial pre- frontal cortex 
(DMPFC) activity during negative self-view were correlated with significant reductions 
in social anxiety in the MBSR group. Hölzel et al. (2013) found that people undergoing 
MBSR, when compared to a stress management group, showed changes in ventrolateral 
prefrontal regions (VLPFC) activation and amygdala–prefrontal connectivity and these 
were associated with improvements in generalised anxiety disorder. 
2.4.3.2.2 Depression. 
2.4.3.2.2.1 Mindfulness. Six RCTs indicated that MBCT led to a significant 
decrease in residual depressive symptoms (Batink et al., 2013; Bieling et al., 2012; 
Kuyken et al., 2010; Shahar, Britton, Sbarra, Figueredo, & Bootzin, 2010; van Aalderen 
et al., 2012) and relapse (Kearns et al., 2015; Kuyken et al., 2010). These effects were 
found to be mediated by significant increases in overall mindfulness (Kearns et al., 2015, 
Kuyken et al., 2010; Shahar et al., 2010), acceptance without judgment (Batink et al., 
2013; van Aalderen et al., 2012) and curiosity (Bieling et al., 2012).  
2.4.3.2.2.2 Rumination. Rumination refers to “a mode of responding to distress 
that involves repetitively and passively focusing on symptoms of distress and on the 
possible causes and consequences of these symptoms”(Nolen-Hoeksema, 1991, p. 1). 
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Two MBCT studies indicated that significant reductions in depression were mediated by 
rumination (van Aalderen et al., 2012) and brooding as a component of rumination 
(Shahar et al., 2010), while the outcomes of other studies have determined that the 
effects of MBCT were not mediated by rumination as a total score (Batink et al., 2013; 
Bieling et al., 2012; Kearns et al., 2015) or reflective pondering, as a component of 
rumination (Shahar et al., 2010). 
 2.4.3.2.2.3 Worry, affect and self-compassion. Worry refers to “a chain of 
thoughts and images that are affectively negative and relatively uncontrollable” 
(Borkovec, Robinson, Pruzinsky, & DePree, 1983. p. 10). Two MBCT studies using the 
same dataset (Batink et al., 2013; van Aalderen et al., 2012) tested worry as a proposed 
mediator of change by using self-report measures and found that it mediated the effects 
of MBCT on depressive symptoms. Regarding affect, two studies assessed whether 
increased positive affect acted as a mediator of the effect of MBCT on depression, using 
experience sample methods (ESM). The first (Geschwind, Peeters, Drukker, van Os, & 
Wichers, 2011), showed that increased positive affect (PA), activity pleasantness, and 
reward experience (SE) were associated with decreases in depression. The second 
(Batink et al., 2013), found that an increase in positive affect and a decrease in negative 
affect were mediated MBCT effects on depression. In another study, learning self-
compassion was found to have a mediating role in the relationship between MBCT 
participation and depression over a 15 months follow up period (Kuyken, Watkins, et al., 
2010). Self-compassion is defined as “being touched by and open to one’s own suffering, 
not avoiding or disconnecting from it, generating the desire to alleviate one’s suffering 
and to heal oneself with kindness” (Neff, 2003, p. 87). 
2.4.3.2.2.4 Cognitive and emotional reactivity. Kuyken et al. (2010) found that 
high levels of cognitive reactivity predicted a poorer outcome in terms of depressive 
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symptoms and relapse rate in the m-ADM group, but for the MBCT group this link 
between reactivity and outcome was weakened. With regards to emotional reactivity 
which is defined as “progressively prolonged or intensified negative affect in response to 
stress” (Britton et al., 2012, p. 366), Britton, Shahar, Szepsenwol, & Jacobs (2012) 
conducted a laboratory study to test emotional reactivity to a social stress task in people 
with recurrent depression. The results indicated that improvements in emotional 
reactivity mediated the relationship between MBCT and depression.  
2.4.3.2.2.5 Cognitive function and attentional processing. Jermann et al. (2013) 
 examined five cognitive functions (autobiographical memory, shifting abilities, 
dysfunctional attitude, mindful attention and rumination), using a combination of 
cognitive tasks and self-report measures. They found that the participants in the MBCT 
group showed a significant decrease in dysfunctional attitudes at 9 months follow up. 
Van den Hurk and colleagues (2012) tested different components of attentional 
processing (alerting, orienting and executive attention) by using an attentional network 
test. The results indicated that MBCT led to reductions in depression and rumination and 
increases in mindfulness skills when compared to TAU, but no significant differences in 
components of attention between MBCT and TAU were found. In terms of testing the 
mediating role of attentional processing, the results suggested that attentional processing 
did not mediate the relationship between MBCT and depression when compared to the 
TAU group.  
2.4.4 Risk of Bias in the RCTs 
Risk of bias assessments are shown in Tables 2.4 and 2.5. Regarding the studies 
with physical conditions populations, the majority had shortcomings regarding sequence 
generation and allocation concealment. However, most did adequately describe 
eligibility criteria and data collection tools valid. For the studies regarding psychological 
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conditions, the majority adequately described sequence generation, allocation 
concealment and selective reporting. These studies also effectively reported eligibility 
criteria, power calculations, compliance with intervention and data collection tools valid. 
2.4.5 Evaluating the Ability of the Studies to Assess Mechanisms or Mediators 
Each study was also evaluated based on our previously mentioned framework 
(see Tables 2.6 and 2.7). In this section, we present, first, whether each included study 
was able to meet the eight criteria of this review framework and then, we report how well 
all of them met the four questions that represent the eight criteria.  
With regards to the studies pertaining to physical conditions, that by Bränström et 
al. (2010), which targeted females with cancer, met five of the eight criteria of this 
review, but it did not reflect different perspectives in terms of assessing mediators of 
MBSR. In addition, two time-point assessments were used, which meant that they were 
not able to prove that the change in their proposed mediator (mindfulness skills) 
preceded the observed changes in the study outcomes. The study by Labelle et al. (2010) 
that also studied females with cancer met five criteria, but could not meet 3, 6 or 7. The 
authors relied on self-report measures to assess their mediators (mindfulness and 
rumination) and used two time-points, which meant that temporal precedence could not 
be established and therefore, true mediation could not be tested. Labelle and her 
colleagues in their recent study (2015) with people with cancer met seven criteria 
however, they used only self-report measures to assess rumination, mindfulness skills 
and worry as proposed mediators of the effects of MBSR. The study by O’Doherty et al. 
(2015) that focused on people with coronary heart disease met six criteria, but did not 
satisfy 3 and 8. The correlation analysis that was used in this study was not able to test 
the full mediation of effects of MBCT on depression.  
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Regarding the studies focussed on psychological conditions, the studies that 
targeted people with anxiety disorders (Goldin et al., 2012; Hoge et al., 2015; Hölzel et 
al., 2013; Vøllestad et al., 2011) met between five and six of the eight criteria. These 
studies used two assessments, hence being unable to show the temporal precedence 
between mediators and outcomes. In terms of studies that targeted people with 
depression using MBCT, Kuyken et al., (2010) met all the eight criteria of this review 
framework, whilst others (Bieling et al., 2012; Kearns et al., 2015) met seven and could 
not meet criterion 3.  The studies by Batink et al. (2013), Shahar et al. (2010), van 
Aalderen et al. (2012) van den Hurk et al. (2012) met five criteria and had limitations in 
term of relying on self-repost measures, using just two time-points and not showing the 
temporal precedence. The studies by Geschwind et al. (2011) and Jermann et al. (2013) 
met between four and five of the eight criteria, not being able to satisfy criteria 6,7, 8, 
having shortcomings in terms of not using enough time point assessments, not showing 
the temporal precedence and not using the appropriate statistical analyses.   
2.4.5.1 Did the study use a theory?  
The mechanisms need to be identified based on a theory or treatment rationale for 
articulating the mechanisms through which the treatment is hypothesised to work 
(Kazdin, 2007). While all studies reported using some theory, very few articulated a 
coherent account of universal and/or specific vulnerabilities driving the problems or 
explained exactly how MBCT/MBSR would target these mechanisms. We found that the 
studies with participants with physical conditions, especially those focusing on cancer 
populations, represented good attempts to develop models that linked mindfulness and 
emotions regulation as mediators for MBSR effects on cancer. There is a need for further 
studies that consider clearly articulated mechanisms, such as those proposed in reviews 
conducted by Carlson et al. (2012) and Loucks et al. (2015). With regards to studies 
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focussed primarily on psychological conditions, the majority with depression populations 
used a well-designed theoretical model of MBCT intervention for recurrent depression. 
However, many looked at a single mediator and did not consider the issue of universal 
versus specific vulnerabilities or the inter-play between different mechanisms. 
2.4.5.2 Did the study use process measures that assess the constructs, if 
necessary, from a variety of perspectives? 
 The use of measures that can consider different viewpoints, such as experimental 
and neuropsychological measures, is another important matter that needs to be 
considered (Kazdin, 2007). All the included studies used some form of measures to 
assess the mediators; however, there was wide variability in the types used. We found 
that the studies of physical conditions (n = 4) relied completely on self-report measures 
to assess mediators, such as mindfulness, rumination and cancer-related worry. In the 
studies of psychological conditions, whilst the majority (n = 10) used self-report 
measures, we did find some examples of more objective measures, such as fMRI and 
laboratory tests, to assess self-referential brain network, brain connectivity as well as 
emotional and cognitive reactivity.   
2.4.5.3 Did the study design ensure the hypotheses can be addressed? 
  It is worth noting that the best design is one that can assess changes over 
different time points within an RCT design (Kazdin, 2007). Even though most the studies 
(n = 15) were RCTs, which is considered as the gold standard for testing efficacy and 
effectiveness, the number of time assessments included in these was not optimal to for 
testing mechanisms or mediators. Only two of the five studies focusing on populations 
with physical conditions (Labelle et al., 2015; O’Doherty et al., 2015) and three of the 
depression and anxiety studies (Bieling et al., 2012; Kearns et al., 2015; Kuyken, 
Watkins, et al., 2010) used three or more time points.  
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The majority of the studies looked at changes from Time 1 to Time 2 in both 
constructs, meaning temporal precedence (change from Time 1 to Time 2 in the mediator 
predicts change between Time 2 and Time 3 in the outcome) could not be established 
(and reverse causality remained a possibility). However, all the studies in this review 
failed to assess the changes over several time points.   
2.4.5.4 Did the study use appropriate statistical analyses? 
Some statistical criteria have been suggested that can help in testing mediation 
effects (Kazdin, 2007, 2009; Kraemer et al., 2002). For example, establishing significant 
relationships between the intervention, the proposed mediator and the outcome, as well 
as between the proposed mediators and the outcomes. Another important criterion is 
establishing the precedence between the changes in mediators and changes in outcomes. 
In this review, we found that whilst the majority of studies used some form of mediation 
analyses, the rest employed analyses that could not test mediation. Moreover, it was not 
possible to conduct a full test for mediation due to insufficient time points in many of the 
studies. 
2.5 Discussion 
In this review, we first aimed to review the potential mechanisms of change in 
MBCT and MBSR for people with physical and/or psychological conditions. A second 
aim was to see whether there are universal mechanisms of mindfulness interventions that 
apply across populations/conditions as well as specific mechanisms that pertain to a 
particular population/condition. The evidence from the included studies was evaluated 
based on Kazdin’s framework (Kazdin, 2007, 2009). The results of the review are 
consistent with the two recent reviews (Gu et al., 2015; van der Velden et al., 2015). 
While there is promising evidence that MBCT/MBSR treatment effects are mediated by 
hypothesised mechanisms, such as mindfulness and rumination, there is a lack of 
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methodological rigour in the field of testing mechanisms and mediators of action in both 
MBCT and MBSR that precludes definitive conclusions.  
Moreover, the lack of a consensually agreed theoretical framework of what 
universal and specific mechanisms drive change in MBCT/MBSR means that we do not, 
as yet, have the basis for articulating what degree of change, in which mechanisms (e.g., 
orienting attention, executive control, compassion), through which components of 
MBCT/MBSR (e.g., particular formal mindfulness practices) drive change, with which 
populations (e.g., adults with recurrent depression, health related anxiety), for which 
aims (e.g., reduce depressive relapse). Our findings provide insights that can inform 
future experimental and mechanisms studies embedded in trials to better articulate these 
elements. 
Moreover, our review highlights that less attention has been given to studying the 
mechanisms of change through MBCT/MBSR in populations with physical conditions 
when compared to populations with psychological ones. Moreover, the few studies 
examining physical health conditions focused primarily on psychological symptoms 
outcomes such as stress, anxiety and depressive symptoms and neglected physical health 
outcomes. 
In two out of the four studies, mindfulness and rumination seem to mediate the 
effects of MBCT/MBSR on perceived stress, posttraumatic avoidance, depression, 
positive state of mind and psychosocial adjustment to illness for people with physical 
conditions (heart conditions and cancer). However, only one out of the four physical 
studies focused on mediating factors that were specifically related to the populations, 
namely cancer-related worry in a cancer population (Labelle et al., 2015). Examining 
mechanisms that are specific to a population or intervention is essential to test whether 
universal and specific vulnerabilities/mechanisms are being targeted.  
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In the studies of psychological conditions, we found that depression has received 
much attention with regards to mechanisms of action in MBCT, while anxiety has 
received most attention in relation to MBSR. The majority of the included studies 
considered mindfulness as a universal mediator. In most, mindfulness shows potential as 
a mediator of change in MBCT/MBSR for people with depression, anxiety and stress. In 
addition to mindfulness, rumination, worry and self-compassion have been investigated 
for mediation effects.  
Other proposed mediators, such as attention and emotional reactivity, were 
assessed to a lesser degree. To assess attention and reactivity well requires experimental 
paradigms that the majority of the studies to date have not included. Moreover, studies 
sometimes used different measures of the same outcome; for example, in depression 
relapse some prevention studies used depressive relapse/recurrence whilst others used 
residual depressive symptoms as a proxy. It is possible that different mechanisms could 
be at play for each of these.  
There was evidence that global changes in mindfulness were linked to better 
outcomes. This evidence pertained more to interventions targeting psychological rather 
than physical health problems. Some variables hold up strongly as a candidate universal 
mechanism or mediator of change in MBCT/MBSR across psychological and physical 
populations (e.g., enhancing mindfulness) whilst others seem promising as specific to 
particular populations (e.g., decentring from negative thinking with depression). 
Moreover, there may be universal mechanisms that have specific manifestations in a 
given population (e.g., repetitive thinking as a universal mechanism; in recurrent 
depression, the focus is on the causes, meanings and consequences of depression 
whereas in cardiovascular disorders it may be on the causes, meaning, consequences 
around physical health). These hypotheses need to be tested in future work. 
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Most studies relied on self-report measures and very few were adequately 
powered to examine mediation. Triangulation of measures and sufficient power will 
enable more exploratory examination of as yet “unknown” mechanisms. For example, 
the two studies that examined neuroscience mechanisms suggested particular brain 
networks as candidate mechanisms. These studies suggest that there could be a range of 
possibilities regarding how MBCT/MBSR interventions produce their effects and future 
work might usefully triangulate across neuroscience, experimental and self-report 
measures.  
An important feature we highlighted in our review was the constituent studies’ 
design regarding the timeline of changes. In this regard, it was found that majority of 
studies did not establish a timeline that would provide a full test of mediation. This 
means that the findings of such studies regarding the role of a specific mediator are just 
preliminary and future research needs to ensure temporal sequencing of assessments that 
enables change in mechanisms to be assessed separately and temporally before change in 
outcomes. Many of the included studies were conducted with the primary aim of 
assessing the effectiveness of MBCT/MBSR interventions, with identifying mechanisms 
being a secondary goal. Furthermore, some studies that tested mediators in detail were 
post hoc analyses using datasets obtained from effectiveness studies. As discussed above, 
it is essential to design mechanisms studies that choose time points and time scales so as 
to uncover the temporal relationships between mediators and outcomes over short and 
long-term trajectories of change.  
In most of the studies, both MBCT and MBSR demonstrated significant 
reductions in the proposed mediators and targeted outcomes compared to the different 
control groups (active, waitlist) as well as for different populations (physical and 
psychological). This suggests that there are associations between the intervention, the 
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mediator and the outcome. However, a significant relationship between the mediator and 
the outcome was not supported in some of the studies. This inconsistency we argue 
provides fertile ground for hypothesis generation that can be tested in improved study 
designs. Recently, there has been a growing interest in causal mediation analysis that 
includes methods for dealing with multiple mediators (Tingley, Yamamoto, Hirose, 
Keele, & Imai, 2014). Such methods should be considered in future studies aimed at 
testing multiple mediators. Moreover, there has been growing interest in developing 
models that can test what works for whom.  
2.6 Strengths and limitations   
This review was aimed at understanding mechanisms of change in MBCT and 
MBSR when used for people with physical and/or psychological conditions. This work 
has the potential to shed light on the theory underpinning the conditions that 
MBCT/MBSR seek to address as well as enhancing outcomes by enabling these 
interventions to be better targeted at both universal and specific vulnerabilities. For this 
review, we assessed the quality of the appropriate studies based on Kazdin’s (2007, 
2009) recommended framework for enhancing methodological quality in this area.   
There are several limitations of this review. First, we reviewed only randomised 
and non-randomised controlled studies. Other types of studies, such as observational and 
case studies, might produce more detailed data concerning the mechanisms of how and 
the reasons why MBCT/MBSR interventions can lead to change. A second limitation is 
that the main targeted population in this review comprised adults with diagnosed 
physical and/or psychological conditions. Focusing on other types of population, such as 
healthy people or children, might highlight different mechanisms underlying mindfulness 
interventions at different stages of the lifespan and with different profiles of universal 
and specific vulnerability. Thirdly, only published studies were included in this review 
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and so there might be some publication bias in the findings. Fourth, this review did not 
consider the fidelity of the MBCT and MBSR, nor how they were implemented by 
participants. We hypothesise that this would significantly influence the mechanisms and 
mediators being examined and is essential for future work to incorporate. 
2.7 Recommendations  
This review suggests that the field of testing mechanisms of mindfulness 
interventions might benefit from delineating universal and specific vulnerabilities in 
populations with physical and/or psychological conditions, so that we can better 
understand what any mindfulness-based intervention can change and what a 
mindfulness-based intervention adapted for particular populations specifically change. 
The emerging theoretical framework for MBCT/MBSR draws on aspects of 
cognitive science (e.g., attention and executive control and decentering) and trans-
diagnostic work (e.g., repetitive thought and experiential avoidance). This emerging 
model is being clarified and developed as empirical understanding is built. Future 
mechanisms studies should clearly articulate which aspect of this framework and which 
specific mechanisms they are investigating. The second point is that following the 
criteria suggested by Kazdin (2007, 2009) could assist researchers when conducting 
future studies aimed at identifying mechanisms of change in interventions. More recent 
developments in conceptual thinking and methodology can further enhance this field. 
Future research in this area might benefit from this focus on universal and specific 
mechanisms and triangulating experimental, neuroscience and self-report measures to 
test potential biological, psychological and social processes that might lead to a better 
understanding of how MBCT/MBSR interventions work in populations with physical 
and/or psychological conditions. Finally, researchers need to build in sufficient time 
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points in their study designs so as to be able to determine the shape and temporal 
sequencing of change.  
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Table 2.1 
Inclusion/exclusion criteria of the review  
 Inclusion criteria Exclusion criteria 
Types of trials Randomised controlled trial and 
controlled trial aimed at 
examining mechanisms or 
mediators of change 
Case-control trials, cohort 
trials, cross-sectional trials, 
case reports, series and 
qualitative trials 
Types of 
publication 
Published trials reported in any 
language 
Non-published trials and 
dissertations 
Types of 
participants 
Adults, 18 years and older, 
diagnosed with a physical health 
condition and/or, diagnosed with 
any psychological problem 
Children and healthy people  
Types of 
interventions 
Studies of MBCT as specified by 
Segal et al., (2002, 2013) and 
MBSR as outlined by Kabat-Zinn 
(1990, 2013)  
Other mindfulness 
interventions and short duration 
MBCT or MBSR 
Types of 
outcomes 
Any  
Types of 
comparators 
Any comparator. This might 
include inactive control such as 
treatment as usual (TAU) and 
waiting list or active group, such 
as antidepressants or other 
psychological interventions 
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          Figure 2.1. Flow of Studies Identification and Eligibility Determination 
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 Table 2.2 
Characteristics of studies with physical conditions populations 
Author, 
year and 
country 
Population Inter-
vention 
Disorders Study 
design 
Comparator Time-point 
assessments 
Mediators 
studied 
(Assessment 
tool) 
Statistical 
analysis used 
Outcomes 
targeted 
Outcome of Intervention Findings in relation to 
‘mechanism of intervention’ 
Bränström 
et al., 2010 
 
Sweden 
N = 71 
Male (n=1) 
and female 
(n=70) 
(Mean age 
52 yrs.) 
 
MBSR 
 
8 weeks 
Cancer RCT 
 
Adapted 
MBSR versus 
waitlist 
control 
 
Two time-
points (pre-
and post-
treatment) 
• Mindfulness 
(Five-Facet 
Mindfulness 
Questionnaire/
FFMQ) 
 
Baron & 
Kenny method 
 
Psychological 
outcomes. 
-Primary 
(perceived 
stress) 
-Secondary 
(depressive 
symptoms, 
anxiety, 
posttraumatic 
avoidance 
symptoms and 
positive states) 
• MBSR led to significant 
improvements in 
perceived stress, 
posttraumatic avoidance 
symptoms, positive states 
of mind and mindfulness 
compared to the control 
group. 
• MBSR effects on perceived 
stress, posttraumatic avoidance 
symptoms and positive states of 
mind were mediated by 
increases in mindfulness skills. 
Labelle  
et al., 2010 
 
Canada 
N = 77 
Female 
(Mean age 
53 yrs.) 
MBSR 
 
8 weeks 
Cancer CT 
 
Adapted 
MBSR versus 
waitlist 
control 
 
Two time-
points (pre-
and post-
treatment) 
• Mindfulness 
(Mindful 
Attention 
Awareness 
Scale 
(MAAS) 
• Rumination 
(Rumination-
Reflection 
Questionnaire
-Rumination 
Subscale/RRQ
) 
 
- Change 
scores 
- Baron & 
Kenny method 
-
Nonparametric 
Bootstrapping 
(Preacher & 
Hayes method) 
Psychological 
outcomes. 
 
-Primary 
(depressive 
symptoms) 
•People in MBSR showed 
significant decreases in 
depressive symptoms and 
rumination and increases 
in mindfulness compared 
to the control group. 
 
• MBSR effect on depression 
was mediated by a decrease in 
rumination 
 
• Significant changes in 
mindfulness did not show a 
mediating role. 
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Table 2.2 cont. 
Characteristics of studies with physical conditions populations 
 
  
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-point 
assessments 
Mediators 
studied 
(Assessment 
tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Labelle  
et al., 
2015 
 
Canada 
N = 211 
Male and 
female 
(Mean age 
53 yrs.) 
MBSR 
 
8 weeks 
cancer CT 
 
Adapted 
MBSR versus 
waitlist 
control 
 
Three time-
points (pre, 
mid and post 
treatment) 
• Mindfulness  
(Mindful 
Attention 
Awareness 
Scale 
(MAAS) and 
Five-Facet 
Mindfulness 
Questionnaire 
(FFMQ) 
• Rumination 
(Rumination-
Reflection 
Questionnaire
-Rumination 
Subscale/RRQ
). 
• Worry (Penn 
State Worry 
Questionnaire/
PSWQ). 
Two-level 
hierarchical 
linear model 
(HLM) 
Psychological 
outcomes. 
 
-Primary (stress 
symptoms and 
mood 
disturbance) 
 
-Secondary 
(mindfulness, 
rumination, worry 
and experiential   
avoidance)  
•MBSR group showed a 
significant decrease in 
stress, mood disturbance, 
rumination, worry, 
experiential avoidance 
and increases in 
mindfulness skills.   
• Decreases in rumination and 
worry (cancer-related worry) 
mediated the effects of MBSR on 
outcomes.  
 
 • Changes in total of mindfulness 
measure did not mediate the 
effects of MBSR on outcomes.  
 
.   
O’Doherty  
et al. 2015 
 
Ireland 
N = 117  
Male and 
female 
(Mean age 
59 yrs.)  
MBCT 
 
8 weeks 
Coronary 
heart 
disease 
(CHD) 
and 
current 
MDE 
CT MBCT versus 
waitlist 
control  
 
 
Three time-
points (pre, 
post and 6-
month follow 
up) 
• Mindfulness  
(Mindful 
Attention 
Awareness 
Scale/MAAS) 
Correlation 
analysis 
Psychological 
outcomes.  
 
-Primary (current 
MDD in people 
with CHD) 
-Secondary 
(psychological 
adjustment and 
quality of life) 
•MBCT group 
demonstrated significant 
improvements in 
depression, anxiety, 
psychological adjustment, 
mood, quality of life and 
mindfulness. 
 
 
• The study found that significant 
associations between 
improvements in (depression, 
anxiety, psychological adjustment, 
quality of life and mood) and 
changes in mindfulness. 
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Table 2.3 
Characteristics of studies with psychological conditions populations 
 
                                                 
9 The EQ measure was developed to measure "decentering" and "rumination", however, the authors in this study (Bieling et al., 2012) used it to refer to "wider 
experience" and “rumination”. 
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-
point 
assessmen
ts 
Mediators studied 
(Assessment tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Batink 
et al. 2013 
 
Netherland
s 
N = 130 
Male and 
female  
(Mean age 
44 yrs.) 
MBCT 
 
8 weeks 
Current 
residual 
depressive 
symptoms 
after at 
least one 
episode of 
MDD 
RCT MBCT + TAU 
versus  
TAU alone 
 
 
 
Two time-
points (pre-
and post-
treatment) 
• Mindfulness skills 
(Kentucky Inventory 
of 
Mindfulness/KIMS) 
 •Worry (Penn State 
Worry 
Questionnaire/PSWQ
) 
• Rumination 
(Rumination on 
Sadness Scale/RSS) 
 •Positive affect (PA) 
and negative affect 
(NA) (experience 
sampling method-
ESM) 
- Sobel-
Goodman 
mediation 
analysis. 
- Multiple 
regression 
analysis 
Psychological 
outcomes. 
 
-Primary 
(residual 
depressive 
symptoms) 
•MBCT group had 
significant decreases in 
depressive symptoms, 
worry and rumination and 
an increase in 
mindfulness skills. 
• Effects of MBCT on depressive 
symptoms were mediated by  
- An increase in a mindfulness 
skill (accept without judgment). 
- A decrease in worry. 
- An increase in positive affect. 
- A decrease in negative affect.  
 
• Rumination did not have a 
mediating role. 
Bieling  
et al. 2012 
 
Canada 
 
 
 
N = 84 
Male and 
female 
(Mean age 
42-46 yrs.) 
MBCT 
 
8 weeks 
Recurrent 
depression 
with 
current 
residual 
depressive 
symptoms 
RCT MBCT + 
medication 
taper versus 
maintenance 
antidepressants 
(m-ADM) 
versus placebo 
+ medication 
taper  
 
 
 
Three 
time-points 
(pre, post 
and 
6-month 
follow up) 
• Decentering 
(Toronto 
Mindfulness 
Scale/TMS) 
• Curiosity 
(Toronto 
Mindfulness 
Scale/TMS) 
•Wider 
Experiences 
(Experiences 
Questionnaire/EQ) 
 •Rumination 
(Experiences 
Questionnaire/EQ
9
) 
 
-Multiple 
regression 
-Kraemer 
Method   
Psychological 
outcomes. 
 
-Primary 
(relapse rate and 
residual 
depressive 
symptoms) 
• No differences between 
MBCT and m-ADM 
groups in terms of 
depression outcomes.   
•MBCT group showed increases 
in decentering, wider experiences 
and curiosity.  
•The increases in wider 
experiences and curiosity 
predicated depression at 6-month 
follow up.   
•Decentering and rumination did 
not have a mediating role. 
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Table 2.3 cont. 
Characteristics of studies with psychological conditions populations 
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-point 
assessments 
Mediators 
studied 
(Assessment 
tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Britton  
et al. 2012 
 
USA 
N = 52 Male 
and female  
(Mean age 
48 yrs.) 
MBCT 
 
8 weeks 
Recurrent 
depression 
with 
residual 
depressive 
symptoms 
RCT MBCT versus 
waitlist 
control 
 
 
 
Two time-
points (pre-
and post-
treatment) 
 •Emotional 
reactivity to 
social stress 
(laboratory-
based stress 
induction + 
Spielberger 
state anxiety 
measure/STAI-
YI ) 
Preacher 
and Hayes 
approach  
Psychological 
outcomes. 
-Primary 
(residual 
depressive 
symptoms). 
•MBCT led to significant 
decreases in depression 
and emotional reactivity. 
• Significant decreases in 
emotional reactivity mediated 
the effects of MBCT on 
depression. 
Geschwind 
et al. 
2011 
 
Netherlands 
 
N = 130 
Male and 
female 
(Mean age 
44 yrs.) 
MBCT 
 
8 weeks 
Current 
residual 
depressive 
symptoms 
after at 
least one 
episode of 
MDD 
RCT 
 
MBCT versus 
waitlist 
control 
 
 
 
Two time-
points (pre-
and post-
treatment). 
• Activity 
pleasantness 
(Experience 
Sampling 
Method-ESM) 
• Positive affect 
(ESM) 
• Negative 
affect (ESM) 
• Reward 
experience. 
Correlation 
analysis 
Psychological 
outcomes. 
 
-Primary 
(residual 
depressive 
symptoms). 
•MBCT group showed 
significant improvements 
in depressive symptoms, 
affect, activity 
pleasantness and reward, 
worry and rumination. 
• Significant decreases in 
depression were associated with 
increases in: 
- Positive affect.  
- Activity pleasantness. 
- Reward experience. 
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Table 2.3 cont.  
Characteristics of studies with psychological conditions populations 
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-point 
assessments 
Mediators 
studied 
(Assessment 
tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Goldin et 
al. 
2012 
 
USA 
N = 56 
Male and 
female 
(Mean age 
32 yrs.) 
MBSR 
 
8 weeks 
Social 
Anxiety 
Disorder 
RCT 
 
MBSR versus 
Active control 
(Aerobic 
exercise/ 
AE) 
 
 
 
Two time-
points (pre-
and post-
treatment) 
• Self-referential 
brain network 
(Self-
Referential 
Encoding Task) 
+ fMRI 
Multiple 
regression 
Psychological 
outcomes. 
 
-Primary (social 
anxiety 
symptoms) 
•MBSR group showed an 
increase in positive self-
views and decrease in 
negative self-views when 
compared to a AE group. 
• Significant changes in self-
views as well as dorsomedial 
pre- frontal cortex (DMPFC) 
activity during negative self-
view were associated with 
significant reductions in social 
anxiety in the MBSR group. 
Hoge et al. 
2015 
 
USA 
N = 38 
Male and 
female 
(Mean age 
38 yrs.) 
MBSR 
 
8 weeks 
Generalised 
Anxiety 
Disorder 
RCT Adapted -
MBSR versus 
active control 
(stress 
management 
education/ 
SME) 
 
 
Two time-
points (pre-
and post-
treatment) 
• Mindfulness 
(Five-Facet 
Mindfulness 
Questionnaire/F
FMQ) 
• Decentering 
(Experience 
Questionnaire 
/EQ) 
Multiple 
mediation 
model and 
Preacher 
and Hayes 
approach 
(bootstrappi
ng)  
Psychological 
outcomes. 
 
-Primary 
(generalised 
anxiety 
symptoms) 
•MBSR group had a 
significant decrease in 
generalised anxiety. 
• Effect of MBSR on anxiety 
was mediated by an increase in 
decentering. 
• Effect of MBSR on worry was 
mediated by increases in 
mindfulness (awareness and 
non-reactivity). 
Holzel et 
al. 
2013 
 
USA 
N = 29 
Male and 
female 
(Mean age 
36 yrs.) 
MBSR 
 
8 weeks 
Generalised 
Anxiety 
Disorder 
RCT Adapted- 
MBSR versus 
active control 
(stress 
management 
education: 
SME) 
 
 
Two time-
points (pre-
and post-
treatment) 
• Brain 
activation and 
connectivity  
(fMRI)  
Multiple 
regression 
Psychological 
outcomes. 
 
-Primary 
(generalised 
anxiety 
symptoms) 
• People in MBSR 
showed changes in 
ventrolateral prefrontal 
regions (VLPFC) 
activation and amygdala–
prefrontal connectivity.  
• The changes in ventrolateral 
prefrontal regions (VLPFC) 
activation and amygdala–
prefrontal connectivity were 
associated with improvements 
in generalised anxiety disorder. 
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Table 2.3 cont.  
Characteristics of studies with psychological conditions populations 
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-point 
assessments 
Mediators 
studied 
(Assessment tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Jermann et 
al. 
2013 
 
Switzerland 
N = 60 
Male and 
female 
(Mean age 
45 yrs.) 
MBCT 
 
8 weeks 
Recurrent 
depression 
 
3 groups 
(Remitted 
people, 
depressed 
group and 
non-
depressed 
group)  
RCT MBCT +TAU 
versus  
TAU 
 
Three time-
points (pre, 
post and 9 
month follow 
up) for only 
MBCT group.  
 
One 
assessment for 
depressed and 
non-depressed 
groups.  
• Cognitive 
functioning: 
- Autobiographical 
memory 
(Autobiographical 
Memory Test/AMT) 
- Shifting abilities 
(PM task) 
- Dysfunctional 
attitude 
(Dysfunctional 
Attitude Scale/DAS) 
- Mindful Attention 
(Mindfulness 
Attention 
Awareness 
Scale/MAAS) 
-Rumination 
(Rumination/ 
Reflection 
Questionnaire/RRQ) 
Correlation 
analysis 
Psychological 
outcomes. 
 
Cognitive 
functioning. 
•MBCT group showed 
significant decrease in 
depressive symptoms, and 
dysfunctional attitude. 
 
MBCT group showed a 
significant decrease in 
dysfunctional attitudes at 9 
months follow up. 
Kearns et 
al.  
2015 
 
Australia 
N = 203 
Male and 
female 
(Mean age 
48 yrs.) 
MBCT 
 
8 weeks 
Recurrent 
depression  
RCT 
 
MBCT + 
DRAM versus 
depression 
relapse active 
monitoring 
(DRAM). 
 
 
 
Three time-
points (pre, 
post and 2 
years’ follow-
up) 
•Rumination 
(Rumination 
Response Style 
Questionnaire/RR
S). 
•Mindfulness 
(Five-Facet 
Mindfulness 
Questionnaire/FF
MQ). 
-Regression  
-Non-
parametric  
Boot-
strapping  
Psychological 
outcomes. 
 
-Primary 
(relapse rate) 
•MBCT group showed 
significant reductions in 
relapse rate. 
• MBCT effects on depressive 
relapse were mediated by 
significant increases in 
mindfulness. 
• Rumination did not mediate 
the relationship between MBCT 
and relapse.   
 
  
98 
 
Table 2.3 cont.  
Characteristics of studies with psychological conditions populations 
 
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-point 
assessments 
Mediators 
studied 
(Assessment 
tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Kuyken  
et al. 
2010 
 
UK 
 
N = 123 
Male and 
female 
(Mean age 
49 yrs.) 
MBCT 
 
8 weeks 
Recurrent 
depression 
 with 
residual 
depressive 
symptoms 
RCT 
 
MBCT+ 
discontinuation 
of 
antidepressants 
(ADM) versus 
maintenance 
antidepressants 
(m-ADM) 
 
 
 
Three time-
points (pre, 
post and 15 
month 
follow up) 
•Mindfulness 
skill (Kentucky 
Inventory of 
Mindfulness/KI
MS) 
•Self-
compassion 
(Self-
Compassion 
Scale/SCS) 
•Cognitive 
reactivity 
(laboratory task 
+ Dysfunctional 
Attitude 
Scale/DAS). 
 
Mediation 
and 
moderation 
analytic 
framework 
(Kraemer 
method) 
Psychological 
outcomes. 
 
-Primary 
(relapse rate and 
residual 
depressive 
symptoms). 
• The effects of MBCT 
were similar to m-ADM 
in terms of relapse and 
residual depressive 
symptoms. 
 
 
•MBCT’s effects were mediated 
by significant increases in:  
-Mindfulness  
-Self-compassion. 
 
•High reactivity predicted a 
worse outcome for m-ADM 
group, but this relationship did 
not show up in MBCT group. 
 
Shahar 
et al. 
 2010 
 
USA 
 
N = 52  
Male and 
female  
(Mean age 
47 yrs.)  
MBCT 
 
8 weeks 
Recurrent 
depression 
 with 
residual 
depressive 
symptoms 
RCT MBCT versus 
waitlist control 
 
 
Two time-
points (pre-
and post-
treatment) 
 
• Brooding 
(Rumination 
Response 
Scale/RRS) 
• Reflective 
pondering 
(Rumination 
Response 
Scale/RRS) 
• Mindfulness 
(The Mindful 
Attention 
Awareness 
Scale/MAAS) 
Preacher 
and Hayes 
approach  
Psychological 
outcomes. 
 
-Primary 
(residual 
depressive 
symptoms). 
• People in MBCT group 
reported significant 
decreases in depression 
compared to waitlist 
group.  
 
•The relationship between 
MBCT and depression was 
mediated by  
-increases in mindfulness. 
-decreases in brooding. 
 
•Reflective pondering did not 
play a role in the mediation.  
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Table 2.3 cont.  
Characteristics of studies with psychological conditions populations 
Author, 
year and 
country 
Population Inter-
vention  
Disorders Study 
design 
Comparator  Time-point 
assessments 
Mediators 
studied 
(Assessment 
tool) 
Statistical 
analysis 
used  
Outcomes 
targeted  
Outcome of Intervention Findings in relation to  
‘mechanism of intervention’ 
Van 
Aalderen  
et al. 
2012 
 
Netherlands 
N = 219 
Male and 
female 
(Mean age 
48 yrs.) 
MBCT 
 
8 weeks 
Current or 
recurrent 
depression  
RCT MBCT + 
TAU versus  
TAU alone 
 
 
 
Two time-
points (pre-
and post-
treatment). 
•Rumination 
(Rumination on 
Sadness 
Scale/RSS) 
•Worry (Penn 
State Worry 
Questionnaire/P
SWQ) 
•Mindfulness 
skills (Kentucky 
Inventory of 
Mindfulness/KI
MS). 
Multivariate 
model. 
Boot-
strapping. 
Psychological 
outcomes. 
 
-Primary 
(residual 
depressive 
symptoms or 
current 
depressive 
symptoms). 
•MBCT group showed 
significant decreases in 
depressive symptoms, 
worry and rumination and 
an increase in 
mindfulness skill. 
•The relationship between 
MBCT and depression was 
mediated by  
-A decrease in rumination; 
-A decrease in worry;  
- An increase in a mindfulness 
skill (accept without judgment). 
 
 
Van den 
Hurk et al.  
2012 
 
Netherlands 
 
 
N=71 
Male and 
female 
(Mean age 
49 yrs.) 
MBCT 
 
8 weeks 
Recurrent 
depression  
RCT MBCT + 
TAU versus  
TAU alone 
 
 
 
Two time-
points (pre-
and post-
treatment) 
•Attentional 
processing 
(Attentional 
Network Test). 
Correlation 
analysis 
Psychological 
outcomes. 
-Primary 
(residual 
depressive 
symptoms or 
current 
depressive 
symptoms). 
•MBCT led to reductions 
in depressive symptoms 
and rumination and 
increases in mindfulness 
when compared to TAU. 
• No significant 
differences between 
MBCT and TAU in 
components of attention  
 
 
•Attentional processing did not 
mediate the relationship 
between MBCT and depression.  
 
Vøllestad  
et al. 
2011 
 
Norway 
 
N=76 
Males and 
female 
(Mean age 
43 yrs.)  
MBSR 
 
8 weeks 
Anxiety 
disorders 
RCT MBSR versus 
waitlist 
control 
 
 
Two time-
points (pre-
and post-
treatment 
 
6-month 
follow up for 
MBSR group 
only  
 
•Mindfulness  
(Five-Facet 
Mindfulness 
Questionnaire/F
FMQ) 
-Baron & 
Kenny 
method 
-Non-
parametric  
Boot-
strapping 
(Preacher & 
Hayes)  
Psychological 
outcomes. 
-Primary (acute 
anxiety 
symptoms). 
-Secondary 
(worry and trait 
anxiety).  
•MBSR group showed 
significant decreases in 
anxiety, depression and 
worry and an increase 
mindfulness. 
•Effects of MBSR on acute 
anxiety, worry and trait anxiety, 
but not depression were 
mediated by increases in 
mindfulness.  
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Table 2.4  
Risk bias in studies with physical conditions 
Study  Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting 
Eligibility 
criteria 
specified 
Power 
calculation 
Compliance 
with 
interventions 
Data 
collection 
tools 
valid 
All participants 
accounted for 
Bränström  
et al. 2010 
Low Unclear High High Low Low Yes Yes Unclear Yes Yes 
Labelle et al. 
2010 
High High High High Low Low Yes Unclear Yes  Yes Yes 
Labelle et al.  
2015 
High High High High Low Low Yes Unclear Unclear Yes Yes 
O’Doherty  
et al. 2015 
High High High High Low Low Yes Yes Yes Yes Yes 
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Table 2.5  
Risk bias in studies with psychological conditions 
Study  Random 
sequence 
generation  
Allocation 
concealment  
Blinding of 
participants 
Blinding of 
outcome 
assessment  
Incomplete 
outcome 
data 
Selective 
reporting  
Eligibility 
criteria 
specified  
Power 
calculation  
Compliance 
with 
interventions 
Data 
collection 
tools 
valid 
All 
participants 
accounted 
for  
Batink et 
al. 2013 
Low Low High Unclear Low Low Yes Yes Yes Yes Yes 
Bieling   
et al. 2012 
Low Low High Low Low Low Yes Unclear Yes Yes Yes 
Britton et 
al. 2012 
Low Low High Low Low Low Yes Yes Yes Yes Yes 
Geschwind 
et al. 
2011 
Low Low High Low Low Low Yes Yes Yes Yes Yes 
Goldin et 
al. 2012 
Low Unclear High High Low Low Yes Yes Unclear Yes Yes 
Hoge et al. 
2015 
Low Low High Low Low Low Yes Unclear Yes Yes Yes 
Hölzel et 
al. 2013 
Low Low High Low Low Low Yes Unclear Yes Yes Yes 
Jermann et 
al. 2013 
Low Low High Low Low Low Yes Yes Yes Yes Yes 
 
Kearns et 
al. 2015 
Low Low High Low Low Low Yes Yes Yes Yes Yes 
 
Kuyken  
et al. 2010 
Low Low High Low Low Low Yes Yes Yes Yes Yes 
 
Shahar et 
al. 2010 
Low Low High High Low Low Yes Yes Unclear Yes Yes 
Van  
Aalderen 
et al. 2012 
Low Low High Unclear Low Low Yes Yes Yes Yes Yes 
Van den 
Hurk et al. 
2012 
Low Low High Unclear Low Low Yes Yes Yes Yes Yes 
Vøllestad 
et al. 2011 
Unclear Unclear High High Low Low Yes Unclear Yes Yes Yes 
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Table 2.6 
Evaluation of studies with physical conditions populations based on the review framework 
Study name  1. Did 
the study 
use a 
theory? 
2. Did the study 
use measures to 
assess the 
mediators? 
3. Did the 
study use 
measures that 
can reflect 
different 
perspectives? 
4. Did changes 
in processes are 
specifically 
targeted by 
MBCT/MBSR? 
5. Did changes in 
potential 
mediators occur 
during the 
MBCT/MBSR? 
6. Did changes in 
mediators precede 
changes in 
outcomes? 
7.Did the 
study use 
enough time-
point 
assessments? 
8. Did the 
study use an 
appropriate 
statistical 
analysis? 
Total of 
scores 
Bränström et al. 
2010 
1 1 0 
1 
1 0 0 1 
5 
Labelle et al. 
2010 
1 1 0 
1 
1 0 0 1 
5 
Labelle et al.  
2015 
1 1 0 
1 
1 1 1 1 
7 
O’Doherty et al. 
2015 
1 1 0 
1 
1 1 1 0 
6 
Note. 1= Yes, 0=No  
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Table 2.7  
Evaluation of studies with psychological conditions populations based on the review framework 
Study name  1. Did 
the study 
use a 
theory? 
2. Did the 
study use 
measures to 
assess the 
mediators? 
3. Did the 
study use 
measures that 
can reflect 
different 
perspectives? 
4. Did changes 
in processes are 
specifically 
targeted by 
MBCT/MBSR? 
5. Did changes in 
potential 
mediators occur 
during the 
MBCT/MBSR? 
6. Did changes in 
mediators 
precede changes 
in outcomes? 
7. Did the 
study use 
enough time-
point 
assessments? 
8. Did the 
study use an 
appropriate 
statistical 
analysis? 
Total of 
scores 
Batink et al 2013 1 1 0 1 1 0 0 1 5 
Bieling et al. 
2012 
1 1 0 1 1 1 1 1 7 
Britton et al. 
2012 
1 1 1 1 1 0 0 1 6 
Geschwind et al. 
2011 
1 1 0 1 1 0 0 0 4 
Goldin et al. 2012 1 1 1 1 1 0 0 1 6 
Hoge et al. 2015  
1 1 0 1 1 0 0 1 5 
Hölzel et al. 2013 1 1 1 1 1 0 0 1 6 
Jermann et al. 
2013 
1 1 1 1 1 0 0 0 5 
Kearns et al. 
2015 
1 1 0 1 1 1 1 1 7 
Kuyken et al. 
2010 
1 1 1 1 1 1 1 1 8 
Shahar et al. 2010 1 1 0 1 1 0 0 1 5 
Van Aalderen et 
al. 2012 
1 1 0 1 1 0 0 1 5 
Van den Hurk et 
al. 2012 
1 1 1 1 1 0 0 0 5 
Vøllestad et al. 
2011 
1 1 0 1 1 0 0 1 5 
Note. 1= Yes, 0=No 
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3.1 Abstract  
Background: Somatic symptoms co-occurring with physical health conditions 
are highly prevalent in depression, being associated with increased morbidity, greater 
health care use, poor medical outcomes, greater severity and duration of depression as 
well as decreased quality of life. Consequently, it has been suggested that if treatments 
can more effectively target these somatic symptoms and physical health comorbidities, 
then the depression outcomes could be improved, and the health burden of depression 
might be decreased. Mindfulness-Based Cognitive Therapy (MBCT) as a body-mind 
treatment has shown positive effects in decreasing relapse rates and residual depressive 
symptoms. However, its effects on somatic symptoms or physical health comorbidity 
have yet to be established. Consequently, the aim of this secondary analysis is to explore 
the impact of MBCT on somatic and physical health symptoms. Methods: A secondary 
analysis of the PREVENT randomised controlled trial comparing MBCT to 
antidepressants (ADM) was conducted, focusing on changes in the Medical Symptoms 
Checklist (MSCL) as a measure of somatic and physical health symptoms as well as 
whether baseline MSCL levels moderate depression outcomes. Results: The findings of 
exploratory factor analysis showed the MSCL measure loaded onto two factors (physical 
and psychological). There was no significant difference between MBCT and ADM 
conditions at 12 and 24 months in the extent to which they reduced either physical or 
psychological symptoms on the MSCL. Baseline MSCL physical symptoms moderated 
treatment response, such that those with higher levels of symptoms did better in MBCT 
relative to m-ADM in terms of greater residual depression symptom relief and lower 
depression relapse rates. Conclusions: Baseline MSCL physical symptoms showed a 
moderation role for the effects of MBCT vs. m-ADM on relapse rates and residual 
106 
 
depressive symptoms. This result could help with understanding for whom MBCT may 
be suited.  
Keywords: MBCT, depression, medical symptoms, secondary analysis. 
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3.2 Background 
The somatic symptoms of depression are defined as “various bodily sensations 
that an individual with depression perceives as unpleasant or worrisome” (Kapfhammer, 
2006, p. 229). According to the Diagnostic and Statistical Manual of Mental Disorders-
fifth edition (DSM-5), three out of the nine symptoms of a major depressive disorder are 
of a somatic nature, including insomnia or hypersomnia, fatigue/ loss of energy, and 
change in appetite (DSM-5, 2013, p. 161). Other common somatic symptoms include 
headache, constipation, weakness, general aches and pains and backache. These 
symptoms are highly prevalent, with almost two thirds of individuals with major 
depressive disorder reporting them (Tylee & Gandhi, 2005). These somatic symptoms 
are often underdiagnosed and undertreated (Tylee & Gandhi, 2005) and frequently co-
occur with significant physical health comorbidity in depression (the presence of medical 
conditions or symptoms alongside depression). Such comorbidity is very common in 
depression (Katon, 2003, 2011; Kisely et al., 2005; Moussavi et al., 2007; Naylor et al., 
2012), with  rates of physical health problems being elevated in people with it compared 
to those without (Katon, Lin, & Kroenke, 2007). 
Both somatic symptoms of depression and medical comorbidity have been found 
to be associated with increased morbidity, health care use, suicide as well as poor 
medical outcomes and decreased quality of life (Barsky, Orav, & Bates, 2005; Blair, 
Robinson, Katon, & Kroenke, 2003; Chisholm et al., 2003; Fortin et al., 2006; Katon, 
2011; Kisely et al., 2005; Moussavi et al., 2007; Sareen. et al., 2006). Importantly, they 
often lead to increases in the severity and duration of depression as well as increased risk 
of subsequent relapse (Jeong et al., 2014; Ohayon, Schatzberg, & Ohayon Mm, 2003; 
Richards, 2011; Trivedi, 2004). Regarding which, Iosifescu et al. (2003) found that 
higher medical comorbidity is associated with a poorer response to antidepressants and 
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lower remission rates. Hence, depression outcomes may be improved, if treatments can 
more effectively target these somatic symptoms and physical health comorbidities. This 
might also help promote a full recovery and decrease the health burden of depression 
(Trivedi, 2004).  
Mindfulness-based cognitive therapy (MBCT) has been designed as a prevention 
programme for helping people who are at high risk of recurrent depression (Segal, 
Williams & Teasdale, 2002, 2013). A range of evidence currently suggests that such 
therapy is comparably effective as maintenance anti-depressant medication in preventing 
depressive relapse (Kuyken et al., 2015; Segal, Martin & Joseph, 2010). There is also 
emerging evidence that MBCT is effective at treating residual depression symptoms in 
those only partially in recovery and in treating acute depression (Barnhofer et al., 2009; 
Eisendrath et al., 2016; van Aalderen et al., 2012). However, whether MBCT can repair 
somatic/physical health symptoms or medical morbidity remains an open question.  
There are reasons to hypothesise that mindfulness may be helpful in ameliorating 
somatic/physical health symptoms. A key component of MBCT involves helping 
individuals train a style of attention where they focus on bodily sensations in a non-
judgmental way (Crane et al., 2017). This may in part act by modulating interoceptive 
awareness (Craig, 2002), defined as the “the ability to detect changes in the body 
(including muscles, skin, joints and viscera), enabling individuals to experience bodily 
‘feelings’ such as pain, temperature” (Dunn et al., 2010, p. 1133). People with depression 
have been found to show reduced interoceptive awareness (Dunn et al., 2010; Dunn, 
Dalgleish, Ogilvie, & Lawrence, 2007) and there is a growing awareness of the wide-
ranging effects of modulating such awareness via mindfulness practice on a range of 
cognitive, affective and physical health outcomes (Farb et al., 2015).   
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If MBCT is better able to treat the somatic symptoms of depression than other 
approaches, it means that it should be differentially effective in repairing depression in 
those individuals who present at baseline with elevated levels of somatic symptoms and 
physical health comorbidities. In other words, the presence of these symptoms should 
moderate both acute treatment outcomes and long-term rates of recovery. Moderators 
pertain to variables that can be assessed prior the initiation of an intervention, which 
need to be correlated with the outcome and intervention statistically, being able to 
explain the relationship between the intervention and the outcomes (Johansson & 
Høglend, 2007; Murphy, Cooper, Hollon & Fairburn, 2009).  
Accordingly, the present study was aimed at testing whether MBCT is effective 
in modulating somatic/physical health symptoms and whether the presence of 
somatic/physical health symptoms at baseline moderates the response to MBCT. To this 
end, a secondary analysis of the PREVENT trial (Kuyken et al., 2016) was conducted. 
This study examined the effects of MBCT with tapering versus maintenance 
antidepressants (m-ADM) in preventing depression relapse in people with a history of 
recurrent depression and found that both were effective at reducing relapse rates at two 
years. The PREVENT trial also included the Medical Symptoms Checklist (MSCL; 
Travis, 1977), which measures a wide range of medical symptoms. Kuyken et al. (2016) 
reported that there was no difference between the two groups in change in the total 
MSCL score from baseline to 12 or 24 months follow up. However, close inspection of 
the MSCL reveals that it involves a mixture of items considering physical health/somatic 
symptoms and items measuring general psychological distress. The psychometric 
properties of the MSCL have never been robustly examined and it is possible that a two-
factor solution will emerge, measuring these physical and psychological items. 
Consequently, the present study will involve, first, factor analysing the MSCL and then 
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examining whether MBCT differentially repairs physical symptoms factor on the MSCL 
relative to m-ADM. Second, it will examine if baseline scores on the MSCL physical 
symptom factors predict a superior response to MBCT relative to m-ADM.  
3.3 Method  
3.3.1 Summary of the PREVENT Trial 
Participants were recruited through GPs and advertisements in four areas of the 
south west of the UK (Exeter and East Devon, North and mid-Devon, South Devon, and 
Bristol). Eligible participants were adults 18 and older who: had a diagnosis of recurrent 
major depressive disorder (either in full or partial remission); had suffered three or more 
previous major depressive episodes; and who were on maintenance antidepressant 
medication in line with the British National Formulary (BNF) and NICE guidance. 
Randomisation was conducted based on a computer-generated random number sequence. 
The stratification variables were the recruitment site (Exeter and East Devon, North and 
mid-Devon, South Devon and Bristol) and severity of depression (asymptomatic vs. 
partially symptomatic at intake). Participants were randomised into MBCT or 
maintenance antidepressant (m-ADM) groups. MBCT is a programme outlined by Segal 
et al. (2002, 2013) and developed based on Mindfulness-Based Stress Reduction 
(MBSR). It comprises an individual orientation session and eight weekly 2.5-hour group 
sessions, which involve mindfulness meditation exercises and certain cognitive therapy 
techniques. This course was designed to help people become aware of problematic styles 
of thinking and reacting, decentre from these and to respond more adaptively at times of 
potential depressive relapse. The primary outcome of PREVENT was time to depressive 
relapse rate up to two years, which was assessed based on Longitudinal Interval Follow-
up Evaluation, a form of the Structured Clinical Interview for DSM-IV (SCID). The 
secondary outcomes were residual depressive symptoms assessed by two measures: the 
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GRID-Hamilton Rating Scale for Depression (GRID-HAMD) and the Beck Depression 
Inventory (BDI-II). One of strengths of PREVENT regarding assessing acute depression 
outcomes is that the researchers used both people’s reported subjective outcomes and 
clinician assessed objective one (for detailed procedures, see Kuyken et al. (2010, 
2016)). Of particular relevance to the current study, physical health/somatic symptoms 
were assessed as an additional secondary outcome using the Medical Symptoms 
Checklist (MSCL; Travis, 1977). 
3.3.2 Measures used in the Analysis  
 3.3.2.1 The Medical Symptoms Checklist (MSCL).  
The Medical Symptoms Checklist (MSCL) was developed by John Travis in 
1977 (Travis, 1977) and is a self-reported measure of 109 medical symptoms. Ninety-
five items apply to both males and females, including headache, loss of balance, dizzy 
spells, shortness of breath with normal activity, itching or burning skin, and pain in 
abdomen, worrying lot, lonely or depressed as well as nervousness or anxiety. Three 
items apply to males only, such as painful testicles and 11 items apply to females only, 
such as menstrual problems and painful breasts. Participants are asked if they have had 
these symptoms over the last month, with the responses being Yes or No. The total score 
is the total number of symptoms endorsed, with a minimum of 0 and the maximum being 
98 for males and 106 for females. The MSCL has been used frequently in the 
mindfulness literature to index physical health outcomes (e.g., Carmody & Baer, 2008; 
Kabat-Zinn, 1982; Kabat-Zinn, Lipworth, & Burney, 1985; Kuyken et al., 2016), but its 
psychometric properties have yet to be established. Consequently, in the present study 
the aim was to establish its validity and reliability and then moved on to test the core 
hypotheses.   
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3.3.2.2 The Beck Depression Inventory (BDI-II).  
The Beck Depression Inventory (BDI-II; Beck & Steer, Brown, 1996) is a 21-
item self-report measure of depression severity, with each item being rated from 0 to 3, 
giving a minimum score of 0 and a maximum of 63. The BDI-II assesses psychological, 
cognitive and physical symptoms of depression, including hopelessness, guilt feelings, 
fatigue, sense of failure, self-dissatisfaction, suicidal ideas, crying, irritability, social 
withdrawal, body image, work difficulties, insomnia as well as appetite and weight loss. 
This measure has been widely used with different populations. The BDI-II has showed 
good psychometric properties with Cronbach's Alpha (0.94) in the UK (Cameron et al., 
2011).  
3.3.2.3 The GRID-Hamilton Depression Rating Scale (GRID-HAMD).  
The GRID-Hamilton Depression Rating Scale (GRID-HAMD; Williams, 1998) is 
an interview to assess depression severity, which is administered by a health care 
professional. It contains 21 items covering the core symptoms of depression, each of 
which is rated from 0 (absent) to 3 (severe). The first 17 items measure the severity of 
core depressive symptoms and the remaining four assess additional symptoms sometimes 
related to depression (including paranoia, obsessional and compulsive symptoms). The 
GRID-HAMD is scored based on the first 17 items only, identifying four categories: not 
depressed (0–7), mild depression (8–16), moderate depression (17–23) and severe 
depression (24-51).  
3.3.3 Statistical Analyses  
Data analysis was performed based on the Intent-To-Treat (ITT) sample that 
considers all randomised participants using SPSS 23.0. The analysis protocol was 
outlined before accessing the data. To establish the psychometric properties of the 
MSCL, exploratory factor analysis and Cronbach's alpha were used focusing only on 
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items pertaining to both genders. To examine how well MBCT performed versus m-
ADM repair physical health symptoms, analysis of covariance (ANCOVA) was used to 
examine effects of the two on medical symptoms based on the total MSCL measure at 12 
and 24 months, controlling for baseline MSCL severity and the PREVENT trial 
stratification variables (recruitment site and severity of depression at randomisation). The 
recruitment site was dummy coded, while the severity of depression at randomisation, as 
a binary stratification, was entered as 0 and 1. Cox’s regression was used to assess 
whether baseline total MSCL moderates the relapse rates outcomes in MBCT vs. m-
ADM at 12 and 24 months. Also, a linear regression was used to assess whether baseline 
MSCL moderates residual depressive symptoms, as assessed by BDI and GRID-HAMD 
in MBCT vs. m-ADM at post intervention, 9 months and 12 months. The Kraemer 
moderation approach (Kraemer et al., 2002) was followed, additionally adjusting for 
PREVENT trial stratification variables. Consequently, at Step One, the recruitment site, 
severity of depression for the randomisation group (MBCT vs. m-ADM) and the 
moderator (baseline MSCL, measures before the intervention) were entered. At Step 
Two, the interaction between group and the moderator was entered. Moderation was 
indicated by a significant increase in model fit from Step One to Step Two and if a 
significant moderation were found, the Hayes method of simple slopes would be used to 
resolve the interaction (Hayes, 2012).  
3.4 Results 
3.4.1 Sample Characteristics 
A total of 424 people was recruited through 95 GPs at four sites: Exeter, North 
Devon, South Devon and Bristol. Of the 424 people, 24 % were male and 76 % female 
with a mean age of 49 and ranging from 20 to 79 years of age. Approximately 99 % were 
of White British ethnic origin and 48 % were married. There were no significant 
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differences between the two groups for all the demographic data, except for gender. 
Descriptive statistics of the MSCL and the number of people who completed it at 
baseline, 12 months and 24 months for the MBCT and m-ADM groups are shown in 
Table 3.1.  
3.4.2 Psychometrics Characteristics of the MSCL Measure Results   
3.4.2.1 Exploratory factor analysis (EFA). 
Exploratory factor analysis (EFA) was carried out on 95 out of the 109 items of 
the MSCL measure10 and to ascertain whether the data were suitable for factor analysis, 
all 424 valid cases were included in the initial screening. Prior to analysis, the suitability 
of EFA was assessed through two tests: Kaiser-Meyer-Olkin (KMO)11 and Bartlett’s test 
of sphericity12. The findings showed that the overall Kaiser-Meyer-Olkin (KMO) 
measure was 0.80, with a classification of 'adequate', according to Kaiser (1974), whilst 
Bartlett’s test was highly significant (2 = 11530.38, p < 0.000), thus indicating that 
EFA was appropriate.  
 Initial EFA revealed 32 components (their eigenvalues were smaller than one), 
which explained approximately 49.5 % of the total variance. However, visual inspection 
of the scree plot indicated that only two of these components should be retained (a line 
clearly flattened out after two factors) (Cattell, 1966). The two-component solution 
explained 15.5 % of the total variance. These two factors were named physical and 
psychological according to the nature of each factor’s symptoms. Initially, a range of 
rotation methods (e.g., varimax, promax and direct oblimin) was examined, where only 
small differences were found in the solutions reached. Eventually, the decision was made 
to focus on a direct oblimin rotation, because it assumes that all the factors are correlated 
                                                 
10 14 items specific to gender (for males or females only) were excluded. 
11 This test assesses whether factors are available or not.   
12 This test assesses the overall significance of all the correlations within the correlation matrix. 
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(the component correlation matrix for the two factors was larger than 0.32). However, 
only the items that loaded most strongly (loadings < 0.40) onto separate factors were 
kept. The component loadings of the rotated solution are presented in Table 3.2. 
3.4.2.2 Reliability of the MSCL. 
The reliability of the total MSCL and the two factors were good. Cronbach's 
alpha for the total MSCL was (0.93), for the physical component was (0.83) and for the 
psychological component was (0.85). Moreover, the correlation between the two factors 
was relatively high r =.42, p < .01. 
3.4.3 Aim One: Evaluating the Extent to which MBCT vs. m-ADM Alleviates 
Medical Symptoms  
The means and standard error (SEM) for the total MSCL as well as the MSCL 
factors (physical and psychological) at 12 months and 24 months are presented in 
Figures 3.1, 3.2 and 3.3. An ANCOVA (adjusting for baseline severity and the 
stratification variables) found that the MBCT and m-ADM groups did not differ 
significantly in their medical symptoms at 12 months or 24 months in terms of the 
MSCL total score, Fs < 1. Similar analyses were repeated based on the two factors of the 
MSCL (physical and psychological). The findings show that there were no differences 
between the MBCT and m-ADM groups in either factor at 12 months or 24 months, 
Fs < 1.  
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3.4.4 Aim Two: Evaluating Whether Baseline Medical Symptoms Moderate the 
Relationship Between MBCT When Compared to m-ADM and Depression 
Outcomes  
3.4.4.1 Moderation analysis for depression relapse rates.  
The results indicated that baseline medical symptoms (the total MSCL) moderate 
the effects of MBCT vs. m-ADM on the hazard of relapse at 12 and 24 months. At 12 
months, the main effect of the total MSCL at Step One was significant (Wald = 10.73,  
p < .001, hazard ratio = 1.02) and there was also a significant interaction between the 
total MSCL and group at Step Two (Wald = 10.93, p < .001, hazard ratio = 1.03) (see 
Figures 3.4 and 3.5). At 24 months, the main effect of the total MSCL (Wald = 9.64, p < 
.002, hazard ratio = 1.02) and the interaction between the total MSCL and group (Wald = 
8.91, p < .003, hazard ratio = 1.03) were also significant (see Figures 3.6 and 3.7). This 
means that high MSCL symptoms at baseline predicted worse 12 and 24-month survival 
rates. This effect was driven by the m-ADM group, in that higher MSCL symptoms 
predicted higher relapse rates in this group, but not in the MBCT group.  
A similar pattern emerged when looking at the physical and psychological factors 
at both 12 and 24 months. At 12 months, the main effects and interactions were 
significant for both the physical factor (main effect, Wald = 5.27, p < .02, hazard 
ratio=1.10; interaction, Wald = 6.00, p < .01, hazard ratio = 1.11) and the psychological 
factor (main effect, Wald = 6.22, p < .01, hazard ratio = 1.10, interaction, Wald = 6.46, 
p < .01, hazard ratio = 1.12). At 24 months, the main effect and interaction were 
significant for the physical factor (main effect, Wald = 3.29, p < .07, hazard ratio = 1.03; 
interaction, Wald = 5.76, p < .02, hazard ratio = 1.10) and the psychological factor (main 
effect, Wald = 4.21, p < .04, hazard ratio = 1.04; interaction, Wald = 4.67, p < .03, 
hazard ratio = 1.10). This means that high MSCL physical and psychological symptoms 
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at baseline predict worse 12 and 24-month survival rates. This effect was driven by the 
m-ADM group, in that higher MSCL physical and psychological symptoms predicted 
higher relapse rates in this group, but not in the MBCT one.  
3.4.4.2 Moderation analysis for residual depressive symptoms. 
3.4.4.2.1 BDI results. At post-intervention, Step One of the overall model was 
significant, F = 22.37, p < .001, and accounted for (30 %) of the variance in residual 
depressive symptoms. However, when adding the interaction term at Step Two, the 
model did not significantly improve (F change = 0.76, p = .38). Similarly, at 9 months, 
Step One of the overall model was significant (F= 10.1, p < .000) and accounted for 
(18 %) of the variance in the outcome. However, after adding the interaction term in Step 
Two, the model did not improve (F change = 2.41, p = .12).    
At 12 months, the overall model one was significant (F = 14.48, p < .000) and 
accounted for 23 % of the variance in the outcome. When adding the interaction term at 
Step Two, the model improved significantly (F change = 3.73, p < .054, B = 0.14, Beta = 
0.13, t = 1.93) (see Table 3.3). To resolve this interaction, depression symptoms were 
plotted as a function of the MSCL for each condition separately, thus showing that high 
MSCL symptoms at baseline predicted worse 12-months residual depressive symptoms.  
This effect was driven by the m-ADM group, in that higher MSCL symptoms predicted 
higher residual depressive symptoms in this group, but not in the MBCT one (see Figure 
3.8). 
The same analyses were repeated based on the two factors of the MSCL (physical 
and psychological). The physical symptoms moderated the effects of MBCT vs. m-ADM 
groups on residual depressive symptoms at 9 months (see Figure 3.9) and were 
marginally significant at 12 months (See Table 3.4). Regarding the psychological 
component, no moderation effects were found at both of the follow-ups (see Table 3.5).  
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3.4.4.2.2 GRID-HAMD results. Table 3.3 shows that baseline MSCL moderated 
the relationship between MBCT vs. m-ADM and residual depressive symptoms, as 
assessed by GRID-HAMD at 9 months, but not at post-intervention and 12 months. At 9 
months, the overall model one was significant (F = 8.43, p < .000) and accounted for 
(13 %) of the variance in the outcome. When adding the interaction term at Step Two, 
the model improved significantly (F change = 6.58, p < .01, B = 0.11, Beta= 0.18, t = 
2.57). This means that high MSCL symptoms at baseline predicted worse 9-month 
residual depressive symptoms. This effect was driven by the ADM group, in that higher 
MSCL symptoms predicted higher residual depressive symptoms in this group, but not in 
the MBCT one (see Figure 3.10).  
The same analyses were repeated based on the two factors of the MSCL (physical 
and psychological). The physical symptoms moderated the effects of MBCT vs. m-ADM 
groups on residual depressive symptoms at 9 months (see Figure 3.11) and marginally at 
post-intervention (See Table 3.4). Regarding the psychological component, no 
moderation effects were found in any of the follow-ups (see Table 3.5).  
3.5 Discussion  
In the current secondary analysis, the first aim was to explore whether MBCT 
could better alleviate medical symptoms (physical and psychological) compared to those 
on antidepressants. The second aim was to see to what extent those symptoms moderate 
the effects of MBCT versus antidepressant medication in terms of the depression relapse 
rate and residual depressive symptoms. The aim was also to establish the reliability and 
factor structure of the MSCL. Overall, the findings of exploratory factor analysis showed 
the MSCL measure loaded onto two factors (physical and psychological). Also, no 
differences were found between the MBCT and m-ADM groups in terms of change in 
the physical and psychological factors of the MSCL. Regarding the moderation analyses, 
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the findings largely supported the perspective that baseline medical symptoms, as 
assessed by MSCL, play a role as a moderator of effects of MBCT vs. m-ADM. This 
pattern was most clearly demonstrated in terms of relapse rate, but also emerged, to some 
extent, in terms of residual symptom severity with the effects hold when looking solely 
at physical symptoms not psychological ones.  
MBCT vs. m-ADM did not help to alleviate medical symptoms (physical and 
psychological) at either 12 or 24 months. These findings are not in line with an 
uncontrolled study (Carmody & Baer, 2008) that used mindfulness-based stress 
reduction (MBSR) with people with chronic pain and psychological symptoms, which 
elicited that MBSR showed positive effects (pre-post intervention) on medical 
symptoms, as assessed by MSCL, with a large effect size. This could be explained by the 
fact that these authors used an uncontrolled design, which meant that robust conclusions 
could not be drawn. Also, it could have been due to the populations (recurrent depression 
vs. chronic pain with psychological symptoms) and interventions (MBCT vs. MBSR) 
being different. The current study extends the secondary results presented in Kuyken et 
al. (2016), as it has been demonstrated that this pattern plays out in terms of both 
physical and psychological symptoms.  
The baseline total score of the MSCL moderated the effects of MBCT vs. m-
ADM on relapse rate at 12 and 24 months. Moreover, it played a moderation role on the 
relationship between MBCT vs. m-ADM and residual depressive symptoms, as assessed 
by BDI at 12 months and HAMD at 9 months. The simple slopes for the interaction 
between the MSCL and groups show that participants in the m-ADM group with high 
medical symptoms reported high depressive symptoms at 12 and 24 months, whilst this 
picture was not clear for the MBCT group. Similar findings were found regarding the 
physical factor of the MSCL as for the participants in the m-ADM group, with high 
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physical symptoms reported high depressive symptoms as assessed by BDI at 12 months 
and HAMD at 9 months, whilst this picture did not show up in the MBCT group. Thus, 
the outcomes of the current study point to the potential role that medical symptoms, 
especially those associated with physical health, play in relation to effects of MBCT on 
essential depression outcomes, such as relapse and residual depressive symptoms. This is 
inconsistent with a study by Nyklíček, van Son, Pop, Denollet & Pouwer (2016), who 
examined the role of medical comorbidity on the effects of MBCT on anxiety, depressive 
symptoms and perceived stress in people with diabetes, finding that medical comorbidity 
did not have a moderation effect on the relationship between MBCT vs. a control group. 
One explanation for this inconsistency is that the populations were different (recurrent 
depression vs. diabetes with psychological symptoms). Another explanation could be due 
to the nature of the moderator, as in the current analysis the focus was only on medical 
symptoms, while in previous one they focused on medical conditions.  
Interestingly, the main effects of the total MSCL and the sub-physical symptoms 
on residual depressive symptoms, as assessed by BDI and GRID-HAMD, were mostly 
significant at post-intervention, 9 and 12 months, whilst the interaction effects were not 
significant at some of these follow up times. This could indicate that medical symptoms, 
especially the physical side, did have an impact on depression outcomes regardless of the 
group that the participants were in. This is consistent with the literature regarding the 
role of medical symptoms in relation to depression outcomes (Chisholm et al., 2003; 
Jeong et al., 2014; Trivedi, 2004). 
However, whilst the MBCT participants did not experience repaired medical 
symptoms when compared to the antidepressant group, interestingly, those undertaking 
MBCT seemed to outperform the antidepressant group in relation to the subgroups with 
high medical symptoms and high physical ones. One explanation for this might be that 
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MBCT may help with an individual’s reaction to/awareness of physical symptoms rather 
than changing them (Dunn et al., 2010; Parkin et al., 2014).  
3.6 Strength and limitations  
 To the best of our knowledge, this study is the first that has examined medical 
symptoms as a moderator of MBCT effects on depression outcomes. Moreover, the 
sample size used in the analyses was large. In addition, this study is the first that 
established the psychometric properties of the Medical Symptoms Checklist (MSCL).  
However, it does have several limitations. First, the analysis was performed 
based on intention-to-treat (ITT) only and not per-protocol analysis. Using both methods 
has been recommended by the Consolidated Standards of Reporting Trials (CONSORT) 
(Moher et al., 2001; Schulz, Altman & Moher, 2010). Second, the role of medical 
symptoms as a moderator was based on a sample of people with three or more depressive 
episodes and thus, it is important to see whether the same moderator would show up in 
other populations, such as people with fewer depressive episodes or those with current 
depression. Third, the exploratory factor analysis carried out was based on a population 
with pure recurrent depression and consequently, checking the validity of the MSCL in 
other populations, such as people with chronic disorders might reveal a different 
underlying factor structure. Finally, the two-component solution of the exploratory factor 
analysis explained only a small proportion of the total variance.   
3.7 Future research 
It would be interesting to explore the role of physical health symptoms as a 
mediator to see if change in physical health symptoms accounts for superior acute 
symptom recovery and relapse prevention in MBCT versus antidepressant populations. 
In the current analysis, it was not possible to measure this, given that the MSCL scores 
were not assessed immediately post treatment. Also, it would be useful to focus on 
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attitude/awareness of somatic symptoms using new measures, such as multidimensional 
assessment of interoceptive awareness (MAIA; Mehling et al., 2012). In addition, 
replicating the findings in terms of the two-structure factors of the MSCL through the 
deployment of populations with chronic physical conditions would help to establish 
whether the same factors in the current study hold in this other context.  
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Table 3.1 
Descriptive statistical of MSCL at baseline, 12 and 24 months follow up in MBCT and 
m-ADM groups.  
MSCL MBCT m-ADM 
 N M (SD)  N M (SD)  
Baseline  210 22.8 (13.9)  206 21.7 (13.7)  
12 months  167 20.9 (14.0)  156 19.2 (13.7)  
24 months  169 22.1 (14.6)  167 21.6 (16.2)  
Note. N: number of participants; M: Mean; SD: Standard deviation.  
 
 
Figure 3.1. Means and SEM for the Medical Symptoms as Assessed by the Total 
MSCL. 
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Figure 3.2. Means and SEM for Physical Factor of the MSCL (18 items) 
 
 
 
 
Figure 3.3. Means and SEM for Psychological Factor of the MSCL (14 items) 
 
 
 
  
1
1.5
2
2.5
3
3.5
4
4.5
5
Baseline 12 months 24 months
MSCL Physical Symptoms 
MBCT m-ADM
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
Baseline 12 months 24 months
MSCL Psychological Symptoms 
MBCT m-ADM
125 
 
 
 
 
Figure 3.4 Relapse Rate in People with low Medical Symptoms at 12-Month 
 
 
Figure 3.5 Relapse Rate in People with high Medical Symptoms at 12-Month 
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Figure 3.6 Relapse Rate in People with low Medical Symptoms at 24-Month 
  
 
Figure 3.7 Relapse Rate in People with high Medical Symptoms at 24-Month 
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Figure 3.8. Baseline Medical Symptoms as a Moderator of Effect of MBCT vs.m-
ADM on Residual Depressive Symptoms as Assessed by BDI at 12-Months 
 
 
Figure 3.9. Baseline MSCL Physical as a moderator of effect of MBCT vs. m-ADM 
on residual depressive symptoms as assessed by BDI at 9-months 
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Figure 3.10. Baseline Medical Symptoms as a Moderator of Effect of MBCT vs. m-
ADM on Residual Depressive Symptoms as Assessed by HAMD at 9-Months 
 
 
Figure 3.11. Baseline MSCL Physical as a Moderator of Effect of MBCT vs. m-
ADM on Residual Depressive Symptoms as Assessed by HAMD at 9-Months 
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Table 3.2  
Pattern matrix for the EFA with Direct Oblimin rotation of a two-factor solution for medical symptoms checklist (MSCL) 
Item no  Items F1 F2 
52  Weakness in arms or legs  .538  
4 Loss of balance  .535  
5 Dizzy spells  .526  
27 Shortness of breath with normal activity  .501  
59 Itching or burning skin  .489  
56 Leg cramps  .488  
7 Blurry vision  .479  
33 Pain in abdomen   .453  
11 Eye pain or itching  .439  
50 Swollen joints .434  
53 Painful feet  .419  
20 Wheezing or grasping  .418  
28 Swollen feet or ankles  .415  
39 Pain in rectum  .414  
42 Itching rectum  .413  
40 Hearing difficulties  .408  
13 Noises in ears  .405  
16 Back or shoulder pains  .404  
71 Worrying lot   -.674 
67 Lonely or depressed   -.622 
64 Difficulty making decisions     -.600 
61 Nervousness or anxiety   -.590 
77 Annoyed by little things  -.532 
65 Lack of concentration   -.516 
76 Angered easily   -.501 
69 Hopeless outlook   -.484 
74 Shy or sensitive   -.473 
75 Dislike criticism   -.468 
66 Loss of memory   -.457 
73 Feeling of desperation   -.443 
70 Difficulty relax   -.434 
68 Frequent cry   -.405 
Note. F1: Factor one (Physical symptoms); F2: Factor two (Psychological symptoms). 
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Table 3.3  
Linear regression analyses examining the total MSCL as a moderator of the effects of MBCT vs. m-ADM on residual depressive 
symptoms  
 Main effect    Interaction effect   
Outcome B ßeta t p  B ßeta t p 
BDI          
Post-intervention  0.11 0.15 2.67 .01  0.06 0.04 0.87 .38 
9 months follow up  0.05 0.08 1.14 .26  0.12 0.11 1.55 .12 
12 months follow up 0.09 0.14 2.23 .02  0.14 0.13 1.93 .05 
`GRID-HAMD          
Post-intervention  0.09 0.23 4.33 .00  0.11 0.09 1.31 .19 
9 months follow up 0.10 0.22 4.23 .00  0.11 0.18 2.57 .01 
12 months follow up 0.10 0.23 4.33 .00  0.05 0.08 1.43 .25 
Note. B= unstandardised regression coefficient; ßeta= standardised coefficient 
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Table 3.4 
Linear regression analyses examining the physical symptoms of MSCL as a moderator of the effects of MBCT vs. m-ADM on residual 
depressive symptoms  
 Main effect    Interaction effect   
Outcome B ßeta t p  B ßeta t p 
BDI          
Post-intervention  0.37 0.14 2.76 .01  0.32 0.08 1.23 .21 
9 months follow up  0.20 0.08 1.31 .19  0.56 0.14 1.94 .05 
12 months follow up 0.25 0.10 1.87 .06  0.49 0.13 1.91 .06 
`GRID-HAMD          
Post-intervention  0.41 0.26 5.10 .00  0.27 0.12 1.75 .08 
9 months follow up 0.37 0.24 4.51 .00  0.42 0.18 2.63 .01 
12 months follow up 0.23 0.15 2.86 .00  0.24 0.12 1.64 .10 
Note. B= unstandardised regression coefficient; ßeta= standardised coefficient. 
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Table 3.5 
Linear regression analyses examining the psychological symptoms of MSCL as a moderator of the effects of MBCT vs. m-ADM on 
residual depressive symptoms  
 Main effect    Interaction effect   
Outcome B ßeta t p  B ßeta t p 
BDI          
Post-intervention  0.13 0.05 0.81 .42  0.16 0.05 0.68 .49 
9 months follow up  0.09 0.04 0.53 .59  0.36 0.10 1.31 .19 
12 months follow up 0.31 0.13 2.00 .05  0.35 0.10 1.45 .15 
`GRID-HAMD          
Post-intervention  0.13 0.21 4.14 .00  0.23 0.11 1.54 .12 
9 months follow up 0.19 0.13 2.43 .02  0.24 0.12 1.57 .16 
12 months follow up 0.62 0.18 3.55 .00  0.13 0.07 0.93 .35  
Note. B= unstandardised regression coefficient; ßeta= standardised coefficient.
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4.1 Abstract 
Background: Depression co-occurs in 20 % of people with cardiovascular 
disorders, can persist for years, and predicts worse physical health outcomes. There is 
increasing evidence that psychological mechanisms, including self-efficacy, self-care, 
rumination and worry may explain why depression is linked to CVDs. Mindfulness-
based cognitive therapy, as a mind-body treatment, has shown promising effects in a 
wide range of physical conditions with small to medium effect sizes. Developing a 
bespoke form of MBCT for people with CVDs and co-morbid depression to maximise 
the effect sizes and targeting some of the mechanisms linked between these conditions 
could prove beneficial. Developing and refining such an approach is the focus of the 
current work. Methods: This study reports an uncontrolled manual development pilot 
group (n = 9) to develop a bespoke adaptation of MBCT for individuals with depression 
and cardiovascular disorders. Repeated measurements of depression, mindfulness and 
illness perceptions were taken throughout the pilot group. Results: Nine people took part 
in the pilot group and all completed the full course, with the levels of attendance and 
home mindfulness practice being high. With regards to the primary outcome 
(depression), six out of the nine participants showed significant clinical change for the 
better. Some changes were made to the MBCT manual in terms of the main themes and 
home practice, based on feedback from the delivering therapist and participants. 
Conclusions: The findings of this pilot group seem promising in terms of adapting the 
MBCT manual for people with depression and cardiovascular disorders. Retention and 
attendance rates were high, depressive symptoms and illness perceptions were reduced, 
and self-reported mindfulness was increased. This suggests it is reasonable to proceed to 
the next level of developing MBCT for people with depression and CVDs (a feasibility 
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randomised controlled trial of the approach compared to another active mindfulness 
intervention and a control arm).  
Keywords: MBCT, depression, cardiovascular disorders, manual development, 
pilot group.    
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4.2 Background  
According to the World Health Organisation (WHO), depression and 
cardiovascular disorders will be the leading cause of morbidity and mortality worldwide 
by 2020 (World Health Organization, 2012). In the United Kingdom approximately 20% 
of people with CVDs suffer from depression (Davidson, 2012; Huffman et al., 2013). 
The comorbidity between depression and CVDs is associated with worse psychological 
and physical outcomes and increases the burden on individuals and health service 
providers (Baumeister et al., 2015; Dickens, Katon, et al., 2012; Naylor et al., 2012; 
Pelletier et al., 2015; Rustad et al., 2013).  
This comorbidity can be explained through a combination of various biological, 
psychological, and social factors. For instance, at the biological level increased 
inflammation and platelet activation have been found to be associated with both 
conditions (Dickens, 2015; Guarneri, Mercado, & Suhar, 2009; Miller & Blackwell, 
2006). Additionally, psychological factors, such as self-efficacy, self-care, and health 
related concerns, have also been shown to be linked to these conditions (Greco et al., 
2014; Morgan et al., 2014; Tovar et al., 2015; van der Wal et al., 2016; Volz et al., 
2016). Moreover, it has been suggested that perseverative negative cognitive processes, 
such as worry or rumination, influence both symptoms of anxiety and depression (Nolen-
Hoeksema, 1991) and are associated with CVDs such as coronary heart disease and 
hypertension (Gerin et al., 2012; Kubzansky et al., 1997; Radstaak et al., 2011). 
Consequently, psychological interventions that can target the key mechanisms 
underlying CVD and co-morbid depression need to be developed to improve the physical 
and psychological outcomes for this population.  
Mindfulness interventions were developed as integrated therapies to target the 
mind-body relationship. Mindfulness-Based Cognitive Therapy (MBCT) has been 
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designed to target negative thinking styles that make individuals with a chronic history of 
depression vulnerable to relapse (Segal et al., 2002, 2013). A number of studies have 
shown that MBCT has promising effects in terms of relapse prevention and treating 
residual depressive symptoms, with these effects having been found to be comparable to 
the results for antidepressants (Kuyken et al., 2016; Segal et al., 2010). Moreover, 
MBCT has also shown promising results in terms of treating depressive symptoms and 
psychological problems in some physical conditions, including cancer, diabetes, 
inflammatory bowel disease (IBD) and multiple chemical sensitivities (MCS) (Schoultz 
et al., 2015; Skovbjerg et al., 2012; Van Der Lee & Garssen, 2012; van Son et al., 2014).  
However, the evidence thus far that supports the effects of MBCT in terms of 
physical outcomes is mixed as well as the benefits of it being found mostly to be small in 
magnitude (Abbott et al., 2014). With regards to CVDs, as far as we are aware, only one 
non-randomised trial has evaluated the efficacy of MBCT for people with heart 
conditions and current depression (O’Doherty et al., 2015). The results indicated that 
MBCT had medium to large effect sizes on reducing current depression, anxiety, and 
illness perception and increasing quality of life. However, the non-randomised design 
used preclude strong conclusions from being drawn and thus further research is needed.  
It is likely to be beneficial to develop a bespoke form of MBCT for people with 
CVDs and co-morbid depression to maximise the effect sizes and target some of 
mechanisms linked between depression and CVDs. Standard MBCT primarily 
emphasises specific mechanisms that apply to depression, including rumination about 
causes, meanings and the consequences of low mood, but individuals experiencing 
CVDs appear to have different cognitive patterns (Larsen & Christenfeld, 2009; 
Rozanski et al., 1999). For instance, they may be concerned about having another heart 
attack or stroke or rumination about the causes, meanings and consequences of a cardiac 
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condition. Moreover, due to the nature of CVDs, people may feel insecure with their 
body and thus, a different focus during mindfulness practice may be required. 
Furthermore, existing evidence suggests that people with CVDs have low confidence 
regarding their ability to take care of their condition (i.e. low self-efficacy), which 
undermines their self-care (Greco et al., 2014; Riegel et al., 2011, 2007; Tovar et al., 
2015; Volz et al., 2016). A bespoke intervention that addresses these issues is likely to be 
optimally effective. Developing and refining such an approach is the focus of the current 
paper. 
The recent UK Medical Research Council guidelines (MRC) (Craig et al., 2008) 
suggest criteria for ensuring high quality and efficacy of developing or improving 
complex interventions. Also, the National Institutes of Health (NIH) stage model (Onken 
et al., 2014) proposes six developmental stages to follow to enhance the potency of a 
novel intervention and to fit into the service delivery system. Dimidjian & Segal (2015) 
carried out a careful review of the existing mindfulness interventions literature and 
conclude that mindfulness studies tend to jump to examine an intervention's efficacy or 
effectiveness without carefully considering the processes for improving the intervention. 
Therefore, the authors proposed a “mapping approach” based on the NIH stage model to 
assist with development of new versions of mindfulness interventions and suggested 
recommendations that enhance the ways of tailoring the intervention to fit a certain 
population, thus filling the existing gaps between research and practice.  
Therefore, to ensure that any MBCT adaptations are optimally effective and 
likely to be implementable in practice, this study has followed the MRC and NIH 
models. We adapted the standard MBCT protocol for people with depression and CVDs 
through different phases. In the first phase, we conducted two systematic reviews 
(Abbott et al., 2014; Alsubaie et al., 2017) and two secondary analyses, which 
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established that presumably that there is a need for a novel, bespoke, MBCT that needs 
to carefully be mapped into specific mechanisms. The current study represents the 
second phase of our project “Heart and Living Mindfully (HeLM), which is aimed at 
developing and piloting a bespoke MBCT manual targeting depression in the context of 
comorbid CVD.  
The aims of the HeLM pilot group: 
1. Refining the standard MBCT manual so as to make it acceptable to and feasible for 
people with depression and cardiovascular disorders; 
2. Testing the feasibility of recruitment to an MBCT course for people with depression 
and cardiovascular disorders;  
3. Assessing the MBCT-HeLM course acceptability (e.g., rates of attendance, retention 
and completion assessment);  
4. Assessing the weekly changes in participants’ depressive symptoms, mindfulness and 
illness perceptions through the MBCT-HeLM course, to see whether the course was 
useful to participants. 
5. If these aims are met, the next stage of the project will be to conduct a feasibility 
randomised controlled trial evaluating this approach.   
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4.3 Method 
4.3.1 Manual Development  
The HeLM- MBCT manual was developed across different stages and involved 
conducting two pilot groups. The aim of this work was to make it applicable for people 
with depression and cardiovascular disorders, with the hope that these changes would 
meet some of the needs of this population. During the first stage of developing the 
manual, monthly meetings were held between HeLM projects members, who have 
expertise in mindfulness interventions and cardiovascular problems over seven months 
(January to July 2013). Through these meetings, the original MBCT manual was 
reviewed and the best ways to make it more appropriate for people with cardiovascular 
disorders were discussed in detail. The first meeting of this series, involved two members 
of a Public and Patients Involvement (PPI) group who had experience with depression 
and cardiovascular disorders. The lead researcher attended all the meetings in addition to 
completing a study that formed the first phase of the HeLM project as part of the lead 
researcher master’s degree.  
 For the second stage of developing the manual, a first pilot group was conducted 
in July/Aug 2013 using the first draft of the manual. The group comprised three members 
of the HeLM team as well as people from the PPI group and eight patients (people with 
depression and cardiovascular disorders). The aim of conducting this group was to 
identify any changes to the manual that were necessary through discussions between the 
HeLM members, PPI group and people with cardiovascular disorders week by week base 
throughout the course. More details about this group are presented in Appendix A.  
In the third stage of developing the manual, we conducted the second pilot group 
in October/Nov 2014 using the second draft after making the changes. Weekly meetings 
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were held after each session between the therapists (WK and AE) and the lead researcher 
(MA) to discuss the manual.  
4.3.2 Study Design 
This study is an uncontrolled group with repeated measurements of depression, 
mindfulness and illness perceptions throughout the HeLM-MBCT course. 
 4.3.3 Inclusion and Exclusion Criteria  
Inclusion criteria for this group were as follows: (a) adults aged 18 and older; and 
(b) a diagnosis of a cardiovascular disorder (heart conditions or stroke); c) a history of 
depression (major depressive disorder) and/or low grade depressive symptoms. We 
excluded people who were currently depressed (given that the standard MBCT course 
has been designed to target people with recurrent depression who are in a remission 
phase), had co-morbid diagnoses of current substance dependence or abuse, had organic 
brain damage, had current or past psychosis, exhibited persistent antisocial behaviour, 
and carried out persistent self-injury and those who were engaged in formal 
psychotherapy.  
 4.3.4 Recruitment 
One of the main aims of conducting this pilot group was to test the feasibility of 
recruitment to an MBCT-HeLM course for people with depression and cardiovascular 
disorders. Different strategies to recruit people to this group were used. First, the 
researchers (MA and RV) visited the inpatient cardiology ward at the Royal Devon and 
Exeter hospital to explain the study to cardiac nurses and to ask them to refer potential 
people to the group. Second, MA attended the outpatient’s clinic at the cardiology 
department once weekly (mornings and afternoons), for five weeks. During these visits, 
the study was explained to 32 people with given them a poster and a reply form that they 
could fill it out and return to the researchers using the free envelope supplied. Third, the 
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study summary was emailed to the AccEPT Clinic/Mood Disorders Centre top referring 
GPs to inform them what the research would entail. We also posted this to the north 
Devon cardiac nurse and the Stroke Association with freepost return envelopes for any 
person wishing to participate. Fourth, we distributed the poster in some shops and fitness 
centres in Exeter with phone and address contact details. In the screening phase, the 
researcher (RV) screened all interested people via phone to assess their eligibility, based 
on the inclusion and exclusion criteria of the pilot group. The summary of study was 
resent to all interested and eligible people along with an invitation to an orientation 
session with (WK). The group’s starting date had to be rescheduled twice, from October 
2013 to May 2013 and then October 2014 due to difficulties in recruiting people.  
4.3.5 Adapted-MBCT Course (HeLM) 
The adapted-MBCT group was conducted by qualified therapists (WK and AE) 
with experience in running mindfulness interventions. This adapted course involved one 
orientation session (1 hour) plus eight weekly sessions lasting 2.5 hours. The therapists 
used the second draft of HeLM manual, which, as aforementioned, was modified based 
on the PPI group and the comments made by those who attended the first pilot group. 
Participants were provided with CDs to help them practise at home, which they were 
encouraged to do for six days per week. The home practice sheets were seen by the 
therapist session by session and a copy of them was added to the participants’ folders. In 
addition, three measures were applied before and after the course as part of the AccEPT 
Clinic/ Mood Disorders Centre routine.  
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4.3.6 Weekly Assessments  
Weekly assessments were conducted to assess changes in depression, 
mindfulness and illness perceptions, with the aim of seeing whether the adapted-MBCT 
(HeLM) course was helpful for people with depression and cardiovascular disorders.  
4.3.7 Outcomes  
Demographic data collected included: age, gender, ethnicity, marital status, and 
type of cardiovascular disorder. Three questionnaires were administrated at baseline, 
weekly during the course, at the end of the group and three months after the completion 
of the group. Given this study is important as it is one of the first that targets people with 
cardiovascular disorders and due to the difficulties in recruiting people that we had, we 
decided to reduce the burden on participants as much as possible so as maximise 
retention by using three measures with less items in each of them. Depression was 
assessed as the primary target of this course. We used illness perceptions as a secondary 
outcome, as there is evidence that people’s beliefs can affect the efficacy of any 
treatment and also their level of compliance with it (Petrie et al., 1996; van der Wal et 
al., 2016). Finally, we chose to assess mindfulness skills as these are the main target of 
all the mindfulness interventions. 
4.3.7.1 The Patient Health Questionnaire-9 (PHQ-9). 
Depressive symptoms were assessed using the Patient Health Questionnaire-9 
(PHQ-9; Spitzer, Kroenke, Williams, & Group, 1999). Each of 9 items describing the 
core symptoms of depression are scored between 0 (not at all) and 3 (nearly every day) 
with total scores ranging between 0 and 27. The cut-off points of the PHQ-9 are 5, 10, 
15, and 20, which reflect none/minimal depression (0-4), mild depression (5-9), 
moderate depression (10-14), moderately severe depression (15-19), and severe 
depression (20-27) respectively. The PHQ-9 has adequate reliability and validity in 
145 
 
 
primary care in the UK (Cameron, Crawford, Lawton, & Reid, 2008) as well as for 
people with coronary heart disease (Haddad et al., 2013).  
4.3.7.2 Five Facet Mindfulness Questionnaire (FFMQ). 
The five facet mindfulness questionnaire (FFMQ; Baer et al., 2006) was designed 
to assess different aspects of mindfulness. It consists of 39 items, reflecting five facets: 
non-reactivity to inner experience, observing, acting with awareness, describing and non-
judging of experience. Each item is rated on a 5-point Likert scale, ranging from 1 (never 
or very rarely true) to 5 (very often or always true). The FFMQ has good internal 
consistency, with Cronbach’s alpha between 0.72 and 0.92 for the five facets (Baer et al., 
2006, 2008).  
 4.3.7.3 Illness Perception Questionnaire-Brief (IPQ-Brief).  
The illness perception questionnaire-brief (IPQ-Brief; Broadbent, Petrie, Main, & 
Weinman, 2006) was used to assess participants’ beliefs about their illness. This is a 
short form of the illness perception questionnaire (IPQ) that was developed to assess 
cognitive representations. The IPQ-brief contains 9 items that assess time line 
acute/chronic, time line cyclical, consequences, personal control, treatment control, 
illness coherence (understanding) and emotional representations. Each item is scored 
between 0 (no affect at all) and 10 (severely affects my life)13. The IPQ-brief has good 
validity and reliability (Broadbent et al., 2006). We used the short form of IPQ as it is 
appropriate for repeated measures design and to decrease the burden on the participants. 
  
                                                 
13 Low scores on IPQ-Brief represent improvements.   
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4.3.8 Data Entry and Management  
 4.3.8.1 Entering data and dealing with missing data.  
The data were entered into SPSS version 22.0 To deal with missing data, the 
instructions provided in the measure manual, if applicable, were followed. We used 
multi-imputation to replace missing data as suggested by Rubin (1996), which involves 
calculating an average of items and then replacing the missing data with it. 
4.3.8.2 Cleaning data.   
The cleaning of the three measures (PHQ-9, IPQ-brief and FFMQ) was carried 
out through two steps. First, we checked each measure in terms of item range, total score 
ranges and the subscale score ranges. Second, we checked the outliers and the normality. 
As we had one group with pre-and post-scores, a difference score for pre-and post-
intervention was computed first and then the normality and outliers for the difference in 
scores were checked. The data cleaning protocol is presented in Appendix C.  
4.3.9 Statistical Analysis 
The characteristics of the participants were summarised using the means and 
standard deviations for the continuous variables and percentages for the categorical ones. 
Due to the absence of a control group and the small sample size in this pilot study, the 
study data were analysed using three methods. First, we calculated the pre- and post-
intervention means, SDs, Cohen effect sizes (Cohen, 1992), and confidence intervals for 
PHQ-9, FFMQ and the IPQ-Brief. This method is recommended by the guidelines for 
good practice in designing, analysing and reporting pilot and feasibility studies 
(Lancaster, 2015; Lancaster, Dodd, & Williamson, 2004). Second, we used the clinically 
significant methods (the cut-off points of PHQ-9 and reliable change index (RCI; 
Jacobson & Truax,1991) that consider individuals’ changes across time. Specifically, the 
cut-off points method measures that whether the individuals are in the clinical or non-
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clinical range. The reliable change index (RCI) formula of Jacobson & Truax, (1991) 
was used as an indication of the improvement in each participant. Third, graphs 
representing the weekly changes in depression, mindfulness and illness perceptions for 
each participant were created. 
4.4 Results 
4.4.1 Recruitment 
12 people were recruited between February and July 2014 through referrals from 
the outpatient’s clinic (PCI) at the cardiology ward (n = 5) and cardiac rehab at the Royal 
Devon & Exeter Hospital (n = 3), cardiac nurses in North Devon (n = 3) and the Stroke 
Association (n = 1). One participant died before the orientation session and two people 
were excluded during it as they had current depression. Nine participants gave their 
written consent and took part in the group. 
4.4.2 Manual Development  
The adaptations were made to the manual and hand-outs with regard to the main 
themes, meditation practices and home exercises. In the adapted manual, there is more 
emphasis on encouraging people to have more positive feelings about their body, taking 
care of the self and getting to know reciprocal relationship of stress/low mood/anxiety 
and bodily experience. In addition, there is consideration of how to adjust to living with a 
long-term condition. For more details of this manual see Table 4.1 as well as Chapter 
5.0. 
4.4.3 Demographic Data 
Table 4.2 shows the demographic data of the pilot group. The average age of the 
nine people in the group was 58.78 years (SD = 11.1). Seven participants were males and 
two females. Eight were white British and one was Asian-British. Six participants were 
married, one was single and three were divorced. Eight out of the nine participants had 
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heart conditions while one woman had had a stroke. Five out of the eight people with 
heart conditions had had a heart attack. Three participants had more than one 
cardiovascular disorder (heart condition and hypertension). 
4.4.4 Acceptability Results  
4.4.4.1 Course completion and attendance.  
There were no dropouts (0 %) with high rates of attendance: five participants 
(56 %) completed all eight sessions, while the other four (44 %) attended seven. 
4.4.4.2 Completion of assessments.  
With regards to completing the weekly assessments, four participants completed 
all ten (one baseline, eight sessions and one follow up), while five completed between 
six and nine assessments.  
4.4.5 Efficacy Estimates  
4.4.5.1 Means, SDs, effect sizes and confidence intervals. 
Table 4.3 and 4.4 show the means, standard deviations, effect sizes and 
confidence intervals for PHQ-9, IPQ-Brief and FFMQ at baseline, post-intervention and 
three months follow up. The mean PHQ-9 score prior to the course was 10.8 (SD = 4.9), 
reducing to 4.2 (SD = 2.9) and 2.0 (SD = 2.6) after the course and at the three-months 
follow up consecutively. The mean baseline FFMQ was 112 (SD = 12.4), increasing to 
143.2 (SD = 20.2) and 146 (SD = 17.1) after the course and at the three-months follow 
up, consecutively. The IPQ-brief score prior to the course was 41.0 (SD = 12.6), while it 
was 36.1 (SD = 12.4) and 32.1 (SD = 8.1) after the course and at the three-months follow 
up, consecutively. The effect sizes for PHQ-9 and FFMQ were large, while that for IPQ-
Brief was small.  
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4.4.5.2 Clinical significance methods. 
 4.4.5.2.1 Cut-off points method. As a group, the baseline mean of PHQ-9 
indicates that the group mean was within the moderate level. However, the post-
intervention and follow up means reveal that the group means moved to the non-
depressed level. Individually, it can be seen in Table 4.5 and 4.6 that eight out of the nine 
participants scored above the cut-off points for PHQ-9 (˂ 5) at baseline. After the course 
the findings show that six of the nine participants showed a clinically significant change. 
Of the two participants that did not show a clinically significant change after the course, 
one of them moved from a moderate to a mild level and the other one moved from a 
severe to a mild level. At the three months follow up, five of the seven participants who 
completed the follow up assessment showed a clinically significant change, while one 
moved from a moderate to a mild level.  
4.4.5.2.2 The reliable change index method (RCI). This method was developed 
by Jacobson and Traux (1991), who proposed a formula14 to assess how much change 
has occurred during the course of an intervention. If the change is ≥ 1.96, this indicates 
that the participant has improved (i.e., falls outside the 95 % confidence interval for 
baseline scores). As shown in Table 4.7, five participants showed a reliable clinically 
improvement for PHQ, while the rest did not at the post course assessment. At the three 
months follow up, five participants showed a reliable clinically improvement for PHQ, 
while the rest did not. 
  
                                                 
14 RCI formula: Client post-score - Client pre-score /Sdiff;  
Sdiff= √2( SE)2; SE=SD pre 𝑥 √1-r.   
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4.4.5.3 Graphs of weekly changes. 
Graphs of weekly changes in PHQ-9, FFMQ and IPQ-Brief for each participant 
in the MBCT-HeLM pilot group are presented at the end of the Chapter. 
4.4.5.3.1 Summary of the PHQ-9 weekly scores. At baseline, the participants’ 
scores on the PHQ-9 varied from 4 to 21, with the majority falling within the level of 
moderate depression. Throughout the course, seven out of the nine participants showed a 
gradual decrease in their depressive symptoms, while two maintained the same score 
from the first week until the follow up session. Some increases in depressive symptoms 
were observed in the middle of the course for two participants in week 4 and 5, and for 
one in week 4. In sum, all participants who completed the PHQ-9 follow-up had a 
reduction in their score when compared to their baseline score. 
4.4.5.3.2 Summary of the FFMQ weekly scores. 
4.4.5.3.2.1 FFMQ total. At baseline, the participants’ total scores on FFMQ 
varied from 98 to 133. Five out of the nine participants showed an increase in their 
scores from baseline to post-intervention and follow up, while four did not experience 
any change throughout the course. One woman showed a substantial improvement in her 
mindfulness skills as she scored 98 at baseline, which went up to 167 at follow up.  
4.4.5.3.2.2 Observe subscale. The participants’ scores on the observe subscale 
varied at baseline. Five participants showed an increase in their scores from baseline to 
post-intervention and then to follow up. Four did not show any changes in their scores 
throughout the course, with two participants showing decreases in weeks 4 and 5.  
4.4.5.3.2.3 Describe Subscale. At baseline, the participants’ scores for the 
describe subscale varied. Three showed an increase in their scores from the baseline to 
the follow up, whilst one had a lower score on this subscale compared to other 
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participants, which did not change throughout the course. Other participants did not 
show any improvement throughout the course.  
4.4.5.3.2.4 Act with Awareness Sub-scale. At baseline, three participants had high 
scores on this subscale, whilst three others started with low scores and these did not 
change throughout the course. One participant scored lower than the other participants at 
the baseline, gradually decreasing more until week 5 and then showed an increase in 
weeks 6 and 7.  
4.4.5.3.2.5 Non-reactivity Subscale. The participant’s scores on this subscale 
were similar at baseline. Four showed increases at follow up, whilst one who had a 
slightly lower score on this subscale. Other participants did not show any change 
throughout the course.  
4.4.5.3.3 Summary of the IPQ-Brief. At baseline, the participants’ total scores on 
IPQ-Brief varied from 21 to 62. Three out of the nine participants showed a decrease in 
their scores from baseline to post-intervention and follow up, while the others did not 
experience any change. 
4.5 Discussion 
The main aims of this pilot group were to refine a bespoke MBCT course for 
people with depression and cardiovascular disorders and to assess its acceptability for 
this population. We also aimed to test the feasibility of recruitment to this course and to 
see whether the course was helpful for participants in terms of decreasing depressive 
symptoms, negative illness perceptions and increasing mindfulness skills.   
Some changes were made to the original MBCT manual in terms of the main 
themes, meditation practices and home exercises, with there being more focus on self-
care, self-efficacy and the adjustments to having a long-term health condition.  
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 Recruiting people to this pilot group was challenging and difficult with a one-
year delay in running it due to failing to find a sufficient number of participants. We used 
different strategies to recruit people with cardiovascular disorders, but with focus was 
mainly on specialist centres, such as the cardiology department at the Royal Devon & 
Exeter hospital and a cardiac nurse in North Devon. These methods of recruitment were 
costly in terms of time (six months of recruitment with approximately two participants 
acquired per month). Regarding GPs, even though we asked some of GPs to refer 
potential participants, the efficiency of the recruitment of people through GPs were not 
tested.  
The rates of retention and attendance in this pilot group were very encouraging; 
no dropouts with a high attendance rate. The participants were highly committed to the 
home practice and most completed all the ten assessments. It seems that the course did 
not cause any harm and was well-tolerated.   
While caution needs to be taken when interpreting outcomes of a pilot group with 
this size, preliminary evidence suggests the course is helpful for participants. The effect 
sizes found in this group were large in terms of decreasing depressive symptoms and 
increasing mindfulness skills. Moreover, the clinical significance methods used with this 
group considering individuals’ differences have shown promising results in terms of 
decreasing depressive symptoms. However, the uncontrolled design that was used in this 
study along with the small number of participants means these results require replication.  
With regards to measures, the changes that were noticed for PHQ-9 across the 
MBCT-HeLM course indicated that this measure was sensitive to change in this 
particular population. The scores on the FFMQ varied substantially across the subscales 
and participants. However, some participants had improved scores on observe, describe, 
act with awareness and non- reactivity subscales by end of the course. Hence, the FFMQ 
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measure showed a good sensitivity to change throughout the MBCT-HeLM course. With 
regards to IPQ-Brief measure, when considering the total of the IPQ-Brief scores, no 
significant changes were found. However, when the subscales were analysed it was 
noticed that some participants experienced decreases after the MBCT-HeLM course. 
That is, some of their negative beliefs would appear to have been diminished. These 
results suggest future research may wish to focus on the subscales of IPQ rather than the 
total score.  
4.6 Limitations and recommendations for future research 
This group has achieved its goals in terms of refining the MBCT manual for 
people with depression and CVDs, checking its usefulness, acceptability and testing 
ways to recruit people with CVDs. However, one main limitation should be mentioned 
regarding the design. The absence of control group means that the reductions in 
depression, changes in negative illness perceptions as well as increases in mindfulness 
skills could be explained by other factors not specifically related to MBCT-HeLM. These 
results are encouraging enough to now move onto the next level of developing the 
MBCT manual for this population (the feasibility trial).  
Also, some considerations that should be done in the next level. For example, in 
terms of inclusion criteria related to depression, the main criterion to recruit people was 
history of major depressive disorder with or without current depressive symptoms. 
However, other types of depression such as dysthymia or minor depression are 
considered to be very prevalent and cause high burden on people with CVDs (Davidson, 
K.W., 2012; Holzapfel et al., 2009). Therefore, the inclusion criteria will be reviewed to 
include such types of depression. Moreover, assessing depression was not based on a 
standard interview therefore, it will be important for the feasibility study to use a 
standard clinical interview. Also, it was clear that recruiting people through cardiac 
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specialist services or referrals from GPs are time costly therefore using other methods 
such as asking GPs to screen their records and then send letters to potential participants it 
might increase the number of approached people.  
In summary, the findings of this pilot group seem promising in terms of adapting 
the MBCT manual for people with depression and cardiovascular disorders, retention 
and attendance rates, decreasing depressive symptoms and illness perceptions and 
increasing mindfulness. These outcomes have encouraged the HeLM team to proceed to 
the next level of developing MBCT for people with depression and CVDs (A feasibility 
RCT of the approach compared to other active treatments). However, the challenges of 
recruitment should be held in mind and this is the major uncertainty the feasibility trial 
will need to focus on.
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Table 4.1  
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Orientation 
Session 
Main themes 
 
 
Learn about the factors associated with the 
onset and maintenance of depression 
 
Learn about the factors associated with the 
onset and maintenance of long term 
physical and mental health problems 
 
Agenda 
 
Explain background aims of MBCT 
Outline the structure of the MBCT 
programme 
Emphasise that MBCT will require hard 
work and the need for patience and 
persistence in the work  
Determine if client is likely to benefit 
 
In addition: 
Learn about the way the person’s physical 
health has affected their mental health and 
vice versa 
Introduce the journey/map/road block and 
oxygen mask metaphors 
Extra background information includes:  
the idea of symptoms as a guide from the 
body and how mindfulness and self-care 
are ways of responding to these messages 
(navigating the road blocks of living with 
a long-term health condition) 
reacquainting with the body in a positive 
way 
moving from reactivity to responsiveness 
There was a lot of variety in the extent to which 
physical health and mental health were related, 
with some people having long mental health 
histories and late onset vascular disorder and 
others having had a lot of trouble adapting to their 
changed health status post MI/stroke.   
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 Table 4.1 cont.  
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 1 
Main Themes 
Seeing the significance of autopilot in our 
lives 
Seeing how bringing awareness to 
experience change the experience 
Building a supportive environment 
Introducing the course  
Intentions for taking part in the group 
Problems can be worked with 
MBCT for depressive relapse 
 
Emphasis on gently turning towards bodily 
experience 
Widened to MBCT for people with 
vascular disorders and associated low 
mood, stress and anxiety 
Focus on all that is right with the body 
Before introductions coming into the body 
Before the raisin coming into the body 
with some gentle stretches 
In the raisin and body scan a woman used the 
practice to become more aware of the way her 
body had been affected by stroke, and how worry 
thinking could be problematic. Experienced in 
both practices being with those symptoms in a 
way that was "okay." 
“P” talked about NFP, normal for P, 
acknowledging that impairment and symptoms 
were normal. This was significant because he 
described grieving/loss for the former P. 
A man described in the body scan developing a 
sense of an "innocent" relationship with his body, 
i.e. experiencing his body as it is not caught up in 
high states of worry/anxiety/self-judgment.  
Two participants talked about shallow breathing / 
tight shoulders that eased during the practice - 
this was new for them. 
Sense of new possibilities.  
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 Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 1 
Meditation 
Practices 
Eating meditation (raisin) 
 
Body Scan 
Brief coming in to the body before 
introductions. Brief movement prior to the 
raisin exercise 
Extra guidance about ways of lying, sitting 
for the practice 
 
 
Other exercises 
 
Setting guidelines 
Introductions 
Feedback and discussion of raisin exercise 
Feedback and discussion of body scan 
Finish with 2 – 3 stages focusing on the 
breath 
 
Outline of heart condition in introductions  
Home Practice Body Scan 
Be mindful of a routine activity 
Eat one meal mindfully  
2 versions of body scan approximately 30 
and 20 minutes in duration 
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Table 4.1 cont.   
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 2 
Main Themes 
 
Working 
with difficulties in a new way 
Coming home to the body 
Seeing the layers, we add to experience 
Focus of attention shows the ‘chatter’ of 
the mind. 
Relationship between thoughts and 
feelings and the way this affects mood 
Importance of taking care of ourselves 
(and the issues this can raise). 
Adapted to pick up issues related to 
symptoms, interpretation of symptoms, 
taking care of self and obligations to 
others 
Really nice examples of importance of first and 
second reactions (2 darts) (emotional and 
cognitive) in the thoughts and feelings exercise. 
Importance of putting oneself first quite novel for 
many, the oxygen mask analogy worked well 
here. 
We also shared how in the body scan her arm had 
been very achy to begin and calling for attention. 
She was able to attend to the rest of her body and 
when she got to her arm it no longer ached so 
much. 
Meditation 
practices 
Body Scan 
Mindfulness of Breathing 
Guiding around the heart area in the Body 
Scan 
 
Other exercises Thoughts, feelings and sensations exercise New scenario “You wake up in the 
morning and you feel unwell and very 
tired (but you’ve got important plans, 
which also involve other people and you 
are not sure you can even get out of bed” 
 
Home Practice 45-minute body scan 6/7 days 
10 minutes’ mindfulness of breathing 6/7 
days. Routine activity. 
Focus on and record pleasant events 
 M spoke of enjoying the sensations in the body. 
W spoke of how ‘shocking’ it was to see how 
difficult it was to find time for the BS practice 
and yet juicing was her routine activity and she 
could see how it nourished her in many ways to 
take this time. 
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations  
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 3  
Main Themes 
 
The body is a place to be with experience 
Awareness that the mind can be busy and 
scattered 
Taking awareness intentionally to the 
breath 
Discovering ‘being present’ 
Heart / breathing during mindful 
movement 
Older male described how he had become aware 
how low mood was associated with his shoulders 
stooping and some changed sensations in his 
chest, but was quite avoidant of discussing these. 
He was able to describe a sense of chest 
"congestion" in the torso with associated worry 
thoughts.  
 
Other Exercises in 
Session 
 
Practice Review  
Home Practice review including inquiry of 
pleasant events 
Use body diagram with pleasant events 
feedback 
 
Meditation 
Practices in 
Session 
5 minutes seeing or hearing exercise 
30-40-minute sitting meditation 
3 stage breathing space 
Mindful stretching and review 
Mindful walking and review 
Changing order of practice 20 mins of 
gentle mindful movement covering 
movements on the CD after seeing/hearing 
practice. 
Shortened sitting practice – 15 -20 mins’ 
posture, breath and body. No walking 
Noting how the body was more limited than 
perhaps it had been in the past, and a sense that 
this needed to be accepted.   
One middle-aged male described how the 
movement was really enjoyable. 
Home Practice Stretch and breath practice on days 1, 3 
and 5. Mindful movement practice on days 
2, 4 and 6. Keeping a daily record of the 
experience of unpleasant events 
3 stage breathing space 3 times each day 
Short sitting practice instead of stretching 
and breath. Option to continue with Body 
scan instead of mindful movement. 
Encourage noticing of unpleasant events 
connected with vascular disorder 
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 Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 4  
Main Themes 
 
MBCT for prevention of depressive 
relapse 
The mind is mostly scattered when trying 
to cling to some things/ avoid things. 
Becoming aware of the tendency to react 
with aversion 
Mindfulness offers a way to be present – 
offers another place from which to view 
things. 
Developing awareness of ways to respond 
to stressful situations/experiences 
Getting to know territory of depression 
Getting to know the territory of stress/low 
mood/anxiety and how it relates to bodily 
experience in a reciprocal relationship. 
Use the RAIN acronym (Recognise, 
Allow, Inquire and thoughts are Not facts), 
with the first stage being recognition when 
fear and aversion arise. 
 
Some of the more driven qualities (and busyness) 
that might be present in this population manifest 
in the practice and approach to the practice. 
A woman became very aware of how external 
events are registered / manifest in the body, e.g. 
racing heart. 
Group resonated with the automatic thoughts, 
with a sense of tension and mood change. For 
some this was resentment / anger, possibly 
picking up underlying “hostility.” Real sense of 
common humanity in the decentering. 
Only this week was there more of an opening up 
of vulnerability.  
Meditation 
Practices in 
Session 
5 minutes seeing or hearing 
40-minute sitting meditation 
3 stage breathing space and review 
Reduced to a 30-minute sitting (Choice 
less awareness not included) 
Walking practice 
3 stage breathing space 
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 Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 4 
 
Other Exercises in 
Session 
Practice Review 
Home Practice Review 
Review of unpleasant events. Defining 
Territory of Depression – Automatic 
thoughts questionnaire and diagnostic 
criteria for depression 
Watch 1st half of MBSR video 
‘Body’ diagram used to review unpleasant 
events calendar 
Adapted version of automatic thoughts 
used 
Selected clips from ‘Healing from within’ 
video – Link given to view whole 
programme 
Introduce RAIN acronym 
Introduce second arrow metaphor 
 
Home Practice Sitting meditation 
CD 6 out of 7 days 
3 stage breathing space – regular (3 times 
a day) 
3 stage breathing space – responsive 
(when notice unpleasant 
Alternating full sitting CD (30 minutes) 
with mindful movement or walking 
Recognising where stress is in the body 
using the ‘Body’ diagram 
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 5  
Main Themes 
 
Bringing a sense of allowing things to be 
Acceptance 
Title of session changed to ‘Softness and 
Strength.’ 
The RAIN acronym progresses here to the 
A and possibly the I directed towards 
bringing in a difficulty linked to the 
physical / mental health interface. This is 
the session where themes around 
fear/hyper-arousal or sadness/loss may 
well be picked up more fully with a view 
to beginning to really decentre from the 
proliferation and over-identification. 
Metaphor of the second dart explored in 
the "I" or inquiry. 
Being mode as a vehicle for this shift and 
“insight.” 
Building sense of self-care (reminding 
people of the oxygen mask if necessary). 
 
Woman with stroke described pins and needles 
sensations in her head, which were linked to 
stress. She used a light touch breathing space that 
broke the cycle of escalating stress. 
Another man whose normal mode was to be lost 
in proliferative worry thought, had a real 
awakening to the impact of his heart attack.  
In the body diagram a lot about body sensations, 
usual sensations in chest, stomach, neck, head. 
But associated thoughts really linked to heart 
disease “can I afford to get this stressed,” “people 
wanting my time, but I may not have a lot of time 
left” with associated feelings of being over-
whelmed, broken, isolated, injustice. 
Meditation 
Practices in 
Session 
30 – 40-minute sitting meditation – 
introducing difficulty. Breathing space and 
review. 
3 stage breathing space – coping and 
review. 
Short standing at beginning of sitting 
practice 
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 5 
 
Other Exercises in 
Session 
Practice Review 
Home Practice Review 
Read Rumi’s poem the guest house 
Watch second half of MBSR video  
 
Feedback on the Body diagram – linking 
the physical barometer with the body 
diagram to identify impact of stress. 
Selected clips from ‘Healing from within’ 
video that speak to allowing and 
softness/strength. 
 
Home Practice 
 
 
 
 
 
 
 
Sitting meditation 6 out of 7 days (use CD 
days 1, 3 and 5 use no CD days 2, 4 and 6) 
3 stage breathing space regular (3 times a 
day) 
3 stage breathing space- responsive 
(whenever notice unpleasant feelings). 
Optional ‘working with difficulty’ CD  
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 Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 6 
Main Themes 
 
Thoughts are not facts 
 
Negative moods effect our experience 
 
Recognising patterns of thoughts can help 
us 
 
We can choose to work with thoughts 
Change of title to ‘Symptoms as messages 
from the body; thoughts are not facts’ 
The RAIN acronym progresses here to the 
Inquiry and thoughts are Not facts. 
Freeing self from impact of fear-based 
thinking/imagery, sadness/loss and 
proliferative thinking through dis-
identification with these habitual patterns 
of reacting.  
Beginning to note the possibility of 
responding compassionately with 
discernment / wisdom. 
Introducing self-care front and centre 
(remind of oxygen mask if necessary. 
Themes around fight, flight and freeze came up in 
reaction to the thoughts. Following a 3MBS there 
was a loosening up of the reactivity. However, the 
group had already been doing this in the 
homework.  
One man with significant muscle damage to his 
heart has become more aware of when heart rate 
increases there is need to breathe harder which 
can in reactive mode create anxiety. In responsive 
mode, he was able through cutting out worry 
control his heart rate. This included greater 
acceptance of negative thoughts, like “I have a 
disability.” 
One woman had the thought that an external 
stressor (a former partner) re-emerging could 
trigger another vascular event.  
Meditation 
Practices in 
Session 
30 – 40-minute sitting meditation 
Breathing space and review discuss 
breathing space as first step before wider 
view of thoughts 
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 6 
 
Other Exercises in 
Session 
Practice Review 
Home Practice Review.  Preparation for 
end of course 
Moods, thoughts and alternative 
viewpoints exercise. 
Building on the body diagram to 
differentiate reactivity (proliferation) and 
responsiveness. 
 
 
 
Home Practice 
 
Practice with a selection from series 2 
tapes for 40 minutes a day 
3 stage breathing space (regular) 
3 stage breathing space (responsive) 
For 30 minutes a day 
 
 
 
Session 7 
Main Themes 
Taking care of oneself 
Recognising the warning signs of 
depression 
Ways of Responding 
The same themes work well here, but with 
greater emphasis on recognising warning 
signs of stress as well as low mood. 
Ways of responding and taking care of 
oneself remain equally important. 
People commented on how there was a real shift 
in their way of being, especially in relationship to 
the body. A man with a very ruminative mind 
talked about how this mind state could make 
every activity depleting, whereas in a mindful 
state every activity can be nourishing. 
A real sense of care within the group. 
Emerging sense of permission to take care of 
oneself. "Working and working didn't do me any 
good, in fact it led to a heart attack."  
Choices starting to emerge, even in very stressful 
situations.  
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 7 
 
Meditation 
Practices in 
Session 
30 – 40-minute sitting meditation – 
awareness of breath and body 
3 stage breathing space or mindful walking 
  
Other Exercises in 
Session 
 
 
 
 
 
Practice review 
Home Practice Review 
Exercise to explore links between activity 
and mood 
Generate list of pleasure and mastery 
activities – plan how to best schedule such 
activities 
Identifying relapse signatures 
3-stage breathing space as the first ‘step’ 
before choosing whether to take mindful 
action 
Shift to taking care of oneself physically 
and mentally, rather than mood.  Explore 
what nourishment feels like in the body. 
Responsiveness exercise with dyadic work 
and walking developed this experientially. 
Relapse signature replaced with the body 
diagram, mapping out responsiveness (as 
opposed to reactivity). 
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 Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Home Practice Select from all of the different forms of 
practice, a pattern you intend to use on a 
regular basis 
3-stage breathing space (regular) 
3-stage breathing space (coping) 
Develop early warning system for 
detecting relapse 
Develop action plan to be used in the face 
of lowered moods 
Completion of responsive side of the body  
diagram. 
Self-care plan 
 
 
 
 
 
Session 8 
Main Themes 
Maintaining a balance in life is helped by 
regular mindfulness practice. 
Supporting intentions – linking practice to 
positive outcomes 
How to keep up momentum and discipline 
Building any physical care (medication, 
exercise) integrally into self-care plan. 
 
Real sense of group cohesion, because of a real 
sense of common humanity among people with 
similar concerns and human need to connect with 
others. Facilitated by pair work. 
Man with very ruminative, "in his head" cognitive 
style noticed in the body scan his heart beat for 
the first time.  
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations 
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 8 
Main theme  
  Woman with stroke was able to notice symptoms 
of stroke with equanimity and being to respond to 
these with a sense of care. 
Generally, there was a sense of people being more 
aware of body sensations.  
One man described a real sense of vulnerability. 
Self-care really enhanced for people, for example 
using practice tactically to help with sleep.    
Attendance has been exceptional, possibly 
through a real sense of commitment and the 
contact with people throughout recruitment and 
orientation. 
Meditation 
Practices in 
Session 
Body scan practice 
Ending meditation 
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Table 4.1 cont. 
MBCT-HeLM manual development: MBCT outline, adaptations and case Illustrations  
Session MBCT for prevention of depressive 
relapse 
Adaptations through piloting Individual stories 
Session 8 
Other Exercises in 
Session 
 
 
Practice Review 
Home Practice Review (including early 
warning systems and action plans) 
Check and discuss plans, and link them to 
positive reasons for maintaining practice 
Discuss how to keep up momentum and 
discipline in practice 
Review whole course 
 
Working wisely with stress/low mood  
Home Practice Settle with programme of practice   
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Table 4.2 
Demographic data of the MBCT-HeLM pilot group (n = 9) 
Characteristics 
 
Number of 
participants 
Percentage 
Age mean (SD) 58.78 (11.1)  
Gender    
Male 7 78% 
 Female 2 22% 
Marital status    
Single 1 11% 
Married 6 67% 
Divorced 2 22% 
Widowed 0 0% 
Ethnicity    
White British/Irish 8 89% 
White other 0 0% 
Other ethnics groups 1 11% 
Employment status    
Employed 3 33% 
Unemployed 0 0% 
Retired 6 67% 
Type of cardiovascular disorders    
Heart conditions 8 89% 
Stroke 1 11% 
Hypertension 0 0% 
More than one cardiovascular 
disorders 
 
 
3 
 
33% 
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Table 4.3 
Means, standard deviations, Cohen’s effect sizes and confidence intervals for PHQ-9, FFMQ 
and IPQ-Brief from baseline to post-intervention 
                                                                                                                                              95% CI 
 N Mean (SD) Effect size Lower upper 
PHQ-9 
Baseline 
Post-intervention 
9 
 
10.8 (4.9) 
4.2 (2.9) 
 
 
1.74 
 
 
-1.46 
 
 
3.63 
FFMQ-Total  
Baseline  
Post-intervention 
 
9 
 
 
112 (12.4) 
143 (20.2) 
 
 
1.98 
 
 
-10.1 
 
 
11.1 
FFMQ-Observing 
 Baseline  
Post-intervention 
 
9 
 
22 (4.5) 
28 (5.4) 
 
 
1.28 
 
 
-4.22 
 
 
2.25 
FFMQ-Describing 
 Baseline  
Post-intervention 
 
9 
 
25 (4.9) 
29 (6.7) 
 
 
0.72 
 
 
-3.92 
 
 
3.65 
FFMQ-Act with awareness  
Baseline  
Post-intervention 
 
9 
 
24 (6.1) 
28 (4.5) 
 
 
0.79 
 
 
-4.78 
 
 
2.15 
FFMQ- Nonjudgment  
Baseline  
Post-intervention 
 
9 
 
28 (6.2) 
32 (6.8) 
 
 
0.65 
 
 
-4.70 
 
 
3.79 
FFMQ- Nonreactive 
Baseline  
Post-intervention 
 
9 
 
19 (4.4) 
24 (7.3) 
 
 
0.88 
 
 
-3.75 
 
 
3.89 
IPQ-Brief  
Baseline  
Post-intervention 
 
9 
 
 
41.0 (12.6) 
36.1 (12.4) 
 
 
0.42 
 
 
-7.82 
 
 
8.52 
Note. N: Number of participants; SD: standard deviation; PHQ-9: Patient Health Questionnaire-9; FFMQ: 
Five Facet Mindfulness Questionnaire; IPQ-Brief: Illness Perception Questionnaire-Brief.  
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Note.  N: Number of participants; SD: standard deviation; PHQ-9: Patient Health Questionnaire-9; FFMQ: 
Five Facet Mindfulness Questionnaire; IPQ-Brief: Illness Perception Questionnaire-Brief.  
 
  
Table 4.4  
Means, standard deviations, Cohen’s effect sizes and confidence intervals for PHQ-9, FFMQ 
and IPQ-Brief from baseline to follow up 
                                                                                                                                               95% CI 
 N Mean (SD) Effect size Lower upper 
PHQ-9 
Baseline  
Follow up  
 
7 
 
 
9.7 (3.5) 
2.0 (2.6) 
 
 
2.62 
 
 
0.33 
 
 
4.54 
FFMQ-Total  
Baseline  
Follow up 
 
7 
 
 
121 (14.0) 
146 (17.1) 
 
 
1.68 
 
 
-11.48 
 
 
12.34 
FFMQ-Observing 
Baseline  
Follow up 
 
7 
 
 
22 (4.6) 
29 (6.3) 
 
1.37 
 
-4.78 
 
3.30 
FFMQ-Describing 
 Baseline  
Follow up 
 
7 
 
 
25 (4.4) 
30 (5.9) 
 
1.04 
 
-4.30 
 
3.33 
FFMQ-Act with awareness  
Baseline  
Follow up 
 
7 
 
 
25 (6.5) 
29 (5.6) 
 
0.71 
 
-5.53 
 
3.44 
FFMQ- Nonjudgment  
Baseline  
Follow up 
 
7 
 
 
29 (6.6) 
33 (5.2) 
 
0.73 
 
-5.62 
 
3.12 
FFMQ- Nonreactive 
Baseline  
Follow up 
 
7 
 
 
19 (5.0) 
24 (6.1) 
 
0.97 
 
-4.67 
 
3.55 
IPQ-Brief  
Baseline  
Follow up 
 
7 
 
 
40.6 (14.2) 
32.1 (8.1) 
 
 
0.76 
 
 
-8.52 
 
 
6.76 
173 
 
 
Note. PHQ-9: Patient Health Questionnaire-9; the cut-off points for PHQ-9 (˂ 5) 
 
Table 4.6 
Cut-off points of PHQ-9 scale for the MBCT-HeLM pilot group  
 Post-intervention 
(n=9) 
Follow up 
 (n=7) 
Moved into non-clinical range (recovered)  6 5 
Did not show a clinically significant 
recovery, but moved to a less clinical range 
2 1 
Remained in non-clinical range 1 1 
Note. PHQ-9: Patient Health Questionnaire-9 
  
Table 4.5 
Cut-off points of the PHQ-9 scale for the MBCT-HeLM pilot group   
Participant 
No 
PHQ-9 baseline 
level 
(score ) 
PHQ-9 post level 
(score) 
PHQ-9 follow up 
(score) 
 
Participant 1 Moderate None None 
Participant 2 Moderate None None 
Participant 3 Mild  None None 
Participant 4 None  Mild None  
Participant 5 Mild  None - 
Participant 6 Severe  Mild - 
Participant 7 Moderate Mild Mild 
Participant 8 Moderate  None None 
Participant 9 Moderate  None None  
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The PHQ-9 weekly changes 
Participant 1. This participant had a PHQ-9 score of 14 at baseline, 0 at session eight and also at 
follow up 
 
Figure 4.1. Participant 1 Scores for the PHQ-9 Depression Measure at each Time of Assessment 
 
Participant 2. This participant had a PHQ-9 score of 11 at baseline and 2 at follow up 
 
Figure 4.2. Participant 2 Scores for the PHQ-9 Depression Measure at each Time of Assessment 
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Participant 3. This participant had a PHQ-9 score of 6 at baseline, 0 at session eight as well as at 
follow up 
Figure 4.3. Participant 3 Scores for the PHQ-9 Depression Measure at each Time of Assessment  
 Participant 4. This participant had a PHQ-9 score of 4 at baseline, 5 at session eight and 0 at 
follow up 
 
Figure 4.4. Participant 4 Scores for the PHQ-9 Depression Measure at each Time of Assessment 
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Participant 5. This participant had a PHQ-9 score of 8 at baseline and 3 at session eight, but did 
not complete the follow up 
 
Figure 4.5. Participant 5 Scores for the PHQ-9 Depression Measure at each Time of Assessment 
 Participant 6. This participant had a PHQ-9 score of 21 at baseline and 9 at session seven  
 
Figure 4.6. Participant 6 Scores for the PHQ-9 Depression Measure at each Time of Assessment  
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Participant 7. This participant had a PHQ-9 score of 10 at baseline, 7 at session eight and also,  
at follow up  
 
Figure 4.7. Participant 7 Scores for the PHQ-9 Depression Measure at each Time of Assessment  
Participant 8. This participant had a PHQ-9 score of 12 at baseline and 4 at follow up 
 
Figure 4.8. Participant 8 Scores for the PHQ-9 Depression Measure at each Time of Assessment  
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Participant 9. This participant had a PHQ-9 score of 11 at baseline and 1 at session eight 
 
Figure 4.9. Participant 9 Scores for the PHQ-9 Depression Measure at each Time of Assessment 
 
The FFMQ weekly changes 
Participant 1. This participant had a total score of 106 on the FFMQ at baseline, 138 at the post 
group and 140 at the three-month follow-up 
 
Figure 4.10. Participant 1 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
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Participant 2. This participant had a total score of 98 on the FFMQ at baseline and 167 at the 
three-month follow-up 
 
Figure 4.11. Participant 2 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
 
Participant 3. This participant had a total score of 127 on the FFMQ at baseline, 144 at the post 
group and 146 at the three-month follow-up 
 
Figure 4.12. Participant 3 Scores for the FFMQ Mindfulness Measure at each Time of   
Assessment 
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Participant 4. This participant had a total score of 131 on the FFMQ at baseline, 134 at the post 
group and 144 at the three-month follow-up 
 
Figure 4.13. Participant 4 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
Participant 5. This participant had a total score of 122 on the FFMQ at baseline, 158 at the post 
group
 
Figure 4.14. Participant 5 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
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Participant 6. This participant had a total score of 109 on the FFMQ at baseline and 121 at 
session 7 
 
Figure 4.15. Participant 6 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
Participant 7. This participant had a total score of 133 on the FFMQ at baseline, 124 at the post 
group and 121 at the three-month follow-up 
 
Figure 4.16. Participant 7 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
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Participant 8. This participant had a total score of 122 on the FFMQ at baseline, 133 at the post 
group and 133 at the three-month follow-up 
 
Figure 4.17. Participant 8 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
Participant 9. This participant had a total score of 129 on the FFMQ at baseline, 168 at the post 
group and 168 at the three-month follow-up 
 
Figure 4.18. Participant 9 Scores for the FFMQ Mindfulness Measure at each Time of 
Assessment  
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The IPQ-Brief weekly changes 
Participant 1. This participant had a total score of 54 on the IPQ-Brief at baseline, 45 at the post 
group and 31 at the three-month follow-up  
 
Figure 4.19. Participant 1 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment 
Participant 2. This participant had a total score of 62 on the IPQ-Brief at baseline, 51 at the post 
group and 39 at the three-month follow-up 
 
Figure 4.20. Participant 2 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment 
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Participant 3. This participant had a total score of 21 on the IPQ-Brief at baseline, 23 at the post 
group and 29 at the three-month follow-up 
 
 Figure 4.21. Participant 3 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time 
of Assessment 
Participant 4. This participant had a total score of 32 on the IPQ-Brief at baseline, 24 at the post 
group and 27 at the three-month follow-up  
 
Figure 4.22. Participant 4 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment  
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Participant 5. This participant had a total score of 37 on the IPQ-Brief at baseline, 29 at the post 
group 
 
Figure 4.23. Participant 5 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment 
Participant 6. This participant had a total score of 48 on the IPQ-Brief at baseline, 46 at the post 
group 
 
Figure 4.24. Participant 6 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment  
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Participant 7. This participant had a total score of 36 on the IPQ-Brief at baseline, 45 at the post 
group and 46 at the three-month follow-up
 
 Figure 4.25. Participant 7 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time 
of Assessment  
Participant 8. This participant had a total score of 33 on the IPQ-Brief at baseline, 18 at the post 
group and 21 at the three-month follow-up.  
 
Figure 4.26. Participant 8 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment 
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Participant 9. This participant had a total score of 46 on the IPQ-Brief at baseline, 44 at the post 
group and 32 at the three- month follow-up 
 
Figure 4.27. Participant 9 Scores for the Illness Perceptions Measure (IPQ-Brief) at each Time of 
Assessment 
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5.1 Abstract 
Background: Depression co-occurs in 20 % of people with cardiovascular 
disorders, can persist for years, and predicts worse physical health outcomes. While 
psychosocial treatments have been shown to treat acute depression effectively in those 
with comorbid cardiovascular disorders, to date, there has been no evaluation of 
approaches aiming to prevent relapse and treat residual depression symptoms in this 
group. Consequently, the current study aimed to examine the feasibility and acceptability 
of a randomised controlled trial design evaluating an adapted version of mindfulness-
based cognitive therapy (MBCT) designed specifically for people with co-morbid 
depression and cardiovascular disorders. Methods: A 3-arm feasibility randomised 
controlled trial was conducted, comparing MBCT adapted for people with cardiovascular 
disorders plus treatment as usual (TAU), mindfulness-based stress reduction (MBSR) 
plus TAU, and TAU alone. Participants completed a set of self-report measures of 
depression severity, anxiety, quality of life, illness perceptions, mindfulness, self-
compassion and affect and had their blood pressure taken immediately before, after, and 
three months following the intervention. Those in the adapted-MBCT arm additionally 
underwent a qualitative interview to gather their views about the adapted intervention.  
Results: 3,400 potentially eligible participants were approached when attending an 
outpatient appointment at a cardiology clinic or via a GP letter following a case note 
search. 242 (7.1 %) were interested in taking part, 59 (1.7 %) were screened as being 
suitable, and 33 (<1 %) were eventually randomised to the three groups. Of 11 
participants randomised to adapted MBCT, seven completed the full course, levels of 
home mindfulness practice were high, and positive qualitative feedback about the 
intervention was given. Twenty-nine out of 33 randomised participants completed all the 
192 
 
 
assessment measures at all three-time points. The means PHQ-9 scores for the MBCT-
HeLM group were lower at post-intervention and at the three-month follow-up compared 
to the MBSR and TAU groups. The sample was heterogeneous in terms of whether they 
reported current depression or had a history of depression and the time since the onset of 
cardiovascular disease (one to 25 years). Conclusions: The adapted MBCT intervention 
was feasible and acceptable to participants, however, certain aspects of the trial design 
were not. In particular, low recruitment rates were achieved and there was a high 
withdrawal rate between screening and randomisation. Moreover, the heterogeneity in 
the sample was high, meaning the adapted intervention was unlikely to be well tailored 
to all the participants needs. This suggests that if the decision is made to move to a 
definitive trial, study recruitment procedures will need to be revised to recruit a target 
sample that optimally matches the adapted intervention.   
Keywords: MBCT, depression, cardiovascular disorders, feasibility, 
acceptability   
 
  
193 
 
 
 
5.2 Background 
Depression occurs in approximately 20 % of people with cardiovascular disorders 
(CVDs) (Davidson, 2012; Huffman, Celano, Beach, Motiwala, & Januzzi, 2013), often 
running a chronic and/or recurrent course; being associated with significant functional 
impairment in its own right and predicting worse medical outcomes (Baumeister, 
Haschke, Munzinger, Hutter, & Tully, 2015; Khawaja, Westermeyer, Gajwani, & 
Feinstein, 2009; Pelletier et al., 2015; Win et al., 2011). The comorbidity between 
depression and CVDs is associated with poor medication adherence and reduced physical 
and psychological quality of life (Dickens, Cherrington, & McGowan, 2012; Khawaja et 
al., 2009; Rustad, Stern, Hebert, & Musselman, 2013). Moreover, this comorbidity 
predicts a substantial increase in hospital admission rates and the use of health services 
(Baumeister et al., 2015; Guthrie et al., 2016; Naylor et al., 2012; Rustad et al., 2013). 
Notably, depression is often associated with an increase in essential CVD risk factors, 
including unhealthy behaviours, such as poor diet and smoking (Bonnet et al., 2005; 
Katon, 2011; Khawaja et al., 2009; Luppino et al., 2010). This comorbidity also 
negatively affects people self-care (Cameron et al., 2009; Holzapfel et al., 2009; Riegel 
et al., 2011) and leads to a greater inability to perform routine activities (Walters, Barley 
Mann & Phillips, 2014). 
There may be underlying psycho-biological mechanisms in depression that 
directly exacerbate cardiovascular risk (Carlson, 2012; Naylor et al., 2012). In terms of 
biological factors, both depression and CVDs are associated with elevated platelet 
activation and inflammation (Dickens, 2015; Guarneri, Mercado & Suhar, 2009; Miller 
& Blackwell, 2006). On the psychological level, people with these conditions experience 
low self-efficacy, low self-care and negative illness perceptions (Greco et al., 2014; Loo, 
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Jiang, Koh, Lim, & Wang, 2016; Morgan et al., 2014; Riegel et al., 2011; Sarkar et al., 
2007; Schoormans et al., 2014; Stafford, Berk, & Jackson, 2009; Tovar et al., 2015; van 
der Wal et al., 2016; Volz et al., 2016). In addition, perseverative negative cognitive 
processes (worry about the future and rumination about the past) have been associated 
with symptoms of depression (Nolen-Hoeksema, 1991). Rumination has been shown to 
increase the likelihood, severity and duration of depression (Watkins, 2008; Watkins & 
Teasdale, 2004). Also, these perseverative cognitive processes were found to be 
associated with CVDs, such as coronary heart disease and hypertension (Gerin et al., 
2012; Kubzansky et al., 1997; Radstaak et al., 2011). Consequently, effective 
psychosocial treatments need to be developed to manage depression in this group, both 
to counter it and to enhance physical health outcomes.  
Mindfulness-based programmes already have a proven track record in addressing 
both physical and mental health symptoms. Mindfulness is defined as “paying attention 
in a particular way: on purpose, in the present moment, and non-judgementally” (Kabat-
Zinn, 1994, p. 4). Mindfulness-based programmes are based on some common, essential 
features, including a shared model of human experience, which addresses the causes of 
human distress and pathways to relieving it, and the centrality of mindfulness practice as 
an experiential inquiry-based learning process. However, different programmes have 
somewhat different emphases, depending on their specific intentions, the target contexts 
and populations (Crane et al., 2017).  
Mindfulness-Based Stress Reduction (MBSR) has been used since 1979 to help 
relieve pain and distress in people with chronic health problems (Kabat-Zinn, 1990, 
2013). Mindfulness-Based Cognitive Therapy (MBCT), which combines meditation 
exercises and certain cognitive therapy techniques, was developed to target negative 
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thinking styles in individuals with a history of depression who are at a high risk of 
depressive relapse and recurrence (Segal, Williams & Teasdale, 2002, 2013).  
Both MBCT and MBSR were developed as approaches to develop “a new 
relationship” with experience characterised by present moment focus, decentring and an 
approach orientation” (Crane et al., 2017). They constitute a range of formal mindfulness 
practices as a key method for training attentional control as well as the non-judgemental 
attitudinal dimensions of mindfulness (Crane et al., 2017). During MBSR, people are 
exposed to core mental exercises that focus on breathing and body scanning along with 
movement exercises that concentrate on bodily sensations.  
MBCT helps people to understand what factors make them vulnerable to 
depression recurring (based on a cognitive science account of depressive relapse) and 
introduces cognitive, behavioural and meditation strategies to manage these 
vulnerabilities. MBCT releases the mind from habitual patterns that undermine coping 
and lead to anxiety and depression (Kuyken et al., 2010), thus facilitating more resilient 
responses to challenges. Also, it enables perseverative cognitions, such as worry and 
rumination, to be recognised and responded to in a “decentred” way. MBCT addresses 
both universal vulnerabilities addressed by any mindfulness-based intervention and 
specific vulnerabilities implicated in depressive relapse (Crane et al., 2017). MBCT is 
based on psychological models of mechanisms that maintain and exacerbate common 
psychological problems and uses behavioural, cognitive and mindfulness strategies to 
address these mechanisms (Kingston et al., 2007; Michalak et al., 2011; van Aalderen et 
al., 2012). A recent systematic review provides promising evidence that both MBSR and 
MBCT are effective through the hypothesised mechanisms of increasing mindfulness 
and supporting decentring (Alsubaie et al., 2017). 
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MBSR has been found to have positive effects on anxiety, worry (Hoge et al., 
2013) and high blood pressure in people with cancer (Carlson, Speca, Faris, & Patel, 
2007) as well as people with unmedicated hypertension (Hughes et al., 2013). However, 
other studies have found that MBSR did not have effects on high blood pressure in 
people with cancer (Blom et al., 2014; Campbell, Labelle, Bacon, Faris, & Carlson, 
2012). Regarding MBCT, whilst it was originally designed as an approach to preventing 
depressive relapse in people at risk of depression (Kearns et al., 2015; Kuyken, Hayes, et 
al., 2016), it has also been evaluated in people with sub-clinical residual symptoms 
(Eisendrath et al., 2016) and people suffering from physical health conditions (Schoultz 
et al., 2015; Van Der Lee & Garssen, 2012; van Son et al., 2014). MBCT has 
demonstrated effects on worry, rumination, postive and negative affect, mindfulness and 
self-compassion (Geschwind et al., 2011; Kearns et al., 2015; Kuyken et al., 2008; van 
Aalderen et al., 2012). To our knowledge, there has only been one study that has 
examined the effects of MBCT on depression in people with coronary heart disease 
(CHD) (O’Doherty et al., 2015). Whilst the outcomes of this study indicated that people 
in the MBCT group showed improvements regarding current depression, anxiety, quality 
of life and illness perceptions compared to a waiting list group, the non-randomised 
design used precludes strong conclusions from being drawn. Moreover, limited 
information is provided about the adaptations made to the MBCT programme for CHD. 
Therefore, further research is needed. Crane et al. (2017) have argued that mindfulness-
based programmes have several essential ingredients and that there are and should be, 
variants to accommodate particular populations and contexts.  
Maximising the potential benefits of MBCT for people with comorbid depression 
and CVD, requires careful consideration of the mechanisms that drive psychological 
distress in people with CVD as well as their particular intentions and functional 
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limitations. In particular, standard MBCT focuses mainly on depression specific 
mechanisms, for example, rumination about causes, meanings and the consequences of 
low mood. However, people with cardiovascular disorders worry about the 
cardiovascular event returning or the causes, meanings and consequences of a cardiac 
condition (Larsen & Christenfeld, 2009; Rozanski et al., 1999). Moreover, given the 
nature of cardiovascular disorders, the body cannot be assumed to provide a safe, neutral 
anchor for mindfulness practice and a different focus may be required; attending to 
bodily sensations may increase anxiety by activating worries of a further cardiac event, 
which can increase pulse and/or heart rate. Furthermore, a number of studies have 
indicated that people with CVDs have low confidence regarding their ability to take care 
of their condition, also known as self-efficacy, and the associated impacts on their self-
care, which can lead to worse medical outcomes (Greco et al., 2014; Riegel et al., 2011, 
2007; Tovar et al., 2015; Volz et al., 2016). Hence, care is needed to consider how best 
to enhance self-efficacy.  
MBCT adaptations are intended to target more specifically the specific 
mechanisms that drive both depression and cardiovascular disorders (e.g., rumination 
and worry specific to CVD, lower self-efficacy and poor self-care) as well as the general 
mechanisms targeted by any mindfulness-based intervention (Alsubaie et al., 2017). As a 
result, we hypothesise that such adaptations should enhance MBCT’s acceptability and 
effectiveness compared with a more generic mindfulness-based intervention. One way to 
test this hypothesis is to compare MBCT adapted for CVD with a non-adapted 
mindfulness-based programme, such as MBSR. Accordingly, we designed this study 
with three arms: MBCT adapted for CVD plus treatment as usual (TAU), a non-adapted 
generic mindfulness intervention (MBSR) plus TAU and TAU alone. We hypothesised 
that MBCT adapted for people with cardiovascular disorders and depression would be 
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more acceptable and effective than MBSR and TAU. To help ensure the adaptations 
made to MBCT were optimally effective and likely to be implementable in practice, for 
our project, the Heart and Living Mindfully “HeLM”, we followed the recent UK 
Medical Research Council guidelines (MRC) for developing complex interventions (P. 
Craig et al., 2008) and the National Institutes of Health (NIH) stage model (Onken et al., 
2014). First, we established the evidence base around adapting MBCT for physical 
health conditions by conducting two systematic reviews (Abbott et al., 2014; Alsubaie et 
al., 2017). Second, an MBCT manual was adapted for people with depression and 
cardiovascular disorders, following a co-design process with service-users and clinicians. 
Third, this manual was iteratively piloted with two groups of participants. The current 
study (Alsubaie et al., 2018) represents the final phase of the project, namely, a 
feasibility RCT to establish MBCT-HeLM’s feasibility15 and preliminary acceptability16.   
The study objectives 
1. Establishing the feasibility of conducting a large-scale randomised controlled 
trial of adapted-MBCT for people with depression and cardiovascular disorders, 
which includes: 
a. Evaluating the recruitment methods; 
b. Estimating the trial recruitment, eligibility and completion rates (e.g. percentage of 
eligible people taking part / percentage of participants completing the trial); 
c. Evaluating the randomisation, inclusion criteria and the data collection procedures;  
                                                 
15 Feasibility studies are defined as those aimed at evaluating (a) the recruitment method and 
sample characteristics, (b) the optimisation of the data collection method and measures, (c) the 
acceptability of the intervention, (d) the availability of resources, and finally (e) the preliminary 
assessment of responses to the intervention (see Orsmond & Cohn, 2015). 
16 Acceptability refers to a “multi-faceted construct that reflects the extent to which people 
delivering or receiving a health-care intervention consider it to be appropriate, based on the anticipated or 
experiential cognitive and emotional responses to the intervention” (Sekhon, Cartwright, & Francis, 2017, 
p. 5) 
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d. Describing the data on primary and secondary outcomes using descriptive 
statistics; 
e. Estimating the standard deviation for continuous outcome measures that will be 
used in the calculation of the sample size for the large-scale trial.  
2. Establishing the acceptability of adapted-MBCT for people with depression and 
cardiovascular disorders.  
These objectives were formed in line with the guidelines for good practice in 
designing, analysing and reporting pilot and feasibility studies (Lancaster, Dodd, & 
Williamson, 2004; Lancaster, 2015).   
5.3 Method 
5.3.1 Manual Development 
The MBCT-HeLM manual was developed across three stages and included two 
pilot MBCT groups with people with CVDs. During the first stage of the manual 
development, seven monthly meetings were held between HeLM projects members with 
expertise in mindfulness interventions and people drawn from a Patient and Public 
Involvement (PPI) group, who had cardiovascular problems (January to July 2013). 
Some of the people with CVD also had co-morbid mood disorders. Through these 
meetings, the original MBCT manual was reviewed and the best ways to make it more 
appropriate for people with cardiovascular disorders were discussed in detail. For the 
second stage of developing the manual, a pilot group was conducted in July/Aug 2013 
using the first draft of the manual. The group comprised four members of the HeLM 
project team (WK, CD, AE and RV) as well as people from the PPI group and eight 
further participants with depression and CVD. The aim in conducting this group was to 
identify any changes to the manual that were necessary through discussions amongst the 
HeLM members, PPI group and people with cardiovascular disorders on a week by week 
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basis throughout the course. In the third stage of developing the manual, we conducted a 
second pilot group in October/Nov 2014 using the MBCT manual incorporating learning 
from phase 2. Weekly meetings were held after each MBCT session between the 
therapists (WK and AE) and the lead researcher (MA) to discuss the manual.  
5.3.2 Study Design  
This project is a feasibility study of a three-arm randomised controlled trial 
comparing adapted-MBCT (HeLM) plus treatment as usual (TAU), standard 
mindfulness-based stress reduction (MBSR) plus TAU, and TAU alone, for the treatment 
of depressive symptoms in people with comorbid depression and cardiovascular 
disorders. The study was conducted in the AccEPT Clinic/ Mood Disorders Centre at the 
University of Exeter. Participants completed a set of self-report questionnaires and blood 
pressure was recorded at baseline, post intervention and at three-month follow-up. Those 
in the adapted-MBCT (HeLM) group additionally took part in a short qualitative 
interview after completing the course to assess the acceptability of the adapted MBCT 
intervention. 
5.3.3 Study Participants 
Eligible participants were adults aged 18 and older with a cardiovascular disorder 
(heart condition, stroke or hypertension). Participants also needed to have either a history 
of clinical depression (major depression disorder, minor depression or dysthymia) and/or 
current minor depression with or without anxiety symptoms. We excluded those who met 
the criteria for a current episode of major depression disorder. Other exclusion criteria 
were co-morbid diagnoses of current substance dependence or abuse, organic brain 
damage, current or past psychosis, persistent antisocial behaviour, persistent self-injury 
and formal concurrent psychotherapy. Each participant received £10 as a token of 
appreciation for participating in the study every time (s)he completed the assessments 
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with the researcher (£30 maximum per participant). The sample characteristics of the 
participants in the three groups are described in Table 5.1. The mean (SD) age was 64.8 
(10.0); 58 % were male; 61 % were married; and 94 % were white British or Irish. 
Approximately two thirds were suffering from heart conditions, one third had had a 
stroke, four people had hypertension and five had two or more cardiovascular disorders. 
Seventy-six percent (76 %) of the participants were not receiving any antidepressant.  
5.3.4 Sample Size 
We calculated the sample size based on the assumptions that about 20 % of 
people with recent acute coronary diseases have major depression and a further 20 % 
have raised symptoms of depression that do not meet the diagnostic threshold. There are 
about 1,000 patients per year passing through the Exeter cardiology service following 
having experienced acute coronary diseases. The aim was to recruit for seven months 
and based on that we expected the following: 
1. Approximately 580 patients (7/12*1000) would pass through in that period; 
2. Approximately 230 patients (40 % of the 580) would have at least mild depression; 
3. Approximately 92 patients (40 % of the 230) would participate in the study;  
4. Approximately 74 patients (80 % of the 92) would be followed up at 3 months 
(approximately 24 per group, based on running two groups for each of MBCT and 
MBSR). 
The 580 patients with acute coronary diseases would be large enough to estimate 
the percentage with at least mild depression with a margin of error no greater than +/- 4 
percentage points, based on the width of the 95 % confidence interval. The 230 patients 
with mild depression would be large enough to estimate the percentages that participate 
with a margin of error no greater than +/- 7 percentage points. The 92 trial participants 
would be large enough to estimate the percentage followed up at 3 months with a margin 
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of error no greater than +/- 11 percentage points. The 74 participants that provide data at 
3 months' follow-up would be large enough to estimate the standard deviation for a 
continuous outcome to within 20 % of the true value. 
5.3.5 Recruitment  
The recruitment process was conducted through three resources: primary care 
(GPs), specialised services (the cardiology department at Royal Devon & Exeter 
Hospital), and in the community in Exeter via distributed materials, with one objective 
being to assess the efficiency of these methods. 
Physicians and nurses in the cardiology department were invited to inform 
in/outpatients about the study and the outpatients clinic nurses were asked to screen 
interested people using Patient Health Questionnaire-8 (PHQ-8). This tool contains eight 
of the nine items of Patient Health Questionnaire-9 (PHQ-9) designed to evaluate major 
depressive disorder (MDD), as defined by the criteria stated in the Diagnostic Statistical 
Manual of Mental Disorders-Fourth Edition (DSM-IV). This brief version of the PHQ-9 
has shown good validity and reliability for a general population (Kroenke et al., 2009) as 
well as for people with depression and heart conditions (Pressler et al., 2011). We chose 
to use this version excluding the suicide ideation or attempts item, as we anticipated 
delivering some of these questionnaires by post and we considered that this version 
might be more acceptable to patients completing the assessment in the absence of any 
researcher or clinician on hand to respond to any immediate concerns. We also added a 
question to assess whether the patient had a history of depression (no specific number of 
episodes) either after or before cardiovascular disorder onset. If a patient had a score 
between 5 and 15 (minimal to moderate depression) according to PHQ-8 cut offs or had 
a history of depression, (s)he received a copy of a poster (see Appendix D1) containing a 
brief description of the study and a summary information sheet (see Appendix D2). GPs 
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were also invited to refer suitable patients to the study. They were asked to identity 
patients registered at their surgery against the study's inclusion and exclusion criteria. 
Following this, patients were sent letters from the GP with a summary information sheet, 
which informed potentially eligible people that they could contact the researcher by post 
using the free-envelope, telephone or e-mail. In addition, posters containing information 
on the study were distributed in cafés and restaurants; the posters were put on tables so 
potential participants could take one. 
All interested people were contacted by telephone and screened after providing 
verbal consent. The full information sheets (see Appendix D3) were sent to all eligible 
people by post. Subsequently, they were invited to an initial interview with the lead 
researcher (MA), to have the study explained further and to ensure they met the study 
inclusion criteria, using the structured clinical interview for DSM-IV-TR (SCID-I) (First, 
Gibbon, Spitzer, & Williams, 2002) (see Appendix E). In this interview, informed 
written consent (see Appendix F) was obtained from all the participants and the baseline 
assessment was administered using questionnaires. In addition, each participant’s blood 
pressure was measured using an automatic blood pressure monitor.  
The first screen (see Appendix G1) was conducted during the first four months of 
the recruitment to check the inclusion/exclusion criteria of the study by MA and RV. The 
second (see Appendix G2) was undertaken two weeks prior to the baseline by MA. 
During this phase, we checked current depression in people who were found eligible in 
the first screen. The reason for conducting two screens was that we thought four months 
duration of recruitment (the period between initial recruitment and randomisation) was a 
relatively long period of time for checking current depression and we wanted to make 
sure that people still wanted to take part so as to minimise drop out post randomisation. 
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5.3.6 Randomisation and Blinding 
Participants were randomised using sealed envelopes to conceal allocation. 
Blocking was used with randomly permuted block sizes in a non-systematic sequence. 
Randomisation of participants was stratified to ensure balance between the three trial 
arms based on severity of depression (based on PHQ cut-off) and type of cardiovascular 
disorder (heart conditions, stroke and hypertension) (see Appendix H). The 
randomisation process was conducted by an independent researcher after the baseline 
assessment. It was not possible for the lead researcher (MA) to be blind at the post-
intervention and follow up assessments. Participants were informed about their allocation 
status by post and those in the MBCT and MBSR groups were asked to provide 
convenient times for meeting the mindfulness teacher (AE) for a one-hour orientation 
session before starting the intervention. 
5.3.7 Interventions 
5.3.7.1 Adapted-MBCT (HeLM). 
Mindfulness-Based Cognitive Therapy (MBCT) is a programme outlined by 
Segal et al. (2002, 2013) and developed based on Mindfulness-Based Stress Reduction 
(MBSR). It comprises an individual orientation session and eight weekly 2.5-hour group 
sessions. MBCT entails extensive mindfulness practices as well cognitive-behavioural 
exercises. It is designed to help people become aware of problematic styles of thinking 
and reacting, to decentre from these and respond more adaptively at times of a potential 
depressive relapse. The MBCT-HeLM manual maintained the essential structure and 
content of the original MBCT manual, but the focus and themes were reoriented to those 
that characterise people with low mood and CVDs. For example, in the first half of the 
programme participants were oriented to turning towards bodily experiences associated 
with CVD, with curiosity, friendliness and care. Instead of an exclusive focus on 
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depressive thinking, the emphasis was shifted to the ways in which physical symptoms 
were interpreted, for example, ‘catastrophic thinking. In session 4, the focus was on how 
stress/low mood/anxiety relates to bodily experience in a reciprocal relationship. We 
used the RAIN acronym (Recognise, Allow, Inquire and thoughts are Not facts). The 
first stage involves recognising when distressing bodily sensations, thoughts and images 
and feelings arise. Over time the intention is to support an ability to decentre and 
disengage from problematic ways of reacting and learn to respond with greater 
understanding and compassion. In session 5, the title of the session was changed to 
‘Softness and Strength’. In this session, the RAIN acronym progresses to participants 
being invited to turn towards difficulties with a sense of allowing and inquiry. In this 
session, the themes around fear/hyperarousal or sadness/loss are picked up more fully 
with a view to beginning to decentre clearly from proliferation and over-identification. In 
session 6, the title of the session was changed to ‘Symptoms as messages from the body; 
thoughts are not facts’. In this session, the RAIN acronym progresses to Inquiry and 
‘thoughts are not facts.’ The intention is to recognise, allow and decentre from fear-based 
thinking/imagery, sadness/loss and proliferative thinking through dis-identification with 
these habitual patterns of reacting. This session also includes beginning to note the 
possibility of responding compassionately with discernment / wisdom. Throughout the 
programme there was a greater emphasis on mental and physical self-care. The main 
differences between MBCT-HeLM, standard MBCT and MBSR are presented in Table 
5.2. Participants were asked to complete a daily home practice dairy six day per week, 
and they were given mindfulness CDs to guide this practice. They were also invited to a 
long-day practice after Session 6 to make sure that those in both groups were receiving 
the same dose of MBCT and MBSR. The participants were asked to continue with 
treatment as usual (their normal clinical care). After completing the study, all the MBCT-
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HeLM participants were invited to regular reunion sessions in the AccEPT Clinic/ Mood 
Disorders Centre at the University of Exeter.  
5.3.7.2 Standard MBSR. 
Mindfulness-Based Stress Reduction (MBSR; Kabat-Zinn, 1990, 2013) consists 
of eight weekly 2.5 hours sessions with up to 30 participants and includes a full day of 
practice. MBSR comprises extensive formal and informal mindfulness-based exercises 
(e.g., body scan, breathing awareness, mindful yoga, mindful eating and mindful 
walking). The intention is to develop awareness and a new relationship with experience 
characterised by present moment focus, approach orientation, compassion, understanding 
and equanimity. Participants were asked to complete a daily home practice dairy six day 
per week, and they were given mindfulness CDs to guide this practice. They were also 
asked to continue with treatment as usual (their normal clinical care). After completing 
the study, all the MBSR participants were invited to regular reunion sessions in the 
AccEPT Clinic/ Mood Disorders Centre at the University of Exeter. 
5.3.7.3 Treatment as usual (TAU). 
In this group, the participants were asked to continue their normal clinical care. 
Treatment as usual (TAU) could include psychiatric treatment, outpatient consultation, 
routine visits to the GP and support programmes from the mental health or cardiac nurse. 
These participants were offered standard MBCT service AccEPT Clinic at the Mood 
Disorders Centre after completing the follow up assessment.   
5.3.8 Assessment Time-Points 
Participants were assessed at three-time points: a baseline assessment conducted 
three weeks prior to randomisation; a post-intervention assessment taking place at the 
end of the MBCT-HeLM and MBSR groups; and a three-month follow-up after the 
interventions completion. For the TAU group, all assessments were at the same point 
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post-randomisation. The lead researcher (MA) conducted all three assessments at face-
to-face meetings with the participants. 
5.3.9 Outcomes 
5.3.9.1 Feasibility. 
The feasibility of MBCT-HeLM intervention in people with depression and 
cardiovascular disorders was established based on recruitment (recruitment methods, 
screening and baseline phases), retention rate (course completion), attrition rate 
(dropouts), participants’ adherence (attendance, home practice and assessment 
completion) and other procedures, including randomisation, therapist adherence, 
inclusion/exclusion criteria and outcome measures. The rate of recruitment was 
quantified by the percentage of eligible people that were recruited and randomised. 
Retention and attrition were assessed by determining the percentage of completers and 
dropouts. The participants’ adherence was measured using attendance rate and total time 
spent on the home mindfulness practice. In terms of assessment completion, we 
measured the percentage of people who fully completed each outcome assessment in 
each of the three groups.   
5.3.9.2 Acceptability. 
 We developed a short interview schedule with questions focusing on the MBCT-
HeLM participants’ overall satisfaction with the study, their views regarding the MBCT-
HeLM techniques, home practice, the group format, and the physical and psychological 
advantages/ disadvantages from having taken part. The interviews were carried out face-
to-face at the Mood Disorders Centre/University of Exeter. All the people who 
completed the MBCT-HeLM course were interviewed. In addition, those who dropped 
out were asked about their overall experience with the study and their reasons for 
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dropping out. Each interview was audio recorded and took between 15 and 25 minutes, 
being subsequently transcribed verbatim by a transcription service. 
5.3.9.3 Measures.  
The primary outcome was depression symptoms. Secondary outcomes were 
physical health related, including blood pressure, which is considered to be an important 
risk factor for developing a cardiovascular disorder (Kelly & Fuster, 2010) and heart-
focused anxiety (HFA), which has been found to be linked to increased anxiety, 
depression and lower quality of life among people undergoing cardiac surgery (Hoyer et 
al., 2008). Further secondary outcomes, are illness perceptions (participants’ beliefs 
about their illness), which are associated with the speed and quality of recovery after 
myocardial infraction (Petrie et al., 1997) and general and specific quality of life in 
people with cardiovascular disorders, which are considered to be important indicators of 
the effectiveness of any treatment in people with heart disorders (Thompson & Yu, 
2003). Additionally, we used three process measures that we might use in a definitive 
trial to examine hypothesised mechanisms of action in MBCT-HeLM: mindfulness, self-
compassion and positive and negative affect. These processes have been identified as 
mediators of outcome in previous studies of MBCT (Geschwind, Peeters, Drukker, van 
Os & Wichers, 2011; Kuyken et al., 2010; Shahar, Britton, Sbarra, Figueredo, & 
Bootzin, 2010). Also, mindfulness has been found to be a mediator of the effects of 
MBCT in people with coronary heart diseases (O’Doherty et al., 2015). See Appendix I 
for the measures that were used in this study.  
5.3.9.4 Primary measure.  
5.3.9.4.1 Depression. Depressive symptoms were assessed using Patient Health 
Questionnaire-9 (PHQ-9; Spitzer, Kroenke, Williams, & Group, 1999), which contains 
nine items reflecting Diagnostic Statistical Manual of Mental Disorders-Fourth Edition 
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(DSM-IV) criteria of major depression disorder (MDD). Each item is scored between 0 
and 3 with, a range of total scores between 0 and 27. The cut-off points of PHQ-9 are 5, 
10, 15, and 20, which define the following levels of severity: none/minimal depression 
(0-4), mild depression (5-9), moderate depression (10-14), moderately severe depression 
(15-19), and severe depression (20-27). PHQ-9 has been found to have adequate 
psychometric properties in the UK (Cameron et al., 2008) as well as in people with 
coronary heart disease (Haddad et al., 2013).  
5.3.9.5 Secondary measures. 
5.3.9.5.1 Blood pressure. Levels of blood pressure in each participant were 
recorded using an Advanced Clinically Validated Blood Pressure Arm Monitor, which 
provides readings of systolic and diastolic blood pressure.  
5.3.9.5.2 Generalised anxiety. Severity of general anxiety symptoms was 
assessed using Generalised Anxiety Disorder-7 (GAD-7; Spitzer, Kroenke, Williams, & 
Lowe, 2006). This questionnaire comprises seven items reflecting the DSM-IV criteria of 
generalised anxiety disorder (GAD). Each item is rated between 0 and 3 with, a range of 
total scores between 0 and 21 with four levels of severity: none (0-4), mild anxiety (5-9), 
moderate anxiety (10-14), and severe (15-21). GAD-7 has been found to have good 
reliability and validity (Spitzer et al., 2006).  
5.3.9.5.3 Cardiac anxiety. The Cardiac Anxiety Questionnaire (CAQ; Eifert et 
al., 2000) was used to assess heart-focused anxiety (HFA). The CAQ is a self-report 
containing 18 items reflecting three clinical aspects: cardio-protective avoidance 
behaviour, heart-focused attention and fears about heart sensations. Each item is scored 
from 0 (never) to 4 (always) with a range of total scores between 0 and 72. Higher scores 
indicate greater heart-focused anxiety (HFA). The CAQ has been found to have good 
210 
 
 
internal consistency (Eifert et al., 2000). In the HeLM study, this questionnaire was used 
with people with heart conditions only.  
5.3.9.5.4 Health-related quality of life. The RAND 36-Item Health Survey 1.0 
(Hays et al., 1993) was used to assess the participants’ general quality of life. It contains 
36 items, covering eight domains: physical functioning (PF), role-physical (RP), bodily 
pain (BP), general health (GH), vitality (V), social functioning (SF), role-emotional (RE) 
and mental health (MH). These domains can be grouped into two main components: 
physical and psychological. Each item is recoded on a 0 to 100 range and then an 
average of the scores for the items in each domain is obtained, with higher scores being 
consonant with greater functioning and enhanced well-being. The RAND 36-Item has 
been found to have good psychometric properties (Hays, Sherbourne, & Mazel, 1995).  
5.3.9.5.5 Health-related quality of life in people with cardiac problems. The 
Seattle Angina Questionnaire (SAQ; Spertus et al., 1995) is a specific measure that has 
been widely used to assess the health outcomes in people with angina. It contains 19 
items, covering five clinical dimensions (subscales): physical limitations, angina 
stability, angina frequency, treatment satisfaction and disease perception. Each subscale 
is scored by reordering each response, summing up the scores for each subscale and then 
transforming the scores to a range 0-100. No actual total for SAQ could be obtained, but 
those with higher scores indicate high levels of health and satisfaction. The SAQ has 
shown good validity and reliability in the UK (Garratt, Hutchinson, & Russell, 2001). In 
the HeLM study, we used this questionnaire with people with heart conditions only. 
5.3.9.5.6 Illness perception. The Illness Perception Questionnaire-Revised (IPQ-
R; Moss-Morris et al., 2002) was used to assess participants’ beliefs about their illness. 
This measure is a revised version of the illness perception questionnaire (IPQ) that was 
developed to assess cognitive representations. The IPQ-R measure comprises three 
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sections; the first and third sections are called identity and causality. The second section 
contains 38 items covering seven dimensions: timeline acute/chronic, timeline cyclical, 
consequences, personal control, treatment control, illness coherence and emotional 
representations. In the HeLM study, we used the second section with the 38 items, each 
being rated between 1 and 5. The IPQ-R was scored by reversing some items and then 
summing up scores for each of the seven dimensions. No total for IPQ-R could be 
obtained. The IPQ-R measure has been used with people suffering from heart diseases 
and has showed good psychometric properties in the UK (Moss-Morris et al., 2002).  
5.3.9.6 Process measures.  
5.3.9.6.1 Mindfulness. The Five-Facet Mindfulness Questionnaire (FFMQ; Baer, 
Smith, Hopkins, Krietemeyer, & Toney, 2006) was designed to assess different aspects 
of mindfulness. It consists of 39 items, reflecting five facets: non-reactivity to inner 
experience (7 items), observing (8 items), acting with awareness (8 items), describing (8 
items) and non-judging of experience (8 items). Each item is rated on a 5-point Likert 
scale ranging from 1 (never or very rarely true) to 5 (very often or always true). The 
questionnaire is scored by reversing some items and then summing up the scores for each 
of the five facets. The total FFMQ score is obtained by summing up the five facet scores. 
The FFMQ has been found to have good psychometric properties (Baer et al., 2006, 
2008).  
5.3.9.6.2 Self-compassion. The Self-Compassion Scale (SCS; Neff, 2003) is a 
measure assessing the overall compassion according to three components: self-kindness, 
common humanity and mindfulness. Each component has a negative aspect: self-
judgment, isolation and over-identification, respectively. It contains 26 items that are 
rated on a Likert scale from 1 (almost never) to 5 (almost always). The SCS subscales 
are scored by calculating the mean of responses on each subscale. The total SCS is 
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scored by reversing scores of the negative subscales (self-judgment, isolation, and over-
identification) and then computing a mean of the subscale means. The SCS has been 
found to have good validity and reliability across different cultures (Neff, 2003).  
5.3.9.6.3 Positive and negative affect. The Positive and Negative Affect Scale 
(PANAS; Watson, Clark, & Tellegen, 1988) was used to assess participants’ mood. It 
comprises 20 self-administered items that can be used to evaluate one’s mood at various 
times-points. The items are rated using a Likert scale from 1 (very slightly) to 5 
(extremely). The positive affect subscale is scored by adding the scores of items 1, 3, 5, 
9, 10, 12, 14, 16, 17, and 19. The negative affect subscale is scored by adding the scores 
of items 2, 4, 6, 7, 8, 11, 13, 15, 18, and 20. The PANAS has shown good validity and 
reliability in the UK (Crawford & Henry, 2004).  
5.3.10 Home Practice  
The home practice record sheet was used to assess which mindfulness practice 
participants were completing it and the amount of time spent on practice each week. 
Participants in the MBCT-HeLM and MBSR groups were asked to complete this sheet 
each week throughout the course and return it to the mindfulness teacher. The lead 
researcher photocopied the sheets and they were returned to the participants the 
following week.  
5.3.11 Structured Clinical Interview for DSM-IV-TR (SCID-I) 
The Structured Clinical Interview for DSM-IV-TR (SCID-I) (First et al., 2002) 
was used to assess the presence of psychiatric diagnoses. In this study, we used some 
parts of the mood episodes section (current major depressive episode (MDE), past MDE 
and current dysthymic disorders) in order to assess a potential participant’s eligibility in 
detail. 
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5.3.12 Therapist Adherence and Competence  
Both the MBCT-HeLM and MBSR groups were conducted by a trained and 
experienced mindfulness–based therapist (AE) with a considerable length of practice. 
The therapist received weekly supervision from an independent supervisor. The group 
sessions were video-recorded, and an independent mindfulness therapist evaluated two 
MBCT and two MBSR sessions for competence and adherence. The Mindfulness-based 
Intervention: Teaching Assessment Criteria (MBI: TAC) (Crane et al., 2013), which is 
rated on a scale from 1 (incompetent) to 6 (advanced), was used (see Appendix J). 
5.3.13 Statistical Analysis 
The data were analysed in line with the guidelines for good practice in designing, 
analysing and reporting pilot and feasibility studies (Lancaster, Dodd, & Williamson, 
2004; Lancaster, 2015). The percentage of eligible people that consented to participate is 
reported with 95 % confidence intervals. Similarly, the percentage of the participants that 
provided follow-up data and the percentage of those in the MBCT-HeLM and MBSR 
arms that completed the interventions are reported. The characteristics of the participants 
in each trial arm are summarised using means and standard deviations for continuous 
variables and percentages for categorical ones. Given the study aims were to assess the 
feasibility and acceptability of MBCT-HeLM, but not testing hypotheses, we report the 
quantitative results in a descriptive way and have not reported P-values. Instead, we 
provide 95 % confidence intervals, which illustrate the amount of uncertainty there is 
regarding the true intervention effect. For each of the primary and secondary outcomes, 
we used the means, standard deviations (SDs), mean differences and 95 % confidence 
intervals between the groups. For the process measures, we used a similar method of 
using the means, standard deviations (SDs), mean differences and 95 % confidence 
intervals between the groups. Regarding the qualitative analysis, the NVivo programme 
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was employed to help with coding the data. We used the thematic analysis method with 
the six phases suggested by Braun and Clarke (2006) in order to analyse the interviews 
(see Appendix K). 
5.4 Results 
The results of the study are reported according to guidelines for good practice in 
designing, analysing and reporting pilot and feasibility studies (Lancaster, Dodd, & 
Williamson, 2004; Lancaster, 2015). In addition, we used the Consolidated Standards of 
Reporting Trials (CONSORT) extension guidelines for reporting pilot and feasibility 
studies (Thabane et al., 2010). 
5.4.1 The Feasibility of an RCT of MBCT-HeLM for People with Depression and 
CVD   
The first aim of this study was to establish the feasibility of conducting a 
randomised controlled trial of MBCT-HeLM in addition to TAU vs. MBSR along with 
TAU vs. TAU alone. In general, the results indicate that there are several positive 
indicators about the feasibility, with the main challenge being recruitment.  
5.4.1.1 Recruitment rate. 
5.4.1.1.1 Recruitment methods. Three methods of recruitment (GPs, cardiology 
department at Royal Devon and Exeter hospital and advertisement) were used in the 
HeLM feasibility study. The recruitment and screening phases were conducted over four 
months (July to October 2014). Invitations were sent to 3,340 people through three GPs 
(two in Exeter and one in Exmouth), while a summary of the study was handed to 50-60 
patients out of approximately 144 patients passing through the outpatients’ clinic for 
about 12 weeks by the cardiac nurses in the cardiology department. This was different to 
our calculation of the sample size as we estimated that 82 patients would pass every 
month (250 for the 12 weeks). In addition, 600 copies of a study poster were distributed 
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in nine cafés and restaurants in Exeter city centre, three weeks before the recruitment 
ended.  
5.4.1.1.2 Screening and baseline phases. As shown in the CONSORT diagram 
(Figure 5.1), of the 3,340 people approached through GPs, 239 people (7.1 %) were 
interested, 180 people (5 %) showed no interest (i.e. People who sent the reply form back 
to the researchers stating that they were not interested in the study) and the remainder 
(88 %) did not respond to the letters (i.e. People who did not send the reply form back to 
the researchers). Regarding the cardiology department, we had three interested people 
(5 % of the 60 people who were approached through the cardiology department) and no 
individuals responded to the advertisements. During the first screen, 183 out of the 242-
interested people (76 %) were excluded for the following reasons: no low mood as 
people reported (n = 99), no cardiovascular disorder (n = 20), not interested anymore 
(n = 15), could not attend the group dates (n = 20), non-contactable (n = 12) and other 
reasons (n = 17). This resulted in 59 out of the 3,340-approached people (1.7 %) meeting 
the criteria of the first screen. For the second screen, two people were excluded, as they 
had current major depression, another one was non-contactable and 15 did not wish to 
continue the study. The reasons for withdrawing were health (n = 8), family (n = 2), 
work (n = 3), or holding the view that the mindfulness course did not seem right for them 
(n = 2). In the baseline phase, 41 people who met the study criteria were invited to a 
diagnostic interview where the SCID was applied to check for past and current major 
depressive disorder (MDD), minor depression as well as dysthymia. In this phase, three 
people were excluded, as two had current major depression and one was misusing drugs. 
Two people quit for health reasons (they had shortness of breath and found it hard to 
come to the Mood Disorders Centre/ Exeter University) and three did not show up (one 
of them could not come as he had a cardiac problem). Finally, 33 out of the 59-eligible 
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people (56 %; 95 % CI: 43 % to 68 %) gave their consent and were randomly allocated 
to the three groups: MBCT-HeLM (N = 11), MBSR (N = 11) and TAU (N = 11). Given 
the total of the sent invitations comprised 3,340 letters and summaries, this meant we 
managed to recruit only 1.0 % (95 % CI: 0.7 % to 1.4 %) of these. In the orientation 
sessions, one participant from the MBSR group was excluded from the study, as it was 
agreed that her chest pain was stress-related and not a cardiovascular disorder. As this 
woman had recurrent major depression, she was referred to the AccEPT Clinic for 
standard care. 
5.4.1.2 Retention (course completion) and attrition (dropouts) rates. 
Seven of the 11 participants (64 %; 95 % CI: 36 % to 86 %) in the MBCT-HeLM 
group completed the course. Of those who dropped out, three could not make the 
scheduled group times, two found it hard to alter their work times and one had a severe 
chest infection. After the third session, one woman dropped out for family reasons. 
Regarding the MBSR group (n = 10), six people (60 %) started and after the second 
session of MBSR, a woman dropped out as she said that it was hard for her to complete 
the home practice and come to the Mood Disorder Centre/University due to her serious 
physical disability caused by a stroke. The other people (n = 4) could not attend the 
group dates; one participant got a new job, one participant had to babysit a child, one had 
had a surgery and one did not attend due to work-related issues.  
5.4.1.3 Participant adherence.  
5.4.1.3.1 Attendance. In the MBCT-HeLM group, seven out of the eight people 
who took part attended between six and eight sessions, while one woman only attended 
two. In the MBSR group, of the six who took part, four attended eight while one attended 
seven sessions and one woman attended two. Regarding the full-day mindfulness 
practice, six people from the MBCT-HeLM and five from the MBSR groups attended.  
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5.4.1.3.2 Home practice. We asked the MBCT-HeLM group to practise some 
formal and informal exercises at home for six days per week so as to integrate 
mindfulness into their daily life. Five out of the seven people who completed the course 
provided five out of the seven home practice sheets and two completed three. The 
average amount of practice was 5 days per week. 
5.4.1.3.3 Assessment completion. Twenty-nine out of the 33 participants 
randomised into the trial (88 %; 95 % CI: 77 % to 98 %) completed the assessment at 
post-intervention and at the 3-month follow-up phase. All participants in the MBCT-
HeLM (n = 11) and MBSR (n = 10) groups completed the post-intervention and follow-
up assessments, whilst three from the TAU group (n = 11) did not.   
5.4.1.4 Therapist adherence and competence.  
For therapist adherence and competence, we used the Mindfulness-based 
Interventions: Teaching Assessment Criteria (MBI: TAC), which is rated on a scale from 
1 (incompetent) to 6 (advanced), with the average rating being 5 (proficient) for both the 
MBCT-HeLM and MBSR.  
5.4.1.5 Describing the primary and other outcomes data.  
Table 5.3 shows the clinical characteristics at baseline for all the study outcomes 
(primary, secondary and process). 
5.4.1.5.1 Primary outcome. Table 5.4 shows the PHQ-9 means, SDs, mean 
differences and 95 % confidence intervals for MBCT-HeLM vs. MBSR and MBCT-
HeLM vs. TAU at post-intervention and at three-month follow-up. The mean PHQ-9 
scores for the MBCT-HeLM group was 0.2 (CI: -3.4 to 2.9) lower at post-intervention 
and 1.4 (CI: -3.8 to 1.0) lower at three-months follow-up, than for the MBSR group. The 
MBCT-HeLM mean was 2.3 (CI: -7.23 to 2.57) lower at post-intervention and 5.2 (CI: -
8.56 to -1.83) lower at the three-month follow-up compared to the TAU group.  
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5.4.1.5.2 Secondary and process outcomes. Tables 5.5 and 5.6 summarise the 
means, SDs, mean differences and 95 % confidence intervals across the three groups at 
post-intervention and three-month follow-up for the study’s secondary and process 
outcomes. The mean blood pressure for the MBCT-HeLM was lower at three-months 
follow up compared to the MBSR and TAU groups. The mean GAD and CAQ scores for 
the MBCT-HeLM and MBSR groups were lower at post-intervention and at three-
months follow-up compared to the TAU group. The mean RAND 36-Item 
(psychological domain) scores for the MBCT-HeLM and MBSR groups were higher at 
both post-intervention and at three-months follow-up than for the TAU group, while the 
mean RAND 36-Item (physical domain) for the MBSR group was higher at three-months 
follow-up compared to both the MBCT-HeLM and TAU groups. The means of the SAQ-
angina stability and SAQ-diseases perception subscales for the MBCT-HeLM were 
higher than for the MBSR and TAU groups at both post-intervention and at three-month 
follow-up, while those for SAQ-physical limitations and SAQ-angina frequency for the 
TAU group were higher than the other two groups at three-months follow-up. The means 
of some of the IPQ-R subscales (timeline acute, emotional representations and 
consequences) for the MBCT-HeLM group were lower at both post-intervention and at 
three-months follow-up than for the MBSR and TAU groups, while those for the 
personal and treatment control subscales of IPQ-R for MBSR were lower than the means 
of the MBCT-HeLM and TAU groups. Regarding the process measures, the mean 
FFMQ for MBCT-HeLM was 4.0 higher than for the MBSR and 18.0 higher than for the 
TAU group, at post-intervention assessment, whilst it was 6.0 lower than for the MBSR 
group and 10.0 higher than for TAU, at the follow up assessment. Regarding SCS, both 
the MBCT-HeLM and MBSR means were higher than for the TAU group at both time-
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point assessments. Finally, the mean of PANAS-Positive was higher for the MBSR 
group compared to the other groups at both time-point assessments.    
5.4.2 The Acceptability of MBCT-HeLM 
The second aim of this study was to see how acceptable MBCT-HeLM was for 
people with depression and cardiovascular disorders. Those who completed the MBCT-
HeLM course (six people with heart conditions and one participant with stroke) 
described it and their overall experience as enjoyable; considering it different to other 
psychological programmes that they had in the past; finding it flexible and helpful. They 
had joined the course with the expectation that it would help in controlling physical 
symptoms, such as high blood pressure and heart complaints as well as understanding 
depression and making them calmer. Participants felt that the course had met some of 
their expectations in terms of understanding depression and seeing things in a different 
way, but less in terms of managing physical symptoms. They reported that the one-to-
one orientation session was helpful in terms of understanding the content of course. They 
generally agreed that eight sessions represented a good course length, in that they 
thought that they needed time to understand mindfulness and to integrate it into their 
daily life and two of them felt that the course needs to be more than eight sessions. All 
seven participants said that the 3-Step Breathing Space exercise was the most useful and 
four of them found the Body Scan helpful. Participants described some challenges with 
the MBCT-HeLM course, in particular, being in a group and making the course a priority 
in their lives. Additional feedback is summarised in Table 5.7. 
5.5 Discussion 
The first aim of the HeLM study was to establish the feasibility of conducting an 
adequately powered randomised controlled trial of MBCT-HeLM for people with 
depression and cardiovascular disorders. The second aim was to assess how acceptable 
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this course was to the participants. The results were encouraging in terms of MBCT-
HeLM’s acceptability and participants’ engagement with the course. However, the large 
funnel between potentially eligible participants and those who participated in the trial 
suggests serious challenges with regard to recruitment to such a trial.  
Recruiting through GP practices was the most useful resource of the three 
methods used, accounting for 239 people (99 %) of all interested people. However, the 
percentage of those who replied to the invitation letters was only 1 %, which means that 
the future definitive trial will need to invite 1,000 people to get 10 consenting 
participants. This is less than reported for other MBCT trials (e.g., Kuyken et al., 2016). 
While recruiting to clinical trials is a challenge for many areas of research, this may be 
especially so for mental health ones (Barton, 2000; TenHave, Coyne, Salzer, & Katz, 
2003), despite the high prevalence rates of mental health problems. In addition, there is 
limited access to evidence-based treatment. Recruitment through specialist CVD services 
was not successful (Figure 5.1). Cardiac nurses are typically very busy and triaging to 
this study added to their busy schedules. Moreover, people who visit cardiac wards often 
attend with unstable conditions and are not in a position to consider taking part in a 
psychosocial intervention like MBSR or MBCT. Moreover, direct advertising did not 
yield any responses.  
The screening procedures worked well (Figure 5.1). In addition, conducting a 
second screen enabled a further check on eligibility before moving to baseline 
assessment. However, in the first screen, the way to ascertain whether people were 
suffering from depression was mostly based on asking them a few questions about their 
history of depression. In future studies, it would be beneficial to use an in-depth screen in 
the early stage of recruitment, which could capture the history of depression in detail and 
might increase the eligibility rate. During the orientation sessions, one female participant 
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was excluded due to uncertainty as to whether she was suffering cardiac problems or 
stress-related chest pain. In this study, the evaluative process to determine the presence 
of a cardiovascular disorder was based on the self-reporting of the participants. In future 
studies, an alternative method of determining a person’s condition should be used, such 
as obtaining a clinical diagnosis from a potential participant’s healthcare professional. 
The initial drop-out rates were relatively high as 9 of the 21 (42 %) randomised 
people in the MBCT and MBSR groups could not attend the group dates. The drop-out 
rate reported in this study is similar to that in the MBCT study conducted by O’Doherty 
and colleagues (2015) in people with coronary heart diseases as they had 47 % drop-out 
rate. Specifically, only 32 out of 60 people in the MBCT group and 30 out of 57 people 
in the control group completed the study. In a non-controlled study (Olivo, Dodson-
Lavelle, Wren, Fang, & Oz, 2009) using a shortened MBSR course with people with 
coronary heart diseases (n = 35) the drop-out rate reported was only 11% (n = 4), which 
is lower than ours. However, those two studies (O’Doherty et al., 2015; Olivo et al., 
2009), targeting mindfulness and heart conditions used nonrandomised/controlled 
designs. In addition, the study by (O’Doherty et al., 2015) recruited people and 
conducted the interventions over approximately three years, while that by (Olivo et al., 
2009) used a short intervention (4 MBSR sessions). In our study, the reasons given for 
withdrawing and dropping out varied, but health issues was the most common one 
provided. Research concerning elderly populations indicates that older people report 
higher chronic physical symptoms (Naylor et al., 2012) and therefore, it might be useful 
to consider delivering MBCT in ways and locations that are more convenient for this 
population. The second most common reason was work commitments, suggesting that it 
is important to consider the timing of MBCT sessions, which could lead to an increase in 
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the participation rate in future studies. In sum, the need to enhance the accessibility of 
any psychosocial intervention for this group is evidenced. 
With regards to course completion, attendance and home practice, this study 
attained good rates of compliance. Of those people who did engage with MBCT-HeLM, 
they attended most sessions and engaged with the mindfulness practice throughout the 
course. This suggests that of the sub-group who do attend, the course is acceptable. The 
3-Step Breathing Space and Body Scan seemed to be the most important practices.  
  Regarding assessment completion, the study had a good rate as the majority of 
participants completed the questionnaires at the post-intervention and follow-up phases, 
which indicates that the measures employed were acceptable to them. This completion 
rate is relatively similar to those reported in other mindfulness studies with heart 
conditions (O’Doherty et al., 2015; Olivo et al., 2009). The randomisation and 
stratification process was successful, which can be concluded because the main 
characteristics baselines were similar in the three groups. There was significant sample 
heterogeneity in terms of whether the sample was currently depressed (minor depression) 
or had a history of depression as well as regarding the time since the cardiac event (heart 
attack or stroke) and the onset of cardiovascular disorders. Importantly, there was 
significant heterogeneity regarding whether depression had happened before or after a 
CVD.  
Participants who engaged with MBCT-HeLM reported a good satisfaction level 
with the course in terms of its content, exercises, home practice and completion of the 
measures. The majority of them found the 3-Step Breathing Space and Body Scan 
helpful. Being in a group was a challenge for some, although others said that it was 
helpful in terms of seeing how they were lucky compared to others. The participants’ 
challenges in this course were mainly about how to make it a priority. Regarding the 
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quantitative results, it is important to emphasise that we did not set out to establish 
effectiveness, nor was it sufficiently powered to do so. Moreover, the wide confidence 
intervals illustrate the imprecision with which the intervention effects are estimated. 
5.6 Summary and recommendations for the definitive trial  
To summarise, to our knowledge, this is the first randomised controlled trial with 
three arms aimed at understanding the issues surrounding the feasibility and acceptability 
of delivering MBCT for people with depression and cardiovascular disorders. This study 
provides some methodological considerations for future studies, such as the use of the 3-
arm design, randomisation and blindness, as well as rates of recruitment, retention, 
attrition and participants adherence. We have demonstrated that an MBCT-HeLM course 
was feasible and acceptable to people who took part in the study. The number of people 
who were randomised (n = 33), despite the short period of recruitment (4 out of the 7 
months that we planned in early stage of the study), was good. Moreover, retention and 
engagement rates were encouraging. However, the pool of potentially eligible 
participants was much larger and suggests some key barriers to the accessibility of an 
intervention such as MBCT, as well as to a trial such as this. Regarding the participants’ 
feedback on the study in relation to the course content, home practice and assessments, 
this was broadly positive.  
In any definitive trial, further effort should be given to recruiting a more 
representative sample in terms of targeting people with depression and cardiovascular 
disorders. It would also be useful to maximise the accessibility of the intervention 
through, for example, offering the course in appropriate places for interested people as 
well as offering evening classes that would suit those in full time employment. Also, it is 
worth considering introducing MBCT/MBSR to participants who are inpatients on 
cardiology wards. In addition, using a detailed screen for depression in the early stages 
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of the recruitment process might lead to an increased eligibility rate. When people are 
provided with group dates prior to randomisation to check to see whether they are 
available, which improves engagement and retention. With regards to the length of 
follow up, in any future definitive randomised controlled trial, a longer follow-up period 
would be required. Finally, if the decision is made to move to a definitive trial, the study 
recruitment procedures will need to be revised in order to recruit a large enough sample. 
5.7 Compliance with Ethical Standards  
The HeLM study was approved by the Cornwall and Plymouth Research Ethics 
Committee (REC reference: 14/SW/0048) on 17 of April 2014. The NHS/HSC R&D 
management approval was obtained on 6 June 2014 (see Appendix M). The authors 
assert that all procedures performed in this study were in accordance with the ethical 
standards of the relevant national and institutional committees on human research and 
with the Helsinki Declaration of 1964 and its later amendments. All participants 
provided full informed consent.
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Figure 5.1. CONSORT diagram of HeLM participant flow 
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Table 5.1  
Demographic characteristics 
 
Total 
(N = 33) 
MBCT-HeLM group 
(N = 11) 
MBSR group 
(N = 11) 
TAU group 
(N = 11) 
Age, mean (SD) 64.8 (10.0) 64.2 (11.6) 64.8 (10.6) 65.4 (8.4) 
Gender, n (%)     
 Male 19 (58 %) 5 5 9 
 Female 14 (42 %) 6 6 2 
Marital status, n (%)     
 Single 4 (12 %) 1 2 1 
 Married 20 (61 %) 6 6 8 
 Divorced 8 (24 %) 3 3 2 
 Widowed 1 (3 %) 1 0 0 
Ethnicity, n (%)     
 White British/Irish 31 (94 %) 10 10 11 
 White other 1 (3 %) 1 0 0 
 Asian British 1 (3 %) 0 1 0 
Employment Status, n (%)     
 Employed 10 (30 %) 4 4 2 
 Unemployed 2 (6 %) 1 0 1 
Retired 21 (64 %) 6 7 8 
Type of CVD, n (%)     
Heart conditions 18 (55 %) 6 5 7 
 Stroke 10 (30 %) 4 4 2 
 Hypertension 4 (12 %) 1 1 2 
 Not-specified 1 (3 %) 0 1 0 
Having more than one CVD, n (%) 5 (15 %) 0 3 2 
On antidepressant medication, n (%)     
 Yes 8 (24 %) 1 2 5 
 No 25 (76 %) 10 9 6 
 Note. TAU: Treatment As Usual; SD: Standard Deviation; CVD: Cardiovascular Disorders. 
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Table 5.2 
The main differences between MBSR, standard MBCT and adapted-MBCT (HeLM) 
Session MBSR  Standard MBCT MBCT-HeLM: adapted for people 
with depression and cardiovascular 
disorders. 
Orientation 
session 
Learning about stress 
and mindfulness.  
Learning about the factors 
associated with the onset and 
maintenance of depression. 
Learning about the factors associated 
with the onset and maintenance of long 
term physical and mental health 
problems. 
Session 1 Seeing the 
significance of 
autopilot in our lives. 
Seeing the significance of 
autopilot in our lives. 
Seeing the significance of autopilot in 
our lives. Emphasising turning towards 
bodily experience. 
Session 2 Perception and 
creative responding. 
How we see things. 
The relationship between 
thoughts and feelings and the 
way this affects mood. 
The relationship between thoughts and 
feelings and the way this affects mood. 
Session 3 Pleasure and power 
of presence.  
The body is a place to be with 
experience. 
Discovering ‘being present’. 
The body is a place to be with 
experience. 
Discovering ‘being present’. 
Session 4 Shadow of stress: 
learning about our 
patterns of reactivity.  
Getting to know territory of 
depression. 
Getting to know territory of low mood, 
stress and anxiety.   
Learning experientially how maintenance 
cycles play out. 
Introduce the RAIN acronym: 
Recognising, allowing, inquiry and 
thoughts are Not facts. 
Session 5 Finding space for 
responding.  
Bringing a sense of allowing 
things to be. 
Acceptance. 
Title of session changed to (Softness and 
Strength). 
-The RAIN acronym progresses here to 
the Allow. 
Session 6 Working with 
difficult situations. 
Communication.  
Thoughts are not facts. 
Negative moods affect our 
experience. 
Recognising patterns of thoughts 
can help us. 
Title of session changed to Symptoms as 
messages from the body; thoughts are 
not facts. 
The RAIN acronym progresses here to 
the Inquiry and thoughts are Not facts. 
All day 
practice  
This all-day session 
is a main part of 
MBSR. 
This all-day session is an 
optional part of MBCT. 
This all-day session is part of MBCT-
HeLM to provide enough time for 
practice. 
Session 7 Cultivating kindness. Recognizing the warning signs of 
depression 
Self-care: nourishing activity 
More focus on stress as well as low 
mood. 
Self-care: nourishing activity 
Session 8 Keeping mindfulness 
alive.  
Keeping mindfulness alive. Keeping mindfulness alive. 
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Table 5.3 
Clinical characteristics at baseline 
 MBCT-HeLM group  MBSR group  TAU group  
Mean SD  Mean SD  Mean SD 
Primary outcome         
 Patient Health Questionnaire-9 (PHQ-9) 8.4  4.8  8.5 4.6  7.0 5.0 
Secondary outcomes          
 Blood Pressure         
 Blood pressure / Systolic 126.7 10.5  142.3 21.8  128.5 21.3 
 Blood pressure / Diastolic 73.8  12.7  77.6 14.3  70.6 8.3 
 Generalised Anxiety Questionnaire-7 (GAD-7) 8.2   3.5  7.0 5.2  4.8 3.3 
 Cardiac Anxiety Questionnaire (CAQ) 17.0  9.1  22.2 8.6  34.0 13.6 
 RAND 36-Item Physical 53.3  18.2  43.0 24.3  59.1 31.5 
 RAND 36-Item Psychological 53.1   21.2  42.3 13.3  51.8 19.3 
 Five-Facet Mindfulness Questionnaire (FFMQ) 121.0 15.4  122.0 17.9  113.7 16.4 
 Self-Compassion Scale (SCS) 2.5 0.5  2.6 0.6  2.4 0.6 
 PANAS-Positive affect  30.3   7.5  27.4 5.9  25.3 9.4 
 PANAS-Negative affect  20.0   8.5  17.4 6.1  18.0 6.9 
 Illness Perception Questionnaire-Revised (IPQ-R)         
 IPQ-R timeline acute/chronic  20.9  7.1  23.6 4.5  25.7 4.4 
 IPQ-R timeline cyclical 11.7  5.1  10.6 3.4  11.0 5.2 
 IPQ-R consequences 17.1  5.1  20.3 6.9  20.2 3.9 
 IPQ-R personal control 22.1  4.9  22.2 4.6  19.9 5.4 
 IPQ-R treatment control 18.9  3.5  15.9 2.8  17.3 4.4 
 IPQ-R illness coherence 17.5  4.7  19.2 5.8  19.6 4.7 
 IPQ-R emotional representations 18.3  6.2  20.7 2.6  19.7 4.3 
 The Seattle Angina Questionnaire (SAQ)         
 SAQ- physical limitations 52.5  13.8  48.1 17.8  37.8 18.7 
 SAQ- angina stability 56.0  21.9  36.6 8.1  36.0 16.7 
 SAQ- angina frequency 70.5   11.5  70.6 14.8  58.0 27.0 
 SAQ- treatment satisfaction 59.8  17.0  62.3 10.1  68.0 13.8 
 SAQ- disease perception 52.1  20.6  47.8 19.2  43.8 28.6 
Note. TAU: Treatment As Usual; SD: Standard Deviation.  
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Table 5.4 
Comparison of PHQ-9 at post-intervention and follow-up 
Outcome  MBCT-HeLM 
(N = 11) 
Mean (SD) 
MBSR 
(N = 10) 
Mean (SD) 
TAU 
(N = 8) 
Mean (SD) 
 MBCT-HeLM vs. MBSR 
 
MBCT-HeLM vs. TAU 
Mean diff. 95% CI Mean diff. 95% CI 
Baseline          8.4 (4.8) 8.5 (4.6) 7.0 (5.0) 
 
      
Post-intervention   6.1(3.1) 6.3 (3.6) 8.4 (6.3) 
 
 -0.2 -3.4 to 2.9  -2.32 -7.23 to 2.57 
3- months follow-up 3.8(2.5) 5.2 (2.4) 9.0 (4.1)        -1.4 -3.8 to 1.0  -5.20 -8.56 to -1.83 
Note. PHQ-9: Patients Health Questionnaires-9; TAU: Treatment As Usual; SD: Standard Deviation; CI: Confidence Interval.  
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Table 5.5  
Comparison of secondary outcomes at post-intervention 
Outcomes 
MBCT-HeLM 
(N = 11) 
MBSR 
(N = 10) 
TAU 
(N = 7) 
 
MBCT-HeLM vs. MBSR 
 
MBCT-HeLM vs. TAU 
Mean (SD) Mean (SD) Mean (SD)  Mean diff. 95 % CI  Mean diff. 95 % CI 
Blood pressure          
 Systolic blood pressure (mmHg) 130.4 (20.7) 143.8 (20.7) 129.8 (14.8)  -13.4 -42.5 to 15.7  0.6 -20.3 to 21.4 
 Diastolic blood pressure (mmHg) 73.2 (16.4) 76.5 (17.8) 73.5 (9.3)  -3.3 -24.2 to 17.7  -0.3 -15.9 to 15.3 
GAD-7 4.8 (4.8) 4.4 (2.8) 6.4 (3.9)  0.4 -3.6 to 4.4  -1.6 -6.2 to 3.0 
CAQ* 18.3 (14.3) 18.0 (1.4) 30.5 (13.6)  0.3 -16.5 to 17.2     -12.1 -33.1 to 8.8 
RAND 36-Item Health Survey 1.0            
 RAND 36-Item Physical 49.5 (15.3) 56.4 (28.1) 59.1 (32.7)  -6.9 -27.6 to 13.9  -9.6 -40.2 to 21.2 
 RAND 36-Item Psychological 55 .5 (19.1) 60.8 (14.6) 48.7 (23.7)  -5.3 -21.6 to 11.0  6.8 -14.7 to 28.3 
FFMQ (Total) 128.0 (18.0) 124.0 (18.3) 110.0 (6.7)  4.0 -15.6 to 23.4  18.0 2.1 to 33.3 
SCS (Total) 2.6 (0.6) 2.8 (0.8) 2.4 (0.7)  -0.2 -0.9 to 0.5  0.2 -0.5 to 0.8 
PANAS-Positive 25.3 (7.1) 32.7 (4.3) 28.2 (7.4)  -7.4 -13.6 to -1.3  -2.9 -10.6 to 4.7 
PANAS-Negative 18.7 (9.8) 16.3 (6.6) 19.4 (9.1)  2.3 -6.3 to 11.0  -0.7 -10.8 to 9.3 
IPQ-R          
 IPQ-R timeline acute/chronic 18.1 (3.6) 18.6 (2.8) 18.7 (6.7)  -0.5 -3.8 to 2.8  -0.6 -6.0 to 4.7 
 IPQ-R timeline cyclical 11.5 (4.0) 11.1 (3.2) 10.4 (4.4)  0.4 -3.4 to 4.3  1.1 -3.5 to 5.7 
 IPQ-R consequences 19.7 (6.2) 18.8 (5.3) 19.0 (6.1)  0.9 -5.0 to 6.6  0.7 -5.8 to 7.2 
 IPQ-R personal control 23.2 (3.7) 19.2 (3.9) 23.1 (4.8)  4.0 0.1 to 7.8  0.1 -4.4 to 4.5 
 IPQ-R treatment control 16.8 (2.2) 13.8 (4.2) 17.7 (2.4)  3.0 -0.4 to 6.5  -0.9 -3.4 to 1.7 
 IPQ-R illness coherence 20.3 (2.3) 16.5 (5.9) 18.8 (2.8)  3.8 -0.7 to 8.4  1.5 -1.3 to 4.3 
 IPQ-R emotional representations 17.5 (5.2) 19.3 (5.1) 18.1 (4.6)  -1.8 -7.2 to 3.6  -0.6 -6.0 to 4.8 
SAQ**          
 SAQ- physical limitations 43.8(19.2) 41.8(21.4) 41.9(5.3)  2.0 -25.7 to 29.7   1.9  -25.8 to 29.5 
 SAQ- angina stability 52.0(17.8) 60.0(20.0) 50.0(20.5)  -8.0 -35.7 to 19.8  2.0 -1.3 to 65.3 
 SAQ- angina frequency 68.1(13.3) 68.3(13.6) 45.8 (17.6)  -0.2 -18.8 to 18.2  22.3 -6.1 to 50.5 
 SAQ- treatment satisfaction 58.0 (18.5) 64.7(11.4) 65.0 (11.9)  -6.7 -29.2 to 15.8  -7.0 -36.8 to 22.8 
 SAQ- disease perception 50.6 (23.4) 58.6(12.8) 44.4 (27.7)  -8.0 -35.5 to 19.5  6.2 -38.3 to 50.8  
Note: TAU: Treatment As Usual; SD: Standard Deviation; CI: Confidence Intervals; GAD-7: Generalised Anxiety Questionnaire-7; CAQ: Cardiac Anxiety Questionnaire; FFMQ: Five Facet 
Mindfulness Questionnaire; SCS: Self-Compassion Scale; PANAS: Positive and Negative Affect Scale; IPQ-R: Illness Perception Questionnaire-Revised. SAQ: Seattle Angina Questionnaire;  
* CAQ was completed by participants with heart conditions only (MBCT, n=6; MBSR, n=5; TAU, n=3); ** SAQ was completed by participants with heart conditions only (MBCT, n=6; 
MBSR, n=5; TAU, n=3).  
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Table 5.6 
Comparison of secondary outcomes at 3-month follow-up 
Outcomes 
MBCT-HeLM 
(N= 11) 
MBSR 
(N= 10) 
TAU 
(N= 8) 
 
MBCT-HeLM vs. MBSR 
 
MBCT-HeLM vs. TAU 
Mean (SD) Mean (SD) Mean (SD)  Mean diff. 95% CI  Mean diff. 95% CI 
Blood pressure          
 Systolic blood pressure (mmHg) 122.6 (16.3) 130.4 (14.1) 127.8 (14.8)  -7.8 -26.4 to 10.8  -5.2 -24.3 to 13.9 
 Diastolic blood pressure (mmHg) 65 (20.5) 73 (15.2) 70.7(9.6)  -8.0 -29.9 to 13.9  -5.7 -24.8 to 13.4 
GAD-7 3.2 (2.4) 3.5 (1.6) 8.0 (5.0)  -0.3 -2.4 to 1.8  -4.8 -8.6 to -0.9 
CAQ* 16.6 (10) 23.0 (4.9) 30.0 (6.2)  -6.3 -17.5 to 4.8  -13.3 -26.4 to -0.2 
RAND 36-Item Health Survey 1.0          
 RAND 36-Item Physical 51.6 (21.4) 59.1 (24.4) 54.9 (32.4)  -7.5 -29.0 to 14.0  -3.3 -32.1 to 25.7 
 RAND 36-Item Psychological 63.8 (18.2) 61.3 (18.3) 51.6 (20.9)  2.5 -14.8 to 19.8  12.1 -6.9 to 31.2 
FFMQ (Total) 125 (19.0) 131 (26.4) 115 (14.6)  -6.0 -28.0 to 14.8  10.0 -7.3 to 26.7 
SCS (Total) 2.8 (.51)   2.9 (0.69) 2.7 (0.6)  -0.1 -0.8 to 0 .4  0.1 -0.1 to 1.0 
PANAS-Positive 27.9 (6.1) 32.1 (9.8) 28.3 (9.9)  -4.2 -11.8 to 3.4  -0.4 -8.2 to 7.3 
PANAS-Negative 18.6 (7.4) 18.8 (7.7) 17.3 (9.6)  -0.2 -7.9 to 6.4  0.8 -7.4 to 9.0 
IPQ-R          
 IPQ-R timeline acute/chronic  21.3 (5.5) 23.8 (4.1) 26.7 (3.5)  -2.6 -7.5 to 2.3  -5.5 -10.2 to -0.7 
 IPQ-R timeline cyclical 11.5 (3.7) 10.0 (3.7) 11.4 (4.7)  1.5 -2.1 to 5.2  0.2 -3.9 to 4.2 
 IPQ-R consequences 18.3 (4.9) 20.4 (5.8) 20.6 (5.6)  -2.1 -7.3 to 3.1  -2.4 -7.4 to 2.7 
 IPQ-R personal control 22.1 (3.5) 23.5 (3.6) 21.6 (4.4)  -1.4 -4.9 to 2.1  0.5 -3.4 to 4.3 
 IPQ-R treatment control 17.0 (2.6) 17.3 (2.9) 19.0 (2.7)  -0.3 -3.0 to 2.5  -2.0 -4.6 to 0.6 
 IPQ-R illness coherence 19.3 (4.0) 18.1 (5.1) 20.0 (4.3)  1.1 -3.2 to 5.5  -0.7 -4.7 to 3.2 
 IPQ-R emotional representations 17.9 (4.8) 18.6 (6.1) 17.8 (6.1)  -0.7 -6.0 to 4.6  0.1 -5.1 to 5.4 
SAQ**          
 SAQ- physical limitations 46.6 (14.2) 43.5 (19.5) 48.1 (19.5)  3.1 -18.9 to 25.1  -1.5 -28.1 to 25.1 
 SAQ- angina stability 63.3 (15.0) 50.0 (24.5) 40.0 (17.0)  13.3 -12.8 to 39.5  23.3 -4.1 to 50.8 
 SAQ- angina frequency 72.2 (10.0) 66.6 (11.7) 75.0 (11.7)  5.6 -8.6 to 19.7  -2.8 -23.5 to 17.9 
 SAQ- treatment satisfaction 63.4 (8.8) 62.6 (11.0) 64.2 (16.8)  0.8 -12.1 to 13.7  -0.8 -22.0 to 20.4 
 SAQ- disease perception 56.6 (13.1)  51.1 (19.6) 46.0 (28.2)  5.6 -15.9 to 27.1  10.0 -23.3 to 43.3  
Note: TAU: Treatment As Usual; SD: Standard Deviation; CI: Confidence Intervals; GAD-7: Generalised Anxiety Questionnaire-7; CAQ: Cardiac Anxiety Questionnaire; FFMQ: Five Facet 
Mindfulness Questionnaire; SCS: Self-Compassion Scale; PANAS: Positive and Negative Affect Scale; IPQ-R: Illness Perception Questionnaire-Revised. SAQ: Seattle Angina Questionnaire; * 
CAQ was completed by participants with heart conditions only (MBCT, n=6; MBSR, n=5; TAU, n=3); ** SAQ was completed by participants with heart conditions only (MBCT, n=6; MBSR, 
n=5; TAU, n=4).  
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Table 5.7  
Themes and sample quotes from the HeLM acceptability interviews  
Themes Summary  Quotes 
Diversity of 
expectations   
 
Participants joined the course with different expectations of it. Two hoped 
to get benefit for their heart condition and high blood pressure as well as 
their depression. Another two wanted something to help with their 
depression and anxiety, so they could see things in a different and calmer 
way. One woman joined the course as she had a personal interest in 
learning cognitive therapy and meditation. One other participant joined the 
course without any expectations and he reported that he had no enough 
information about the course.   
“Well basically that I'd come out feeling calmer and look at things in a 
different perspective. Instead of being a black and white person seeing things 
in a calmer way perhaps” (Participant 3) 
 
“I wanted to know about depression. Because you never know enough about 
it and maybe that's probably why we're depressed because we don't know 
enough how we need to avoid some things (Participant 7) 
Motivation  
The reasons that made people to take part in the course were different, such 
as meeting other people, the experience its self (e. g trying new things, 
coming to the university or learning meditation). One participant said that it 
was an opportunity and he thought he should take advantage of it. Other 
participants pointed out that the nature of MBCT, as a kind of 
psychotherapy, would not cause them any harm.  
Another mentioned attending so it would be possible to avoid psychiatric 
medications. Two participants wanted to deal with their physical conditions 
(heart conditions and blood pressure) and depression. Another two 
participants wanted to get help with their depression.  
“I wanted something to help me, I felt I needed some help with my  
condition both with the mental condition I found myself in after I got ill and 
the illness itself and I thought anything like this is at least worth trying” 
(Participant 2)  
 
“Because at the time I was feeling rather down, and I thought it would be a 
way of speaking to somebody, mixing with different people and 
communicating to me is pretty important anyway” (Participant 3) 
“I'm a supporter of anything that will take us away from chemicals. This is 
not a chemical or a physical intervention, it's about the mind. and therefore, 
you can only benefit from it” (Participant 5) 
Challenges  
1.Being in 
group 
 
Five of the seven participants joined the group with some worries around 
being in a group, mainly being worried about talking to new people, talking 
about personal issues with others and/or due to a language barrier. However, 
these people’s experience was very positive, with reporting that the 
environment was encouraging, and they worked well as a team. One of the 
things that seemed to help people to deal with their worries is that there was 
no pressure to talk or share feelings about depression or their physical 
symptoms, such as having a heart attack or stroke, if they did not wish to do 
so. Participant 1 did not see the course as a group therapy but more as an 
opportunity to share personal experiences with others, while Participant 5 
said that being in a group helped in not being introspective.   
Oh, my God, I was worried. First because of my language and second it was 
really difficult to meet new people, you know that feeling, having looked at 
you, you know, maybe someone start to ask you know what you've done 
before but yes it was a really different experience I was talking to nice 
people” (Participant 7).  
“I haven't ever taken part in what I understand to be group therapy, but I 
think it is people sharing their experiences” (Participant 1)  
“I think that if it were not a group it would be very easy to become 
extremely introspective in your perceptions of what was going on and why 
you were doing it. When you have a group, there is this group thing that 
takes over”. (Participant 5) 
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 Table 5.7 cont.  
Themes and sample quotes from the HeLM acceptability interviews  
Themes Summary  Quotes 
2. Making 
mindfulness 
a priority 
Four participants agreed that making the course a priority in their lives had 
been a challenge for them. They reported how they needed to push 
themselves and had to allocate time to undertaking homework every day.  
 
“If I were in your position I would be very aware that people have 
difficulties and you have to persuade them to priorities this project, the 
exercises” (Participant 5). 
 
 
Effective 
techniques 
1. Orientation session:  
The seven participants seemed to agree that the orientation session with the 
therapist was very helpful in terms of providing good information about the 
course and what was going happen. They reported that the therapist was 
easy to talk to.  
2. Exercises:  
The seven participants agreed that the 3-step breathing space was useful for 
different reasons. For example, participant 5 thought that it is short and that 
it suited his lifestyle as he could use it anywhere, while participant 2 said 
that he felt better regarding his breathing with this exercise.  
The body scan was useful for four participants. For example, participant 1 
described her experience with it as it having helped her to see how lucky she 
was comparing to other people who had physical problems.  
Also, talking to other people and the therapist seemed to be helpful to some 
participants.  
3. Homework and Questionnaires 
Participants 1, 3, 6 and 7 described their experience with doing homework 
as being easy, but they had to allocate time to undertaking it. Participant 4 
thought that it was demanding. Participants 2 and 5 thought that the 
homework was flexible and it had helped them to do what they wanted to do.   
Regarding the questionnaires, participants agreed that completing them was 
fine. However, some said that some items did not apply to them and some 
were repetitive.  
4. The course overall 
It seemed that the course as overall was acceptable to people. For example, 
three participants liked how flexible it was. Participant 1 described the 
course as delivering “A more relaxed attitude to life”.  
“The breathing space suits my life and the way I live” (Participant 5). 
 
“When I'm faced with a stressful situation the first thing that happens is my 
breathing shuts down a little bit, there is already a heart condition that causes 
a problem with that so it's twice as bad but then I think about the responsive 
breathing, the breathing practice and It does seem to help there's no doubt 
about that” (Participant 2). 
“it was quite demanding and filling in the forms but then if you didn't have 
the forms I think there wouldn't have been the incentive to keep going so yes 
it was quite demanding but I think it probably needed to be quite 
demanding” (Participant 4). 
“A more relaxed attitude to life. I remember we were asked that question in 
the group and the answer just came to me. I hadn't articulated it before. I felt 
that the words had been put into my mouth almost without my having to 
think about them” (Participant 1). 
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 Table 5.7 cont.  
Themes and sample quotes from the HeLM acceptability interviews  
Themes Summary  Quotes 
Ineffective 
 techniques    
1. Exercises:  
Six out of the seven participants found that the movement exercise was not 
helpful. Four said that as they had other physical complaints that limited 
their ability to do it. Participant 3 said that it was very slow, so she did not 
like it. While participant 7 thought that it did not help her to feel calm. 
However, participant 5, who had hypertension, found this exercise helpful. 
2. Handouts. Participant 2 pointed to that there was a need to emphasise 
more the fact that this course was for people with CVD. He also mentioned 
that some of terms in the handout needs to be explained further, such as 
automatic pilot.  
 
“Do you know I've gone to the whole 8 weeks and this business about it 
being special for heart conditions, hasn't really been emphasized very 
much. I know that's what you've got because you've got two groups, a 
control group and all the rest of it but there wasn't a lot of mention of that of 
the physical side of people's conditions in the course. It was about the 
mindfulness itself” (Participant 2). 
Physical 
/Psychological 
benefits    
The benefits that participants obtained from the course were mainly around 
breathing, understanding depression and facing stress. For example, two 
participants reported that the course had helped them regarding their 
breathing and three said that it was helpful in terms of having another way 
of controlling stress as well as providing them with a different way of seeing 
things. One participant thought that after having the course she was able to 
understand depression better.   
 
“I think it's helped some of the way I think about things, not necessarily to 
do with my illness but maybe to do with if I feel depressed I can think 
'these are just thoughts' I try to if I'm thinking very negative thoughts I 
could sometimes look at the thoughts and think I don't need to think like 
this, so it had helped me” (Participant 4). 
 
“First I feel very clear about that now, about depression and that so I can 
explain to someone myself what is this and how you can fight that” 
(Participant 7). 
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Chapter 6.0 
 General Discussion  
6.1 Summary of the PhD Rationale  
Comorbid depression is highly prevalent in cardiovascular disorders (CVDs), leading 
to worse medical outcomes, high morbidity, poor quality of life and high health care costs 
(Baumeister, Haschke, Munzinger, Hutter & Tully, 2015; Dickens, Cherrington, & 
McGowan, 2012; Naylor et al., 2012; Pelletier et al., 2015; Rustad, Stern, Hebert & 
Musselman, 2013; Win et al., 2011). A wide range of psychological, social and biological 
factors have been suggested to explain this comorbidity. Notably, psychological factors, such 
as rumination, health related worry, self-efficacy and self-care have been found to be 
associated with both conditions (Greco et al., 2014; Holzapfel et al., 2009; Loo et al., 2016; 
Riegel, Lee & Dickson, 2011; Tovar et al., 2015). As a result, it has been suggested that any 
psychological intervention targeted at treating co-morbid depression in CVDs needs to take 
account of these factors (Greco et al., 2014).  
 Mindfulness-Based Cognitive Therapy (MBCT), which was originally designed for 
relapse prevention and residual symptoms treating, has been found to be effective regarding 
the psychological symptoms of people suffering from physical health conditions (Schoultz, 
Atherton, & Watson, 2015; Van Der Lee & Garssen, 2012; van Son et al., 2014). MBCT has 
also shown promising results with some of the common psychological links between 
depression and CVDs, such as rumination and worry (Kingston, Dooley, Bates, Lawlor, & 
Malone, 2007; Michalak, Holz, & Teismann, 2011; van Aalderen et al., 2012). However, 
whether MBCT can help manage comorbid depression in this population remains unclear and 
hence, this PhD, as part of Heart and Living Mindfully (HeLM) project, was aimed at 
addressing this issue.  
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In this Chapter, a summary of the PhD thesis (HeLM project phases) aims, findings 
and the discussion of the findings are provided. Also, some lessons learnt from the feasibility 
trial are provided. Finally, the strengths and limitations of each phase and suggestions for 
future research will be discussed  
6.2 Summary of the PhD Aims  
This PhD was aimed at developing a bespoke MBCT for people with comorbid 
depression and CVDs through a phased approach, including establishing the evidence base 
around MBCT adaptations (Chapters 2.0 and 3.0) and then piloting a bespoke MBCT 
(Chapter 4.0). A main part of this project was to establish the feasibility and acceptability of 
this bespoke MBCT using a 3-arm randomised controlled trial (Chapter 5.0). Besides the aim 
of adapting MBCT for people with CVDs, the core goal was to increase its effective and 
implementation in practice. Accordingly, the “HeLM” project was established based on the 
UK Medical Research Council guidelines (MRC) for developing complex interventions 
(Craig et al., 2008) and the National Institutes of Health (NIH) stage model (Onken, Carroll, 
Shoham, Cuthbert & Riddle, 2014) 
6.3 HeLM phase 1 (Basic Research) 
6.3.1 Systematic review. 
6.3.1.1 Aims. A systematic review was conducted as part of establishing the evidence 
base for adapting MBCT for people with depression and CVDs. In the review, the evidence 
in relation to how mindfulness interventions (MBCT/MBSR) can produce beneficial health 
effects for people with physical and/or psychological conditions was presented, with the main 
focus being on investigating the common and specific mechanisms across both conditions. 
Moreover, the methodological adequacy of the evidence was evaluated systematically using a 
framework of the criteria for examining mechanisms of change in treatments.
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. 
6.3.1.2 Findings. We found four studies with physical conditions populations and 14 
studies with psychological conditions populations. A wide range of potential mindfulness 
mediators, have been studied, including mindfulness, rumination, worry, self-compassion, 
cognitive and emotional reactivity. The most consistent result was that greater changes in 
mindfulness are associated with better psychological outcomes. Some studies suggested that 
rumination and worry mediated the effects of MBCT/MBSR in both physical and 
psychological conditions. Importantly, the review suggests that some factors show up as a 
candidate universal (common) mechanism or mediator of change in MBCT/MBSR across 
psychological and physical populations (e.g., enhancing mindfulness) whilst others seem 
promising as specific to particular populations (e.g., decentring from negative thinking with 
depression). Lastly, very few studies have fully met the framework criteria for examining 
treatment mechanisms. 
6.3.1.3 Discussion of the findings. The systematic review examining mechanisms of 
action regarding MBCT/MBSR highlighted that limited attention has given to studying 
mechanisms in people with physical conditions when compared with psychological 
conditions and hence, main focus has been on psychological not physical outcomes. This was 
not surprising, as the field of mindfulness interventions with physical condition populations is 
still in its very early phase. It was clear that examining physical condition populations related 
mediators has generally been ignored, although a wide range of mechanisms have been 
studied.  
A methodology evaluation revealed that the field of examining mechanisms of 
MBCT/MBSR in both physical and psychological populations has clear methodological 
limitations and hence, that no definitive conclusions can be drawn. This is in consistent with 
other recent reviews (Gu, Strauss, Bond & Cavanagh, 2015; van der Velden et al., 2015). The 
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limitations that noticed were mainly in relation to time-points used and the assessment 
methods.  
In CVD populations, we hypothesise that MBCT-HeLM is intended to target more 
specifically the specific mechanisms that drive both depression and cardiovascular disorders 
(e.g., rumination and worry specific to CVD, illness beliefs, lower self-efficacy and poor self-
care) as well as the general mechanisms targeted by any mindfulness-based intervention 
(Alsubaie et al., 2017). This is, in part, supported by our HeLM systematic review (Alsubaie 
et al., 2017). For example, rumination was considered as a mediator of the effects of MBCT 
and MBSR in three studies focusing on psychological conditions and in both studies 
investigating its role in physical conditions. Also, worry was found to mediate the 
relationship between MBCT/MBSR and psychological problems in all the studies for 
psychological and physical conditions.  
It seems that some variables, such as changes in mindfulness and rumination, show up 
as universal mechanisms or mediators of action in MBCT/MBSR in both populations 
(psychological and physical). Rumination/worry as universal mechanisms would appear to 
have specific manifestations in a given population (e.g., repetitive thinking as a universal 
mechanism; in recurrent depression, the focus is on the causes, meanings and consequences 
of depression), however, in cardiovascular disorders, there may be a different focus (e.g., it 
may be on the causes, meaning and consequences around physical health). These hypotheses 
need to be tested in a definitive trial.  
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6.3.2 Secondary analysis. 
6.3.2.1 Aims. Another part of establishing the evidence base was a study investigating 
the role of MBCT on medical symptoms. This was a secondary analysis of a large RCT that 
compared MBCT plus support with tapering or discontinuing maintenance antidepressant 
medication (MBCT-TS) along with maintenance of antidepressants (m-ADM) in terms of 
depression outcomes (relapse and residual symptoms) and a range of secondary outcomes, 
including medical comorbidities, in people with recurrent depression as assessed by MSCL 
(PREVENT; Kuyken et al., 2016).  
6.3.2.2 Findings. To establish the structural factor of the main measure (MSCL), an 
exploratory factor analysis was carried out and the findings showed the MSCL measure 
loaded onto two factors (physical and psychological). Also, the findings showed that the 
MBCT and m-ADM groups did not differ significantly in their physical or psychological 
symptoms, as assessed by the MSCL, at follow-up assessments. The moderation analyses 
indicated that baseline total medical symptoms as well as the two factors (physical and 
psychological) moderate the effects of MBCT vs. m-ADM on the relapse rate at both follow-
up assessments. Regarding the residual depressive symptoms, the findings showed that 
baseline total score of MSCL and physical factor of the MSCL have a moderating effect at 
different time assessments.   
6.3.2.3 Discussion of the findings. Whilst the findings did not show any differences 
between MBCT vs. m-ADM regarding medical symptoms, the significant main effects meant 
that medical symptoms, especially the physical factors, had a negative impact on depression 
relapse and residual symptoms, regardless of the group. This highlights that medical 
symptoms played an important role on depression outcomes.  
The findings of moderation analysis indicated that baseline medical symptoms played 
a role as a moderator of the effects MBCT vs. m-ADM on depression outcomes. Moreover, 
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this was clearer regarding the physical component than for the psychological one of the 
MSCL. This was inconsistent with a recent study (Nyklíček et al., 2016) in that it showed that 
medical comorbidity did not affect the relationship between MBCT and psychological 
outcomes in people with diabetes. However, our study looked at physical symptoms while the 
previous work was interested in physical conditions. Interestingly, those undertaking MBCT 
seemed to outperform the antidepressant group in subgroups of high medical symptoms as 
well as high physical ones. To summarise, physical symptoms can play a role as moderators 
of the effects of MBCT on depression outcomes. The better results that MBCT showed in 
terms of dealing with high baseline medical symptoms may indicate that it has the potential 
of helping people with physical conditions populations.  
To summarise, the basic research phase provided the HeLM team with useful 
information regarding developing the MBCT-HeLM manual (for information on the early 
basic research work see Appendix A). This PhD systematic review highlighted that 
mindfulness as mediator showed up as a consistent mediator that played a role in both 
physical and psychological conditions. Thus, it may that people with a physical condition, 
such as CVD, would gain benefits from taking part in an intervention that includes a 
mindfulness construct. The review also found that rumination and worry were important 
common mediators in both physical and psychological conditions. Hence, the manual was 
adapted to include those two measures through expanding the MBCT focus from depression 
specific mechanisms to specific cardiovascular ones (Larsen & Christenfeld, 2009; Rozanski, 
Blumenthal & Kaplan, 1999). Regarding the secondary analysis of the impact of MBCT on 
physical symptoms, the study indicated that MBCT may have a potential to work better with 
people with high physical conditions. Consequently, the next level of the MRC guidelines 
that included developing the manual and testing its acceptability in a pilot group was applied.  
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6.4 HeLM phase 2 (Manual Development Piloting). 
6.4.1 Aims. 
To develop the intervention, we followed the MRC framework (Craig et al., 2008) 
and NIH model (Onken et al., 2014). This began with adapting and piloting (Chapter 4.0). 
The pilot group was aimed mainly at further development of a bespoke MBCT for people 
with depression and cardiovascular disorders. This group was also convened for assessing the 
bespoke MBCT’s acceptability for this population, testing the feasibility of recruitment to the 
group and to see whether the course was helpful for the participants in terms of decreasing 
depressive symptoms as well as negative illness perceptions and increasing their mindfulness 
skills. 
6.4.2 Findings. 
 The changes that were made to the original MBCT manual were based on working 
with service user feedback going through the manual session by session. The changes 
generally were around the main themes, meditation practices and home exercises, with there 
being particular focus on self-care, self-efficacy and the adjustments in relation to having a 
long-term health condition. Also, we aimed to expand the MBCT focus from depression 
specific mechanisms to cardiovascular specific mechanisms. Some of the exercises were 
shortened (For more details, see Chapter 4.0, Table 4.1). The pilot group showed high 
acceptability with no drop out and high engagement in terms of attendance rate and weekly 
measures completion. Pre-follow up comparisons and clinical significance methods results 
showed some improvements changes in the participants’ depressive symptoms, mindfulness 
skills at the three-month follow-up.  
6.4.3 Discussion of the findings. 
The standard MBCT manual was adapted for people with comorbid depression and 
CVDs with the aim being to focus on the underlying links between those conditions. Teasdale 
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et al. (2003) have proposed that mindfulness interventions could have an impact on common 
mechanisms in different populations. Crane and colleagues argued that any adaptation for 
new populations and contexts needs to consider carefully what changes are needed to 
enhance acceptability and effectiveness (Crane et al., 2017).  
For the HeLM manual, the same standard MBCT length of course and most of the 
sessions were kept. The changes that were added to some sessions were aimed at expanding 
the MBCT focus from depression specific mechanisms to cardiovascular specific 
mechanisms (Larsen & Christenfeld, 2009; Rozanski, Blumenthal & Kaplan, 1999). In 
addition, there was careful attention paid to body sensations in terms of avoiding participants 
with serious cardiac event experiences (e.g., heart attack or stroke) having to attend suddenly 
to bodily sensations that could increase the anxiety of a further cardiac event. Moreover, we 
considered some other factors, including self-efficacy and self-care that have been associated 
with worse cardiac and psychological outcomes (Greco et al., 2014; Loo et al., 2016; Morgan 
et al., 2014; Riegel et al., 2011; Sarkar et al., 2007; Schoormans et al., 2014; Stafford et al., 
2009; Tovar et al., 2015; van der Wal et al., 2016; Volz et al., 2016). The manual piloting 
was successful with high acceptability, which meant MBCT-HeLM was well-tolerated and 
not harmful, so we moved to next step of the MRC framework.  
6.5 HeLM phase 3 (Feasibility and Acceptability RCT) 
6.5.1 Aims.  
In line with the second element of the MRC framework and stage 1 (phase B) in the 
NIH model regarding piloting/feasibility of the targeted intervention, a randomised controlled 
trial on the feasibility and acceptability of MBCT for people with depression and 
cardiovascular disorders was conducted. The study was aimed, primarily, at drawing out the 
key uncertainties around the intervention and trial design that needed to be resolved to help 
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decide whether to proceed to a definitive trial. Also, the acceptability of this course was 
established. 
6.5.2 Findings. 
The findings indicated that recruiting people through GPs was the most helpful 
method of getting participants, while targeting a cardiology department and distributing 
advertisements were not successful. High withdrawal rates (between initial recruitment and 
randomisation) and dropout rates (between randomisation and prior interventions started) 
were noticed. Other parameters, including randomisation, blinding and inclusion/exclusion 
criteria were tested. In addition, the study showed positive indicators of acceptability of the 
course content, home practice, the measures and participants’ adherence (attendance, 
retention) for participants who started it.   
6.5.3 Discussion of the findings.  
The feasibility trial has provided HeLM team with essential information regarding 
feasibility parameters, such as recruitment, retention and attrition rates as well as in relation 
to randomisation and blinding. This work was aimed at examining the feasibility of 
conducting a definitive trial and consequently, reducing the risk of failure of any future 
mindfulness RCT targeting comorbid depression and CVD populations.  
The current study’s recruitment rate (number of assessed people) (7.1 %) was lower 
than that reported (between 30 % to 74 %) in mindfulness studies targeting heart conditions 
populations (O’Doherty et al., 2015; Olivo et al., 2009; Nyklíček et al., 2014). This could 
have been due to the nonrandomised/controlled designs used in studies (O’Doherty et al., 
2015; Olivo et al., 2009), the longer length of recruitment (two to three years) in studies 
(Nyklíček et al., 2014; O’Doherty et al., 2015) or the boarder inclusion criteria for depression 
(Olivo et al., 2009; Nyklíček et al., 2014).  
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Our study initial dropout rate (42 %) is similar to that reported (47 %) in the study 
(O’Doherty et al., 2015) using an 8 MBCT sessions. Those rates are higher than those 
reported (16 %) in other mindfulness studies using the full version of MBCT with 
psychological conditions populations (Khoury et al., 2013), indicating that the attrition issue 
is another challenge to mindfulness researchers working with CVD populations. 
Moreover, the studies that used short mindfulness interventions for people with heart 
conditions received fewer drop outs (11 %) (Nyklíček et al., 2014; Olivo et al., 2009). This 
might indicate that a less demanding intervention in terms of course length could be more 
acceptable to this population. However, the length of course was discussed with our 
participants who completed the MBCT-HeLM and they agreed that 8 sessions was necessary 
to understand mindfulness and to be able to integrate into their daily lives, thus not agreeing 
with the idea of having a shorter course. Notably, in our study, the withdrawal and drops out 
rate was in between the initial recruitment and randomisation, with the most common reasons 
given relating health or job issues, rather than the intervention content.  
The participants’ adherence was high in terms of course completion, attendance at 
sessions and the long-day practice. However, it is important to note that the MBCT-HeLM 
acceptability could have been influenced by the fact that all the participants joined the study 
with stability regarding their CVDs. Consequently, future studies would need to target people 
with acute cardiac problems, such as people with a recent heart attack or stroke.  
With regards to home practice, the participants reported a high amount of practice, 
however, most of found it difficult to allocate time to undertake it. The relationship between 
home mindfulness practice and outcomes has been examined in some prior research. For 
example, people with depression who spent more time on practice showed a lower relapse 
rate (Crane et al., 2014), lower rumination and depressive symptoms (Hawley et al., 2014) as 
well as higher mindfulness and well-being (Carmody and Baer., 2008), compared to people 
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who practised less. A similar picture also can be seen in studies targeting people with 
physical conditions (Rosenzweig et al., 2010). However, in our feasibility study, we did not 
examine effects of home practice on outcomes, thus future studies targeting comorbid 
depression in CVD populations would need to consider this issue.  
Regarding assessment completion, the high rate that we had was relatively similar to 
those reported in studies by (O’Doherty et al., 2015; Olivo et al., 2009). This high rate, in 
addition to the small amount of missing data, indicated that the measures were acceptable to 
participants. However, some participants mentioned that some items did not apply to them, 
while others said that there were repetitive items in some measures.  
Prior to the intervention started, most participants worried about being in a group and 
talking to new people or talking about personal issues (mental or physical problems, such as a 
heart attack or stroke). However, more a positive attitude developed throughout the course, 
including seeing the group as an opportunity to share personal experiences with others and 
helping them not to be introspective. Other qualitative studies in MBCT have reported a 
similar theme (Mason & Hargreaves, 2001).  
In addition, making mindfulness practice a priority seemed to be a challenge for most 
of the participants in relation to allocating time to undertake the exercises and pushing 
themselves to keep practising. In the adapted manual, some of the exercises were shortened 
and efforts were made to make the course more flexible. However, this challenge seems not 
to be specific to physical populations. For example, a mindfulness research with recurrent 
depression has reported a similar challenge (Mann et al., 2016). 
There was a diversity of participants’ expectations in relation to joining the MBCT-
HeLM, including help with heart conditions or high blood pressure, understanding 
depression, learning ways to feel calm and living the experience itself (mindfulness 
experience). In the psychotherapy field, it has been suggested that the initial expectations are 
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likely to have an impact on outcomes, including depression and anxiety disorders and 
participant’s engagement with the intervention (Mason & Hargreaves, 2001; Webb, Kertz, 
Bigda-Peyton, & Björgvinsson, 2013). Hence, it would be useful to examine the role of 
expectations on outcomes in any future mindfulness studies for CVDs.  
The 3-stage breathing space and body scan were found to be useful exercises for most 
of participants. Mindful movement seemed less helpful, as most of participants were old and 
suffering from other physical limitations. It is evident that high chronic physical symptoms 
are common in elderly populations (Naylor et al., 2012) and thus, this could be another 
barrier that should be considered in future trials. However, in a standard MBCT study (Foulk, 
Ingersoll-Dayton, Kavanagh, Robinson, & Kales, 2013) with older people with depression 
and anxiety, the participants showed high engagement with all the exercises and hence, the 
disengagement with some of MBCT-HeLM exercise, such as mindful movement, cannot be 
attributed to age only. One possible explanation might be that some people with cardiac 
problems have the misunderstanding that physical activity leads to worse cardiac outcomes 
(Klompstra, Jaarsma, & Strömberg, 2015; Rogerson, Murphy, Bird, & Morris, 2012). Hence, 
it would be useful to examine this issue using a qualitative method in future studies.   
There were positive estimates of MBCT-HeLM usefulness. For example, means 
comparison regarding the primary outcome (depression) revealed that MBCT-HeLM and 
MBSR showed more benefits over TAU alone, with even better changes for MBCT-HeLM at 
the three months follow up. Additionally, the PHQ-9 clinical change indicated that both 
MBCT-HeLM and MBSR group were beneficial when compared to TAU. With regards to 
secondary outcomes, both MBCT-HeLM and MBSR showed more benefits compared to the 
TAU, indicating that a design with an active group, such as when using MBSR, would be a 
true test for MBCT-HeLM effects in future studies.  
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The relapse rate, as an outcome, was not examined in our study due to the feasibility 
constraints, however, any future definitive trial would need to include this to see whether 
MBCT-HeLM can help with protecting people with depression and CVDs from relapse 
comparing to an active group (e.g., MBSR). The HeLM feasibility study used MBSR, not 
standard MBCT, as comparator group for two reasons. First, MBSR was designed to help 
relieve pain and distress in people with chronic health problems (Kabat-Zinn, 1990, 2013), 
while MBCT, which combines meditation exercises and certain cognitive therapy techniques, 
was developed to target negative thinking styles in individuals with a history of depression, 
who are at a high risk of depressive relapse and recurrence (Segal, Williams & Teasdale, 
2002, 2013). The comparison between adapted-MBCT and MBSR is important to achieve the 
objectives of the next phase of this project, aiming to determine the efficacy of an MBCT-
HeLM on the treatment and prevention of depression. Another reason is in relation to 
mechanisms of action in MBCT and MBSR. MBCT addresses both universal vulnerabilities 
targeted by any mindfulness-based intervention, such as MBSR and specific ones implicated 
in depressive relapse (Crane et al., 2017). Thus, MBCT adaptations are intended to target 
more specifically the specific mechanisms that drive both depression and cardiovascular 
disorders (e.g., rumination and worry specific to CVD, lower self-efficacy and poor self-care) 
as well as the general mechanisms targeted by any mindfulness-based intervention (Alsubaie 
et al., 2017). As a result, it is hypothesised that such adaptations will enhance MBCT’s 
acceptability and effectiveness compared with a more generic mindfulness-based 
intervention. One way to test this hypothesis is to compare MBCT adapted for CVD with a 
non-adapted mindfulness-based programme, such as MBSR. It is believed here that the use of 
standard MBCT as a comparator group would make it difficult to test the proposed common 
and specific mechanisms put forward and to prove that adapted-MBCT is capable of 
preventing relapse. 
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6.5.4 Some lessons learnt for the definitive trial.   
The feasibility trial outcomes raise some important considerations that need to be 
taken into account for any future studies targeting CVDs with comorbid depression. First, the 
difficulties that were encountered in terms of recruiting people with depression and CVDs 
meant that conducting a definitive trial in the next phase may not be feasible. Hence, the 
suggestion put forward is to undertake a pilot RCT focusing on outcomes and resolving the 
issues around recruitment before carrying out a definitive trial, as suggested by Orsmond & 
Cohn, (2015). This may also help to focus more on differences between MBCT-HeLM and 
MBSR, which were not possible to explore in the feasibility trial, especially in relation to the 
relapse rate. We are aware of an equivalent definitive trial is currently being conducted in the 
US aimed at examining the effects of adapted MBSR for people with CVDs. It is anticipated 
that the findings of this trial will help to guide us in terms of whether we go ahead with a 
definitive trial or not.   
Second, a better recruitment method, most likely involving multiple sites and over an 
extended period of time, is important to consider in the proposed RCT pilot. Third, the 
inclusion and exclusion criteria will need to be tightened in terms of those currently 
depressed (minor depression) or who have had a history of depression as well as the time 
since the cardiac event (heart attack or stroke) and depression onset (prior to or after a CVD). 
Fourth, it would be helpful to use an in-depth screening during the early stages of 
recruitment, which would capture the history of depression in detail, thereby increasing the 
eligibility rate. Fifth, an alternative method of determining cardiovascular disorder condition 
should be used, such as obtaining a clinical diagnosis from a potential participant’s healthcare 
professional.  
A critical issue to consider is the acceptability of adapted MBCT for people with 
depression and CVDs, given the high level of drop-out rate in this arm. A central aim of the 
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approach was to develop a tailored version of MBCT that would have high levels of 
acceptability for this population. It is known that high acceptability typically goes hand in 
hand with reduced drop-outs. Given incomplete information for reasons for drop out, it 
remains an open question as to whether high drop out in this trial does indeed sub-optimal 
acceptability of the intervention. Nevertheless, a number of suggestions can be made on the 
basis of the acceptability interviews. Firstly, participants expressed concern about being in a 
group or talking about personal issues. Secondly, the participants reported challenges 
associated with prioritising mindfulness practice in that they found it difficult to set aside 
adequate time to undertake the exercises. Furthermore, their expectations varied widely from 
gaining an understanding of depression to helping with high blood pressure and heart 
conditions. In the psychotherapy field, it has been suggested that the initial expectations are 
likely to have an impact on outcomes, including participant engagement with the intervention 
(Mason & Hargreaves, 2001; Webb, Kertz, Bigda-Peyton, & Björgvinsson, 2013). Another 
factor that could have contributed to high dropout is the considerable heterogeneity in the 
participants recruited into groups, with individuals varying in time since disease onset and 
also in the nature of disease (heart attack versus stroke). This may have reduced a sense of 
group cohesion and identification as the issues people were struggling with and their 
experiences of illness may have differed.  
These issues should have equally affected both arms, however, and so cannot really 
account for the sub-optimal attrition in the MBCT arm. It does nevertheless suggest that any 
subsequent revisions of this approach should focus on building motivation to attend a group, 
ensuring people are at a point of life they can commit to the home practice, and ensuring they 
understand the focus of the approach. The orientation session is likely to be critical here. 
Moreover, it may be useful to consider reducing the home practice burden given participants 
are struggling with some current depression symptoms and are recovering from cardiac 
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disease. There is a trade-off here between acceptability and ensuring individuals receive a 
sufficient ‘minimum dose’ to benefit. Finally, it may be useful to either recruit a more 
homogeneous group of individuals (for example, just those who have suffered from a heart 
attack) or to adapt the course materials to more clearly pull out commonalities in experiences 
across conditions groups. 
A more prosaic reason for drop out is that often there was a gap between participants 
being randomised and the start of treatment. In the interval between randomisation and 
treatment start, participant life circumstances may have changed. If they drop out in this 
phase, it may have nothing to do with perceived acceptability of MBCT. Future trials should 
consider robustly checking people availability and commitment prior to randomisation 
occurring. Also, the timing and locations of the groups may not have been optimal, for 
example being run in the day in a university setting. Further consultation with service user 
groups may help inform timing and location of the groups going forwards.  
Given these concerns about adapted MBCT acceptability on the basis of high drop 
outs, it is important to acknowledge this remains a key unresolved uncertainty before moving 
towards a definitive trial. Further feasibility work is required to answer this issue before 
making the decision to move forwards with the next stage of the work.  
6.6 The Strengths and Limitations of the PhD 
 To the best of my knowledge, this PhD is the first that has involved adapting MBCT 
for people with comorbid depression and CVDs. The adaptation of the manual was conducted 
systematically based on a phased approach suggested by the MRC and NIH. Throughout the 
project, there was cooperation with the public and patient group aimed at increasing the 
acceptability of the adapted MBCT. The feasibility study was conducted as an RCT with 3-
arms and provided detailed data that can help with conducting any future trial. Moreover, 
when analysing and reporting the feasibility trial, there was adherence to the good practice 
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guidelines for designing, analysing and reporting pilot/feasibility studies. In addition, the 
qualitative study that assessed the acceptability provided information about the participant’s 
experiences in relation to the course and study. The feasibility trial involved using measures 
that are not commonly deployed in the mindfulness field, including illness perception and 
cardiac anxiety level. These measures might help to uncover factors that have not received 
enough attention, despite having been associated with compliance and adherence to 
treatment.   
However, the PhD has several limitations. First, the pilot group was designed as an 
uncontrolled with small sample size, thus any efficacy indicators should be taken with a high 
degree of caution. Second, the feasibility sample was heterogenous in terms of onset and 
types of depression and CVDs. Third, the HeLM high level of dropout rate should be 
considered as a significant limitation of the study as well as a potential sign that the tailored 
MBCT may not be more acceptable to people with CVDs and depression than standard 
MBCT or MBSR programmes. Fourth, in the feasibility trial, the assessor was not blind to the 
assessments at post intervention and follow up. In addition, the home practice was assessed 
only throughout the 8 MBCT sessions and therefore, the long-term effects have yet to be 
examined.  
6.7 Future Research 
As discussed in Chapter 2.0, very limited attention has paid to studying the common 
and specific mechanisms of MBCT for people with CVDs and hence, future studies will need 
to consider this issue. One possible mechanism that could be targeted is reactivity 
(physiological, cognitive and emotional) to stress that has been found to be associated with 
developing and progressing some CVDs (Carney et al., 1995; Key, Campbell, Bacon, & 
Gerin, 2008; Salomon, Clift, Karlsdóttir, & Rottenberg, 2009). The HeLM team had a plan to 
run a laboratory study aimed at assessing cognitive, emotional and physiological reactivity to 
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and recovery from a stress task in people with depression and CVDs who have or have not 
completed a mindfulness course. All the preparatory work for this study (i.e. the study 
protocol, ethics application form, stress task, recovery response and testing the procedures 
using four people from the PPI group) was completed over one year. However, the NHS 
ethics committee thought that the inclusion criteria should be tightened, which meant that 
recruiting enough people with depression and CVDs who had trained in mindfulness would 
be difficult. Consequently, the decision was made to drop this study. 
Moreover, triangulating self-report, experimental and neuroscience methods would be 
helpful for targeting any common or specific mechanisms. Also, future studies would need to 
consider the Kazdin criteria carefully, which could help with improving the field of studying 
the mechanisms of mindfulness interventions. Moreover, it would be important for future 
studies to focus more on cardiac related outcomes, such as illness perceptions and cardiac 
anxiety, to uncover areas that are important to this population. Also, a more homogeneous 
sample regarding types and onset of CVDs and depression might help MBCT to target certain 
changes that can increase its effectiveness.  
Importantly, the barriers addressed in the feasibility trial would need to be considered 
in any future studies aimed at increasing accessibility of a mindfulness intervention service 
for people with depression and CVDs. Some suggestions for improving such service for this 
population could be through delivering MBCT in the former of shorter or online courses. In 
addition, other barriers that might prevent people with such conditions from engaging with 
mindfulness interventions will need to be examined.  
6.8 Summary of the PhD (HeLM Project) 
This PhD, as a part of the Heart and Living Mindfully project, was aimed at 
developing a bespoke MBCT for people with depression and CVDs (MBCT-HeLM) through 
three phases. The first phase involved establishing the evidence base for the manual through 
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conducting a systematic review and secondary analysis. The second phase pertained to 
conducting a pilot group for modifying the manual and checking its acceptability. The third 
and last phase was a feasibility RCT to uncover uncertainties around the MBCT-HeLM 
before proceeding with a definitive trial. Overall, the three phases were successful and 
achieved their goals, despite the serious challenge in recruiting sufficient numbers of people. 
The feasibility RCT provided useful information for future studies in terms of using a 3-arm 
design, recruitment, attrition and retention. 
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Appendices  
Appendix A  
Previous HeLM-Phases 
HeLM Phase Studies 
Phase one (Basic research)   
1. Analysis of AccEPT clinic 
data   
Master thesis:  
First, we examined the efficacy and acceptability of 
MBCT/MBSR for people with depression and 
cardiovascular disorders in a routine clinical setting 
(Accept Clinic/Mood Disorder Centre) that formed my 
master’s thesis. In this study, I analysed some of the 
AccEPT clinic dataset through early 2008 up until early 
2013 using different methods, including pre-post 
intervention comparisons, the reliable change index (RCI) 
and clinically significant change (Cut-off), followed by 
benchmarking against randomised controlled trial studies. 
The study results showed that MBCT has potential effects 
in reducing depression and anxiety and improving the 
quality of life in people with depression and cardiovascular 
disorders.  
Phase one (Basic research) 
2.Systeamtic review  
Second, two systematic reviews were conducted. The first 
was conducted by Abbott and colleagues (2014) to assess 
the effectiveness of mindfulness interventions (MBCT/ 
MBSR) on vascular disorders. This review was published 
in September 2014 and indicated that MBCT and MBSR 
had small and medium effect sizes on stress, depression 
and anxiety, while their effects on medical outcomes, such 
as blood pressure, were mixed.  
Phase two (Manual piloting) 
1.First pilot group  
The demographic characteristics of stakeholders who 
attended the first group as well as their retention and 
attendance rates are presented below. 
Demographic characteristics: 5 males and 3 females, six 
married, 8 white British, 3 employed and 3 retired, 8 with 
heart conditions.  
Completion rate:  4 completed and 4 did not. Attendance 
rate: four attended 6 or 8 sessions and four attended 2 or 3 
sessions.  
Change in CVD criteria: 
After this group, the inclusion and exclusion criteria have 
updated and diabetes as a CVD removed. This change in 
criteria was decided upon following feedback from experts 
in cardiovascular disorders, who were of the opinion that 
diabetes has a different nature in terms of its symptoms and 
its impact on a person’s life.  
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Appendix B 
 HeLM Systematic Review Forms  
 
1. Keywords and example of Search strategy 
Database Name:  
Reviewer: ……………………………… 
 
  
Date Search 
term 
Initial 
results 
Cleaned 
results 
Articles 
read 
Potential 
related 
article  
EndNote 
Exported 
 mindfulness.      
 mbsr.      
 mbct.      
 (mindfulness and 
randomi*ed controlled 
trial*).ti,ab. 
     
 (mbsr and randomi*ed 
controlled trial*).ti,ab. 
     
 (mbct and randomi*ed 
controlled trial*).ti,ab. 
     
 (mindfulness and 
controlled trial*).ti,ab. 
     
 (mbsr and controlled 
trial*).ti,ab. 
     
 (mbct and controlled 
trial*).ti,ab. 
     
 (mindfulness and 
clinical trial*).ti,ab. 
     
 (mbsr and clinical 
trial*).ti,ab. 
     
 (mbct and clinical 
trial*).ti,ab. 
     
 (mindfulness and 
randomi*ed).ti,ab. 
     
 (mbsr and 
randomi*ed).ti,ab. 
     
 (mbct and 
randomi*ed).ti,ab. 
     
 (mindfulness and 
randomly).ti,ab. 
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1. Keywords and example of Search strategy (cont.) 
Database: Name:  
Reviewer: ……………………………… 
Date Search 
term 
Initial 
results 
Cleaned 
results 
Articles 
read 
Potential 
related 
article  
EndNote 
Exported 
 (mbsr and 
randomly).ti,ab 
     
 (mbct and 
randomly).ti,ab 
     
 (mindfulness and 
randomi*ed efficacy 
trial*).ti,ab. 
     
 (mbsr and randomi*ed 
efficacy trial*).ti,ab. 
     
 (mbct and randomi*ed 
efficacy trial*).ti,ab. 
     
 (mbsr and randomi*ed 
controlled trial* and 
mechanism*).ti,ab. 
     
 (mbsr and randomi*ed 
controlled trial* and 
mediator*).ti,ab. 
     
 mbct and randomi*ed 
controlled trial* and 
mechanism*).ti,ab. 
     
 (mbct and randomi*ed 
controlled trial* and 
mediator*).ti,ab. 
     
 (mbsr and controlled 
trial* and 
mechanism*).ti,ab. 
     
 (mbsr and controlled 
trial* and 
mediator*).ti,ab. 
     
 (mbct and controlled 
trial* and 
mechanism*).ti,ab. 
     
 (mbct and controlled 
trial* and 
mediator*).ti,ab. 
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1. Keywords and example of Search strategy (cont.) 
Database Name:  
Reviewer: ……………………………… 
Date Search 
term 
Initial 
results 
Cleaned 
results 
Articles 
read 
Potential 
related 
article  
EndNote 
Exported  
 (mbsr and clinical 
trial* and 
mechanism*).ti,ab. 
     
 (mbsr and clinical 
trial* and 
mediator*).ti,ab. 
     
 (mbct and clinical 
trial* and 
mechanism*).ti,ab. 
     
 (mbct and clinical 
trial* and 
mediator*).ti,ab. 
     
 (mbsr and randomi*ed 
and 
mechanism*).ti,ab. 
     
 (mbsr and randomi*ed 
and mediator).ti,ab. 
     
 (mbct and randomi*ed 
and 
mechanism*).ti,ab. 
     
 (mbct and randomi*ed 
and mediator).ti,ab. 
     
 (mbsr and randomly 
and mechanism*).ti,ab 
     
 (mbsr and randomly 
and mediator*).ti,ab 
     
 (mbct and randomly 
and mechanism*).ti,ab 
     
 (mbct and randomly 
and mediator*).ti,ab 
     
 (mbsr and randomi*ed 
efficacy trial* and 
mechanism*).ti,ab. 
     
 (mbsr and randomi*ed 
efficacy trial* and 
mediator).ti,ab. 
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HeLM Systematic Review Forms (cont.) 
2. Data extraction form 
 
 
Theory and 
Hypotheses 
 
 
 
  
 
 
 
 
 
Aims of study  
 
 
 
 
 
  
 
Inclusion criteria  
 
 
  
 
 
 
 
  
Reference ID:  
 
Notes: 
Author:  
 
 
Year:  
 
 
Journal:  
 
Country:  
 
Settings:  
 
Other  
 
 
Reviewer ID:  
Checked by:  
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HeLM Systematic Review Forms (cont.) 
3. Characteristics of study based on PICOS 
Population / participants  Intervention Yes No 
Uncertai
n 
Age: 
 
 
MBCT  
   
Gender: 
   Male 
   Female 
MBSR    
Is the intervention 
described as 
MBCT/MBSR? 
   
Sample size: 
 Is the duration of the 
intervention 8 weeks? 
   
No. of participants 
in intervention: 
 
Has the intervention 
been adapted for the 
population studied? 
   
No. of participants 
in control group: 
 Home practice? 
 
   
Recourses of 
recruitment  
 
 
 
 
Intervention was 
delivered by 
 
Notes 
   
Comparator Outcomes 
No. of study 
arms: 
 
 
 
Primary 
outcome: 
 
Type of 
intervention 
 Main results 
regarding the 
primary 
outcome. 
 
Type of control 
group: 
 
 TAU 
 Waiting- list 
  Pharmacology 
 Active group* 
 Other* 
Type of 
primary 
outcome: 
 Psychological 
 Physical 
 QOL 
 Other 
Notes: 
Type of group if 
active or other? 
* 
 
 
 
 
 
 
 
 Secondary 
outcomes: 
 
 
 
Main results of 
the secondary 
outcomes 
 
 
 
 
 
Types of 
secondary  
outcomes: 
 Psychological 
 Physical 
 QOL 
 Other 
Notes: 
Study design: 
 RCT 
 CT 
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HeLM Systematic Review Forms (cont.) 
 
4. Mechanisms / mediators data: 
No. of mechanisms / mediators 
assessed: 
 
Mechanisms / mediators 
assessed: 
 
Type of measures used in 
assessing mechanisms / 
mediators? 
 Cognitive Task 
 Behavioural 
 Biological 
 Self-report 
 Interviewer administrated. 
 Other 
Type of measures used in 
assessing outcomes? 
 Cognitive Task 
 Behavioural 
 Biological 
 Self-report 
 Interviewer administrated. 
 Other 
Assessment timeline of 
mechanisms 
  Pre and post, not during 
  Only during 
  Pre, during and post 
  Pre and during (multiple assessments during intervention), not 
post 
  None 
  Other, specify: ______________________ 
Assessment timeline of outcomes 
 Pre and post, not during 
  Only during 
  Pre, during and post 
  Pre and during (multiple assessments during intervention), not 
post 
  None 
  Other, specify: ______________________ 
Follow-up length (if applicable) 
 
Did the dose of MBCT/MBSR 
include at least 4 sessions?* 
 
Statistical analysis of mediators?  
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HeLM Systematic Review Forms (cont.) 
 
5. Assessment quality of studies 
Mechanisms/mediators questions 
Yes No Uncertain 
Scores  
(Yes =1, 
no=0) 
Note 
Was the study guided by a theory? 
     
Are hypotheses about the 
mechanisms/mediators articulated? 
     
Did the study use measures to assess 
potential mechanisms / mediators? 
     
Can the design evaluate the 
mechanisms / mediators? 
 
- Making explicit that 
changes in processes are 
specifically targeted by the 
treatment 
 
- Occur during treatment? 
 
- Precede change in the 
outcome 
 
     
 
 
 
    
     
     
Total of scores: 
 
  
308 
 
 
HeLM Systematic Review Forms (cont.) 
 
6. Risk of bias in RCT 
RISK OF BIAS (low risk, high risk, unclear, NA) 
Random sequence generation (if applicable)  
Notes 
Allocation concealment (if applicable)  
Notes  
Blinding of participants and personnel  
Notes  
Blinding of outcome assessment  
Notes 
Incomplete outcome data  
Notes 
Selective reporting  
Notes 
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6. Risk of bias in RCT (cont.) 
 
  
OTHER bias related aspects (Yes, No, Unclear) 
Eligibility criteria specified?  
notes 
Power calculations made/appropriate sample size?  
notes 
  
Baseline details similar and any imbalances adjusted for (if appropriate) ?  
Notes: 
Compliance with intervention?  
Notes:  
Data collection tools valid and reliable?  
Notes:  
All participants accounted for?  
Notes:  
Appropriate analyses?  
Notes – 
Other comments : ? 
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Appendix C 
Data Management Protocol for the HeLM Pilot Group  
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Appendix D1  
 HeLM Feasibility Poster 
 
Heart and Living Mindfully (HeLM) 
 
Do you have experience of a heart condition and of feeling low? 
 
About the study 
Mindfulness based treatments are already available on the NHS to help with problems 
such as stress, and emotional difficulties, including depression. We are aware that 
people with heart and circulation problems can also suffer from stress and other 
emotional difficulties. 
 
We are conducting a study to see if a new course of Mindfulness-based Cognitive 
therapy (MBCT) specifically adapted for people with vascular disorders and low 
mood can help to manage their physical and mental well-being. 
 
How it will help you 
Your participation in this study would give you an opportunity to learn new skills that 
might help you handling your illness better. 
 
If you are interested in participating or want to find out more, please contact  
Modi Alsubaie using the contact details below: 
 
• Tel:01392 726101 
• Email: msfa202@exeter.ac.uk 
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Appendix D2  
Summary of Participants Information Sheet  
 
 
 
  
Mindfulness-Based Cognitive Therapy 
For people with vascular disorders 
 
 
We are conducting a feasibility study to see if a new course of Mindfulness-based Cognitive 
Therapy (MBCT) can help people with vascular disorders (heart disease or stroke) and low 
mood to manage their physical and mental well-being. 
We would like to invite you to take part in this study, called Heart and Living Mindfully (HeLM). 
  
What is MBCT for people with vascular disorders (heart disease or stroke)? 
In an 8-week mindfulness course, people learn how to increase their focus on the present without 
worrying about the past or the future. We have adapted the course so that it addresses the sorts 
of issues people with vascular disorders have told us cause them to feel low or anxious. 
 
Why have I been contacted?  
You may have seen a poster or advertisement about this study, or a health professional you have 
been seeing has suggested that this study may be of interest to you because you have been 
experiencing some periods of low mood as well as vascular disorder (heart disease or stroke).  
Do I have to take part? 
No, taking part in this study is optional.  
You have the right to refuse to participate or withdraw from the study at any time, without giving 
reasons. 
Your participation in this study will not affect any routine care that you are currently receiving, 
nor will your care be affected if you decide at any stage to withdraw from this study. 
What can I expect if I do take part in this study?  
This is what will happen: 
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Summary of Participants Information Sheet (cont.) 
1. We will need to gather some information about you. We will do this by asking you to 
attend an interview. 
2. You will then be randomly allocated to one of three groups using a computer 
programme. 
3. We will need to gather some information about you. We will do this by asking you to 
attend an interview. 
4. You will then be randomly allocated to one of three groups using a computer 
programme.  
a. MBCT for people with vascular disorders (heart disease or stroke) + your usual 
care. This is the 8-week mindfulness course specially adapted for people with vascular 
disorders; 
OR 
b. Mindfulness - based stress reduction (MBSR) + your usual care. This is the 8-week 
mindfulness course that is for people with a range of health problems, and not 
specifically adapted for people with vascular disorders; 
OR 
c. The usual care alone. That means, the care that you would normally receive if you were 
not taking part in this study 
5. You will need to complete some self-report questionnaires at three different time points.  
6. We will ask to measure your blood pressure at three different time points.  
7. We will invite you again three months later, after completing the therapy to see how you 
are doing. 
Will my participation in this study be kept confidential? 
The collection of all data will be guided by the principle of strict confidentiality. Therefore, your 
name will not be found in any recording made or any questionnaire or form you complete. Your 
personal details will be stored safely and away from any collected data. 
What will happen to the results of the research study? 
All participants will be provided with a summary of all results once the study is completed. The 
results will be used to complete a part of the PhD studies of the lead researcher. It is possible 
that these results might be published as a part of an academic article or might be a part of 
presentation within an academic setting.  
If you would like any further information, please contact: 
Modi Alsubaie (Lead researcher), PhD student 
School of Psychology, University of Exeter,  
Exeter, EX4 4QG 
Tel: 01392 726101, Email: msfa202@exeter.ac.uk 
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Appendix D3 
 Participants Information Sheet  
 
 
Mindfulness-Based Cognitive Therapy 
 
 For people with Cardiovascular disorder 
 
We are conducting a feasibility study to see if a new course of Mindfulness-based Cognitive 
Therapy (MBCT) can help people with cardiovascular disorders (heart disease or stroke) and low 
mood to manage their physical and mental well-being. 
 
Mindfulness-based Cognitive Therapy (MBCT) is an 8-week course based on meditation that encourages 
people to be “in the present moment” and release the mind from negative ruminations that lead to worry, 
low mood and tiredness. The aim of MBCT is to increase awareness and choice and so enable more resilient 
responses to challenges. Living with vascular disorder (heart disease or stroke) is stressful, so developing 
ways to manage this stress can enable people to enjoy a good quality of life.  
 
We would like to invite you to take part in this study, called Heart Living Mindfully (HeLM). 
However, before making a decision please read this information sheet carefully.  
  
What is MBCT for people with vascular disorders (heart disease or stroke)? 
In an 8-week mindfulness course, people learn how to increase their focus on the present without worrying 
about the past or the future. This is achieved through meditation exercises which help people become more 
aware of what is happening in their mind and body. Previously conducted studies have demonstrated that 
learning these mindfulness exercises can lead to positive effects on mood and quality of life. 
We have adapted the course so that it addresses the sorts of issues people with vascular disorders have told 
us cause them to feel low or anxious.  
What is the purpose of this study? 
Low mood and anxiety are common amongst people with vascular disorders and are associated with poor 
long-term health. Mindfulness therapies have been found to have promising effects in reducing low mood. 
HeLM is an initial feasibility study where we are interested in finding out if adapted-MBCT may be helpful 
and acceptable for people with vascular disorders in reducing low mood, anxiety, fears and blood pressure.  
 
Why have I been contacted?  
You may have seen a poster or advertisement about this study, or a health professional you have been 
seeing has suggested that this study may be of interest to you because you have been experiencing some 
periods of low mood as well as vascular disorder.  
  
Do I have to take part? 
 
No, taking part in this study is optional. If you are interested in participating, then please feel free to ask 
any questions that you may have. You will then be asked to sign a consent form that gives us permission to 
collect and store the information that we have about you. You have the right to refuse to participate or 
withdraw from the study at any time, without giving reasons. 
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Participants Information Sheet (cont.) 
 
Your participation in this study will not affect any routine care that you are currently receiving, nor 
will your care be affected if you decide at any stage to withdraw from this study. 
 
What can I expect if I do take part in this study?  
 
This is what will happen: 
 
1- We will need to gather some information about you. We will do this by asking you to attend an interview. 
 
2. You will then be randomly allocated to one of three groups using a computer programme.  
 
a. MBCT for people with vascular disorders + your usual care. This is the 8-week mindfulness 
course specially adapted for people with vascular disorders; 
OR 
b. Mindfulness - based stress reduction (MBSR) + your usual care. This is the 8-week 
mindfulness course that is for people with a range of health problems, and not specifically 
adapted for people with vascular disorders; 
OR 
c. The usual care alone. That means, the care that you would normally receive if you were not 
taking part in this study 
 
You will need to complete some self-report questionnaires at three different time points. . We will ask to 
measure your blood pressure at three different time points.   
 
5. We will invite you again three months later, after completing the therapy to see how you are doing. 
 
What information do you want to collect about me? 
 
We will invite you to an initial interview at which we will gather information regarding your mental and 
physical health, both current and past. This will include any experiences of low mood and how this has 
impacted you. You will also be given the opportunity to ask any questions about this study. The interview 
will take between 30 to 45 minutes. 
 
If following this interview and having had your questions answered, you are still interested in participating 
in this study, we will ask you to: 
 
1. Read and sign the consent form. 
2. Complete a set of questionnaires. 
3. Allow us to measure your blood pressure. 
 
The initial interview and assessments will normally be carried out at the University of Exeter, but we are 
happy to meet at other locations to suit your needs (e.g., your local GP surgery).  
 
Completing the questionnaires and measuring your blood pressure will be done on three separate occasions: 
1. Before you start therapy;  
2. At the last session of the therapy; 
3. Three months after completing the therapy. 
 
Each time you complete an assessment with a researcher you will be given £10 as a token of appreciation 
for your participation in the study. 
We would also appreciate it if you would give permission for us to record the interview on an audio tape. 
This will allow the researchers to be monitored to ensure that they are conducting the research according to 
the study protocol. If you do not want a recording to be made, you may inform the researcher of this at any 
time. 
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All recordings will be kept on a secure university hard drive or in a locked cabinet at the University of 
Exeter and accessed only by the researchers. 
Why are there three groups in this study? 
 
MBCT for people with vascular disorder is a new therapy so; we need to compare this therapy, with the 
standard mindfulness course and usual care. These comparisons will help us to know more about whether 
this new therapy is more helpful for people with vascular disorders than the other types of care.  
 
Who will decide what group I will be in? (Adapted-MBCT, MBSR or usual care)? 
 
After you have completed the initial interview and questionnaires, we will use a computer programme to 
randomly allocate one third of the participants to adapted MBCT, one third to MBSR and one third to the 
usual care.  
 
The MBCT for people with vascular disorder group: 
 
If you are allocated to this group, you will learn some meditation exercises plus certain cognitive therapy 
techniques and you will be asked to:  
 
1. Attend one individual orientation session with your therapist to learn more about the therapy.  This 
will take approximately one hour. 
2. Attend 8 group sessions. These will be held on the same day of the week over 8 consecutive weeks.  
Each session will last for 2 hours and 15 minutes.  
3. Practice daily for 30 min. We will provide you with CDs to help you in doing the practice. 
4. Take part in two short interviews at two different time-points. Each of these will take 
approximately 20 minutes.   
 
The standard MBSR group: 
 
If you are allocated to this group, you will learn some meditation exercises and you will be asked to: 
1. Attend one individual orientation session with your therapist to learn more about the therapy. This will 
take approximately one hour. 
2- Attend 8 group sessions. These will be held on the same day of the week over 8 consecutive weeks.  Each 
session will last for 2 hours and 15 minutes.  
3- Practice daily for 45 min. We will provide you with CDs to help you in doing the practice.  
 
The MBCT group and MBSR group will be run by trained therapists and will take place at the AccEPT 
Clinic at the University of Exeter. 
We would like to video record the group sessions. These recordings will be used to make sure the 
therapists are doing a good job and will also be used to help train therapists in the future. If you are not 
happy with the video recordings being made, please inform the researcher about this.  
 
It should be emphasised that any video recordings will be stored safely in a locked cabinet at the 
University of Exeter or on a password-protected hard drive and accessed only by the researchers. 
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Participants Information Sheet (cont.) 
 
Usual care group: 
As a member of this group, your routine care will continue unchanged and should you have any 
concerns or worries about your physical or mental health you should speak with either your GP or other 
health care professional who can advise of potential treatment options. After completing the study, you 
will be invited to take part in a standard MBCT course or MBSR course at the AccEPT Clinic at the 
University of Exeter if you would like to do so.  
 
What are the possible disadvantages of taking part? 
 
When participating, you will be asked to complete questionnaires and take part in interviews. There 
may be areas of a personal nature that some people might find uncomfortable to talk about. You do not 
have to discuss anything or answer any questions if you don’t wish to do so. 
 
What are the possible benefits of taking part? 
Your participation will help us to explore whether adapted MBCT is feasible and acceptable to people 
with vascular disorders. If this is found to be the case, work will be able to continue to develop future 
MBCT groups for people suffering from vascular disorders.  
 
What happens when the research study stops? 
 
 When the study is finished, you should discuss continuing your usual care with your health 
professional.  
 
What if new information becomes available during the course of the study?? 
 
It is possible that during the course of this study, new information about the treatment we are studying 
will be discovered. In this case, you will be consulted, and you will be able to continue, or withdraw 
from the study.  
If you decide to continue we will ask you to sign an updated consent form. 
 
If you decide to withdraw we will inform your health professional so that you can make plans regarding 
the care you wish to receive. 
In addition, if this information tells us that it is not good for you to continue in this study, we will 
inform you about this and advise you to discuss this situation with your health professional. 
What if something goes wrong? 
In case of any problems, we suggest you contact us without delay. If you were assigned  
to either the MBCT group or MBSR group, you can discuss any issue with the therapist leading the 
group or you can contact the lead researcher (please see details on the back page). 
If you have anything which you would like to discuss with the lead researcher’s supervisor, or the way 
in which the research has been done, you will also find appropriate details on the back page. 
 
There is also the option to contact The National Health Service Complaints Mechanism (Patient Advice 
and Liaison Service) (Tel: 01392 402093). 
 
Will my participation in this study be kept confidential? 
 
The collection of all data will be guided by the principle of strict confidentiality. Therefore, your name 
will not be found in any recording made or any questionnaire or form you complete. Your 
personal details will be stored safely and away from any collected data. 
 
If you decide to participate in this study, we will seek your permission to contact your health 
professional to inform them that you are taking part, and which arm you are allocated to.  
If during the course of the study, information revealed that you were at significant risk of harm to 
yourself or others this information will be discussed with your health professional but normally only 
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Participants Information Sheet (cont.) 
 
after discussion with you. 
 
What will happen to the results of the research study? 
 
All participants will be provided with a summary of all results once the study is completed. 
The results will be used to complete a part of the PhD studies of the lead researcher. It is possible that 
these results might be published as a part of an academic article or might be a part of presentation 
within an academic setting.  
 
We will ensure the privacy and confidentiality of your personal information. Any publications or 
presentations arising from this study will not contain any information which would allow you to be 
identified as a participant.  
 
If you would like any further information, please contact: 
Modi Alsubaie (Lead researcher)           Alternatively, you may contact the Lead  
PhD student                                                       Researcher’s Supervisor: 
The Mood Disorders Centre                              Willem Kuyken    
School of Psychology                                         Professor of Clinical Psychology  
University of Exeter,                                       Co-director Mood Disorders Centre 
EX4 4QG                                                            Tel: 01392 724659 
Tel: 01392 726101                                              EX4 4QG   
Email: msfa202@exeter.ac.uk                            Email: w.kuyken@exeter.ac.uk 
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Appendix E 
 SCID Baseline Template Score Sheet 
 
 
 
A. MOOD EPISODES 
 
A1. CURRENT MAJOR DEPRESSIVE EPISODE in Past month 
1. Depressed or down (2 wks+)    ? 1 2 3 
and / or                                                        
2.           Loss interest/ pleasure (most activities/day).  ? 1 2 3 
 
**IF NEITHER IS CODED “3" SKIP TO A12 (PAST MDE) 
 
3.  Weight change (increased / decreased)   ? 1 2 3 
 
4.  Sleep change (insomnia / hypersomnia)   ? 1 2 3 
 
5.  Psychomotor agitation/retardation   ? 1 2 3 
 
6.  Fatigue/low energy     ? 1 2 3 
 
7.  Worthlessness/Guilt  (NB excessive or inappropriate) ? 1 2 3 
 
8.  Concentration (thinking/indecisiveness)   ? 1 2 3 
 
9.  Suicide       ? 1 2 3 
 
Thought of own death __  Suicidal ideation __  Specific Plan __ Suicide attempt__ 
 
Five sxs coded "3", and at least one of these is item 1 or 2.  1  3 
 
(CRITERION B HAS BEEN OMITED FROM SCID) 
 
C. Functional Impairment     ? 1 2 3 
**IF CODED 1 GO TO A12 (PAST MDE) 
 
D. Not Due to General Medical Condition/ Substance abuse ? 1  3 
**GO TO A43 TO CHECK IF NECESSARY 
 
E. Recent Bereavement     ? 1  3 
 
**IF EITHER D or E 1 GO TO A12 (PAST MDE) 
 
=>MDE IF A, C, D, AND E ARE CODED “3”                      1 3 
 
Total No of MDEs (including current) ___________ (CODE 99 if too many or indistinct) 
 
CURRENT MDE SPECIFIERS 
WITH POSTPARTUM ONSET (A6)     1  3 
WITH CATATONIC FEATURES (A6-A7)    1  3 
WITH MELANCHOLIC FEATURES (A8-A9)    1  3 
WITH ATYPICAL FEATURES (A10-A11)    1  3 
 
**IF Past Major Depressive Episode/s GO TO A12 otherwise GO TO A1 
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SCID Baseline Template Score Sheet (cont.) 
A12 PAST MAJOR DEPRESSIVE SYNDROME 
A 
1. Depressed or down (2 wks+)                ? 1 2 3 
 
2. Less interest/pleasure (most activities/day)                           ? 1 2 3 
**IF A1 / A2 = 1 GOTO A18 – Current Manic 
 
Most recent if in last year OR Worst ever episode if over 1 year 
3.  Weight change (increased / decreased)   ? 1 2 3 
 
4.  Sleep change (insomnia / hypersomnia)   ? 1 2 3 
 
5.  Psychomotor agitation/retardation   ? 1 2 3 
 
6.  Fatigue/low energy     ? 1 2 3 
 
7.  Worthlessness/Guilt     ? 1 2 3 
 
8.  Concentration (thinking/indecisiveness)   ? 1 2 3 
 
9.  Suicide       ? 1 2 3 
 
Thought of own death __  Suicidal ideation __  Specific Plan __ Suicide attempt__ 
 
Five sxs coded "3", and at least one of these is item 1 or 2. 1  3 
 
(NB:  B Criteria not included in the SCID) 
 
C. Functional Impairment     ? 1 2 3 
**IF CODED 1 & there was a worst time GO BACK TO A12 and do ‘worst’ / 1 & no worst time goto A18 
 
D. Not Due to General Medical Condition/ Substance abuse ? 1  3 
**GO TO A43 TO CHECK IF NECESSARY 
 
E. Recent Bereavement      ? 1 3 
 
Age of onset of Past MDE ___________ 
 
Total No of MDEs (including current) ___________ (CODE 99 if too many or indistinct) 
 
(For recording more past MDEs go to J9) 
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SCID Baseline Template Score Sheet (cont.) 
A38 DYSTHYMIC DISORDER (current only)  
IF EVER MANIC OR HYPOMANIC CHECK _____ AND SKIP TO NEXT MODULE 
 
A. Bothered by mild depressed Mood (2yrs+)   ? 1 2 3 
**IF A = 1 GOTO B1 Psychotic Symptoms 
MDE CHRONOLOGY 
FIRST MDE _____ / _____ Age: 
PAST MDE (PAST 2 YEARS) _____ / _____ Age: 
NO LONGER MET MDE PAST TWO YEARS ______ Age: 
 
B.1 Poor Appetite or overeating    ? 1 2 3 
 
2 Insomnia or hypersomnia    ? 1 2 3 
 
3 Low energy or fatigue     ? 1 2 3 
 
4 Low Self-Esteem     ? 1 2 3 
 
5 Poor Concentration/difficulty making decisions  ? 1 2 3 
 
6 Hopelessness      ? 1 2 3 
 
AT LEAST 2 B sxs are CODED “3”     ? 1 2 3 
**If 1 GO TO B1 PSYCHOTIC SYMPTOMS 
C Never symptom free for more than 2 months at a time? 1  3 
**If normal mood for 2 or more months GO TO NEXT MODULE 
D No MDE during dysthymia    ? 1 2 3 
 
E Never been a Manic/Mixed episode or Cyclothymia ? 1  3 
 
F Not superimposed on course of Psychotic disorders ? 1  3 
 
G  Not Due to GMC/ Substance abuse   ? 1  3 
 
H  Functioning       1  3 
 
►DYSTHYMIC DISORDER All 5 coded "3"    1  3  
 
IF CASE INDICATE             1. Early onset (before 21) _____         2. Late onset______ (after 21) 
 
A42. ATYPICAL FEATURES SPECIFIER    1 2 3 
__________________________________________________________________________________ 
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Results of SCID Form 
 
Participant ID: ………………………………                                          Interviewer……………………….. 
Date: ……………………… 
 
 
 
  
Vascular disorder  Current MDE Past MDE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Dysthymia Minor depression  Notes 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Impression: 
1. 
2. 
3. 
4. 
5. 
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Appendix F 
 HeLM Participants Consent 
 
      When you have initialled all the boxes above, please complete below including the date yourself. 
 
_____________________              ___ 
 
_________________ 
 
____________      ___________ 
   Name of participant 
  (BLOCK CAPITALS) 
Date Signature 
I have explained the study to the above patient and he/she has indicated his/her willingness to take part in the study. 
 
____________________        ____ 
 
_________________ 
 
__________________      _____ 
Name of Researcher 
(BLOCK CAPITALS) 
Date Signature 
 
  
 yes No  
1. I have read and understood the information sheet dated 07/05/2014 (version1.2) for the above study 
and have been given a copy to keep. 
  
2. I have had the opportunity to consider the information and ask any questions.  
 
  
3. I have received enough information about the study.  
 
  
4. I agree to take part in the above study 
 
  
5. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason and without my medical care being affected. 
 
  
6. I understand that details of my participation will be stored anonymously on file and may be used in 
the final analysis of data. 
  
7. I agree to the interviews and therapy sessions being audio and video recorded for the purposes of 
therapy, supervision, assessment and feedback for therapists.  
  
8. I agree to my recordings being used for training purposes. I understand that the trainers would be 
staff and students of the University of Exeter bound by their professional codes of conduct.  
 
  
9. I understand that I may order the recordings to be destroyed when my therapy is complete if I do 
not wish them to be used for research/training purposes. 
 
  
10 I agree to my GP/Health professional being informed of my participation in this study and being 
updated with information relevant to my medical care. 
 
  
11. I agree to my contact details being added to the Mood Disorders Centre’s database so that I might 
be invited in the future to take part in other depression research. 
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Appendix G1 
HeLM Feasibility Screening Form (1) 
 
INTERVIEWER DETAILS 
 
Interviewer: _________________________  
 
 
Date of screening interview: ____/_____/_________ 
Duration of call 
Start time:  __________   End time: __________ 
 
Referrer __________________________ 
Referral date:  ___________________________ 
 
SECTION 1a : PARTICIPANT INFORMATION (check correct) 
MDC Number :    __ __ __ __ __ 
 
Forename _______________________  Surname ______________________  Pref name 
________________ 
 
Title 
 Mr      Mrs      Miss      Ms       Other ______________ 
 
Gender 
 Male        Female 
 
DOB:         /         / 
 
GP _______________________ 
 
Surgery ___________________ 
SECTION 1b : PARTICIPANT CONTACT DETAILS  
Main contact details 
Address ______________________________________________________________ 
  _____________________________________________________ 
Telephone numbers      
Home number ________________________ Preferred time: _________________ 
Mobile  ________________________ Preferred time: _________________ 
Work number ________________________ Preferred time: _________________ 
Is it OK to leave a message on the answer phone? ______________________ 
E-mail address   
Main e-mail ________________________ 
Alternative contact details 
Address _____________________________________________________________________ 
  ___________________________________________________________ 
Telephone numbers   ____________________________   E-mail address __________________________ 
 
 
 
325 
 
 
HeLM Feasibility Screening Form (1) (cont.) 
SECTION 1c:  Formal Concurrent Psychotherapy 
Currently in therapy/counselling    Yes (Ask questions below)        No 
       If currently in therapy/counselling: 
       Type of therapy  ____________________________ 
       Duration of therapy __________________________ 
       Will have finished therapy by  __________________ 
SECTION 2: Inclusion Criteria                                                    MDC number: ___________ 
2.1 Experience of Depressive Episode:  
Have you ever experienced depression/ low mood*      Yes        No 
Details: ________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
 
*Assess this by listing symptoms if necessary – collect information 
 
Circumstances with Depression: 
  
Did you need to go to the GP                  Yes 
Are you or have you taken medication for it         Yes 
Any other help?                   Yes Details: 
_______________________________________________________ 
 
Number of previous episodes (self-report) _______________________________ 
 
2.2. Current Depressive Episode (exclusion criteria):  
 Yes        No         since (approx. time) ____________________________ 
 
In past month: 
 Depressed mood or feeling down                              
 Two weeks or more 
 
In past month: 
 Diminished interest/pleasure most activities/days   
 Two weeks or more 
 
Sleep change: 
 Insomnia     Hypersomnia 
Score: 
 
Significant weight change:            Significant appetite change: 
  Loss        Gain                     Loss         Gain 
Score: 
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Psychomotor change: 
 Agitation              Retardation 
Score: 
Energy level change: 
 Fatigue                 Low energy  
Score: 
Feelings about self: 
 
 Guilt             Worthlessness 
Score: 
Concentration problems: 
 
 Thinking       Indecisiveness  
Score: 
Hopeless/Suicide 
 Feeling hopeless or suicidal       Feeling 
persists 
 Considered self-harm   Did self-harm 
Score: 
 
Concern patient is   
suicidal and has  
unmet needs              Yes      No 
 
3. Heart Conditions – Vascular disease (Inclusion criteria) 
 
Do you currently suffer with a heart condition or vascular disease?  Yes     No 
 
Which of the following; Tick and circle appropriate 
 
Coronary heart disease (angina, myocardial infarction – heart attack- and stroke)   
Peripheral vascular disease (poor circulation in the legs / hands)  
Diabetes  
Hypertension (high blood pressure) and hypercholesterolemia (raised cholesterol)  
Experienced a cardiac condition or event;  heart attack, by-pass surgery, angina, angioplasty or 
stents  
 
Notes: 
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SECTION 4: Exclusion Criteria                                             MDC number ______________  
4.1.  Alcohol Use 
Ever caused a problem for you  Yes      No 
Current use is a problem          Yes      No 
Friends comment on use/ Attended AA meeting? 
4.2.  Drug Use 
Ever caused a problem for you  Yes      No 
Current use is a problem           Yes      No 
Friends comment on use/ Attended NA 
meeting? 
 
4.3. Current Psychosis  (SCREEN Questions)             Yes      No 
Previous Diagnosis of Mental Health Problems 
Diagnosis – Manic-Depression       Yes      No 
Diagnosis – Bipolar Disorder       Yes      No 
Ever been diagnosed with any other mental health problem   Yes      No 
 If Yes, what: _________________________  Exclusion ?  Yes      No 
Ever cut, burnt or otherwise injured yourself deliberately   Yes      No 
Suggestion of psychosis on screen ( APPENDIX C: PSQ)   Yes      No 
Further information 
 
 
 
 
Eligible? Interested? Can do group dates? 
 
 
ORIENTATION APPOINTMENT  
Date: ____________________________ 
With: ____________________________ 
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Psychosis Screening Questionnaire 
 
Temp ID number 
      
       
 
I have to ask about a whole range of experiences. Some of these experiences are quite rare. 
However, I would be very grateful if you would bear with me and answer the questions I am going to 
ask you now. 
 
Yes No Unsure 
Q1  Have there ever been times when you felt very 
happy indeed without a break for days on end? 
1 
 (a) 
2 
 Q2 
3 
 Q2 
 (a) Was there an obvious reason for this? 1 
 Q2 
2 
 (b) 
3 
 Q2 
 (b) Did your relatives or friends think it was strange or 
complain about it? 
1 
 Screen  
2 
 Q2 
3 
 (b) 
Q2  Have you ever felt that your thoughts were 
directly interfered with or controlled by some 
outside force or person? 
1 
 (a) 
2 
 Q3 
3 
 Q3 
 (a) Did this come about in a way that many people 
would find hard to believe, for instance, through 
telepathy? 
1 
 Screen  
2 
 Q3 
3 
 Q3 
Q3  Have there ever been times when you felt that 
people were against you? 
1 
 (a) 
2 
 Q4 
3 
 Q4 
 (a) Have there been times when you felt people were 
deliberately trying to harm you or your interests? 
1 
 (b) 
2 
 Q4 
3 
 Q4 
 (b) Have there been times when you felt a group of 
people was plotting to cause you serious harm or 
injury? 
1 
 Screen  
2 
 Q4 
3 
 Q4 
Q4  Have there ever been times when you felt that 
something strange was going on? 
1 
 (a) 
2 
 Q5 
3 
 Q5 
 (a) Did you feel it was so strange that other people 
would find it hard to believe? 
1 
 Screen  
2 
 Q5 
3 
 Q5 
Q5  Have there ever been times when you heard or 
saw things other people couldn’t? 
1 
 (a) 
2 
 End 
3 
 End 
 (a) Did you at times hear voices saying quite a few 
words or sentences when there was no one around 
that might account for it? 
1 
 Screen  
2 
 End 
3 
 End 
If + screening for Psychosis (Q2-Q5): Check whether Sx are associated with depression:  
- About the difficulties you have just described, did these happen only when you were 
depressed or at other times?     Depression with psychotic features   
Psychosis 
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Appendix G2 
 HeLM Feasibility Screening Form (2) 
 
*PHQ-9 Score: (0) not at all – (1) several days – (2) More than half the days – 3 (Everyday) 
  
HeLM Telephone Screening Form/Part2 
 
Interviewer: 
_________________________  
 
 
Date of screening interview: 
____/_____/_________ 
Duration of call 
Start time: __________   End time: 
__________ 
 
HeLM research number:    __ __ __ __ __ 
  
 
3.2 Current Depressive Episode* (exclusion criteria):  
 Yes        No         since (approx. time) ____________________________ 
 
In past month: 
 Depressed mood or feeling down                              
 Two weeks or more 
 
In past month: 
 Diminished interest/pleasure most 
activities/days    Two weeks or more 
 
Sleep change: 
 Insomnia     Hypersomnia 
Score: 
 
Significant weight change:            Significant appetite 
change: 
  Loss        Gain                     Loss         Gain 
Score: 
Psychomotor change: 
 Agitation              Retardation 
Score: 
Energy level change: 
 Fatigue                 Low energy  
Score: 
Feelings about self: 
 
 Guilt             Worthlessness 
Score: 
Concentration problems: 
 
 Thinking       Indecisiveness  
Score: 
Hopeless/Suicide 
 Feeling hopeless or suicidal       Feeling 
persists 
 Considered self-harm   Did self-
harm 
Score: 
 
Concern patient is   
suicidal and has  
unmet needs              Yes      No 
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HeLM Feasibility Screening Form (2) (cont.) 
 
Eligible for baseline interview? 
 
Interested? Can do group dates? 
 
Baseline assessment appointment 
Date: ____________________________ 
 
With: ____________________________ 
  
3.3 Exclusion Criteria                                              
 Alcohol Use 
Ever caused a problem for you  Yes      No 
Current use is a problem          Yes      No 
Friends comment on use/ Attended AA meeting? 
  Drug Use 
Ever caused a problem for you  Yes      No 
Current use is a problem           Yes      No 
Friends comment on use/ Attended NA 
meeting? 
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Telephone Screening Interview Script/ part 1 
HeLM PROJECT for cardiovascular disorders and Heart conditions 
Introduction;  
 
My name is _______ and I’m calling from University of Exeter.  I’m calling because you recently 
expressed an interest in taking part in a study for people with vascular disorders and I am just phoning to 
follow that up.  Is this a convenient time to call? 
 
Purpose of phone call: 
Explain a little more about the project, give you a chance to ask any questions that you may have and 
perhaps ask you some questions to see if our study right for you or not. 
Would that be ok to do now?  It will take about 10/15 minutes in all. 
I am gonna tell you a little bit about the study: 
We are conducting a small study to see if a new course of Mindfulness-based Cognitive Therapy (MBCT) 
can help people with heart disease or stroke and low mood to manage their physical and mental well-
being. 
 
In this study, we will have three groups. The first group will be the new course of mindfulness which was 
adapted especially for people with heart diseases/stroke.  
 
The second group is a standard mindfulness course which has been widely used with people with pain 
and other chronic disorders and the third group will be the usual care; this means you will continue your 
routine care and you will not receive any therapy.  
 
The reason behind having three groups in this study is because MBCT for people with heart disease/stroke 
is a new therapy and so we need to compare this therapy with the other forms that are already available. 
These comparisons will help us to know more about whether the new MBCT therapy is more helpful for 
people with vascular disorders than the other types of care. 
 
We will use a computer programme to randomly allocate you to one of the three groups. We need 30 pts, 
this means 10 participants will allocate to the new course, 10 participants will allocate to the other 
mindfulness course and 10 participants will allocate to the usual care. If you allocated to the usual care, 
after finishing the study, we would invite you to attend the standard mindfulness courses that are available 
at the clinic at the University of Exeter.     
Do you have any questions at this point? 
It may just be helpful if I tell you a little bit about mindfulness.  Do you know much about it or are you 
familiar with it at all?  
If no, mindfulness is a form meditation therapy made up of a number of different practices as well as 
learning different ways to bring your awareness into the everyday activities in life.   
So based on the information I have just given you does this sound like something you are potentially 
interested in taking part in?  
If no, Ok, well thank you for your time and interest in the study, it has been great speaking to you. END. 
If yes, great, what I would like to do now is ask you some questions.  Is now a convenient time?   
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Some of the questions I will ask will involve you giving personal information about your medical and 
psychological history, is that ok? 
Before I start with the questions it may be worth checking that you are able to attend the group dates first. 
The groups will be next Feb and March, every Tues or Wed between 10 am to 12:30 pm. Are you able to 
attend those dates?  
Great, now I’m gonna start with the questions but at any point you want to stop or don’t want to answer 
the question please just say. 
SECTION 1: Participant Information / Contact Details 
 
“To begin with, I’d like to check that we have your information correct and also to ask you a few further 
questions about yourself.” 
1) “Can you confirm that your surname is ______ and your first name is ______? Do you have a 
different preferred name?” 
2) “What is your title?” 
3) “Please can you tell me your age and your date of birth?” 
4) Please could you give me your GP’s name and address?” 
5) “What is your postal address?   
6) “Please can you provide me with your home telephone number and your mobile number? Do 
you have any other contact numbers for you that may be useful to us?” 
“Is it okay to leave a message on that/on your house phone?”   
“Where are you now “if calling mobile”. 
“Do you have a preferred time for us to call you?” 
 
7) “Do you have an email address?” 
 
Formal concurrent psychotherapy 
1) “Are you currently receiving any other type of therapy or are you currently seeing a 
counsellor?” 
(If YES: “What type of therapy are you receiving?”) 
(If YES: “When did you roughly start this therapy?” “Do you have plans to finish the therapy 
over the next 6 months?”) 
Section 2: Inclusion Criteria 
 
2.1. Experience of Past Depressive Episode 
“I’d like to ask you some questions about depression and low mood if that’s ok.  
1) Is depression or low mood something you experience? 
If yes, could you tell me a bit more about that? 
(If need prompting)  If I list a number of symptoms usually associated with low mood, could you perhaps 
tell me if they are something you experience and to what extent?  List symptoms, get further information. 
2) Have you previously experienced other episodes of low mood and/or depression? 
If yes, are you able to say approx. how many? 
2.2. Vascular disorder 
1) Do you currently suffer from a vascular disorder or heart condition? 
(If YES) 
 
 
2) Could you tell me what type of heart condition? 
3) Would you mind telling me a little bit more about that?  Here we are looking for experience, 
how it affected them, when it happened, problems they face etc. 
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(If NO, go to the not currently eligible section) 
SECTION 3: Exclusion Criteria 
3.1 Previous Diagnosis of Mental Health Problems 
1)“Have you ever been diagnosed with bipolar disorder or manic depression?” 
 
2) “Have you ever been diagnosed with any other mental health condition?” 
See appendix C: Past Manic Episode Questions. 
 
3) “Have you ever cut, burnt, or otherwise injured yourself deliberately?” 
(If YES: “When was the last time you cut/burnt/injured yourself deliberately?” 
(If YES: “Are you currently receiving therapy for your self-harming?”) 
3.2. Ability to engage with MBCT /MBSR     
 
“Well that’s the end of the questions but what I’d now like to do is tell you a little bit about taking part in 
MBCT OR MBSR.       
 
“Taking part in MBCT OR MBSR can be quite demanding in terms of the time involvement both during 
the classes and outside of classes. For example, there will be 2 hour classes each week for 8 weeks, and 
there will be homework which is typically 40-60 minutes a day, 6 days a week over the 8 week course. 
Some of the exercises that participants will do in the class may also involve very gentle stretching or 
moving, or sitting still for periods of time. So, some individual exercises may last between 30-40 minutes. 
However, not all exercises will be this long.”  
“Does MBCT OR MBSR sound like something that you’d be willing to engage with?” 
If Not Currently Eligible: 
 “Thank you for taking the time to speak to me today. As I mentioned earlier we can only offer people 
places on the research trial if they meet certain criteria. This is because we are trying to make it a fair 
scientific test and need to control certain factors such as whether people are currently depressed or are 
in another form of therapy. I am sorry but cannot offer you a place on the trial as you do not currently 
meet the criteria that we are looking for. This is because (SELECT APPROPRIATE: you haven’t 
experienced depression/low mood -you are not able to engage with MBCT/MBSR…) 
If Currently Eligible: 
“Thank you for providing this information. Based on this information you have given me so far it 
sounds like you meet the criteria for our study so what I would like to do is call you again in October to 
ask some further questions to make absolutely sure that the study is right for you. 
Explain here that due to the group being a little while away there are some questions that we cannot ask 
right now. 
Does that sound ok to you? 
 “Finally, do you have any questions that you’d like to ask me about the study?  I’ll give you my 
telephone number in case you have any questions in the meantime and please feel free to call me any 
time.  
Thank you for your time today and for answering these questions, speak to you in a few months.  
 
 
 
 
 
  
334 
 
 
Appendix H 
  HeLM feasibility - stratification    
 
HeLM groups (MBCT-HeLM, MBSR, and TAU).  
Type of cardiovascular disorders (Heart condition, Stroke and Hypertension).  
Severity of depression based on PHQ-9 (0-4 Minimal Depression, 5-9 Mild Depression,10-14 Moderate 
Depression, 15-19 Moderately severe Depression, 20-27 Severe Depression.  
  
 
 
Research ID Type of vascular 
disorders 
Severity of depression based on 
PHQ-9* 
Total PHQ-9 
1  Heart condition                                                                                Minimal depression 1 
2  Heart condition                                                                                Moderate depression 10 
3  Heart condition                                                                                 Moderate depression 14 
4  Heart condition                                                                                            Minimal depression 0 
5  Stroke  Mild depression 5 
6  Heart condition  Moderate depression 12 
7  Hypertension  Moderately severe depression 15 
8     Hypertension    Minimal depression 4 
9  Heart condition Mild depression 6 
10  Heart condition                                                                                            Moderately severe depression 15 
11  Heart condition                                                                                                Mild depression 9 
12  Stroke  Minimal depression 2 
13  Stroke  Minimal depression 4 
14  Stroke  Mild depression 7 
15  Hypertension    Mild depression 9 
16  Heart condition  Moderate depression 14 
17  Heart condition Moderate depression 10 
18      Heart condition     Moderately severe depression 17 
19  Heart condition Moderately severe depression 18 
20  Heart condition  Mild depression 7 
21  Stroke  Moderate depression 12 
22   Stroke  Moderately severe depression 19 
23  Stroke  Mild depression 6 
24  Stroke  Moderately severe depression 16 
25  Heart condition and 
stroke 
Moderate depression 10 
26  Heart condition  Minimal depression 3 
27  Heart condition  Minimal depression 2 
28     Hypertension    Mild depression 7 
29  Heart condition Mild depression 6 
30  Heart condition Moderately severe depression 16 
31  Stroke  Mild depression 9 
32  Heart condition Mild depression 9 
33  Heart condition Mild depression 6 
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Appendix I 
HeLM Feasibility measures  
 
1.Background information 
 
The purpose of this questionnaire is to obtain some information about your background, which may be 
relevant to your situation. Any information you provide is strictly confidential. 
1.   
Research Number   
 
Date of birth  
 
Gender □ Male                             □ Female  
Occupation   
 
Education   
Religion   
 
Ethnic group White / Mixed / Asian or Asian British / Black or Black British / Chinese 
or Other Ethnic Group 
Marital Status  □ Single                                           □ Married or living together  
□ Separated or divorced                    □ Widowed  
Email   
GP name  
GP Surgery   
How frequently do you see 
you GP? 
 
 
2. What type of vascular disorders (heart conditions/ stroke/ hypertension) do you suffer from? 
● If you suffer from a heart condition, please specify further what type of heart condition? 
3. Do you suffer from other medical conditions? 
   □   Yes              □ No              If yes, please specify further: 
4. Are you aware of any physical illness or other limitations that may make hearing, sitting, standing, 
walking, or doing simple exercises difficult for you 
□   Yes              □ No  
If yes, please specify further: 
 
 
5. Are you taking any medications (prescribed and non-prescribed) at the moment? 
□ Yes                      □ No 
If yes, please list in the table below 
Medications Dosage Frequency Reason 
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1.    
2.    
3.    
4.    
5.    
6.    
7.    
 
6. Are you currently receiving any therapy/counselling / support regarding your medical condition?  
□ Yes                    □ No                           If yes, please specify further: 
 
7. Are you taking any medications for depression? 
 
□   Yes              □ No  
If yes, please specify further 
 
8. Have you ever received psychiatric or psychological treatment before?   
    □ Yes                    □ No 
If yes, please specify: 
9. Are you currently receiving any therapy\ counselling \ support regarding your mental health?  
□ Yes                    □ No 
If yes, please specify further  
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2.Patient Health Questionnaire 
 
Research Number ……………………………. Date completed…………………….. 
 
 
  Over the last 2 weeks, how often have you  
  been bothered by any of the following problems? 
    (Use “✔” to indicate your answer” 
Not at all 
Several 
days 
More 
than 
half the 
days 
Nearly       
every 
 day 
1.  Little interest or pleasure in doing things. 0 1 2 3 
2.  Feeling down, depressed, or hopeless. 0 1 2 3 
3.  Trouble falling or staying asleep or sleeping too 
much. 
 
  0 
 
  1 
 
  2 
 
  3 
4.  Feeling tired or having little energy. 0 1 2 3 
5.  Poor appetite or overeating.     0 1 2 3 
6.  Feeling bad about yourself — or that you are  
a failure   or have let yourself or your family down. 
 
  0 
 
  1 
 
2 
 
  3 
7.  Trouble concentrating on things, such as reading the 
newspaper or watching television. 
 
  0 
 
  1 
 
2 
 
  3 
8.  Moving or speaking so slowly that other people could 
have noticed?  Or the opposite — being so fidgety or 
restless that you have been moving. around a lot more 
than usual. 
 
 
 
  0 
 
 
 
  1 
 
 
 
2 
 
 
 
 3 
9.  Thoughts that you would be better off dead or of 
hurting yourself in some way. 
 
  0 
 
1 
 
2 
 
 3 
     
  
 Total Score: 
 
Level: 
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3.Generalised Anxiety Disorder-7 
 
Research Number ……………………………. Date completed…………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  Over the last 2 weeks, how often have 
you  
  been bothered by any of the following 
problems 
Not at all Several 
days 
More 
than half 
the days 
Nearly 
every day 
1. Feeling nervous, anxious or on edge 
 
0 1 2 3 
2. Not being able to stop or control 
worrying 
 
0 1 2 3 
3. Worrying too much about different 
things 
0 1 2 3 
4. Having trouble relaxing 
 
0 1 2 3 
5. Being so restless that it is hard to sit still 
 
0 1 2 3 
6. Becoming easily annoyed or irritable 
 
0 1 2 3 
7. Feeling afraid that something awful 
might happen 
0 1 2 3 
  
 
   
Total 
Score 
 
 
 
 
 
 
    Level  
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4.Cardiac Anxiety Questionnaire 
 
Research Number: ………………… Date completed…………………….. 
 
The following lists behaviours that people may do if they are worried about their heart problems. Please 
rate each item by circling the answer (number) that applies to you. 
 
  
 
Never Rarely Sometimes Often Always 
1 I pay attention to my heart beat.  0 1 2 3 4 
2 I avoid physical exertion. 0 1 2 3 4 
3 My racing heart wakes me up at night. 0 1 2 3 4 
4 Chest pain/ discomfort wakes me up at 
night. 
0 1 2 3 4 
5 I take it easy as much as possible.  0 1 2 3 4 
6 I check my pulse. 0 1 2 3 4 
7 I avoid exercise or other physical work. 0 1 2 3 4 
8 I can feel my heart in my chest. 0 1 2 3 4 
9 I avoid activities that make my heart beat 
faster. 
0 1 2 3 4 
10 If tests come out normal, I still worry 
about my heart. 
0 1 2 3 4 
11 I feel safe being around a hospital, 
physician or other medical facility. 
0 1 2 3 4 
12 I avoid activities that make me sweat. 0 1 2 3 4 
13 I worry that doctors do not believe that my 
symptoms are real. 
0 1 2 3 4 
 
When I have chest discomfort or when my heart is beating fast: 
 
  Never  Rarely  Sometimes  Often  Always  
14 I worry that I may have a heart attack. 0 1 2 3 4 
15 I have difficulty concentrating on 
anything else. 
0 1 2 3 4 
16 I get frightened.  0 1 2 3 4 
17 I like to be checked out by a doctor. 0 1 2 3 4 
18 I tell my family or friends.  0 1 2 3 4 
 
 
 
 
 
 
 
  
340 
 
 
5.The Seattle Angina Questionnaire (SAQ) 
 
 
Research Number: ………………… Date completed…………………….. 
 
 
Q1 - The Seattle Angina Questionnaire 
 
1. The following is a list of activities that people often do during the week.  Although for some people with 
several medical problems it is difficult to determine what it is that limits them, please go over the activities 
listed below and indicate how much limitation you have had due to chest pain, chest tightness or angina over 
the past 4 weeks. 
 
Place a tick in one box on each line 
(Scale 1: Physical limitation scale) 
 
Activity 
Severely 
limited 
Moderately 
limited 
Somewhat 
limited 
A little 
limited 
Not 
limited 
Limited or 
did not do for 
other reasons 
Dressing yourself □ □ □ □ □ □ 
Walking indoors on 
level ground 
□ □ □ □ □ □ 
Showering □ □ □ □ □ □ 
Climbing a hill or a 
flight of stairs 
without stopping 
□ □ □ □ □ □ 
Gardening, 
vacuuming or 
carrying groceries 
□ □ □ □ □ □ 
Walking more than a 
block at a brisk pace 
□ □ □ □ □ □ 
Running or jogging □ □ □ □ □ □ 
Lifting or moving 
heavy objects (e.g. 
furniture, children) 
□ □ □ □ □ □ 
Participating in 
strenuous sports (e.g. 
swimming, tennis) 
□ □ □ □ □ □ 
 
 
(Scale 2: Anginal stability scale) 
 
2. Compared with 4 weeks ago, how often do you have chest pain, chest tightness, or angina when doing 
your most strenuous level of activity? 
 
I have chest pain, chest tightness or angina… 
 
Much more often Slightly more often About the same Slightly less often Much less often 
□ □ □ □ □ 
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(Scale 3: Anginal frequency scale – questions 3 and 4) 
 
3. Over the past 4 weeks, on average, how many times have you had chest pain, chest tightness or angina? 
 
I have chest pain, chest tightness or angina… 
 
4 or more 
times per day 
1-3 times 
per day 
3 or more times per 
week but not every day 
1-2 times 
per week 
Less than 
once a week 
None over the 
past 4 weeks 
□ □ □ □ □ □ 
 
4. Over the past 4 weeks, on average, how many times have you had to take nitros (nitroglycerin tablets) for 
your chest pain, chest tightness or angina? 
 
I take nitros… 
 
4 or more 
times per day 
1-3 times 
per day 
3 or more times per 
week but not every day 
1-2 times 
per week 
Less than 
once a week 
None over the 
past 4 weeks 
□ □ □ □ □ □ 
 
(Scale 4: Treatment satisfaction scale – questions 5, 6, 7 and 8) 
 
5. How bothersome is it for you to take your pills for chest pain, chest tightness or angina as prescribed? 
 
6. How satisfied are you that everything possible is being done to treat your chest pain, chest tightness or 
angina? 
 
Not satisfied at all Mostly dissatisfied Somewhat dissatisfied Mostly satisfied Highly satisfied 
□ □ □ □ □ 
 
  
Very 
bothersome 
Moderately 
bothersome 
Somewhat 
bothersome 
A little 
bothersome 
Not bothersome 
at all 
My doctor has 
not prescribed 
pills 
□ □ □ □ □ □ 
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7.  How satisfied are you with the explanations your doctor has given you about your chest pain, chest 
tightness or angina? 
 
Not satisfied at all Mostly dissatisfied Somewhat dissatisfied Mostly satisfied Highly satisfied 
□ □ □ □ □ 
8.  Overall, how satisfied are you with the current treatment of your chest pain, chest tightness or angina? 
 
Not satisfied at all Mostly dissatisfied Somewhat dissatisfied Mostly satisfied Highly satisfied 
□ □ □ □ □ 
 
(Scale 5: Disease perception scale questions – 9, 10 and 11) 
9. Over the past 4 weeks, how much has your chest pain, chest tightness or angina interfered with your 
enjoyment of life? 
 
It has severely 
limited my 
enjoyment of life 
It has moderately 
limited my 
enjoyment of life 
It has slightly 
limited my 
enjoyment of life 
It has barely 
limited my 
enjoyment of life 
It has not limited 
my enjoyment of 
life 
□ □ □ □ □ 
 
10. If you had to spend the rest of your life with your chest pain, chest tightness or angina the way it is now, 
how would you feel about this? 
 
Not satisfied at all Mostly dissatisfied Somewhat dissatisfied Mostly satisfied Highly satisfied 
□ □ □ □ □ 
 
11. How often do you worry that you may have a heart attack or die suddenly? 
 
I can’t stop 
worrying about it 
I often think 
or worry 
about it 
I occasionally worry 
about it 
I rarely think 
or worry 
about it 
I never think or worry 
about it 
□ □ □ □ □ 
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6-Facet Mindfulness Questionnaire 
 
Research Number: ………………… Date completed…………………….. 
 
Please rate each of the following statements using the scale provided.  Write the number in the blank that 
best describes your own opinion of what is generally true for you. 
 
1 2 3 4 5 
never or very 
rarely true 
rarely 
true 
sometimes 
true 
often 
true 
very often 
or always 
true 
 
_____ 1.  When I’m walking, I deliberately notice the sensations of my body moving. 
_____ 2.  I’m good at finding words to describe my feelings. 
_____ 3.  I criticize myself for having irrational or inappropriate emotions. 
_____ 4.  I perceive my feelings and emotions without having to react to them. 
_____ 5.  When I do things, my mind wanders off and I’m easily distracted. 
_____ 6.  When I take a shower or bath, I stay alert to the sensations of water on my body. 
_____ 7.  I can easily put my beliefs, opinions, and expectations into words. 
_____ 8.  I don’t pay attention to what I’m doing because I’m daydreaming, worrying, or otherwise distracted.  
_____ 9.  I watch my feelings without getting lost in them. 
_____ 10. I tell myself I shouldn’t be feeling the way I’m feeling. 
_____ 11. I notice how foods and drinks affect my thoughts, bodily sensations, and emotions. 
_____ 12. It’s hard for me to find the words to describe what I’m thinking. 
_____ 13. I am easily distracted. 
_____ 14. I believe some of my thoughts are abnormal or bad and I shouldn’t think that way. 
_____ 15. I pay attention to sensations, such as the wind in my hair or sun on my face. 
_____ 16. I have trouble thinking of the right words to express how I feel about things 
_____ 17. I make judgments about whether my thoughts are good or bad. 
_____ 18. I find it difficult to stay focused on what’s happening in the present. 
_____ 19. When I have distressing thoughts or images, I “step back” and am aware of the       thought or 
image without getting taken over by it. 
_____ 20. I pay attention to sounds, such as clocks ticking, birds chirping, or cars passing. 
_____ 21. In difficult situations, I can pause without immediately reacting. 
_____ 22. When I have a sensation in my body, it’s difficult for me to describe it because I can’t find the  
right words. 
_____ 23. It seems I am “running on automatic” without much awareness of what I’m doing. 
 _____24. When I have distressing thoughts or images, I feel calm soon after. 
_____ 25. I tell myself that I shouldn’t be thinking the way I’m thinking. 
_____ 26. I notice the smells and aromas of things. 
_____ 27. Even when I’m feeling terribly upset, I can find a way to put it into words. 
_____ 28. I rush through activities without being really attentive to them. 
_____ 29. When I have distressing thoughts or images I am able just to notice them without 
                reacting. 
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_____ 30. I think some of my emotions are bad or inappropriate and I shouldn’t feel them. 
_____ 31. I notice visual elements in art or nature, such as colors, shapes, textures, or patterns   of light and 
shadow 
_____ 32. My natural tendency is to put my experiences into words. 
_____ 33. When I have distressing thoughts or images, I just notice them and let them go. 
_____ 34. I do jobs or tasks automatically without being aware of what I’m doing. 
_____ 35. When I have distressing thoughts or images, I judge myself as good or bad, depending what the 
thought/image is about. 
_____ 36. I pay attention to how my emotions affect my thoughts and behavior. 
_____ 37. I can usually describe how I feel at the moment in considerable detail. 
_____ 38. I find myself doing things without paying attention. 
_____ 39. I disapprove of myself when I have irrational ideas. 
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7.Self-Compassion Scale 
 
Research Number: ………………… Date completed…………………….. 
 
HOW I TYPICALLY ACT TOWARDS MYSELF IN DIFFICULT TIMES 
Please read each statement carefully before answering. To the right of each item, indicate how often you behave 
in the stated manner, using the following scale: 
  
Almost                                                                                                                                     Almost 
 never                                                                                                                                       always 
     1                                     2                                    3                                     4                                5 
 
 
 
  
1 I’m disapproving and judgmental about my own flaws and inadequacies.  
2 When I’m feeling, down I tend to obsess and fixate on everything that’s wrong.  
3 When things are going badly for me, I see the difficulties as part of life that everyone goes 
through. 
 
4 When I think about my inadequacies, it tends to make me feel more separate and cut off 
from the rest of the world. 
 
5 I try to be loving towards myself when I’m feeling emotional pain.  
6 When I fail at something important to me I become consumed by feelings of inadequacy.  
7 When I'm down, I remind myself that there are lots of other people in the world feeling like 
I am. 
 
8 When times are really difficult, I tend to be tough on myself.  
9 When something upsets me I try to keep my emotions in balance  
10 When I feel inadequate in some way, I try to remind myself that feelings of inadequacy are 
shared by most people. 
 
11 I’m intolerant and impatient towards those aspects of my personality I don't like.  
12 When I’m going through a very hard time, I give myself the caring and tenderness I need  
13 When I’m feeling down, I tend to feel like most other people are probably happier than I 
am. 
 
14 When something painful happens I try to take a balanced view of the situation.  
15 I try to see my failings as part of the human condition  
16 When I see aspects of myself that I don’t like, I get down on myself.  
17 When I fail at something important to me I try to keep things in perspective  
18 When I’m really struggling, I tend to feel like other people must be having an easier time of 
it. 
 
19 I’m kind to myself when I’m experiencing suffering.  
20 When something upsets me I get carried away with my feelings 
 
 
21. I can be a bit cold-hearted towards myself when I'm experiencing suffering.  
22 When I'm feeling down I try to approach my feelings with curiosity and openness.  
23 I’m tolerant of my own flaws and inadequacies.  
24 When something painful happens I tend to blow the incident out of proportion.  
25 When I fail at something that's important to me, I tend to feel alone in my failure.  
26 I try to be understanding and patient towards those aspects of my personality I don't like.  
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8.ILLNESS PERCEPTION QUESTIONNAIRE (IPQ-R) 
 
Research Number: ………………… Date completed…………………….. 
 
We are interested in your own personal views of how you now see your current illness (heart 
condition or stroke or hypertension) 
Please indicate how much you agree or disagree with the following statements about your 
illness by ticking the appropriate box. 
 
 VIEWS ABOUT YOUR ILLNESS STRON
GLY 
DISAG
REE 
DISAGR
EE 
NEITHE
R 
AGREE 
NOR 
DISAGR
EE 
AGRE
E 
STR
ONG
LY 
AGR
EE 
IP1 
My illness will last a short time      
IP2 
My illness is likely to be permanent 
rather 
 than temporary 
     
IP3 
My illness will last for a long time      
IP4 
This illness will pass quickly      
IP5 
I expect to have this illness for the rest of 
my life 
     
IP6 
My illness is a serious condition      
IP7 
My illness has major consequences on my 
life 
     
IP8 
My illness does not have much effect on 
my life 
     
IP9 
My illness strongly affects the way others 
see me 
     
IP10 
My illness has serious financial consequences      
IP11 
My illness causes difficulties for those who 
are close to me 
     
IP12 
There is a lot which I can do to control 
my symptoms 
     
IP13 
What I do can determine whether my 
illness gets better or worse 
     
IP14 
The course of my illness depends on me      
IP15 
Nothing I do will affect my illness      
IP16 
I have the power to influence my illness      
IP17 
My actions will have no affect on the 
outcome of my illness 
     
IP18 
My illness will improve in time      
IP19 
There is very little that can be done 
to improve my illness 
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9- Rand-36 (Health Survey) 
 
Research Number: ………………… Date completed…………………….. 
 
Please answer every question. Some questions may look like others, but each one is different. Please 
take the time to read and answer each question carefully by filling in the bubble that best represents 
your response. 
 
1.    In general, would you say your health is: 
 
Excellent  
Very good  
 Good 
 Fair 
 Poor 
 
2.    Compared to one year ago, how would you rate your health in general now? 
 
 Much better now than a year ago 
Somewhat better now than a year ago 
 About the same as one year ago 
 Somewhat worse now than one year ago 
 Much worse now than one year ago 
 
3. The following items are about activities you might do during a typical day. Does 
your health now limit you in these activities? If so, how much? 
 
a. Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
 
b. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing 
golf? 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
 
c. Lifting or carrying groceries. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
d. Climbing several flights of stairs. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
e. Climbing one flight of stairs. 
   Yes, limited a lot. 
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9- Rand-36 Health Survey (cont.) 
   Yes, limited a little. 
   No, not limited at all. 
f. Bending, kneeling or stooping. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all  
g. Walking more than one mile. 
   Yes, limited a lot. 
   Yes, limited little. 
   No, not limited at all. 
h. Walking several blocks. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
i. Walking one block. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
j. Bathing or dressing yourself. 
   Yes, limited a lot. 
   Yes, limited a little. 
   No, not limited at all. 
4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? 
 
a.Cut down the amount of time you spent on work or other activities? 
 Yes                   No 
 
b. Accomplished less than you would like? 
 Yes                   No 
 
c. Were limited in the kind of work or other activities 
 Yes                   No 
d. Had difficulty performing the work or other activities (for example, it took extra time) 
 Yes                   No 
 
5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling depressed 
or anxious)? 
 
a. Cut down the amount of time you spent on work or other activities? 
 Yes                   No 
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9- Rand-36 Health Survey (cont.) 
 
 
 
b. Accomplished less than you would like 
 Yes                   No 
 
c. Didn't do work or other activities as carefully as usual 
 Yes                   No 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
   Not at all 
   Slightly 
   Moderately 
   Quite a bit 
   Extremely 
 
7. How much bodily pain have you had during the past 4 weeks? 
   Not at all 
   Slightly 
   Moderately 
   Quite a bit 
   Extremely 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
 
   Not at all 
   Slightly 
   Moderately 
   Quite a bit 
   Extremely 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have been 
feeling. How much of the time during the past 4 weeks. 
 
a.Did you feel full of pep? 
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time  
 A little of the time  
 None of the time 
b. have you been a very 
nervous person? 
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9- Rand-36 Health Survey (cont.) 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time  
   A little of the time 
  None of the time 
 
c. have you felt so down in the dumps nothing could cheer you up? 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time 
   A little of the time 
   None of the time 
 
d. have you felt calm and peaceful? 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time 
   A little of the time 
   None of the time 
e. did you have a lot of energy? 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time 
   A little of the time 
   None of the time 
f. have you felt 
downhearted and blue? 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time 
   A little of the time 
  None of the time 
g. did you feel worn out? 
   All of the time 
   Most of the time 
351 
 
 
9- Rand-36 Health Survey (cont.) 
   A good bit of the time 
   Some of the time 
   A little of the time 
   None of the time. 
h. have you been a happy 
person? 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time 
   A little of the time 
   None of the time 
i. did you feel tired? 
   All of the time 
   Most of the time 
   A good bit of the time 
   Some of the time 
   A little of the time 
   None of the time 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
   All of the time 
   Most of the time 
   Some of the time 
   A little of the time 
   None of the time 
11. How TRUE or FALSE is 
each of the following 
statements for you/ 
a. I seem to get sick a little 
easier than other people 
   Definitely true 
   Mostly true 
   Don't know 
   Mostly false 
   Definitely false 
b. I am as healthy as anybody I 
know 
   Definitely true 
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9- Rand-36 Health Survey (cont.) 
   Mostly true 
   Don't know 
   Mostly false 
   Definitely false 
c. I expect my health to get 
worse 
   Definitely true 
Mostly true 
   Don't know 
     Mostly false 
   Definitely false 
d. My health is excellent 
   Definitely true 
   Mostly true  
   Don't know  
     Mostly false 
 Definitely false. 
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10. Positive and Negative affect (PANAS) 
 
Research Number: ………………… Date completed…………………….. 
 
 
  
                                
 
This scale consists of a number of words that describe different feelings and emotions. Read 
each item and then mark the appropriate answer in the space next to that word. Indicate to 
what extent you have felt like this in the past few hours. Use the following scale to record your 
answers. 
 
 
 
Very slightly 
or not at all 
a little moderately quite a bit extremely 
    
1 2 3 4 5 
 
 
 
Interested                                                        Irritable              
Distressed                                                       Alert                   
Excited                                                            Ashamed            
Upset                                                               Inspired              
Strong                                                             Nervous             
Guilty                                                              Determined        
Scared                                                             Attentive            
Hostile                                                            Jittery                 
Enthusiastic                                                    Active                
Proud                                                              Afraid                 
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11. Blood Pressure Readings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Research number: Baseline assessment End of group F/UP 
Left SYS    
Left DIA    
PULSE     
NOTES:     
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Appendix J 
Mindfulness-based Interventions: Teaching Assessment Criteria (MBI: TAC)  
Domain  Key features  
(use following pages to offer qualitative feedback)  
Incompetent  
1  
Beginner  
2  
Advanced  
Beginner  
3  
Competent  
4  
Proficient  
5  
Advanced  
6  
Coverage, pacing 
and organisation 
of session 
curriculum 
Adherence to curriculum;  
Responsiveness and flexibility in adhering;  
Appropriateness of themes and content;  
Organisation of teacher, room and materials;  
Session flow and pacing  
      
Relational skills 
 
Authenticity and potency; 
Connection and acceptance; 
compassion and warmth; 
Curiosity and respect, 
Mutuality 
      
Embodiment of 
mindfulness 
 
Present moment focus 
Present moment responsiveness 
Calm and alertness 
Attitudinal foundations 
Person of the teacher 
      
Guiding 
mindfulness 
practices 
Language - precise and spacious 
Key learning for each practice available 
Elements to consider when guiding 
      
Conveying course 
 
themes through interactive inquiry and didactic 
teaching 
Experiential focus 
Layers within the inquiry process 
Conveying learning 
Teaching skills 
Fluency 
      
Holding of group  
 
learning environment 
Learning container 
Group development 
Common humanity 
Leadership style 
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Appendix K 
HeLM Acceptability Interview 
 
  
 
 
 
HeLM end of group interview (MBCT-HeLM only/ completers) 
General questions   
1. How would you describe your experience of the study?   
2. What made you decide to enquire about the trial?    
3. What were your expectations of the trial?   
4. What was it that made you originally decide to take part in the mindfulness trial for heart 
conditions/stroke? 
View of orientation session  
5.  I would like you to think back to your initial meeting with the therapist. What were your 
impressions about that session? Was there anything helpful /unhelpful about it?  
6. What did you think about the group after attending the session?   
7. What were your expectations for what the course might cover? How did you feel about 
this following the meeting?   
View of group sessions   
8. What did you hope to get from attending the group?  
9. How do you feel about this now?   
10. And once the group started how engaged do you feel you were with the group?   
11.  Did this change at all during the course?  
12. Which techniques used in the course have you found helpful? 
13. Which techniques used in the course have you found unhelpful 
14. What would you change about the course?     
Home practice, location length of course and group 
15. How did you find the weekly homework?  
16. How engaged were you with the homework?   
17. What would you change about the weekly homework? 
18. How did you find the questionnaires and assessments throughout the study? 
19. What do you think about the length of the course?" 
20. What do you think about the design of course (group therapy)? 
21. How convenient was the group location for you, parking?   
22.  What would make it more convenient for you?   
23.  Did you encounter any challenges in doing the course?   
I’ve covered all of the questions I have, but before I end, is there anything you would like to 
add?”  
Thank you very much  
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Appendix M 
HeLM Feasibility RCT ethics documents   
1.NHS Ethics Approval 
  
 
NRES Committee South West - Cornwall & Plymouth  
Bristol Research Ethics Committee Centre   
                                                                                   Level 3, Block B, Whitefriars Lewin Mead  
                                                                    Bristol, BS1 2NT,  17 April 2014  
Mrs Modi Alsubaie  
PhD student  
Mood Disorder Centre, Psychology  
University of Exeter   
EX4 4QG  
  
Dear Mrs Alsubaie  
Study title:  Feasibility and Acceptability of Mindfulness-based 
Cognitive Therapy in depressed people with vascular 
disorders: A randomized controlled trial.  
REC reference:  14/SW/0048  
IRAS project ID:  146763  
  
Thank you for your letter of 15 April 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation.  
The further information has been considered on behalf of the Committee by the Chair.  
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details, unless you expressly withhold permission to do so.  
Publication will be no earlier than three months from the date of this favourable opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the REC Manager Miss Georgina Castledine, 
nrescommittee.southwest-cornwall-plymouth@nhs.net.  
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below.  
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HeLM Feasibility RCT ethics documents (cont.)  
Ethical review of research sites  
NHS sites  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of the 
study (see "Conditions of the favourable opinion" below).  
Non-NHS sites  
The Committee has not completed any site-specific assessment (SSA) for the non-NHS 
research site(s) taking part in this study.  The favourable opinion does not therefore apply to any 
non-NHS site at present.  We will write to you again as soon as an SSA application(s) has been 
reviewed.  In the meantime no study procedures should be initiated at non-NHS sites.  
  
Conditions of the favourable opinion  
The favourable opinion is subject to the following conditions being met prior to the start of 
the study.  
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned.  
  
Management permission ("R&D approval") should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements.  
  
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.    
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity.  
 For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of approvals from host organisations  
  
Registration of Clinical Trials  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first participant 
(for medical device studies, within the timeline determined by the current registration and 
publication trees).    
  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment.  We will audit the registration details as part of the 
annual progress reporting process.  
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HeLM Feasibility RCT ethics documents (cont.) 
Approved documents 
  
 
 
  
The final list of documents reviewed and approved by the Committee is as follows:  
 
Document     Version     Date     
Advertisement   1   07 February 2014   
Covering Letter          
Evidence of insurance or indemnity      19 July 2013   
GP/Consultant Information Sheets   1   14 February 2014   
Interview Schedules/Topic Guides   1 - Screening 
Form    
 07 February 2014   
Interview Schedules/Topic Guides   1 - End of group 
interview   
14 February 2014   
Investigator CV      14 February 2014   
Letter from Sponsor      22 February 2014   
Letter of invitation to participant   1   07 February 2014   
Other: FFMQ          
Other: SCS          
Participant Consent Form   1   27 January 2014   
Participant Information Sheet   1   07 February 2014   
Participant Information Sheet   1.1   07 April 2014   
Protocol   1   27 January 2014   
Protocol   1.1   02 April 2014   
Questionnaire: PHQ-9          
Questionnaire: GAD-7          
Questionnaire: CAQ          
Questionnaire: SF-36          
Questionnaire: SAQ          
Questionnaire: IPQ-R          
Questionnaire: PANAS          
Questionnaire: AD-SUS          
Questionnaire: PHQ-9          
REC application      25 February 2014   
Response to Request for Further Information      15 April 2014   
   
 
 
 
 
 
362 
 
 
HeLM Feasibility RCT ethics documents (cont.) 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK.  
  
After ethical review  
Reporting requirements  
 The attached document “After ethical review – guidance for researchers” gives detailed guidance on 
reporting requirements for studies with a favourable opinion, including:  
  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.  
14/SW/0048                          Please quote this number on all correspondence  
  
 
With the Committee’s best wishes for the success of this project.  
Yours sincerely  
  
Canon Ian Ainsworth-Smith Chair  
Email: nrescommittee.southwest-cornwall-plymouth@nhs.net  
  
Enclosures:    “After ethical review – guidance for  
    
  
  researchers” [SL-AR2]  
Copy to:    Ms Gail Seymour  
      Ms Rhianne Lewis, Network Research Facilitator  
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2. R and D approval  
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HeLM Feasibility RCT ethics documents (cont.) 
 
3.GPs Letter to potential participants  
 
Surgery Header/Logo 
Surgery address, phone, names of GPs 
Date as postmark  
 
 
Dear Name of Patient 
 
Referral to Heart and Living Mindfully (HeLM) Research Study  
 
I would like you to consider taking part in a therapy research trial that is looking to see 
if a new course of Mindfulness-based Cognitive Therapy (MBCT) can help people with vascular 
disorders (heart disease or stroke) and low mood to manage their physical and mental well-
being. This letter has been sent to you because in the past you have experienced some form of 
heart disease or had a stroke. We have decided to send this letter to everyone on our records in 
this situation as we know it can be common for people who have experienced these things to 
also suffer from low mood. However, if you do not feel this applies to you please ignore this 
letter. 
You can find out more about this study from the Patient Summary Pamphlet which I’ve 
included with this letter. Please read this carefully and think about whether or not you would 
like to take part in the study. If you have any questions you would like to ask, you can talk to me 
or to Modi Alsubaie, the Lead Researcher (tel. 01392 726101).  
If you would like to be considered for this therapy research trial then you can contact 
the research team on 01392 726101, or by returning the enclosed ready prepared letter, or 
emailing msfa202@exeter.ac.uk to discuss this further. 
I would like to reassure you that the details of your personal medical records will 
always remain confidential within this GP practice care team.  
Thank you for taking the time to read this letter. 
 
Yours sincerely, 
 
GP name 
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HeLM Feasibility RCT ethics documents (cont.) 
 
4. Letters from HeLM team to participants 
First Screen Letter 
 
 
Private & Confidential        
 
Dear  
 
Re: Mindfulness-based Cognitive Therapy Group for Heart Conditions - HeLM 
 
Thank you for taking the time to speak to me regarding our study.  As I said on the phone we will contact 
you again in October to discuss the study further and to ask you some more questions.  It is at this point 
that we will then invite you in to meet with our researcher for your initial assessment.  This assessment will 
confirm that you are eligible to take part and that the study is right for you. 
 
Please find enclosed a full information booklet about the study; please ensure you read this to ensure you 
are happy with the information and are interested to take part. 
 
In the meantime, if you wish to speak to us at any point please do not hesitate to contact us 01392 726101.  
If you leave a message, we will get back to you.   
 
Best wishes, 
 
 
 
Modi Alsubaie 
Researcher  
 
Supervised by  
Willem Kuyken, Professor of Clinical Psychology. 
Chris Dickens, Professor of Psychological Medicine. 
 
 
 
 
 
 
 
 
  
366 
 
 
    
HeLM Feasibility RCT ethics documents (cont.) 
 
5.Baseline Letter 
 
 
Private & Confidential      October 2014  
Letters to control group 
 
Dear  
Re: Mindfulness-based Cognitive therapy for people with cardiovascular disorders. 
Thank you very much for taking part in HeLM project as member of control group. We would like to 
invite you to an assessment session at university of Exeter that will take 40 mints and includes 
completing the same questionnaires that you have completed last November. Alternatively, we can 
send you the questionnaires to complete at home. 
As promised, we offer you a mindfulness course that you could join in once we finish the last 
assessment in June 2015. This year, we have two mindfulness courses. The first one will be held end of 
June and the second will be end of September and you are welcome to take part in any of them. 
I’ve enclosed with this letter a form to fill it out regarding your availability to meet me for the 
assessment and your preferences regarding the mindfulness group that you would like to take part. 
There is a prepaid envelope that you can use to send the form back to me.  
Thank you very much. 
I look forward to hearing from you. 
Yours sincerely, 
 
Modi Alsubaie 
Researcher  
 
Supervised by  
Willem Kuyken, Professor of Clinical Psychology and Chris Dickens, Professor of Psychological 
Medicine. 
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HeLM Feasibility RCT ethics documents (cont.) 
 
6.Letter from HeLM team to GPs 
 
Private & Confidential        
Re: Patient name and address 
HeLM: Mindfulness-based Cognitive Therapy for cardiovascular Disorders 
 
 
 
Dear Dr … 
 
I am writing to inform you that the above patient will be participating in our study examining whether 
a new course of Mindfulness-based Cognitive therapy can help people with vascular disorders to 
manage their physical and mental well-being.  
 
For any questions regarding your patient’s participation in the study or the study itself, please contact 
me on xxxxxxxxxxxx.  
 
 
Best regards, 
 
Researcher  
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HeLM Feasibility RCT documents (cont.) 
 
7.Reply Form  
Heart and Living Mindfully (HeLM)  
 
Thank you for taking the time to read the brief information about the HeLM study.  We 
appreciate that this is a short summary of the study and you may want more information to make 
an informed choice.  If you would like to find out more then please fill out the slip below.  If 
you are not sure feel free to hold onto it until you have decided and contact us via the details 
below; 
  
• Email: msfa202@exeter.ac.uk 
• Telephone: 01392 726101 
 
I am interested in finding out more about the study 
 
I confirm that I have read the information provided and would like to be contacted to discuss it 
further.  I understand that my participation is voluntary and that I am free to withdraw at any 
time. 
 
Name: ________________________________________________________________ 
 
Address:_______________________________________________________________ 
 
______________________________________________________________________ 
 
Preferred telephone numbers: ______________________________________________ 
 
It is OK to leave an answer phone message on this number? YES  /   NO  
   
     
Email address (optional):__________________________________________________ 
 
When is the best time to call?: __________________________________________ 
 
I am not interested in finding out more about the study, thank you.   
 
 
 
  
HeLM Feasibility RCT documents (cont.) 
 
8.Data Management Protocol for HeLM Feasibility RCT  
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HeLM Feasibility RCT documents (cont.) 
 
8.Data Management Protocol for HeLM Feasibility RCT (cont.) 
 
 
 
HeLM Feasibility RCT documents (cont.) 
 
9.MBCT-HeLM Manual  
Session Outlines  
Orientation Session 
THEME 
The initial orientation with the MBCT teacher is a starting point for dialogue between the 
MBCT participant and teacher. Forming a therapeutic relationship with each participant and 
orienting him/her to the rationale for and practicalities of MBCT and certain aspects of the 
trial are likely to enable full participation. It also enables instructors to facilitate enquiry in the 
groups individualised to some degree to individual’s particular history and goals.  
AGENDA 
After reading questionnaires 
• Learn about the factors that have been associated with the onset and maintenance of 
long-term physical and mental health problems (using client terminology), including 
the way the person’s physical health has affected their mental health and vice versa. 
How does it (client terminology for physical health problem) affect your life? How 
does it affect your mood / spirits / relationships? 
• Learn about the beliefs and resources that the person has developed in coping with his / 
her physical and mental health problems to date and reasons for attending. 
• Clarify participants' expectations 
• Introduce the road-block and oxygen mask metaphors 
• Introduce the idea symptoms as guides from the body and how mindfulness and self-
care are ways of hearing and responding to these messages. 
• Explain something of the background and aims of MBCT.  
o To help people who have suffered physical and mental health problems learn 
skills to help manage their symptoms and emotions. 
o To become more aware of bodily sensations, symptoms, concerns, feelings, 
and thoughts, from moment to moment 
o To help participants learn different ways of relating to physical symptoms, 
sensations, thoughts, feelings, situations,  – specifically, mindful acceptance 
and acknowledgement of unwanted feelings and thoughts, rather than 
habitual, automatic, pre-programmed routines that tend to perpetuate 
difficulties, moving to a more responsive rather than reactive place 
o Reacquainting with the body in a more positive way 
o Individualised formulation and way that the practice may need to be adapted. 
o To help participants to be able to choose the most skilful response to any 
unpleasant thoughts, feelings, physical symptoms or situations that they meet. 
o To develop an integrated approach to care 
o To learn from others with similar experiences 
• Outline structure of the MBCT programme 
o Groups of 8-12 
o Eight weekly 2 hour 15min sessions 
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9.MBCT-HeLM Manual (cont.) 
Orientation Session (cont.) 
 
 
o Home Practice  
o Video recording and consent sheet 
o Involvement of other health care professionals 
• Emphasize that MBCT will involve hard work, commitment and a need for patience 
and persistence in that work, over the course of the 8 weeks. 
 
PLANNING AND PREPARATION 
 
• In addition to your personal preparation before the meeting, remember to 
familiarise yourself with any background information about the person’s 
presentation 
 
 
  
9.MBCT-HeLM Manual (cont.)  
Session 1: AUTOMATIC PILOT 
 
THEME 
On automatic pilot, it is easy to drift unawares into “doing” mode and the automatic reactions 
and ruminative/worry thought patterns that can feed old unproductive patterns of thinking and 
behaving. Habitual doing mode also robs us of our potential for living life more fully. We can 
transform our experience by intentionally paying attention to it in particular ways. We begin to 
practice stepping out of automatic pilot by paying attention intentionally, mindfully, to eating, 
to the sensations of the body, and to aspects of everyday experience. 
 
AGENDA 
 
• Establish the orientation of the class 
o Honour the commitment everyone has made 
o Set the ground rules regarding confidentiality, participation and time keeping, 
ease and comfort in the body. Creating a safe place to work. 
• A short reflective practice coming to the body and then dropping in a question about 
intentions for being here. Ask participants to pair up and introduce themselves to each 
other, then to the group as a whole, giving their first names and, what they hope to get 
out of the program and very briefly an outline of their heart/vascular condition and their 
mood/stress.  
• Short movement either sitting or standing as a way of coming into the body 
• The raisin exercise 
• Feedback and discussion of the raisin exercise 
• Body scan practice (with some guidance on posture and ways of sitting/lying) – starting 
with the short breath focus including some focus on the sensations around the heart 
area. Focus on what is right. Feedback and discussion of body scan 
• Home Practice: Discuss and assign for the coming week 
o Body scan  
o Mindfulness of a routine activity 
o Mindfulness of eating 
• Distribute CDs and session 1 participant handouts  
• Discuss in pairs:  
o Timing for home practice 
o What obstacles may arise 
o How to deal with them 
• End the class with a short breath focus 
•  
PLANNING AND PREPARATION 
• Bowl with raisins and a spoon  
• CD body scan 
• Copies of participants’ folders for the programme. 
• Flip chart and pens 
• Handouts 
• Bell 
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9.MBCT-HeLM Manual (cont.) 
Guidelines for MBCT Group. 
 
Housekeeping 
 
Toilets, mobile phones off, fire, bell, chimes/bowl, tea/coffee, video 
 
Ground rules 
 
Time-Keeping 
 
• I aim to start and finish on time. 
 
• From now on, each session begins with period of practice so if you do happen to be 
late, I will always have a chair or mat out for you, just coming in quietly and join in 
practice when you’re ready. 
 
Attendance 
 
• Each session a significant building block to the whole so important to try and attend 
all. 
 
• But just say you have to miss one then I'd really appreciate it if you could let me 
know in advance by phone or email. And we will miss you if you're not here... 
 
• And you don't need to be a certain way to come along – you don't need to come 
with a smiling face!  
 
Confidentiality – does anyone know each other here? 
 
• Important that we create a safe place where we can share and learn from each other..... 
Might be tempting to go home and share what’s happening in the group with friends 
or family and  what I would like to suggest is that it’s fine to talk about your own 
experience or the group in general terms but not to mention any names or speak 
of anyone else’s experience. 
 
• And if you’re out and about and you happen to bump into someone from the group 
and they’re with someone else just to be sensitive to the fact that they may not want to 
be spoken to….  
 
Participation/Sharing 
• We're not here to go over the past or the content of one's problems but seeing instead if 
we can work more helpfully with our patterns of mind and body in the moment – so 
there may be times when I might invite us all to pause if I notice we’re getting caught 
up in lots of thoughts and come back to what's happening now. 
• I really welcome you to share your experiences from the practices but equally there 
is really no obligation to share – tuning into what feels right for you... 
• Listening is as much of an active part of being in a group as speaking... 
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9.MBCT-HeLM Manual (cont.) 
Commitment 
 
• The sessions but particular the home practice can feel intense, difficult, You will 
not necessarily enjoy it – it will feel challenging at times, boredom, impatience etc. 
may all be feelings that arise. And this is all part of it – so as best we can letting go 
of any expectations about how things should be on this course or ought to be 
     'just do it and see what happens' 
 
Support out of session 
 
• My number/email address, messages are checked every ……... 
• Also available after the group if you need to speak to me. 
 
Open Mind and Heart  
 
• Sometimes it may not be clear how what we're doing links with protecting ourselves 
from depression but I would just ask you to bring an open mind to each session, each 
moment… 
  
Gentleness and kindness 
 
Physical needs 
 
• Feel free to stand and stretch and move around the room at any point 
• All guidance is an invitation please leave out what doesn’t feel right for your body or 
adjust 
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9.MBCT-HeLM Manual (cont.)  
Session 2: LIVING IN OUR BODIES & HEADS 
 
THEME 
In doing mode we “know about” our experience only indirectly, conceptually, through 
thought. This means we can easily get lost in rumination and worry, and old patterns 
of reactivity. Mindfulness of the body provides an opportunity to explore a new way 
knowing directly, intuitively – “experimentally” to the body as it is, rather than how 
we think it is. Experiential knowing is a way to be aware of unpleasant experiences 
without getting lost in ruminative thought about the past, worry about the future or 
thinking about the body. Already, most participants will be experiencing some 
difficulties in their practice. These difficulties offer precious opportunities to practice 
letting go of thinking and to connect with direct awareness of the body. Reacquainting 
ourselves with the body in terms of what is right with the body, appreciating the body. 
Importance of taking care of ourselves (and the issues this can raise). 
 
AGENDA 
 
• Body Scan Practice (guiding around sensations in the heart area) and review 
• Home Practice Review – (including body scan, mindfulness of a routine 
activity, Mindfulness of eating) weaving in the theme of importance of taking 
care of ourselves (and the issues this can raise). 
• Sensations, Thoughts and Feelings Exercise. "You wake up in the morning and 
you feel unwell and very tired (but you've got important plans, which also 
involve other people and you are not sure you can even get out of bed). What 
do feel, think, experience in your body? 
• Ten- minute sitting meditation (with guidance on how to sit in a chair) and 
review 
• Distribute Session 2 participant handouts 
• Home Practice assignment: 
o Body Scan CD, 6 out of 7 days 
o 10 minutes mindfulness of breathing daily 
o Pleasant Experiences Calendar (one example daily). 
o  Mindfulness of a new routine activity 
 
PLANNING AND PREPARATION 
 
• Flip chart and pens 
• Guidelines for the group 
• Handouts 
• Flip chart and pens 
• Bell 
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9.MBCT-HeLM Manual (cont.)  
Session 3: GATHERING THE SCATTERED MIND 
 
THEME 
The mind is often scattered and lost in thought because it is working away in the 
background to complete unfinished tasks and strive for future goals. Instead, we need 
to find a way to intentionally “come back” to the here and now. The breath and body 
can offer an ever-present focus on which we can reconnect with mindful presence, 
gather and settle the mind, and ease ourselves from doing into being. For people for 
whom the breath and/or particular parts of the body tend to trigger strong aversive 
reactions another anchor can be found for attention. The focus is on gathering the mind 
with an identified anchor. 
 
AGENDA 
 
• 5 minutes “seeing” (or “hearing”) exercise. 
• 20-minute mindful movement (giving guidance around the heart and breath 
during the movement) and review. 
• Home Practice Review (including body scan, mindfulness of the breath and 
routine activity 
• Pleasant Experiences Calendar – using the body diagram for the feedback 
•  3 Stage Breathing Space and review. 
• Short sitting (Breath/Body) and review 
• Distribute Session 3 participant handouts. 
• Unpleasant Events Calendar. 
• Home Practice assignment (in pairs how to fit it in): 
o Short sitting (breath/body) CD on days 1, 3 and 5. 
o Mindful movement CD on days 2, 4, and 6 or continue with Body Scan 
o Unpleasant Experiences Calendar (a different experience connected with 
vascular disorder daily). 
o  3 Stage Breathing Space, three times daily. 
 
PERSONAL PREPARATION AND PLANNING 
 
• CDs – Movement, Breathing Space, Short Sitting (Breath/Body) 
• Handouts 
• Bell 
• Flip chart and pens 
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9.MBCT-HeLM Manual (cont.)  
Session 4: RECOGNIZING FEAR AND AVERSION 
 
THEME 
The skill of “coming back” needs to be complemented by seeing more clearly what 
“takes us away” into doing, rumination, mind wandering, and worry. We begin the 
experiential investigation of “aversion”, the mind’s habitual reaction to unpleasant 
feelings and sensations, driven by the need not to have these experiences, which is at 
the root of emotional suffering. Aversion is an understandable turning away from 
experiences that may well be fear-based, but will likely fuel physical and mental 
symptoms. Taking a different approach requires considerable courage. Mindfulness 
offers a way of staying present by giving another way to view things. It helps us take a 
wider perspective and relate differently to experience. For MBCT teachers using the 
RAIN acronym (Recognise, Allow, Inquire and thoughts are Not facts) can be helpful 
in teaching and inquiry, with the first stage being recognition when fear and aversion 
arise. 
 
AGENDA 
 
• 30 Sitting Meditation - awareness of breath, body, sounds, and then thoughts. 
• Practice Review. 
• Home Practice Review (including short sitting CD alternating with Mindful 
movement CD, and 3 Stage Breathing Space).  
• Unpleasant Experiences Calendar using the Body Diagram in feedback. 
Introduce 2 darts. 
• Automatic thoughts - defining the “territory” of mental and physical health 
problems 
• 3 Stage Breathing Space and review  
• Mindful Walking and review 
• Review the sequence 
• Selected extracts from Healing From Within DVD 
• Distribute Session 4 participant handouts. 
• Home Practice assignment: 
o Sitting Meditation CD (6 out of 7 days) 
o  3 Stage Breathing Space – Regular (three times a day). 
o  3 Stage Breathing Space – Responsive (whenever you notice unpleasant 
feelings). 
o  Noting Stress Reactions diagram 
PERSONAL PREPARATION AND PLANNING 
• CD Full Sitting 
• Negative Automatic thoughts 
• Handouts 
• Selected extracts from Healing within DVD 
• Bell 
• Flip Charts and pens 
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My life’s not going the way I want it to 
What’s wrong with me? 
I feel like I am up against the world 
I don’t think I can go on 
My future is bleak 
My body just doesn't work the way it should / used to 
Nothing feels good anymore 
I can’t stand this anymore 
I don’t like the way I am 
It’s just not worth it 
The future is scary 
People think there is something wrong with me 
What will happen to me if I can’t look after myself? 
I don’t fit in 
I'm not pulling my weight 
Getting help is hard 
I am a burden to others 
I’m frightened 
I can't provide, money is a worry 
Is it worth it? 
Will it happen again? 
Will I be able to look after myself, and if I can’t… 
Letting people help is hard 
 
 
 
 
 
  
Session 4 
Negative Automatic Thoughts 
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9.MBCT-HeLM Manual (cont.)  
Session 5: SOFTNESS AND STRENGTH 
 
THEME 
Relating differently to unpleasant feelings and sensations – allowing things to be as 
they already are. We can disempower aversion by intentionally bringing to all 
experience a sense of “allowing” it to be, just as it is, without judging it or trying to 
make it different. Such an attitude of acceptance embodies a basic attitude of opening 
to and “softness” with experience that can be experienced as considerable “strength.” 
From this clear seeing we can choose what, if anything, needs to change and the 
beginning of a more empowering approach to self-care. The RAIN acronym 
progresses here to the A and possibly the I. 
 
AGENDA 
 
• 30-40 minute Sitting Meditation – awareness of breath and body; noticing how 
we relate to our experiences through the reactions we have to whatever 
thoughts, feelings or body sensations arise; introducing a difficulty within the 
practice and noting its effects on the body and reactions to it.  
• Practice review. 
• Home Practice Review (Sitting Meditation CD, 3 Stage Breathing Space – 
Regular and Responsive 
• Gathering of the Noting Stress Reactions from the week using The Body 
diagram and linking with the physical barometer Breathing Space (with added 
instructions) as a “first step” with the option of the body door 
• Read The Guest House  
• Further extracts from Healing within DVD that speak to allowing and softness 
and strength 
• Distribute Session 5 participant handouts 
• Home Practice assignment: 
o Sitting Meditation - on days 1, 3, and 5; use no guided practice on days 
2, 4, and 6 instead, but guide yourself through the same meditation. 
o Optional Working with difficulty meditation 
o 3 Stage Breathing Space – Regular (3 times a day). 
o 3 Stage Breathing Space – Added Instructions (whenever you notice 
unpleasant feelings). 
 
PLANNING AND PREPARATION 
 
• Poem “The Guest House”  
• Poster 
• Handouts 
• CD- working with difficulty 
• Bell 
• Flip charts and pens 
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9.MBCT-HeLM Manual (cont.) 
Session 6: SYMPTOMS AS MESSAGES FROM THE BODY; THOUGHTS 
ARE NOT FACTS 
 
THEME 
 
Relating differently to experiences. We free ourselves from the impact of physical 
symptoms, fear-based thinking/imagery and ruminative doing mode when we clearly 
see that physical sensations and negative emotions as passing experiences, and 
negative thinking as the distorted products of those experiences. It is enormously 
liberating to realise that our thoughts are merely thoughts, even the ones that say they 
are not, and to recognise the contexts out of which they are born. Similarly, physical 
symptoms are changing experiences that can be interpreted as messages from the 
body, to be listened to and responded to, however difficult that may sometimes be. The 
RAIN acronym progresses here to the Inquiry and thoughts are Not facts. 
 
AGENDA 
 
• 30 -40 minute Sitting Meditation – awareness of breath, body, sounds, thoughts 
and thoughts / feelings, particularly noticing how we relate to thoughts that 
arise. Choiceless awareness 
• Practice review. 
• Home Practice Review (including Sitting Meditation with and without 
recorded guidance, working with difficulty and breathing spaces). 
• Mention preparation for end of course. 
• Reacting/responding Exercise:1. What is the symptom that causes you stress 
and worry? 2. Imagine it now. Locate it in the body, what are the thoughts and 
emotions. What are your reactions? (may include a diversity of reactive and 
responsive) 3. Gather on flip chart using body diagram. 4. Breathing Space. 5. 
re there any other more compassionate responses? 
• Discuss Breathing Space as the “first step” before the thoughts door 
• Ways to see thoughts differently – gather ideas from the group 
• Discuss Recognising signs and reactions to stress/low mood worksheet 
• Distribute Session 6 participant handouts Home Practice assignments: 
o Practice with a selection of guided meditations for a minimum of 30 
minutes a day.  
o  3 Stage Breathing Space – Regular (3 times a day). 
o  3 Stage Breathing Space – Responsive (whenever you notice unpleasant 
feelings). 
o Recognising signs and reactions to stress/low mood worksheet  
o  
PLANNING AND PREPARATION 
 
In addition to your personal preparation,  
• Handouts 
• Bell 
• Flip chart and pens 
 
9.MBCT-HeLM Manual (cont.) 
Session 7: TAKING CARE OF MYSELF 
 
THEME 
Using skilful action to take care of ourselves. We can improve our mental and physical 
health by intentional skilful action. Developing a personalised self-care plan is a 
proactive way of doing this. At times of stress, after taking a breathing space, we 
kindly take care of ourselves by acts that promote health, give pleasure or a sense of 
mastery. 
 
AGENDA 
 
• 30-40-minute Sitting Meditation – awareness of breath, and body: noticing how 
we relate to our experiences through the reactions we have to whatever 
thoughts, feelings, or body sensations arise; especially when difficulties arise 
within the practice, noting their effects and reactions to them, on the body. 
• Practice review. 
• Home Practice Review (Including shorter meditations and breathing spaces) 
• Review of daylong 
• Links between activity and well-being exercise 
• Plan how best to schedule activities for when physical symptoms and mood 
states threaten to overwhelm 
o Rebalancing nourishing and depleting activities 
o Generating a list of nourishing activities. 
•  3 Stage Breathing Space as the “first step” before choosing whether to take 
mindful action.  
• Responding wisely to stress/low mood worksheet- Identifying actions to deal 
with decreased well-being incorporated with mindful walking. Walking for a 
short while, stopping, turning to a partner and describing one way you can take 
care. Continue and repeat 4-5 times. 
• Distribute Session 7 participant handouts. 
• Home Practice assignment: 
o Select from all the different forms of practice, a pattern you intend to use 
on a regular basis. 
o  3 Stage Breathing Space – Regular (3 times a day). 
o  3 Stage Breathing Space – Responsive (whenever you notice unpleasant 
feelings). 
o Complete responding wisely with stress/low mood worksheet  
o Complete questionnaires and feedback form 
 
PLANNING AND PREPARATION 
 
• Poem “Walking down the street” 
• Handouts 
• Bell 
• Flip chart and pens 
• Post group questionnaires including feedback questionnaire 
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9.MBCT-HeLM Manual (cont.)  
Session 8: MAINTAINING AND EXTENDING NEW LEARNING 
 
THEME 
Planning for a new way of living. Maintaining and extending a more mindful and 
caring way of being requires clear intention and planning. It is helpful to link 
intentions for regular mindfulness practice to a personally significant value or positive 
reason for taking care of oneself. 
 
AGENDA 
 
• Body Scan Practice.  
• Brief practice review. 
• Home Practice Review (including working wisely with stress/low mood 
worksheet 2). 
• Review whole course: what has been learned – in pairs then go around the 
whole group. 
• Collect  questionnaires  
• Discuss how best to keep up momentum and discipline developed over the past 
7 weeks in self-care and (formal and informal) mindfulness practice.  
• Check and discuss plans, and link them to positive reasons for maintaining the 
practice. 
• Distribute Session 8 participant handouts. End the class with a concluding 
meditation (marble, stone, or bead).  Or with participants wishing each other 
well. 
 
PLANNING AND PREPARATION 
 
In addition to your personal preparation,  
• Bell 
• Flip chart and pens 
• A memento for each participant, to mark the end of the programme, depending 
on your practice. 
• Handouts 
• Booklist and resources 
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Name: 
 
Think back to why you came originally – what were your expectations and why did you stay? 
What did you want / hope for? 
 
 
 
What did you get out of coming, if anything? What did you learn? 
 
 
 
 
 
 
What were the costs to you? What are your biggest blocks / obstacles to continuing? What 
strategies might help you not get stuck (in continuing with what you have learned)? 
 
How important has the programme been to you, on a scale of 1 to 10? 
 
 
1 2 3 4 5 6 7 8 9 10 
Not at all important      Extremely important 
 
Why did you give this rating
 
Feedback on the Programme and Thinking to the Future 
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